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General Introduction
Somatostatin and somatostatin receptors
Over three decades have now elapsed since Brazeau and Guillemin origi-
nally detected a somatotropin release-inhibiting factor (SRIF) by chance 
during studies of the distribution of growth hormone-releasing factor in 
the hypothalamus of rats (1). This peptide, called somatostatin because 
of its supposed specifi c function, i.e. the inhibition of somatotropin 
[growth hormone (GH)] release, proved to be a cyclic peptide consist-
ing out of 14 amino acids (Fig. 1). Higher molecular weights forms of 
SRIF immunoreactivity have been reported including a 28-amino acid 
Figure 1. Amino acid sequence of the natural somatostatin peptide SRIF-14.
polypeptide that corresponds to SRIF with a NH
2
-terminal extension of 
14 amino acids. Isolation and characterization of complementary DNA 
(cDNA) clones encoding SRIF indicated that SRIF, like other polypep-
tides, is derived from a larger precursor by proteolytic processing. The 
primary translation product of SRIF messenger RNA (mRNA) is a 116-
amino acid molecule, preprosomatostatin, subsequently processed in a 
92-amino acid prosomatostatin which by itself undergoes proteolytic 
processing, thereby generating the biologically active forms SRIF-14 
and SRIF-28. The production of SRIF occurs in concentrated numbers 
of SRIF-producing cells throughout the central and peripheral nervous 
systems, in the endocrine pancreas, in the gut and in limited cell numbers 
distributed over the thyroid, the retina, adrenals, submandibular glands, 
kidneys, prostate and placenta. SRIF modulates neurotransmission in the 
central nervous system (as a neurotransmitter), regulates the release of 
GH and thyrotropin (TSH) from the anterior pituitary gland (as a neuro-
hormone) and has a regulatory role in the gastrointestinal tract, as well 
as in the exocrine and endocrine pancreas. When synthesized in and re-
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leased by endocrine and nerve cells, SRIF acts in an autocrine, paracrine, 
or neuronal regulatory manner to inhibit glandular secretion, neurotrans-
mission, smooth muscle contractility and absorption of nutrients (2, 3).
Somatostatin receptor subtypes
The various actions of SRIF are mediated through specifi c membrane 
receptors. Five subtypes of the human SRIF receptor (sst) have been 
cloned and characterized (4, 5). Genes for sst
1,3,4,5
 lack classical introns. 
The sst
2
 gene displays a cryptic intron at the 3’ end of the coding seg-
ment, which gives rise to two splice variants, a long (sst
2A
) form and a 
shorter (sst
2B
) form, which differ only in the length of their cytoplasmic 
tail (6, 7). Even though Northern blotting has detected two bands of 2.3 
kb and 8.0 kb size-length in human tissues (6, 8, 9), detailed evidence 
for the (functional) expression of the short sst
2B
 form in humans is still 
lacking. The sst subtypes, which are identical in 42 to 60 percent of their 
amino acid sequences, belong to a superfamily of seven α helical trans-
membrane segments typical of guanine nucleotide binding (G) protein 
coupled receptors (GPCR; Fig. 2). All subtypes share a coupling to the 
Figure 2. Structure and schematic orientation of the SRIF receptor within the plasma mem-
brane encountering seven transmembrane-spanning α-helical domains connected by short 
loops, having an N-terminal extracellular domain and a C-terminal intracellular domain.
second messenger system known to be activated upon SRIF binding to 
its receptors. Hydrophobic and charged amino acids within transmem-
brane domains 3, 6 and 7 are important for the interaction with the ligand 
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(10, 11). However, the extracellular loop 2, between domains 4 and 5 
may also be involved (12-14). The subsequent conformational change of 
the receptor leads to activation of an associated heterotrimeric G-protein 
complex (consisting of α-, β- and γ-subunits) and exchange of GTP for 
GDP on the α-subunit. The common effect of the fi ve sst subtypes is a 
reduction in intracellular cyclic adenosine monophosphate (cAMP) and 
Ca++ as well as an activation of protein phosphatases [Fig. 3; (15)]. The 
fi nal pathway, and hence effect on cellular function, will vary, depending 
on the specifi c sst and SRIF ligand involved. Inhibition of cell secre-
tion may be achieved through several intracellular effector pathways: (1) 
inhibition of adenylyl cyclase activity via inhibitory G proteins (Gαi), 
which are pertussis toxin sensitive, thereby reducing intracellular cAMP 
levels, (2) reduction in intracellular Ca2+ owing to activation and hyper-
polarisation of K+ channels as well as inhibition of the normal depolariza-
tion-induced Ca++ infl ux via voltage-sensitive Ca++ channels (16). Both a 
reduction on intracellular cAMP and Ca++ result in inhibition of secretion. 
Stimulation of protein tyrosine phosphatases and inhibition of MAP ki-
nase activity (17) by sst are thought to be involved in anti-proliferative 
effects of SRIF. Less prominent signaling pathways include inhibition 
of Na+-H+ exchanger and activation of phospholipase A and C (2, 18). 
Figure 3. Schematic representation of SRIF receptor signaling pathways leading to 
inhibition of secretion and cell proliferation.
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Distribution of somatostatin receptor subtypes
Classical SRIF-target tissues such as the central nervous system, the ante-
rior pituitary gland and the pancreas, express multiple sst subtypes (Table 
I) (19). The adult human pituitary gland expresses sst
1
, sst
2
, sst
3
 and sst
5
mRNAs, but not sst
4
 mRNA. As determined by immunohistochemistry, the 
human pancreatic islet cells express all fi ve sst subtype proteins (20). Neu-
roendocrine tumours frequently express a high density of SRIF receptors.
Table I. Distribution pattern of SRIF receptors in humans.
SRIF receptor subtype 
sst1 sst2 sst3 sst4 sst5
Brain + + + + + 
Pituitary + + +  + 
Stomach + + + + + 
Liver + +    
Pancreas + + + + + 
Kidney + +    
Lung + +  +  
Intestine + +   + 
Spleen  +    
Thymus + + +   
Uterus  +    
Thyroid   +  + 
Prostate + + +   
Adrenal  +   + 
The SRIF-receptor subtype distribution (by in situ hybridistation, immunohistochem-
istry, RT-PCR analysis, Northern Blotting) in normal tissues has been extensively re-
viewed. For further details see Refs. (2, 5, 9, 15, 19, 20, 25, 26).
15
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Sst-expressing tumours include pituitary adenomas, carcinoids, islet cell 
tumours, paragangliomas, pheochromocytomas, small cell lung cancers, 
medullary thyroid tumours but also breast cancers, prostate cancers and 
malignant lymphomas (21). The majority of human sst-positive tumours 
simultaneously express multiple sst subtypes, which can be different be-
tween tumour types but also among the same tumour types. The predomi-
nant expression of sst
2
 receptors forms the basis for the successful clinical 
application of the currently available clinical SRIF-analogs. The presence 
of sst
2
 is a prerequisite for sensitivity of inhibition of tumour-related hor-
monal hypersecretion to treatment with octapeptide SRIF-analogs, as has 
been extensively demonstrated in patients with growth hormone (GH)-
secreting pituitary adenomas and islet cell or carcinoid tumours (22, 23). 
Somatostatin receptor physiology
Although the acute administration of SRIF produces a large number of 
inhibitory effects, the initial responses diminishes with continued expo-
sure to the peptide. The ability to regulate their responsiveness to contin-
ued agonist-exposure is a common property of many GPCR’s. Such ago-
nist-induced regulation typically involves receptor desensitization due to 
uncoupling from G proteins as well as receptor internalization and recep-
tor degradation (2). Since the cloning of the fi ve sst subtypes, as already 
described previously, the involvement of the individual sst subtypes in 
the process of receptor-mediated internalization of SRIF has been ex-
tensively investigated (2, 21, 24-26), and it should be taken into account 
that differences have been reported between human and rat sst subtypes 
with respect to their dynamics of agonist-induced internalization. In gen-
eral, the mechanism and route of internalization of sst-agonist complexes 
involves aggregation of the hormone-receptor complex in specialized 
areas of the membrane, followed by internalization of the complex via 
clathrin-coated, as well as uncoated, pits. Subsequently, fusion of these 
vesicles with lysosomes occurs, resulting in hormone degradation or re-
ceptor recycling to the cell surface. The sst subtypes differentially inter-
nalise SRIF and SRIF-analogs. Using CHO-K1 cells, stably expressing 
16
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one of the fi ve sst subtypes, agonist dependent internalization of [125I]LTT 
SRIF-28 ligand in a time- and temperature dependent manner, has been 
demonstrated (27). The human sst
1
 receptor showed low agonist induced 
internalization (4%), whereas sst
3
- and sst
5
-expressing cells displayed the 
highest degree of internalization (78% and 66%, respectively), followed 
by sst
4
 (29%) and sst
2
 (20%). Furthermore, binding of SRIF to monomer-
ic cell-surface sst
1
 and sst
5
 triggers both homo- and hetero-sst dimeriza-
tion. The sst
1
-sst
5
 heterodimers show enhanced ligand-receptor binding 
affi nity likely the result of receptor subtype modifi cation. The functional 
signifi cance of receptor dimerization, restricted to only some sst’s, varies 
according to the receptors involved; human sst
5
 forms heterodimers with 
sst
1
, but not with sst
4 
(28). Using the selective sst
1
 ligand 125I-SCH288, 
no internalization of sst
1
 was observed. However, when sst
1
 receptors 
where co-transfected with a c-tail deletion mutant of sst
5
, a slight but sig-
nifi cant internalization of 125I-SCH288 at 60 minutes was observed, sug-
gesting that processes like functional heterodimerization of sst subtypes 
can determine internalization of sst subtypes (29). Interestingly, Stroh 
and coworkers elegantly demonstrated by the use of biochemical, confo-
cal and microscopic techniques, that a constant population of functional 
rat sst
5
 receptors is maintained at the cell surface at all times through a 
process of receptor recycling and recruitment of intracellular sst
5
 pro-
teins (30). They proposed that these mechanisms might protect sst
5
 from 
long-term desensitization. Furthermore, rat sst
2A
 and sst
3
 are able to form 
homodimers as well. Both sst
2
 and sst
3
 homodimers underwent agonist 
induced endocytosis, but the heterodimer of sst
2a
 and sst
3
, both being 
over-expressed in HEK293 cells, dissociated at the cell membrane and 
only sst
2
 underwent agonist induced endocytosis combined with loss of 
sst
3
 function (31). In addition to this communication between receptor 
subtypes within the same GPCR family, rat sst
2A
 receptor heterodimer-
ization with the μ-opioid receptor (MOR1) has also been demonstrated 
(32). The sst
2A
-MOR1 heterodimers did not signifi cantly alter the li-
gand binding or coupling properties but promoted cross-modulation of 
phosphorylation, internalization and desensitization of these receptors. 
Finally, studies using bioluminescence resonance energy transfer assays 
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(BRET) on living cells, have also indicated that hetero-oligomerization 
of human sst
5
 and the Dopamine D2 receptor occurs following to agonist 
binding (33). The “new receptor” formed by the heterooligomerization 
of the D2 receptor and sst
5
 appeared pharmacologically distinct from its 
receptor homodimers, as it was characterized by a much greater affi n-
ity for binding both dopamine and SRIF-agonists, directly associated 
with enhanced G-protein and effector coupling to adenylyl cyclase. Re-
cently, the fi rst data on heterodimerizaton in vivo has been demonstrated. 
In normal rat astrocytes, sst
2
 and D
2 
receptors formed hetero-oligomeric 
complexes, displaying properties distinct from the native receptors (34).
Acromegaly
Acromegaly is predominantly caused by a GH-secreting pituitary ade-
noma, resulting in high circulating GH and insulin-like growth factor I 
(IGF-I) hormone concentrations. Over the years, a triad of therapeutical 
options has been formed by surgery, irradiation and medical treatment 
(35). These treatment modules had the aim to induce tumor shrinkage and 
normalisation of GH and IGF-I levels, thereby reducing the risk of long 
term complications including the development of malignant neoplasms, 
cardio- and cerebrovascular disease, respiratory and metabolic dysfunc-
tion (36). Effective treatment reduces the 2-3 times raised mortality rate 
for acromegalics (35, 37). Epidemiological studies have confi rmed the 
elevated mortality rate associated with acromegaly and the ability of ef-
fective GH-lowering treatment to improve mortality rate (36-38). While 
surgical resection has been the treatment of choice in most GH-secreting 
pituitary tumours, there has been increasing recognition that curative re-
section is not routinely achieved, even by the most experienced neurosur-
geon. Moreover, a signifi cant number of pituitary adenomas are already 
invasive adenomas at the time of diagnosis, a fi nding that further under-
mines the success of surgical management (39-41). External radiotherapy 
can be an effective adjuvant therapy, but often it takes several years to 
normalise GH and IGF-I levels, there is a risk for the development of an-
terior hypopituitarism and in the long term cerebral damage cannot be ex-
18
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cluded (42). The clinical introduction of stable long acting SRIF analogs, 
Octreotide (OCT) and Lanreotide (Fig. 4), in the early 1980s added a new 
dimension to the treatment of acromegaly (43, 44). OCT and Lanreotide 
form a safe and effective medical therapeutic modality for acromegaly, 
mimicking the action of the native hypothalamic peptide SRIF as the prin-
cipal negative regulator of GH secretion by pituitary somatotrophs (1). 
Biochemical effi cacy of currently available SRIF-analogs
Intravenous administration of SRIF results in a marked inhibition of 
GH release in most acromegalic patients (45, 46). The short half-life 
of SRIF and its subsequent need for intravenous administration, how-
ever, as well as the post-infusion hypersecretion of GH, insulin and 
glucagon, has rendered the native peptide impractical for therapeutic 
use (47). During the 1980s, SRIF-analogs were clinically introduced 
(43, 48). These short, stable synthetic octapeptide SRIF-analogs ap-
peared not to have these disadvantages and were administered in ac-
romegalic patients to assess their role as a novel treatment option in 
acromegaly. Indeed, after the fi rst reports that demonstrated the long-
acting inhibitory effect of OCT on plasma GH level, as well as a rapid 
amelioration of the clinical signs and symptoms, twenty years of en-
docrine practice and science has turned OCT and Lanreotide (Fig.4) 
into a widely accepted medical treatment option for acromegaly (22). 
Cys
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Thr
(ol)
Dphe
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Lanreotide
Figure 4. Amino acid sequence of the two current clinically available SRIF-analogs 
Octreotide and Lanreotide.
Biochemical control
The current clinically available octapeptide SRIF-analogs have been 
consistently shown to be able to reduce hormonal hypersecretion and to 
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normalize IGF-I Ievels in a signifi cant proportion of treated patients. Re-
cently, Freda, summarizing the literature data on this topic (49), showed 
the achievement of safe GH levels in 56% of patients treated with Sand-
ostatin-LAR (OCT incorporated into microspheres of a biodegradable 
polymer that results into therapeutical blood concentrations of the peptide 
for 24-42 days) and in 49% of those treated with Lanreotide 30 mg. The 
respective fi gures for IGF-I normalization were 66% and 48%. However, 
a large majority of the patients enrolled in these studies, were preselected 
for SRIF-analog responsiveness (49). The observation that SRIF-analogs 
successfully achieve long-term biochemical cure when used as secondary 
or adjuvant therapy (50, 51), led to investigations of the use of SRIF-
analogs as primary therapy for acromegaly. Therefore, several studies 
were initiated in which newly diagnosed patients were treated with SRIF-
analogs. To date, effi cacy numbers have been reported for normalizing 
GH (43-79%) and IGF-I (53 and 68%), which are comparable with ef-
fi cacy numbers for adjuvant SRIF-analog therapy (52-58). Furthermore, 
Ayuk and co-workers retrospectively re-analysed GH and IGF-I data 
from a large multicenter European Study in which patients’ biochemi-
cal response to treatment with Sandostatin-LAR as primary or secondary 
therapy was evaluated after 12 months of treatment (59). To eliminate 
preselection bias due to prior debulking of tumor mass, GH and IGF-I 
levels taken from 91 patients at diagnosis were used as baseline values. 
After 48 weeks of treatment, Sandostatin-LAR was equally effective as 
primary therapy in acromegalic patients as well as in patients previously 
treated with surgery and/or radiotherapy (59). Several recent reports have 
evaluated Lanreotide Autogel, the newest long acting SRIF-analog prep-
aration, for the treatment of acromegaly. After 1 year of treatment with 
titrated doses of Lanreotide Autogel (dose increased if GH >2.5 µg/L, 
or decreased if GH < 1 µg/L with normal IGF-I), mean GH and IGF-
I concentration was controlled in 68% of patients (60). In addition, an 
open label multicenter study demonstrated that Lanreotide Autogel, in 25 
acromegalic patients, appeared as effi cacious as compared with the pa-
tients’ previous biochemical effi cacy numbers for Sandostatin-LAR (61). 
SRIF-analog therapy, in general, is well tolerated by most patients. Ad-
20
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verse effects are comparable among the available (long- and short act-
ing) SRIF-analogs and do not limit treatment. The most common side 
effects are gastro-intestinal, i.e. nausea, vomiting, diarrhea and abdomi-
nal discomfort (49). As SRIF-analogs modulate the secretion of insulin 
and glucagon combined via sst expression within the endocrine pan-
creas, reduced glucose tolerance and even overt hyperglycaemia were 
initially expected during long-term therapy. On the contrary, the ef-
fects on glucose homeostasis appeared to be minor and a mild deterio-
ration occurred only in those without impaired glucose tolerance (22).
Sst subtype expression & SRIF-analog effi cacy
Although the clinical introduction of SRIF-analogs has nowadays emerged 
into their use as reference drug for the medical treatment of acromegaly, 
still, no more than approximately two thirds of cases of persistent acro-
megaly respond satisfactory to these agents (62). Human GH-secreting 
pituitary adenomas express multiple SRIF receptor subtypes. Sst
2
 and sst
5
receptors are the predominantly expressed SRIF receptor subtypes, both 
at the mRNA (63, 64) and the protein level (19). Several studies reported 
a variable sst
2
 mRNA expression and a relative high expression of sst
5
(63-65). Sst
2
 seems a predominant receptor in determining the inhibitory 
effect of OCT or lanreotide on circulating GH release in acromegalic pa-
tients. Sst
2
 mRNA expression in GH-secreting pituitary adenomas shows 
a positive correlation with the in vivo GH suppression induced by an acute 
test using a single injection of 200µg OCT (65). Moreover, recently it has 
become clear that apart from sst
2
, sst
5
 receptors play an important role in 
regulating GH secretion by human GH-secreting pituitary adenoma cells 
as well. In this respect the regulation of fetal human GH secretion (66) 
is similar to that in human GH-secreting pituitary adenomas. In primary 
cultures of human GH-secreting pituitary adenomas, new SRIF-analogs 
with enhanced sst
2
 binding affi nities inhibit GH secretion more potent-
ly compared to the clinically used octapeptide SRIF-analogs OCT and 
lanreotide. In addition, some adenomas show a better response to sst
2
-
specifi c analogs, whereas in others sst
5
-specifi c analogs are more potent 
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in suppressing GH release (67). Moreover, the combined activation of 
sst
2
 and sst
5
 results in additive inhibitory effects on GH secretion. Inter-
estingly, the sst
5
 preferential analog BIM-23268 inhibited GH release in 
only 7 of 15 cases, whereas, in agreement with the results of Shimon and 
coworkers (67), partial additive effects in suppressing GH release were 
found in OCT-partially responding cultures when the sst
2
- and sst
5
- spe-
cifi c compounds used in combination. Taken these data together, it can be 
concluded that sst
2
 is the predominant receptor in regulating GH release 
by GH-secreting pituitary adenoma cells, whereas sst
5
 receptors may me-
diate an inhibitory effect on GH secretion as well. The additive inhibi-
tory effects on GH release following activation of both sst
2
 and sst
5 
are 
likely mediated via a functional association of both sst subtypes. Ren and 
coworkers (68) demonstrated in human fetal pituitary cell cultures that 
a sst
2
 selective antagonist was capable of reversing the GH suppressive 
effects of sst
2
/sst
5
 biselective agonists, or that of sst
2
 and sst
5
 agonists in 
combination, indeed suggesting a functional interaction between both sst 
subtypes. In adenomas co-secreting GH and prolactin (PRL), PRL secre-
tion is preferentially inhibited by sst
5
-specifi c SRIF-analogs (63, 67). The 
observed additive GH-suppressive effect of activating both sst
2
 and sst
5
also initiated the development of analogs with selectivity to multiple sst 
subtypes. One of these compounds, the sst
2
- and sst
5
- bispecifi c compound 
BIM-23244, indeed inhibits GH release in a subgroup of partially OCT-
sensitive adenomas more potently compared with OCT. In this subgroup 
of adenomas sst
2
 mRNA expression was nine-fold lower, and sst
5
 mRNA 
expression approximately seven-fold higher than in the OCT-sensitive 
adenomas (65). These studies suggest that in tumors expressing a low sst
2
level and a high sst
5
/sst
2
 ratio, sst
5
 is of increasing importance in regulating 
GH release (65). Another recently developed compound has a more uni-
versal sst binding profi le. Lewis and coworkers succeeded in synthesising 
the multiligand SOM230, a stable SRIF-analog with more universal bind-
ing profi le to sst subtypes, which displays a 30-, 5- and 40- times higher 
binding affi nity to sst
1
, sst
3
 and sst
5
 receptors, respectively, and 2.5 times 
lower affi nity to sst
2
, compared with OCT (69). By using an alanine scan-
ning technology, essential functional groups of the SRIF peptide respon-
22
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sible for the high binding affi nity to all fi ve sst subtypes were detected. 
Incorporation of four synthetic amino acids and two essential amino acids 
of SRIF into a stable cyclohexapeptide template resulted into SOM230. 
In rats, dogs and monkeys SOM230 potently and dose-dependently de-
creases GH and IGF-I levels more effi cacious as compared with OCT (70, 
71). Additional characteristics of SOM230 include a very favourable T½ 
of nearly 24 hours, as well as the preliminary evidence that glucose lev-
els in rats and dogs remain normal during long-term administration (70). 
As already discussed, heterodimerization of sst
5
 and dopamine D2 recep-
tors (D2DR) seems to result in the formation of a novel receptor with 
enhanced biological activity (33). On the basis of these data, including 
the observation that combined SRIF-analog and dopamine agonist treat-
ment inhibits GH hypersecretion in a signifi cant proportion of acrome-
galic patients partially resistant to OCT or lanreotide (72), Saveanu et 
al. (73) recently studied the effects of BIM-23A387, which selectively 
binds with high affi nity to sst
2
 and D2DR receptors, on GH and PRL 
release by 11 cultured GH-secreting pituitary adenomas. In both OCT-
sensitive, as well as in cultures showing partial responsiveness to OCT, 
the maximal inhibition of GH release induced by the individual sst
2
 and 
D2DR analogs and by BIM-23A387 was similar. However, the mean IC
50
for GH suppression by BIM-23A387 (0.2pM) was 50 times lower than 
that of the individual sst
2
 and D2DR specifi c compounds. This enhanced 
potency of chimeric molecules, such as BIM-23A387, may therefore 
lead to potential novel medical treatment options in acromegalic patients. 
Cushing’s disease
The proposition that the pituitary gland is responsible for the clinical fea-
tures of Cushing’s disease was convincingly described for the fi rst time 
in Harvey Cushing’s classic monograph of 1932 (74). Much uncertainty 
remained at that time on the pathophysiologic mechanism of this dis-
order, yet the crucial clinical and pathological observations were made. 
Today it has been recognized that chronic overproduction of cortisol by 
hyperplastic adrenocortical glands is directly responsible for the clinical 
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features of Cushing’s disease, a phenomenon which is primarily driven 
by pituitary adrenocorticotropin hormone (ACTH) hypersecretion (75).
Transsphenoidal surgery is the treatment of choice for pituitary-depen-
dent Cushing’s disease. Although transsphenoidal surgery allows cure of 
Cushing’s disease, the reported success rates vary from 50 to almost 90% 
(76-80). If surgery fails radiotherapy (81) either alone or in combina-
tion with adrenolytic agents may be used (82-85). Unfortunately, none of 
the current treatment modalities ensure a full and permanent cure, as the 
rate of recurrence of the disease, depending on the criteria of initial cure, 
varies from 5 to 24% in the literature (81, 86-90). Therefore, physicians 
explored new medical strategies, preferably based on fundamental and 
(patho-) physiological pathways, in the hope of increasing the curation 
chance in this group of patients. Neuromodulatory agents, such as dopa-
mine and SRIF, have been proposed to be of therapeutic interest in the 
medical treatment of Cushing’s disease. Since the initial report showing 
that SRIF infusion induced a partial decrease of plasma ACTH in fi ve 
patients with Nelson’s syndrome (91), characterized by a rapidly growing 
ACTH-secreting pituitary tumor and skin pigmentation which develops in 
a minority of patients with Cushing’s disease after bilateral adrenalectomy 
(92), there have been a few studies of its action in Cushing’s disease and 
Nelson’s syndrome using the SRIF-analog OCT. The conclusion of these 
various anecdotal reports is that the current clinically available SRIF-an-
alog OCT is ineffective in treating Cushing’s disease (93-95) (Table II). 
SRIF in normal corticotrophs
Data with respect to sst subtype expression in normal mammalian cor-
ticotrophs are equivocal. In rat pituitary cells, co-localization of all fi ve 
sst with ACTH expressing cells has been reported (96). In another study, 
sst
5
 mRNA was found in 38% of normal corticotrophs, and sst
2
 in only 
3% (97), whereas Mezey and coworkers used double immunohistochem-
ical techniques which demonstrated sst
2
 in a large population and sst
5
in a small population of corticotrophs (98). Studies on the role of SRIF 
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and SRIF-receptors on ACTH release are equivocal as well, whereas it 
is generally accepted that sst
2 
and sst
5 
subtypes are mostly involved in 
the regulation of hormone (GH, PRL and TSH) release by human fetal 
anterior pituitary cells (66). No inhibitory effects of 1-100 nM SRIF were 
observed on basal and corticotropin releasing hormone (CRH)-stimu-
lated ACTH release by cultured normal rat pituitary cells and pituitary 
halves (99, 100). In two studies, however, an inhibitory effect of 0.6-6
Table II. Role of SRIF and SRIF-analogs in Cushing’s disease.
First author 
(yr; ref. no)
Patient no. Compound Effect on ACTH 
Cushing’s disease
Benker (1976; 107) 1 (ADNX) 500µg SRIF / 60 min -50%
Julesz (1980; 112) 1 (ADNX) 250µg SRIF / 60 min Decreased 
Lamberts (1989; 93) 3 100µg OCT No effect 
2 500µg SRIF / 60 min No effect Ambrosi (1990; 95)
5 100µg OCT No effect 
Stalla (1994; 94) 5 200µg OCT / 180 min No effect 
Other groups
Tyrell (1975; 91) 5 (Nelson) 500µg SRIF / 60 min -40 to -70% 
1 (Nelson) 500µg SRIF / 60 min -50% Benker (1976; 107)
1 (Addison) 500µg SRIF / 60 min Slight decrease 
Fehm (1976; 111) 5 (ADINS) 500µg SRIF / 60 min -44% 
Julesz (1980; 112) 1 (Nelson) 250µg SRIF / 60 min Decreased 
1 (Nelson) 2 yr 100µg OCT t.i.d. Decreased Lamberts (1989; 93)
2 (Nelson) 100µg OCT Decreased 
Ambrosi (1990; 95) 5 (Addison) 500µg SRIF / 60 min No effect 
Petrini (1994; 114) 1 (Nelson) 2 yr 100µg OCT t.i.d. Decreased 
Kelestimur (1996; 113) 1 (Nelson) 100µg OCT -46% 
ADNX, adrenalectomized; ADINS, adrenal insufficiency of different origin; t.i.d., three 
times daily. 
nM and 10 nM to 1 µM SRIF was reported on CRH and arginine va-
sopressin-stimulated ACTH release by cultured pituitary cells prepared 
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from long-term adrenalectomized rats (101) and by fresh quarters of pi-
tuitary glands (102), respectively. In addition, it was shown that basal 
and CRH-stimulated ACTH release by normal rat pituitary cells were 
insensitive to natural SRIF and OCT in concentrations varying between 
1 pM and 1 µM. However, if the cultured cells were deprived from se-
rum for 48 h, or when they were pre-incubated with the glucocorticoid 
receptor-blocking agent RU 38486, CRH-stimulated ACTH release was 
already signifi cantly suppressed by 1 pM, and maximally suppressed 
by 0.1 nM SRIF. Preincubation with 5 nM dexamethasone (DEX) com-
pletely abolished the sensitivity of ACTH release to SRIF (103). These 
early in vitro studies suggested that normal corticotrophs only respond to 
SRIF with inhibition of ACTH release if the cells have been cultured in 
glucocorticoid-free medium, i.e. sensitivity to SRIF-induced inhibition 
of ACTH by the anterior pituitary is only observed when the physiologi-
cal feedback regulation of ACTH release by glucocorticoids fails (104). 
In agreement with this hypothesis, ACTH secretion in normal individu-
als is not affected by infusions of natural SRIF and OCT (105, 106), but 
in patients with Addison’s disease SRIF suppresses ACTH levels (107). 
The infl uence of the microenvironment in which the anterior pituitary 
cells have been cultured, to alter somatotroph and lactotroph sensitivity 
for SRIF as well, underlines its physiological relevance. Preincubation 
of rat anterior pituitary cells with either low (5 nM) or high (100 nM) 
concentrations of DEX signifi cantly decreased the sensitivity of GH re-
lease to SRIF (108). Also, estrogens have been demonstrated by several 
groups to induce the inhibitory effects of SRIF on prolactin (PRL) re-
lease by lactotrophs, most likely caused by an increase in the number of 
sst sites on normal lactotrophs after estrogen pre-treatment (109, 110). 
SRIF in corticotroph adenomas
As already briefl y discussed, various anecdotal reports concerning the 
current clinically available sst
2
-preferring SRIF-analog OCT, do not 
demonstrate clinical effi cacy in treating Cushing’s disease (Table II). 
Regulation of the expression of sst on corticotroph adenomas by glu-
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cocorticoids, may form a plausible explanation, i.e. the high levels of 
cortisol in patients with pituitary dependent Cushing’s disease can thus 
be responsible for the observed lack of inhibition of ACTH release 
by SRIF and/or OCT (93-95). Moreover, in patients with Nelson syn-
drome and adrenal insuffi ciency of different origin, SRIF and/or OCT 
lower ACTH secretion (91, 93, 107, 111-114) (Table II). These observa-
tions are in agreement with various reports demonstrating that in eight 
ACTH-secreting pituitary adenomas (patients with untreated Cushing’s 
disease) no increased uptake of 111In-diethylenetriamine pentaacetic acid 
(DTPA) octreotide, an sst
2
-preferring radiolabeled SRIF-analog, was 
found (115, 116), whereas 111In-DTPA scintigraphy is positive in two 
invasive ACTH-secreting macroadenomas and two cases of Nelson’s 
syndrome (115, 117). In agreement with SRIF and OCT-mediated in-
hibition of ACTH release in normal corticotroph cells, ACTH release 
from corticotrophinomas seems only sensitive to OCT in the absence of 
peripheral feedback regulation by glucocorticoids, suggesting that the 
sst
2
 might be down-regulated when cortisol levels are high (103, 104).
SRIF receptor modulation, i.e. down-regulation, by glucocorticoids was 
already demonstrated in the early 1980s. Chronic glucocorticoid treatment 
of GH
4
C
1
 cells, a clonal strain of rat pituitary tumor cells, and AtT20/D16 
cells, a clonal strain of mouse corticotroph tumor cells, caused a 20-40% 
decrease in [125I-Tyr1]-SRIF binding (118). Furthermore, with respect to 
SRIF and SRIF-analog mediated inhibitory effects on ACTH release by 
corticotroph tumor cells, numerous reports have been published in which 
consensus is found that SRIF, as well as sst
2
- and sst
5
-preferring SRIF 
analogs, lower ACTH release in mouse corticotroph tumor cells (119-
124). The consequences of SRIF receptor down-regulation by glucocor-
ticoids on the biological responsiveness of corticotroph adenoma cells 
was demonstrated in primary cultures of human corticotroph adenomas, 
in which OCT-induced inhibition of basal and CRH-induced ACTH re-
lease, was abolished if the cells were pretreated with hydrocortisone (94). 
Altogether, the lack of suppressive action of sst
2
-preferring SRIF-analogs 
in patients with untreated Cushing’s disease seems to be prohibited due 
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to the hypercortisolemic condition of the patients, which is suggested to 
down-regulate sst
2
 expression of the corticotroph adenoma. However, little 
is known with respect to the quantitative expression of the fi ve sst subtypes 
in tumoral corticotroph cells. Several studies reported the highest frequen-
cy of expression of sst mRNA for sst
2
 (88%) and sst
5 
(86%), and to a lesser 
extent sst
1
 (63%) (125-128). Although sst
2
 mRNA are detectable in cortico-
troph adenomas, their levels of expression are apparently low, since OCT 
has no effect ACTH secretion in pituitary dependent Cushing’s disease.
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Aim of the Thesis
The main goal of this thesis is to evaluate novel patho-physiological aspects 
of the functional role of human somatostatin receptor subtypes (sst) in pitu-
itary adenomas, in particular the role of sst
2
 and sst
5
 in the regulation of hor-
monal hypersecretion by GH/PRL and ACTH-secreting pituitary adenomas.
In general, although the clinical introduction of sst
2
-preferring SRIF-
analogs has nowadays emerged into their use as reference drug for the 
medical treatment of acromegaly, still, no more than approximately two 
thirds of patients with persistent acromegaly respond satisfactory to these 
agents. The novel multiligand SOM230, investigated in several animal 
models as well as in phase I studies, can become a novel medical tool in 
the treatment of acromegaly. This brings us to the following questions:
Is SOM230 capable of lowering hormonal hypersecretion from hu-
man GH-secreting pituitary adenomas, both in vitro and in vivo?
Which sst subtypes are involved in SOM230- and OCT-mediated 
GH inhibition? 
Is SOM230 a safe drug for acromegalic patients?
First, the in vitro effi cacy of SOM230 compared with OCT will be carried 
out in a series of primary GH-secreting pituitary adenoma cell cultures. 
Quantitative RT-PCR shall be performed to analyse sst mRNA expres-
sion levels of the adenomas which, in addition, will be correlated to the 
inhibitory effects of SOM230 and OCT on GH release by the adenoma 
cells. Second, we will perform the fi rst proof-of-concept trial in acro-
megaly to assess the effi cacy of SOM230, compared with OCT, on cir-
culating GH, total & free IGF-I concentrations. However, even though 
a mild transient hyperglycaemia is observed as an adverse effect in ac-
romegalic patients treated with OCT or Lanreotide, due to the lower-
ing of circulating insulin levels, it is not known whether SRIF-analogs 
can modulate insulin signaling as well. Therefore, circulating insulin 
40
Chapter II
levels as well as plasma glucose and IGFBP-1 levels will be assessed, 
to evaluate whether SOM230 alters glucose homeostasis differently as 
compared with OCT. Additional analyses to evaluate quantitative sst sub-
type mRNA expression in visceral adipose fat tissue, a peripheral tar-
get tissue of insulin action, will be carried out. Also, with the use of a 
human hepatoma cell line, as the liver forms another peripheral target 
tissue of insulin action, we will evaluate whether SRIF-analogs can infl u-
ence insulin-responsiveness directly at the level of the insulin receptor.
Several reports have evaluated the inhibitory effi cacy of sst
2 
and sst
5 
activation in the regulation of GH secretion by use of primary cultures 
of GH-secreting pituitary adenomas. It has been suggested that the sst
2
seems the (pre-) dominant receptor in regulating GH release by GH-se-
creting pituitary adenoma cells, whereas sst
5
 receptors may mediate an 
inhibitory effect on GH secretion as well. A direct proof for this hypoth-
esis is currently lacking, however, which leads to the following question: 
Based on a fundamental approach, is there support for a func-
tional interplay between sst
2
 and sst
5
?
No report yet investigated in a basic experimental design, whether these 
two sst subtypes have a functional interplay with each other. Therefore, 
we will prosecute the pharmacological profi ling of several SRIF-analogs 
as determined by inhibition of cAMP release and radioligand SRIF-14 
membrane binding in HEK 293 cells expressing different sst
2
/sst
5
 ratios. 
Also, over the past years RNA interference has exploded onto the re-
search scene as a new approach to manipulate gene expression in mam-
malian systems. On the basis of a new mammalian expression vector 
that directs the synthesis of short hairpin siRNA-like transcripts, we 
will synthesize a siRNA construct for sst
5 
and evaluate its effi cacy to 
down-regulate sst gene expression in transfected mammalian cell lines.
Although SRIF analogs, as neuro-modulatory agents, have been pro-
posed as a medical treatment option for patients with Cushing’s dis-
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ease, no effi cacy in terms of lowering ACTH or cortisol levels have 
been reported with sst
2
-preferring SRIF-analogs. This is presum-
ably due to a glucocorticoid-induced down regulation of sst
2
. How-
ever, not much is known yet about the role of SRIF-analogs targeting 
sst
5
 receptors in the regulation of ACTH secretion, and in addition, 
quantitative data concerning sst expression levels in ACTH-secret-
ing pituitary adenomas are lacking. This raises several questions:
Which is the quantitative sst subtype expression pattern is ob-
served in human ACTH-secreting pituitary adenomas?
Do SRIF-analogs, targeting sst
5
 or sst
2
 and sst
5
 mediate ACTH re-
lease differently as compared with sst
2
-preferring SRIF-analogs?
In a series of ACTH-secreting pituitary adenoma cell cultures, obtained 
after transsphenoidal surgery of patients diagnosed with Cushing’s 
disease, quantitative RT-PCR will elucidate sst mRNA expression in 
these adenomas. We will also compare the in vitro inhibitory effects of 
SOM230 and OCT on basal and corticotropin-induced ACTH release 
from primary human ACTH-secreting adenoma cells, as well as from 
mouse ACTH-producing corticotroph tumor cells. Functional proper-
ties of sst
2 
and sst
5 
receptors, endogenously expressed in mouse ACTH-
secreting corticotrophs, will be investigated in more detail to further 
explore the patho-physiological role of both sst subtypes, especially 
in the presence of glucocorticoids, in the regulation of ACTH release.
Regarding the proposed role of novel SRIF analogs in the treatment of neu-
roendocrine tumors, novel subtype specifi c and universal SRIF analogs shall 
be critically evaluated with particular emphasis on their clinical potential 
and pitfalls, such as tachyphylaxis to OCT and Lanreotide treatment in a sub-
group of neuroendocrine tumors. Several questions do remain unanswered:
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Is tachyphylaxis sst subtype specifi c?
Why do chimeric SRIF-DA agonists display enhanced effi cacy 
compared with the combined treatment of the individual SRIF 
and DA compounds?
To address the topic of tachyphylaxis, a series of sst subtype specifi c 
SRIF-analogs, as well as the universal ligand SOM230 will be used 
in transiently transfected sst
2 
and/or sst
5
-expressing HEK293 cells, to 
analyse functional responses, in terms of adenylyl cyclase inhibition, 
after prolonged pre-treatment in vitro with the same panel of SRIF-
analogs. Functional characterisation of BIM-23A760, representing 
a group of chimeric compounds that have been launched recently be-
ing one of the potential novel medical tools for the treatment of neu-
roendocrine tumors, will be performed. BIM23A760, targeting both 
sst
2+5
 and dopamine D2 (D2R) receptors will be tested in primary 
GH-secreting pituitary adenoma cell cultures as well as in a series of 
sst
2
+sst
5
+D2R transfected mammalian cells, to retrieve additional func-
tional insights with respect to the potency of these chimeric molecules.
Finally, in the general discussion the results of the studies report-
ed in this thesis are evaluated, and we hypothesize on the pos-
sible clinical signifi cance and potential future developments.
Chapter III
CLINICAL POTENTIAL OF SOM230 
IN THE MEDICAL TREATMENT OF 
ACROMEGALY

Chapter III-1
The novel somatostatin analog 
SOM230 is a potent inhibitor 
of hormone release by growth 
hormone and prolactin secreting 
pituitary adenomas in vitro
J Clin Endocrinol Metab. 2004, 89 (4): 1577-1585
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Abstract
To determine the inhibitory profi le of the novel SRIF-analog SOM230 
with broad SRIF receptor binding, we compared the in vitro effects of 
SOM230, octreotide (OCT), and SRIF-14 on hormone release by cul-
tures of different types of secreting pituitary adenomas. OCT (10nM) 
signifi cantly inhibited GH release in 7 of 9 GH-secreting pituitary ad-
enoma cultures (range -26 to -73%), SOM230 (10nM) in 8/9 cultures 
(range -22 to -68%), and SRIF-14 (10nM) in 6/6 cultures (range -30 
to -75%). Sst analysis showed predominant, but variable levels of sst
2
and sst
5
 mRNA expression. In one culture, completely resistant to OCT, 
SOM230 and SRIF-14 signifi cantly inhibited GH release in a dose-de-
pendent manner with an IC
50
 value in the low-nanomolar range. In the 
other cultures SOM230 showed a lower potency of GH release inhibi-
tion (IC
50
 0.5 nM), compared to OCT (IC
50
 0.02 nM) and SRIF-14 (IC
50
0.02 nM). A positive correlation was found between sst
2
-, but not sst
5
mRNA levels, in the adenoma cells and the inhibitory potency of OCT on 
GH release in vivo and in vitro, and the effects of SOM230 and SRIF-14 
in vitro. In 3 prolactinoma cultures, 10nM OCT weakly inhibited PRL 
release in only one (-28%), whereas 10nM SOM230 signifi cantly inhib-
ited PRL release in 3/3 cultures (-23, -51 and -64.0%). The inhibition of 
PRL release by SOM230 was related to the expression level of sst
5
, but 
not sst
2
 mRNA. Conclusions: 1) SOM230 has a broad profi le of inhibi-
tion of tumoral pituitary hormone release in the low nanomolar range, 
probably mediated via both sst
2
 and sst
5
 receptors. The higher number 
of responders of GH-secreting pituitary adenoma cultures to SOM230, 
compared to OCT, suggest that SOM230 has the potency to increase 
the number of acromegalic patients which can be biochemically con-
trolled. 2) Compared to OCT, SOM230 is more potent in inhibiting PRL 
release by mixed GH/PRL secreting adenoma- and prolactinoma cells.
Introduction
Current treatment options in patients with acromegaly due to a growth 
hormone (GH) secreting pituitary adenoma are surgery, medical therapy 
and radiotherapy. As medical therapy, stable somatostatin (SRIF) ana-
logs, such as octreotide (OCT) and the sustained release depot formu-
lations Sandostatin-LAR and SR-lanreotide are widely used, both as 
primary or secondary therapy (1). Treatment with this generation of oc-
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tapeptide SRIF-analogs results in clinical and biochemical control, i.e. 
normalization of circulating GH and IGF-I levels, in approximately two-
thirds of the acromegalic patients (1). The successful medical treatment 
of acromegaly with octapeptide SRIF-analogs is due to the expression of 
high affi nity (density) SRIF receptors on the adenoma cells, mainly sst
2
, 
which is one of the fi ve known SRIF receptor subtypes, sst
1-5
, and the se-
lective high affi nity binding of these analogs to the sst
2
 subtype (2). The 
molecular basis for the clinical experience that one-third of patients with 
acromegaly are not adequately controlled by treatment with octapeptide 
SRIF-analogs is probably formed by a variable expression of sst
1-5
 in the 
adenomas of these patients (3-9). Several groups have demonstrated that 
sst
2
 and sst
5
 receptors are the most important sst involved in the regula-
tion of GH secretion (2, 9). Using sst selective SRIF-analogs it was shown 
that, in adenomas which were poorly responsive to the sst
2
 selective ago-
nists  OCT and lanreotide, sst
5
 selective or sst
2
-sst
5
 bi-specifi c compounds 
were able to suppress GH release more potently (10, 11). These observa-
tions initiated the development of novel stable SRIF-analogs with a more 
universal sst binding profi le. One of these new compounds, SOM230, 
was recently shown to reduce circulating IGF-I levels in rats by 75% 
after 126 days of continuous infusion. This effect was signifi cantly more 
potent compared to OCT, which suppressed IGF-I release under the same 
experimental condition by only 28% (12). In rats, the terminal elimina-
tion half-life was 23h, which is approximately 11 times longer compared 
to OCT (12). Finally, both in cynomolgus monkeys and beagle dogs, in-
fusion of SOM230, and to a much lesser extent OCT (SMS 201-995), 
lowered IGF-I levels potently (13). Compared with OCT, SOM230 has 
a 30-, 5- and 40-times higher binding affi nity to sst
1
, sst
3
 and sst
5
 recep-
tors, respectively, and 2.5 times lower affi nity to sst
2
 (12). This universal 
binding profi le of SOM230 to sst (Table I), in combination with the im-
portance of sst
2
 and sst
5
 receptors in regulating GH secretion by pituitary 
adenoma cells, was the rationale for the present study to evaluate, for 
the fi rst time, the effects of SOM230, OCT and the native SRIF mol-
ecule SRIF-14 on hormone secretion by human GH-secreting pituitary 
adenomas. Moreover, recent evidence suggests that sst
5
 receptors are also 
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involved in the regulation of PRL secretion by human prolactinoma cells 
(11, 14). Therefore, we compared the effects of OCT and SOM230 on 
PRL secretion by primary cultures of human prolactinomas. A correla-
tion is made with the sst subtype expression pattens in the adnoma cells.
Table I. Binding affinity of SRIF-14, OCT and SOM230 for sst
1-5
.
Compound hsst1 hsst2 hsst3 hsst4 hsst5
SRIF-14 0.93 ± 0.12 0.15 ± 0.02 0.56 ± 0.17 1.5 ± 0.4 0.29 ± 0.04 
OCT 280 ± 80 0.38 ± 0.08 7.1 ± 1.4 >1000 6.3 ± 1.0 
SOM230 9.3 ± 0.1 1.0 ± 0.1 1.5 ± 0.3 >100 0.16 ± 0.01 
Data are reproduced with permission (12) Results are the mean ± SE, IC50 values are 
expressed in nM.
Materials and Methods
Patients
Pituitary tumor samples were obtained by transsphenoidal operation 
from 9 patients with GH-secreting pituitary adenomas and from 3 pa-
tients with prolactinomas as described in detail previously (15). Di-
agnosis was made on the basis of clinical and biochemical character-
istics of the patients, in combination with (immuno)histochemistry 
of the tumor samples. All patients gave their informed consent for 
the use of tumor material for research purposes. Directly after obtain-
ing the tissue, a piece of tissue was snap-frozen on dry ice and stored 
at -80 C until analysis. The remaining tissue was used for cell culture.
To evaluate in vivo responsiveness to OCT, patients received at 9.00 
a.m. a single subcutaneous (s.c.) injection of 100μg OCT. Blood samples 
were collected 30 minutes before and 1 minute before, and hourly until 
8 hours after s.c. injection. At the same time points, blood samples were 
taken at a control day. The effect of OCT on circulating GH levels was 
determined by calculating the mean GH suppression between 2-8 h af-
ter s.c. injection, compared to the same period of time on a control day. 
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Quantitative PCR
Quantitative PCR was performed as described previously (16). Briefl y, 
poly A+ mRNA was isolated using Dynabeads Oligo (dT)
25
 (Dynal AS, 
Oslo, Norway) from freshly isolated pituitary adenoma cell pellets con-
taining 0.5-1.0x106 adenoma cells. Analysis of sst subtype mRNA levels 
in both tissue or freshly isolated cell pellets (n=4) yielded comparable re-
sults (data not shown).  cDNA was synthesized using the poly A+ mRNA, 
which was eluted from the beads in 40 µl H
2
O for 10 minutes at 65 °C, 
using Oligo (dT)
12-18
 Primer (Invitrogen, Breda, The Netherlands). One-
twentieth of the cDNA library was used for quantifi cation of sst subtype 
mRNA levels. A quantitative PCR was performed by TaqMan® Gold nu-
clease assay (Perkin Elmer Corporation, Foster City, CA, USA) and the 
ABI PRISM® 7700 sequence Detection System (Perkin Elmer) for real-
time amplifi cations, according to manufacturer’s protocol. The assay was 
performed using 15µl  TaqMan® Universal PCR Master Mix (Applied 
Biosystems, The Netherlands) , 500 nM forward primer , 500 nM reverse 
primer , 100 nM probe and 10µl cDNA template, in a total reaction vol-
ume of 25 µl. The reactions were carried out in a ABI 7700 Sequence 
Detector (Perkin Elmer, The Netherlands). After an initial heating at 95° 
C for 8 minutes, samples were subjected to 40 cycles of denaturation at 
95° C for 15 seconds and annealing for 1 minute at 60° C. The primer 
and probe sequences that were used are indicated below. The detection 
of hypoxantine-phosphoribosyl-transferase (hprt) mRNA served as a 
control and was used for normalisation of the sst subtype mRNA levels.
The primer sequences that were used included:
hprt forward 5’-TGCTTTCCTTGGTCAGGCAGTAT-3’
hprt reverse 5’-TCAAATCCAACAAAGTCTGGCTTATATC-3’
sst
1
 forward 5’-TGAGTCAGCTGTCGGTCATC-3’
sst
1
 reverse 5’-ACACTGTAGGCACGGCTCTT-3’
sst
2
 forward 5’-TCGGCCAAGTGGAGGAGAC-3’
sst
2
 reverse 5’-AGAGACTCCCCACACAGCCA-3’
sst
3
 forward 5’-CTGGGTAACTCGCTGGTCATCTA-3’
sst
3
 reverse 5’-AGCGCCAGGTTGAGGATGTA-3’
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sst
5
 forward 5’-CATCCTCTCCTACGCCAACAG-3’
sst
5
 reverse 5’-GGAAGCTCTGGCGGAAGTT-3’
The probe sequences that were used included:
hprt 5’-FAM-CAAGCTTGCGACCTTGACCATCTTTGGA-TAMRA-
3’
sst
1
 5’-FAM-ACAGCTGCGCCAACCCCATC-TAMRA-3’
sst
2
 5’-FAM-CCGGACGGCCAAGATGATCACC-TAMRA-3’
sst
3
 5’-FAM-CGGCCAGCCCTTCAGTCACCAAC-TAMRA-3’
sst
5
 5’-FAM-CCCGTCCTCTACGGCTTCCTCTCTGA-TAMRA-3’
Primers and probes were purchased from Biosource (Nivelles, Belgium).
The relative amount of sst subtype mRNA was determined using a stand-
ard curve generated from known amounts of human genomic DNA. For 
determination of the amount of hprt mRNA, a standard curve was gen-
erated of a pool of cDNAs from a human cell line known to express 
hprt. The linear range of amplifi cation ranged between 4 log dilutions 
of genomic DNA or cDNA, respectively.  The relative amount of sst 
subtype mRNA was calculated relative to the amount of hprt mRNA 
and is given in arbitrary units. Each sample was assayed in duplicate.
Cell dispersion and cell culture
Single cell suspensions of the pituitary adenoma tissues were prepared 
by enzymatic dissociation with dispase as described in detail previously 
(15). For short-term incubation of monolayer cultures, the dissociated 
cells were plated in 48-well plates (Corning, Cambridge, MA) at a den-
sity of 105 cells per well per 1 ml culture medium. After 3-4 days the me-
dium was changed and 72-h incubations without or with test-substances 
were initiated. At the end of the incubation the medium was removed 
and centrifuged for 5 min. at 600xg. The supernatant was collected and 
stored at -20oC until analysis. The choice for a 72h incubation was made 
on the basis of previous studies, in which we demonstrated that expo-
sure of GH-secreting pituitary adenoma cells for 4-96 h to octreotide 
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showed a variable, but in all instances during longer incubations statis-
tically signifi cant inhibition of GH release, which paralleled the sensi-
tivity of GH secretion to octreotide in vivo (17). For long-term incuba-
tion studies in Transwells (18), the isolated tumor cells were plated 
in Transwell-COL membranes (Corning) at a density of 105 cells per 
well. The Transwells were then placed into multiwell plates (24-well, 
Corning) containing 1 ml culture medium. After 72 hr the Transwells
were transferred to wells containing fresh medium (without or with test-
substances). Every 3-4 days the cells were placed into fresh medium and 
the incubation media were collected and stored at -20oC until determina-
tion of hormone concentrations. The cells were cultured at 37 C in a CO
2
-
incubator. The culture medium consisted of Minimum Essential Medium 
with Earle’s salts (MEM) supplemented with non essential amino acids, 
sodium pyruvate (1 mmol/L), 10% fetal calf serum (FCS), penicillin 
(1x105 U/L), fungizone (0.5 mg/L), L-glutamine (2mmol/L), and sodium 
bicarbonate (2.2 g/L), pH 7.6. Media and supplements were obtained 
from GIBCO Bio-cult Europe (Invitrogen, Breda, The Netherlands). 
Unfortunately, generally not enough tumor material was obtained to test 
for each tumor the dose-dependency of effects for the indicated drugs.
Hormone determinations
Human GH and PRL concentrations in the media and cell extracts were 
determined by a non-isotopic, automatic chemiluminescence immunoas-
say system (Immulite, DPC Inc., Los Angeles, CA). Intra- and interas-
say CV’s for GH and PRL were 6.0%, 5.7% and 6.2%, 6.4%, respec-
tively. ACTH, LH and FSH concentrations in the culture media were 
determined as well, in order to exclude the presence of contaminating 
normal pituitary cells in the cultures. Human ACTH, LH and FSH con-
centrations were determined by by a non-isotopic, automatic chemi-
luminescence immunoassay system (Immulite, DPC Inc.). Intra- and 
interassay CV’s for ACTH, LH and FSH were 5.6%, 5.7%, 6.4% and 
7.8%, 12.3%, 7.5%, respectively.  Except for the expected hormones 
GH and PRL, none of the other hormones were detectable (not shown). 
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Test-substances
OCT (Sandostatin) and bromocriptine were obtained from No-
vartis Pharma A.G. (Basle, Switzerland). SOM230 was pro-
vided by Novartis Pharma A.G. Somatostatin-14 (SRIF-14) 
was purchased from Sigma Chemical Co. (St. Louis, MO).
Statistical analysis of the data
All data on hormone release are expressed in mean ± SE, n=4 wells 
per treatment group. All data were analyzed by analysis of vari-
ance (ANOVA) to determine overall differences between treatment 
groups. When signifi cant differences were found by ANOVA, a mul-
tiple comparison between treatment groups was made using the New-
man-Keuls test. Correlation analysis was done by the use of the Spear-
man’s rank correlation test. Calculation of IC
50
 values for inhibition of 
hormone release were made using GraphPad Prism (San Diego, CA).
Results
Sst subtype mRNA expression and correlation with in vivo GH 
suppression by octreotide
In 7 out 9 GH-secreting pituitary adenoma samples the sst subtype mRNA 
expression pattern was determined. Figure 1 shows that 2 adenomas ex-
pressed sst
1 
mRNA, three adenomas expressed sst
3
 mRNA, and that all 
adenomas expressed sst
2
 and sst
5
 mRNAs. Expression of sst mRNAs was 
variable between adenoma samples. The difference between the lowest 
and the highest level measured, amounted to 7-, 8-, 3- and 5-fold for sst
1
, 
sst
2
, sst
3
 and sst
5
, respectively. The sst subtype mRNA levels showed no 
statistical correlation (data not shown). The mean percentage in vivo GH 
suppression (range +18 and -91% suppression) between 2-8 hr following 
the administration of a single s.c. dose of 100 µg OCT (patient no. 1, 2, 
3, 5, 6 and 7) was positively correlated with sst
2
 mRNA expression levels 
(fi g. 2, left panel), but not with sst
5
 mRNA levels (fi g. 2, right panel). 
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Figure 1. Relative sst
1
, sst
2
, sst
3
, and sst
5
 mRNA expression levels in GH-secreting 
pituitary adenomas. Values are expressed as the number of copies of the respective sst 
mRNA’s, relative to the number of copies of hprt. nd= not detectable. Note the differ-
ences in the scale of the y-axis between sst
1
, sst
2
 and sst
3
 mRNA levels on the one hand, 
and the higher sst
5
 mRNA levels on the other hand. The relative amount of sst subtype 
mRNA was calculated relative to the amount of hprt mRNA and is given in arbitrary units.
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Figure 2. Correlation between sst
2
 and sst
5
 mRNA levels and the in vivo re-
sponse of GH release to a single s.c. injection of 100µg of OCT in six ac-
romegalic patients. The relative amount of sst subtype mRNA was calcu-
lated relative to the amount of hprt mRNA and is given in arbitrary units.
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Effects of SRIF-analogs on GH secretion
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Figure 3. Effects of OCT (10nM; open bars), SOM230 (10nM; filled bars) and 
SRIF-14 (10nM; hatched bars) on GH release by 9 cultured GH-secreting pituitary 
adenomas. The results are expressed as the percentage inhibition of GH release com-
pared to untreated, control cells. *p<0.01 vs untreated control cells. nd= not done.
In most GH-secreting pituitary adenomas the effect of 10nM OCT, 
SOM230 or SRIF-14 on GH release was evaluated in parallel in vitro. 
Figure 3 shows that GH release was signifi cantly suppressed by OCT in 
7 out of 9 cultures, by SOM230 in 8 out of 9 cultures and by SRIF-14 
in 6 out of 6 cultures. In the majority of the adenomas, the percentage 
suppression using a maximally active concentration of the three com-
pounds, was comparable. Only the adenoma cells of patient 7 showed a 
dissociated response to OCT on the one hand and to SOM230 and SRIF-
14 on the other hand. In this adenoma culture, GH release was not in-
hibited by OCT, whereas both SOM230 and SRIF-14 induced a statis-
tically signifi cant suppression of GH release. In the respective patient, 
OCT 100 µg s.c. did not suppress GH concentrations as well. As seen in 
fi gure 3, the response in terms of GH-suppression was variable between 
the individual adenoma cultures. This variable responsiveness to OCT 
and SOM230 correlated well with the sst
2
 mRNA expression levels in 
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the adenoma cells of the respective patients (fi g. 4, upper panel). Com-
parable to the patients responsiveness to OCT, sst
5
 mRNA expression 
showed no statistically signifi cant correlation with the percentage of GH 
suppression by 10nM OCT. Interestingly, the effects of 10nM SOM230, 
which shows a more universal binding profi le for sst receptors, includ-
ing high affi nity binding to sst
5
, also showed no correlation with sst
5
mRNA expression levels. This is demonstrated in fi gure 4, lower panel.
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Figure 4. Correlation between sst
2
 (upper panel) and sst
5
 (lower panel) mRNA 
levels and the percentage suppression of GH release induced by SOM230 
(10nM) and OCT (10nM). The relative amount of sst subtype mRNA was cal-
culated relative to the amount of hprt mRNA and is given in arbitrary units. 
In several adenoma cultures, the dose-response relationship of the in-
hibitory effects of OCT, SOM230 and SRIF-14 could be evaluated. Fig-
ure 5, right panel shows the effects of the three compounds on GH re-
lease by the adenoma cells of patient 7, which did not respond to OCT. 
The adenoma cells of this patient had the lowest sst
2
 mRNA levels of 
all cases studied (fi g. 1, upper right panel). As shown, GH release by 
the cells of this patient was inhibited in a dose-dependent manner by 
both SOM230 and SRIF-14. The IC
50
 values for the inhibition of GH 
release were 0.5 and 0.6 nM for SOM230 and SRIF-14, respective-
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ly. In the other adenoma cultures both OCT and SRIF-14 were slight-
ly more effi cacious, in terms of IC
50
 values, compared with SOM230. 
The left panel of fi gure 5 shows the mean dose-response of OCT, 
SOM230 and SRIF-14 for the other cultures. Mean IC
50
 values were 
0.02, 0.5 and 0.02 nM for OCT, SOM230 and SRIF-14, respectively. 
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Figure 5. Dose-dependent inhibition of GH release by SOM230 ▼, OCT ■ and SRIF-
14 ○ in cultured pituitary adenoma cells. The left panel represents the mean dose-depen-
dent effects of SOM230 (n=5; adenoma no. 2, 3, 4, 5 and 6), OCT (n=4; adenoma no. 
2, 3, 5 and 6) and SRIF-14 (n=4; adenoma no. 2, 3, 5 and 6). The right panel shows the 
dose-dependent inhibitory effects of the compounds on GH release by cells patient 7.
Effects of SRIF-analogs on PRL secretion
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Figure 6. Effect of 10nM OCT (open bars) or 10nM SOM230 (filled bars) on PRL 
secretion by mixed GH/PRL secreting pituitary adenomas. The results are expressed as 
the percentage inhibition of PRL release compared to untreated, control cells. *p<0.01 
vs untreated control cells.
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Because previous studies demonstrated the involvement of sst
5
 recep-
tors in regulating PRL release, we also compared the effects of OCT 
and SOM230 on PRL release. Five adenoma cultures co-secreted PRL 
as well. OCT (10nM) and SOM230 (10nM) signifi cantly inhibited PRL 
release in 4/5 and 5/5 cultures, respectively (fi g. 6). The percentage 
Table II. Patient and hormone data of the 12 patients with pituitary ad-
enoma
Patient no. Sex Age GH PRL IGF-I In vitro hormone release 
GH-secreting
adenoma 
M/F Yr µg/L µg/L nmol/L GH 
(ng/105 cells/72h) 
PRL
(ng/105 cells/72h) 
1 M 58 9.8 19 175 520±24 1192±60 
2 M 26 31 111 201 547±7 492±7 
3 F 60 5.4 39 66 372±13 1105±71
4 F 55 15 19 184 1021±19 - 
5 M 36 118 24 111 336±35 - 
6 F 44 14 15 289 230±10 - 
7 F 41 72 6.7 285 640±18 - 
8 F 42 6.8 0.9 88.3 55±2 21±2
9 F 65 6.8 9.3 169 246±9 156±5 
Prolactinoma        
10 F 35  2000  - 5638±143 
11 F 64  13520  - 1486±80 
12 F 37  32  - 1700±50 
Normal range for IGF-I: 12-40 nmol/L.
- means not detectable
suppression was between 16 and 66% for OCT and between 38 and 74%, 
for SOM230, indicating its higher effi cacy. In 4/5 cultures (no. 1, 3, 8 
and 9), SOM230 was signifi cantly more potent with regards to its maxi-
mal suppressive effect on PRL release, when compared to OCT (p<0.01). 
In addition to mixed GH/PRL secreting pituitary adenomas, we also com-
pared the effects of OCT and SOM230 on PRL release in 3 primary hu-
man prolactinoma cultures (no. 10, 11 and 12) (table II). Figure 7 shows 
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Figure 7. Upper panel: Effects of SOM230 (10nM), OCT (10nM) and bro-
mocriptine (10nM) on PRL release by 2 cultured prolactinomas (no. 10 and 
11). *p<0.01 vs untreated control cells. Incubation time: 72 hr. Lower pan-
el: sst subtype mRNA expression in the adenoma cells of patient 10 and 11.
that prolactinoma no.10 selectively expresses a high level of sst
5
 mRNA, 
whereas prolactinoma 11 expressed sst
1
 mRNA but very low sst
5
 mRNA. 
In agreement with the low affi nity of OCT for sst
5
 and the very high af-
fi nity of SOM230 for this sst, 10nM OCT did not signifi cantly inhibit 
PRL release by the two prolactinoma cultures, whereas 10nM SOM230 
potently suppressed (-49%) PRL release by cells of adenoma 10 (high 
sst
5
), and slightly (-23%) by cells of prolactinoma no.11 (low sst
5
). Both 
adenoma cultures showed high sensitivity to 10nM of the dopamine 
agonist bromocriptine (-73 and -89% inhibition in cultures 10 and 11, 
respectively). In one prolactinoma culture (no. 12) the long-term in vi-
tro effects of OCT, SOM230 and bromocriptine were studied. Figure 8 
shows that both SOM230 (10nM) and bromocriptine (10nM) suppressed 
PRL release by approximately 90% after 9 days of continuous incubation 
with the compounds. In this particular adenoma, OCT was only slight-
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ly effective (-30% after 9 days). Unfortunately, not enough tissue was 
obtained from this patient to study the sst subtype expression pattern.
0 2 4 6 8 10 12 14
0
25
50
75
100
days of treatment
P
R
L
 r
el
ea
se
 (
%
 c
on
tr
ol
)
*
**
*
*
* * *
* **
*
Figure 8. The effect of long-term in vitro incubation with OCT (10nM), SOM230 (10nM) 
and bromocriptine (10nM) on PRL release by cultured prolactinoma cells of patient no. 
12. The pituitary adenoma cells were cultured in Transwell tissue culture inserts for 14 
days without or with the compounds indicated. Medium was collected and refreshed every 
3 or 4 days and stored at -20 C until determination of PRL concentrations. Values are ex-
pressed as the percentage of hormone release of control cells at each time-point indicated 
and are the mean ± SEM of four wells per treatment group. Symbols represent: ▼OCT, 
○ SOM230, ■ bromocriptine. *p<0.01 vs untreated control cells. Incubation time: 72 hr.
Discussion
SRIF receptor expression on GH-secreting pituitary adenomas forms the 
basis for successful treatment of acromegalic patients using sst
2
-selective 
octapeptide SRIF-analogs (19, 20). Recent in vitro studies have demon-
strated that both sst
2
 and sst
5
 receptors are involved in the regulation of 
GH release by normal human fetal anterior pituitary cells and GH-se-
creting pituitary adenoma cells (2, 9, 11). In addition, evidence exists 
that sst
5
 exclusively regulates PRL secretion from human prolactinoma 
cells (11, 14). Moreover, BIM-23244, a SRIF-analog with high affi nity 
binding to sst
2
 and sst
5
 receptors, was shown to achieve a better suppres-
sion of GH secretion by cultured GH-secreting pituitary adenomas which 
were partially responsive to OCT, suggesting that such bispecifi c SS-ana-
logs could achieve a better control of GH secretion in a larger number of 
acromegalic patients (10). The recent observation that sst subtypes may 
form homo- and heterodimers, resulting in receptors with enhanced bind-
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ing affi nity and modifi ed functional properties (21, 22), may form one 
of the explanations for the enhanced effi cacy of bi-specifi c compounds 
such as BIM-23244. In addition, an sst
2
 antagonist was shown to inhibit 
the GH suppressing action of sst
2
/sst
5
 bi-selective agonists in human fetal 
pituitary cells, supporting the concept of functional interaction between 
sst
2
 and sst
5
 receptors in the regulation of GH secretion (23). Recently, 
a novel stable SRIF-analog, with a more universal binding profi le and 
high affi nity binding to sst
1
, sst
2
, sst
3
 and sst
5
, was introduced (12, 13). 
This SRIF-analog, SOM230, was shown to be signifi cantly more potent 
in lowering IGF-I levels in rats, compared with the sst
2
-preferring analog 
OCT (12). SOM230 has a favourable elimination half-life of 23h (12), 
suggesting that this analog may be suitable for clinical application as well 
(24). On the basis of the involvement of sst
2
/sst
5
 receptors in regulating 
GH secretion and sst
5
 receptors in regulating  PRL secretion, we com-
pared in the present study the effi cacy of SOM230 in the regulation of GH 
and PRL release by primary cultures of human pituitary adenoma cells.
In agreement with previous studies (3-10) we found a variable expression 
of sst mRNAs, predominantly sst
2
 and sst
5
, in our series of GH-secreting 
pituitary adenomas. Only selected cases expressed sst
1
 and sst
3
 mRNA’s, 
suggesting that these sst subtypes are probably of less importance in this 
type of pituitary adenoma. Moreover, in most adenomas, sst
5
 expression 
levels were relatively higher compared with sst
2
 mRNA levels. On the 
other hand, the pre-operative response of acromegalic patients to a single 
s.c. administration of 100μg OCT was positively correlated with the sst
2
mRNA, but not with sst
5
 mRNA levels, in the pituitary adenomas of the 
patients obtained via transsphenoidal surgery. These data demonstrate 
that the sst
2
 subtype is clearly the predominant receptor determining in 
vivo responsiveness to OCT in acromegalic patients. In agreement with 
previous observations (10), sst
2
 mRNA levels were positively correlated 
with the in vitro GH suppression by this sst
2
 selective SRIF-analog as 
well. Surprisingly, although SOM230 shows a very high affi nity for sst
5
receptors, no signifi cant correlation was found between the in vitro GH 
suppression by a maximally active concentration of SOM230 and sst
5
mRNA levels, while a positive correlation was found between the effects 
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of SOM230 and sst
2
 mRNA levels. Although these data were unexpected, 
a previous study by Jaquet et al. (9) in fact already made the same ob-
servation using SRIF-14. In this study, sst
2
 mRNA, but not sst
5
 mRNA 
levels in GH-secreting pituitary adenomas showed a positive correlation 
with in vitro GH suppression by 1 nmol/L SRIF-14. As suggested by Ja-
quet et al. (9), it is not known yet whether the observed sst mRNA levels 
directly correlate with sst protein levels. The importance of the sst
2
 sub-
type in regulating GH secretion by the majority of human GH-secreting 
pituitary adenomas is also evident by our observation that the potency of 
OCT in terms of IC
50
 values measured for the inhibition of GH release are 
slightly higher, compared with SOM230. Nevertheless, SOM230 shows 
a high effi cacy to inhibit GH release, with an IC
50
 value in the low nano-
molar range. In 89% of the cultures SOM230 signifi cantly inhibited GH 
release. In this respect, OCT is slightly less effi cacious, with a signifi cant 
GH-suppressive effect in 7 out of 9 cultures (78%). In one OCT resistant 
culture, SOM230 inhibited GH release with an IC
50
 value comparable 
to that of SRIF-14 (IC
50
 0.5 and 0.6 nM, respectively), confi rming the 
importance of the sst
5
 receptor subtype in mediating GH release, when 
sst
2
 levels are low. However, although SOM230 has a slightly lower po-
tency (IC
50
) for the inhibition of GH release in most cases, compared with 
OCT, its effi cacy is higher compared with OCT in terms of the number 
of responders. Therefore, in addition to the sst
2
/sst
5
 bi-specifi c compound 
BIM-23244, also SOM230 has the potential to achieve better control of 
GH hypersecretion in a larger number of acromegalic patients. More-
over, the very favourable elimination half-life of SOM230 (12) makes 
this compound an interesting candidate for clinical application as well. 
Apart from regulating GH secretion, sst
5 
receptors play a regulatory role 
in normal and tumoral PRL secretion as well (2, 11, 14). A signifi cant 
proportion of GH-secreting pituitary adenomas contain GH and PRL 
expressing cells, either as individual cells expressing GH or PRL or as 
mammosomatotroph cells expressing GH and PRL in the same cells (25). 
In agreement with these data, we observed co-secretion of GH and PRL 
in 56% of the cultures and showed that SOM230 has a potent inhibitory 
effect on PRL secretion in mixed GH-PRL secreting pituitary adenomas 
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and prolactinomas. In 4 out of 5 mixed GH-PRL secreting pituitary ad-
enomas, SOM230 was signifi cantly more potent, compared with OCT, 
in its maximal suppressive effect on PRL secretion. Interestingly, in the 
adenoma cells of patient 7, in which SOM230, but not OCT, inhibited 
GH secretion, also PRL secretion was not suppressed by OCT. PRL se-
cretion was suppressed by approximately 50% by SOM230, however. 
The parallel responses of GH and PRL secretion in this particular case 
suggest that the adenoma contains mainly somatomammotroph cells, 
which were shown to express predominantly sst
5
  receptors (3). Recently, 
it was shown that activation of sst
1
 by the sst
1
-selective agonist BIM-
23296 caused a dose-dependent inhibitory effect in the nanomolar range 
on GH and PRL secretion by GH-secreting pituitary adenomas. In ad-
dition to lowering GH and PRL secretion this SRIF-analog induced a 
decrease in cell viability as well (26). In our series we found that 2/7 
adenomas expressed sst
1
. In selected cases, therefore, sst
1
, may play a 
regulatory role on GH-secreting pituitary adenoma cell function as well.
In three DA-agonist sensitive prolactinomas, SOM230 was signifi cantly 
more potent than OCT in lowering PRL secretion. In two of the pro-
lactinomas there was a clear relationship between the expression of sst
5
mRNA in the adenoma cells and the percentage inhibition of PRL se-
cretion by SOM230. In one prolactinoma culture, which expressed high 
levels of sst
5
 mRNA and no other sst mRNAs, PRL secretion was reduced 
to the same extent as that induced by bromocriptine. One other prolac-
tinoma, which showed a signifi cantly lower responsiveness to SOM230, 
had very low sst
5
 mRNA levels. The lower potency of OCT in reducing 
PRL secretion by prolactinomas seems related to the very low sst
2
 levels, 
as was demonstrated in a series of 10 prolactinomas by Jaquet et al. (14). 
These data further underline the role of sst
5
 in mediating its suppressive 
effect on PRL secretion. However, the potential clinical importance of 
these fi ndings should be considered in view of the very high proportion 
of patients with prolactinomas responding to DA-agonist treatment with 
a normalization of PRL levels and tumor shrinkage (27, 28). In addi-
tion, Jaquet et al. (14) previously showed that the effects of sst
5
 selective 
compounds on prolactinoma cells are superimposable, at higher concen-
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tration to those of the dopamine agonists, but not additive, particular-
ly in adenomas resistant to dopaminergic suppression of PRL release. 
While sst
5
 receptors may mediate antiproliferative effects (29), the role of 
this receptor in the control of pituitary adenoma cell proliferation is unclear. 
Indirect evidence for a role of sst
5
 in the regulation of human GH-secreting 
pituitary adenoma cell proliferation was obtained from the observation of 
a germ line mutation (Arg240Trp) in genomic DNA from pituitary ad-
enoma and peripheral blood mononuclear cells of an acromegalic patient 
resistant to SRIF-analog treatment and a higher proliferation rate of cells 
overexpressing this mutant sst
5
 receptor, compared to cells expressing wild 
type sst
5
 (30). Whether activation of sst
5
 receptors expressed on human 
GH-secreting pituitary adenomas and prolactinomas also mediates an an-
tiproliferative effect in these cell types, remains to be elucidated, however.
Since somatostatin analogs inhibit the secretion of insulin, impaired glu-
cose tolerance was observed after the acute administration of octreotide 
(31). Recently, we observed similar glucose responses to the acute ad-
ministration of SOM230 in vivo (32). However, SOM230 did not modify 
insulin secretion, suggesting another mechanism of action. The inhibitory 
effect of octreotide on insulin secretion is short-lived, and clinically impor-
tant effects on carbohydrate metabolism during long-term therapy are not 
observed (33).  Although the acute rise in glucose levels after SOM230 in-
jection requires further attention, preclinical studies in cynomolgus mon-
keys showed that insulin, glucagon and glucose levels remained unchanged 
after seven days of high-dose infusion with SOM230 (13). In addition, 
126 days treatment of rats with pharmacological doses of SOM230 did 
not modify plasma glucose levels (12). These data suggest that SOM230 
is well tolerated in rats and monkeys with regard to glucose homeostasis. 
In conclusion, the novel universal SRIF-analog SOM230 is a potent in-
hibitor of GH and PRL secretion in GH-secreting pituitary adenomas. 
The higher number of cultures responding to SOM230, compared with 
OCT, suggests that SOM230 has the potential to increase the number 
of patients controlled biochemically, both via sst
2
 and sst
5
. In addition, 
SOM230 is more potent in its inhibitory effect on PRL secretion in mixed 
GH/PRL secreting pituitary adenomas. In prolactinoma cultures, sst
5
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receptors mediate the potent inhibitory effects of SOM230 on PRL se-
cretion. Since the majority of patients with prolactinomas are success-
fully treated using DA-agonists, there may be a role for SOM230 in the 
treatment of prolactinoma patients which are intolerant to DA-agonists.
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Abstract
Somatostatin (SRIF) analogs have been the medical therapy of choice for 
the treatment of acromegaly. Treatment with the SRIF-receptor (sst) sub-
type 2 predominant analogs octreotide and lanreotide, induces clinical and 
biochemical “cure” in about 65% of acromegalic patients. Growth hor-
mone (GH) secreting pituitary adenomas, which are not controlled, also 
express sst
5
. We compared the acute effects of octreotide and SOM230, 
a new SRIF-analog with high affi nity for sst
1,2,3,5
, on hormone release in 
acromegalic patients. In a single dose proof-of-concept study, 100μg oc-
treotide, 100 and 250μg SOM230 were given sc to 12 patients with active 
acromegaly. 100 and 250μg SOM230 dose-dependently suppressed GH 
levels from 2-8 hrs after administration [-38 ± 7.7% vs. -61 ± 6.7%, respec-
tively (resp.); P < 0.01]. A comparable suppression of GH levels by octre-
otide and 250μg SOM230 was observed in 8 patients (-72 ± 7% vs. -65 ± 
7%, resp.). In 3 patients, the acute GH-lowering effect of 250μg SOM230 
was signifi cantly superior to that of octreotide (-70 ± 2% vs. -17 ± 15%, 
resp.; P < 0.01). In one patient, the GH-lowering effect of octreotide was 
better than that of SOM230. Furthermore, in vitro analysis of adenoma 
tissue from two operated patients showed relatively high sst
5
 and low sst
2 
mRNA expression levels in one patient only responsive to SOM230 treat-
ment, suggesting a pivotal role for sst
5
 in mediating the suppressive ef-
fects of SOM230 in this patient. Tolerability for SOM230 was good. Glu-
cose levels were initially slightly elevated after octreotide and SOM230 
compared to control day, whereas insulin levels were only signifi cant-
ly suppressed by octreotide. We conclude that SOM230 is an effective 
GH-lowering drug in acromegalic patients with the potential to increase 
the number of patients controlled during long-term medical treatment.
Introduction
In the majority of patients, acromegaly is caused by a growth hormone 
(GH) secreting pituitary adenoma, resulting in high circulating GH and 
insulin-like growth factor-I (IGF-I) concentrations. First choice of medi-
cal treatment are the somatostatin (SRIF) analogs, a safe and effective 
strategy, mimicking the action of the native peptide SRIF in its inhibi-
tory effect on GH release by the adenoma cells (1). The fi rst clinically 
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available SRIF-analog octreotide has been shown to be effective as pri-
mary or secondary therapy for acromegalic patients (2-4). Several stud-
ies have demonstrated that long-term therapy with octreotide or lanreo-
tide, administered either by subcutaneous (s.c.) or as a long-acting depot 
preparation by intramuscular injection, induced clinical and biochemi-
cal “cure” in about 65% of patients (5-9).  Still, a signifi cant percentage 
of GH-secreting pituitary tumors seems relatively resistant to octreotide 
and lanreotide, and this may be explained in part by a variable tumoral 
expression or reduced receptor density of the fi ve known SRIF-receptor 
(sst) subtypes on the adenomas of these patients (10). Functional evi-
dence for the existence of sst subtypes comes from studies using human 
fetal pituitary cell cultures in which SRIF regulates GH and thyrotropin 
secretion mainly by sst
2 
and sst
5
, and Prolactin (PRL) secretion main-
ly by sst
5
 (11). Most GH-secreting pituitary adenomas predominantly 
express mRNA for sst
2 
and sst
5
, while sst
1
 and sst
3
 are moderately ex-
pressed and sst
4
 not found (12, 13). SRIF binds with high affi nity to all 
fi ve sst subtypes, whereas octreotide and lanreotide display a high, low 
and moderate affi nity to sst
2
, sst
1+4 
and sst
3+5
, respectively. Saveanu and 
coworkers compared the in vivo sensitivity of GH release for octreotide 
in nine acromegalic patients with the tumor mRNA expression for sst
2
and sst
5
 subtypes (14). It was observed that sst
2 
mRNA expression was 
lower and sst
5
 mRNA was higher in adenomas that were partially sensi-
tive to octreotide, compared with octreotide sensitive adenomas. In the 
group of partially octreotide sensitive tumors, both the sst
5
-preferential 
analog BIM23268, but especially the sst
2
 and sst
5
 bi-specifi c compound 
BIM23244, were quite effective in suppressing GH secretion. These 
data indicate that due to the heterogeneous expression of sst
2
 and sst
5
subtypes in GH-secreting adenomas, a bispecifi c analog, such as BIM-
23244 that can activate both receptors, may achieve a better control of 
GH hypersecretion of GH-producing pituitary tumors than octreotide. 
Bruns and coworkers synthesised SOM230, a stable SRIF-analog with a 
more universal binding profi le to sst subtypes (15, 16). By using alanine 
scanning technology, essential functional groups of the SRIF peptide re-
sponsible for the high affi nity to all fi ve sst subtypes were detected. Incor-
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poration of four synthetic amino acids and two essential amino acids of 
SRIFinto a stable cyclohexapeptide template resulted in SOM230, a com-
pound which binds with a high affi nity to sst
1
, sst
2
, sst
3
 and sst
5
, and with 
low affi nity to sst
4
. In rats, dogs and monkeys, SOM230 potently and dose-
dependently decreases GH and IGF-I levels. Only minimal desensitization 
of the suppressing effect of SOM230 on IGF-I levels under physiological 
conditions was observed, which is in contrast to what has been seen in ro-
dents with the effect of octreotide. Additional characteristics of SOM230 
include a favourable terminal elimination half life of 27 hours (hrs) in hu-
mans, as well as the preliminary evidence that glucose levels in rats and 
dogs remain normal during long-term administration of the compound. 
In this paper, we present the detailed analysis of the fi rst single dose 
proof-of-concept study with SOM230 in acromegalic patients. A double-
blind, randomised, cross-over study was performed to compare the in 
vivo effects of a single dose SOM230 to octreotide on GH release, to 
assess its safety and its tolerability in 12 patients with active acromegaly.
Materials and Methods
Patients
Twelve patients with active acromegaly were recruited at the Erasmus 
Medical Center, Rotterdam, the Netherlands. All subjects had biochemi-
cally active disease, with a mean serum GH concentration greater than 5 
μg/L during a 5-hour profi le and elevated circulating IGF-I levels (age- 
and sex-adjusted). GH concentration failed to suppress below 1 μg/L af-
ter a 2-hour 75-g oral glucose tolerance test (oGTT). Table 1 shows the 
biochemical characteristics of the 12 patients. One insulin-treated patient 
with type II diabetes did not undergo an oGTT. Seven patients had been 
treated before (see below). In those patients who have been medically 
treated previously, a wash-out period after the last dose of medication 
had to be at least 1 month, 1 week, 4 months and 1 month for dopamine 
agonists, subcutaneous formulations of octreotide, depot formulations of 
long-acting somatostatin analogs and growth hormone receptor antago-
nists, respectively. One patient had been previously treated by surgery, 
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medical treatment and irradiation. One patient was treated only with sur-
gery. Two patients had only been medically treated and three patients 
were treated with surgery and medical treatment. Five patients were new-
ly diagnosed. Patients with compression of the optic chiasm causing any 
visual fi eld defect or those requiring surgical intervention for relief of 
any sign or symptom possibly associated with tumor compression, were 
excluded. The study was approved by the local ethical committee of the 
Erasmus Medical Center and all patients gave written informed consent.
Table I. Patients’characteristics on study entry.
Patient Sex Age (yr) GH 
(µg/L)a
PRL
(µg/L)a
IGF-I
(µg/L)b
GH after oGTT
(µg/L)c
1 F 43 13.6 13.8 1981 10.1 
2 M 34 7.4 18.1 1301 8.3 
3 F 55 31.6 3.4 1385 29.1 
4 M 48 26.5 7.8 1515 ND 
5 F 36 31.1 7.2 941 21.2 
6 M 35 48.1 19.1 1729 29.0 
7 M 38 19.5 20.9 2027 16.9 
8 M 33 11.0 10.3 1920 11.0 
9 F 79 19.3 0.7 1148 24.6 
10 M 67 6.9 17.7 849 5.5 
11 F 52 5.8 9.8 773 2.5 
12 F 40 57.4 6.7 2180 75.0 
ND, not determined.
a mean fasting GH and PRL values, collected in a 5-h time period. normal values: GH 
< 5 μg/L, PRL < 25 μg/L (men) or < 44 μg/L (women).
b range in healthy population: 107-497 μg/L.
c serum GH level after a 2-hour 75-g oral glucose tolerance test (normal nadir GH < 1 
µg/L after 2 hrs).
Treatment protocol
Patients were hospitalized on the control day for 24 hrs for the assess-
ment of baseline effi cacy parameters. On study day 1, 8 and 15, each 
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patient received at 09:00 a.m. a single s.c. injection of octreotide 100μg, 
SOM230 100μg or SOM230 250μg in a randomized, double-blinded, 
crossover fashion with a minimum 6 days of washout between drug treat-
ments. All patients received standarized meals, served at 08:30 a.m., 
12:30 p.m. and 17:30 p.m. Blood samples, withdrawn through an in-
dwelling venous catheter placed in the forearm, for the assessment of 
GH and PRL concentrations were collected at 30 minutes, one minute 
before, and every hour for 24 hrs after drug administration. This pro-
cedure was repeated on all study days. Furthermore, blood samples for 
glucose and insulin assessments were collected 30 minutes, one minute 
before and every half hour for 2 hrs after lunch. Blood specimens were 
centrifuged and the plasma was frozen at -20°C until it was assayed.
Safety assessments included: vital signs (pulse rate, blood pressure and tem-
perature); electrocardiograms; biochemistry, hematology and urinalysis.
Assays
GH (µg/liter), PRL (µg/liter), and insulin (mU/liter; 1 mU/liter = 7.175 
pmol/liter) levels were determined by use of a non-isotopic, automatic 
chemiluminescence immunoassay system (Immulite, DPC Inc., Los An-
geles, CA). The intra- and inter-assay coeffi cients of variation (CV) for 
GH, PRL and insulin were 6.0%, 5.7%, 4.4% and 6.2%, 6.4%, 5.9%, re-
spectively. Glucose (mmol/liter; 1 mmol/liter = 18.015 mg/dl) was mea-
sured with an automatic hexokinase method (Roche, Almere, the Neth-
erlands). Serum IGF-I (µg/liter) was determined with a commercially 
available non-extraction IRMA (Diagnostic Systems Laboratories, Inc., 
Webster, Texas; intra- and interassay CV’s, 3.9% and 4.2%, respectively).
In vitro studies
Two patients underwent transphenoidal surgery 3 months before they 
entered the study. Adenomatous tissue was collected during operation 
and subsequently, pituitary adenoma cells were isolated as described 
previously (17). The viability of the resulting cell suspension, as deter-
mined by trypan blue dye exclusion, was greater than 95%. The cells 
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were cultured at a density of 0.5-1 x 105 cells/dish·1 ml in multiwell 
plates (Corning Costar, Cambridge, MA). The culture medium was Ea-
gle’s Minimum Essential Medium with Earle’s salts supplemented with 
a 1-fold excess of nonessential amino acids, 1mM sodium pyruvate, 2 
mM L-glutamine, penicillin (100 U/ml), streptomycin (100 μg/ml), and 
fungizone (0.25 μg/ml) and 10% fetal calf serum (Invitrogen, Breda, the 
Netherlands). Media and supplements were obtained from Gibco Bio-
Cult Europe (Invitrogen, Breda, the Netherlands). The cells were allowed 
to attach for at least 3 days before 72-hrs incubation with SRIF (Sigma, 
St. Louis, MO), octreotide or SOM230 (both donated by Novartis, Ba-
sel, Switzerland) in 1 ml complete culture medium were performed with 
the attached cells, using four dishes for every treatment group. These 
pituitary cell cultures are primary cultures which were plated immedi-
ately after the isolation, and they were not passaged before the incubation 
studies were carried out. The results of each experiment were expressed 
as nanograms per dish and compared with control untreated dishes.
Quantitative RT-PCR
Quantitative RT-PCR was performed as previously described (18). Brief-
ly, poly A+ mRNA was isolated during Dynabeads Oligo (dT)
25
 (Dynal 
AS, Oslo, Norway) from adenoma cell pellets containing 0.5-1x106 cells 
per sample. cDNA was synthesized using the poly A+ mRNA captured 
on the Dynabeads Oligo (dT)25 as a solid phase and fi rst primer. In or-
der to quantify sst
2 
and sst
5
 mRNAs a quantitive RT-PCR was performed 
by TaqMan® Gold nuclease assay (The Perlin-Elmer Corporation, Fos-
ter City, CA) and the ABI PRISM® 7700 Sequence Detection System 
(The Perkin-Elmer Corporation) for real-time amplifi cation, according 
to the manufacturers instructions. The specifi c primer sequences (Bio-
source, Nivelles, Belgium) that were used include: sst
2
 forward 5’-TC-
GGCCAAGTGGAGGAGAC-3’; sst
2
 reverse 5’-AGAGACTCCCCA-
CACAGCCA-3’; sst
5
 forward 5’-CATCCTCTCCTACGCCAACAG-3’; 
sst
5
 reverse 5’-GGAAGCTCTGGCGGAAGTT-3’;  hypoxanthine-
guanine phosphoribosyl transferase [(HPRT) as a control] forward 5’-
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TGCTTTCCTTGGTCAGGCAGTAT-3’; HPRT reverse 5’-TCAAATC-
CAACAAAGTCTGGCTTATATC-3’. The probe sequences that were 
used included: sst
2
 5’-FAM-CCGGACGGCCAAGATGATCACC-TAM-
RA-3’; sst
5
 5’-FAM-CCCGTCCTCTACGGCTTCCTCTCTGA-TAM-
RA-3’; HPRT 5’-FAM-CAAGCTTGCGACCTTGACCATCTTTGGA-
TAMRA-3’. The amount of sst
2
 and sst
5
 mRNA was determined by means 
of a standard curve generated in each experiment from known amounts 
of human genomic DNA. For the determination of the amount of HPRT 
mRNA, a standard curve was obtained by including dilutions of a pool 
cDNAs known to contain HPRT. The amount of sst
2
 and sst
5
 mRNA was 
calculated relative to the amount of HPRT and is given in arbitrary units.
Statistical analysis
The assumption of normality of all in vivo data was investigated by 
use of a Kolmogorov-Smirnov (KS) test, in which the null hypothesis 
that the data represented a random sample from the normal distribu-
tion was tested. When this hypothesis was not rejected, a paired Stu-
dent t-test was used for assessing the statistical signifi cance compared 
to the control day. The Wilcoxon’s signed rank test, a non-parametric 
analog to the paired t-test, was used when data did not represent a ran-
dom sample from normal distribution. Correlation analysis was per-
formed by the use of Spearman’s rank correlation test. In the in vitro 
studies, one way analysis of variance was used. When signifi cant over-
all effects were obtained by this method, comparisons were made us-
ing Newman-Keuls multiple comparison test. Data are expressed 
as mean ± sem. A P value less than 0.05 was considered signifi cant.
Results
Safety and tolerability
Tolerability of octreotide and SOM230 was good. Local reactions at 
the injection site were not observed. Side effects probably related to 
the study drug were reported in three different patients and were mild 
(one case of palpitation and sweating after SOM230 100µg, one case 
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of abdominal discomfort after octreotide 100µg and after SOM230 
250µg). No clinically relevant changes in vital signs, routine chem-
istry and urinalysis were observed. Electrocardiogram analyses 
showed no newly occurring or worsening of known cardiac abnor-
malities two and 24 hrs after injection with octreotide or SOM230.
In vivo studies
Figure 1 depicts the mean circulating 24 hrs GH concentrations fol-
lowing a single s.c. injection of 100µg octreotide, 100µg SOM230 and 
250µg SOM230, compared to control day,  for all acromegalic patients 
investigated. Since all three treatment options appeared to induce their 
effect on GH secretion predominantly immediately after s.c. injection, 
effi cacy analysis of octreotide and the two dosages of SOM230 was as-
sessed by analysis of the mean GH suppression between 2-8 hrs after 
s.c. injection, compared to the same period on the control day. The mean 
GH levels from 2-8 hrs after SOM230 250µg, SOM230 100µg and oc-
treotide, were suppressed by 61 ± 6.7% (P < 0.0001),  38 ± 7.7% (P 
< 0.001) and 59 ± 9.2% (P < 0.0001), respectively. Furthermore, the 
250µg dosage SOM230 induced a signifi cantly greater suppressive ef
0 5 10 15 20 25
0
10
20
30
40
50
Time (hrs post-injection)
G
H
 (
�g
/L
)
s.c. injection 9.00 am
�
Figure 1. 24 hrs GH-concentration curves on the control day (■) and on treatment days 
after s.c. injection of octreotide 100μg (*), SOM230 250μg (▲) and SOM230 100μg 
(○). Data are expressed as mean ± sem (n=12).
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fect on circulating GH concentrations than the 100µg dosage SOM230 
(P < 0.01). The inhibitory effect of octreotide on GH levels did not differ 
from SOM230 250µg (P = ns), whereas compared to 100µg SOM230 
a stronger suppression of GH concentrations by octreotide was found, 
although this difference failed to reach statistical signifi cance (P = 0.13).
Analysis of the twelve individual 24 hrs GH profi les on control day and 
following administration of the study drugs, revealed three different pat-
terns of response. As illustrated by the 24 hrs GH profi le of patient 6 (Fig. 
2A), both octreotide and SOM230 250μg induced a similar inhibitory 
effect on circulating GH concentrations [-63%, plasma GH levels 18.9 
± 1.1 μg/L after octreotide (P < 0.05) and -65%, plasma GH levels 17.7 
± 1.7 µg/L after SOM230 (P < 0.01), both vs. 50.8 ± 4.5 μg/L on control 
day (CD)]. A comparable suppressive effect on GH levels by octreotide 
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Figure 2. 24 hrs GH-concentration curves of the different response patterns after s.c. 
injection of the study drugs, represented by patient 6 (A), patient 12 (B) and patient 8 
(C). Symbols display control day (■), octreotide 100μg (*) and SOM230 250μg (▲).
and SOM230 250µg was observed in a total of 8 patients. In this sub-
group of 8 equal responders, both SOM230 and octreotide signifi cantly 
suppressed GH levels by 65 ± 7% (8.0 ± 2.7 µg/L vs. 20.4 ± 6.5 µg/L 
on CD, P < 0.05) and 72 ± 7% (7.5 ± 3 µg/L vs. 20.4 ± 6.5 µg/L on 
CD, P < 0.05; octreotide vs. SOM230, P = ns), respectively (Fig. 3A).
The second pattern of response to the study drugs, observed in a sub-
group of three patients, is illustrated by the 24 hrs GH profi le of patient 
12 (Fig. 2B). In this particular patient, no decline in circulating GH 
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Figure 3. GH suppression 2-8 hrs after s.c. injection. The bars represent mean ± sem per-
centual GH suppression induced by octreotide 100μg (black bars) and SOM230 250μg 
(white bars) compared to the control day. A) Group showing equal response to octreotide 
and SOM230 (n=8). B) Group showing higher sensitivity to SOM230 (n=3; *, P < 0.05).
concentrations after octreotide administration was seen (mean plasma 
GH level 76.7 ± 7.3 µg/L vs. 67.4 ± 4.8 µg/L on CD). However, a sig-
nifi cant suppression of serum GH levels after administration of SOM230 
was found (-68%; 21.9 ± 2.2 µg/L vs. 67.4 ± 4.8 µg/L on CD, P < 0.05; 
SOM230 vs. octreotide, P < 0.01) and interestingly, in this particular pa-
tient the observed potent suppression by the high dose SOM230 250µg 
was also achieved by the low dose SOM230 100µg (-64%; 24.4 ± 3.4 
µg/L). As shown in fi gure 3B, the mean suppression of GH levels in 
these three patients by SOM230 was signifi cantly greater than the sup-
pressive effect by octreotide [-70 ± 2%, 9.7 ± 6 µg/L and -17 ± 15%, 
30.9 ± 23 µg/L, resp. vs. 30.5 ± 19 µg/L on control day (SOM230 vs.
CD, P < 0.01; SOM230 vs. OCT, P < 0.05 and OCT vs. CD, P = n.s.)].
Patient 8 demonstrated a third observed response pattern (Fig. 2C), 
which showed a signifi cant inhibition by octreotide (-79%, mean GH lev-
el 2.9 ± 0.7 µg/L vs. 13.8 ± 0.6 µg/L on CD, P < 0.01). SOM230 was not 
effective during the full 2-8 hrs post-injection time interval to elicit an in-
hibitory effect on circulating GH concentrations (14.5 ± 1.9 µg/L vs. 13.8 
± 0.6 µg/L on CD, P = n.s.). However, this patient was not insensitive to 
SOM230, since a short lasting suppressive effect of SOM230 was estab-
lished (-40%, mean GH level 1-3 hrs after administration 7.2 ± 0.4 µg/L 
B
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vs. 12.4 ± 0.2 µg/L on CD, P < 0.001). Still, in this short period of time, oc-
treotide induced a more powerful 87% suppression of GH concentrations 
(1.6 ± 0.3 µg/L; OCT vs. CD, P < 0.001 and OCT vs. SOM230, P < 0.001).
PRL levels of all twelve patients were within the normal range [mean 
of 5 blood samples below 25 µg/L (men) or 44 µg/L (women); Table 
I]. In two patients plasma PRL levels decreased after s.c. injection of 
octreotide as well as with SOM230 (data not shown). Interestingly, 
the 24 hrs circulating plasma curves of GH and PRL levels in one of 
these patients was highly correlated on control day and at treatment 
days with octreotide and SOM230 (r
s
 = 0.77, 0.99 and 0.95, resp., all 
P < 0.001), which suggests a mixed GH/PRL-secreting pituitary ad-
enoma that co-secreted both hormones from the same adenoma cell.
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Figure 4. Mean (± sem) serum glucose (A) and insulin (B) profiles of 11 pa-
tients (one patient was excluded because of insulin-treated type II dia-
betes) during control day (■) and on treatment days after s.c. injec-
tion of octreotide 100μg (*), SOM230 250μg (▲) and SOM230 100μg (○).
Figure 4 shows the mean glucose and insulin concentrations of 11 patients 
(patient 4 was excluded since he is an insulin-treated patient with type II 
diabetes), starting three hrs after s.c. administration until two hrs after 
lunch compared to the same period of time on control day. Compared to 
the mean glucose level at 12:00 a.m. (3 hrs post-dose) on control day (4.4 
± 0.2 mmol/L), elevated glucose levels were observed after octreotide (6.2 
± 0.3 mmol/L, P < 0.05), SOM230 250µg (6.1 ± 0.8 mmol/L, P < 0.05) 
and SOM230 100µg (5.8 ± 0.6 mmol/L, P < 0.05) administration (Fig. 
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4A). When no study drug was administered, lunch induced a physiologi-
cal increase in mean glucose levels to a maximum of 6.1 ± 0.3 mmol/L. 
Similar postprandial responses were observed on all three treatment days 
(octreotide, 6.8 ± 0.5 mmol/L; SOM230 250µg, 7.1 ± 0.6 mmol/L and 
SOM230 100 µg, 6.8 ± 0.4 mmol/L).  The highest plasma glucose lev-
els were 10.8 and 13.1 mmol/L 5 hrs after injection of octreotide and 
SOM230 250µg, respectively, and were both observed in patient 1, who 
was known to have an impaired glucose tolerance (assessed by oGTT be-
fore start of the trial). Overall, there was a trend that octreotide and both 
SOM230 dosages induced a comparable increase in mean glucose levels, 
that responded equally to a meal at 12:30 p.m. compared to control day. 
Octreotide induced an inhibitory effect on mean plasma insulin levels 
compared to control day which sustained until two hrs after lunch (1200-
1430 h; P < 0.05).  Mean insulin levels seemed not to be affected by both 
SOM230 dosages, since also after lunch a similar increase in insulin lev-
els was observed as on control day (Fig. 4B). Patient 12 had severe insu-
lin resistance. On the control day, 30 minutes after lunch was consumed, 
a sharp increase in plasma insulin levels to a maximum 348 mU/L was 
found. This was even more pronounced after SOM230 250µg was admin-
istered, when insulin levels rose up to a maximum of 903 mU/L (one hour 
after lunch). However, the blood glucose concentrations of this patient 
remained within the range of the other non-diabetic patients (Fig. 4A).
In vitro studies
Apart from the direct effects of octreotide and SOM230 on GH release 
by cultured pituitary tumor cells from two patients, the native peptide 
SRIF was also tested. GH production in the control wells from the ad-
enoma cells of patient 6 and 12 after 72 hrs incubation amounted to 
228 ± 40 ng/dish and 312 ± 18 ng/dish, respectively. In agreement with 
the in vivo response of patient 6 and 12 (Fig. 2A and 2B, resp.), 10 nM 
SOM230 lowered signifi cantly GH secretion by  -32.7 ± 6.8% and -23 ± 
6.9% in the primary tumor cell cultures of patient 6 and 12, respectively 
(P < 0.05 in both instances), whereas 10 nM octreotide only inhibited 
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Figure 5. In vitro data of two patients. Percentual inhibition of GH secretion by 10 
nM of octreotide (OCT), SOM230 and SRIF compared to control, after 72 hrs in-
cubation in primary cultured pituitary adenoma cells from patient 6 (white bars) 
and 12 (black bars). Data are expressed as mean ± sem; *, P < 0.05 treatment 
vs. control (A). Quantitative analysis of RT-PCR showing the different amount 
of sst
2
 and sst
5
 mRNAs in the adenoma tissues of patient 6 and 12 (pat.6 and 12, 
resp.), calculated relative to the amount of HPRT and given in arbitrary units (B).
the GH secretion in the adenoma cells of patient 6 (-26.1 ± 10.5%; P < 
0.05; Fig. 5A). SRIF lowered GH secretion in both primary cultures as 
well (-32.4 ± 8.5% and -30.1 ± 1.8%, resp; P < 0.05, Fig. 5A). Further-
more, evaluation of the relative mRNA expression levels for sst
2 
and sst
5 
in both cases, revealed an interesting difference. The adenoma cells from 
patient 6 who responded to all three compounds, had a relatively high 
expression of sst
2
 (193 copies/HPRT) and a relative low expression of 
sst
5
 (577 copies/HPRT). Compared with mRNA expression levels in the 
adenoma cells of patient 12, which were only responsive to SOM230 
and SRIF treatment, an opposite mRNA expression pattern was found 
(Figure 5B). The pituitary adenoma of patient 12 contained relatively 
high mRNA expression levels for sst
5
 (793 copies/HPRT) and approxi-
mately 5-fold lower sst
2 
mRNA expression levels than those of patient 6 
(37 copies/HPRT). The adenoma was in vivo and in vitro not responsive 
to octreotide, but demonstrated signifi cant sensitivity to both dosages 
SOM230 in vivo and to SOM230 in vitro. This suggests the involvement 
of sst
5
 subtype in the GH-release inhibitory effect in this particular case.
Discussion
In the present study, the recently developed SRIF-analog SOM230, ex-
hibiting an universal binding profi le which was demonstrated to effec-
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tively suppress GH levels in normal monkeys and rodents (15), was ad-
ministered for the fi rst time in acromegalic patients in order to assess its 
effi cacy in comparison to octreotide. The acute effects of a single dose of 
SOM230 250μg and octreotide 100μg on circulating GH concentrations 
demonstrated three patterns of response in the 12 patients investigated. 
In 8 patients both SRIF-analogs were equally effective in lowering GH 
levels. This suggests that in these patients the sst
2
 subtype is the ma-
jor receptor on the pituitary adenoma which is responsible for mediating 
these inhibitory effects. It is well known that sst
2
 especially is involved in 
the inhibitory actions of SRIF and SRIF-analogs on hormone secretion, 
both in primary cultured human fetal pituitary cells and GH-secreting 
pituitary adenoma cells as well (11, 19). The relative amount of mRNA 
expression levels of this receptor subtype was positively correlated with 
the sensitivity to octreotide treatment in vitro (20). The in vitro data of pa-
tient 6 illustrate in this group of equal responders, that the relatively high 
mRNA level for sst
2 
combined with the good affi nity of both SOM230 
and octreotide account for the suppressive effects of both drugs on GH 
secretion in this group of patients. SOM230 has a 2.5 times lower af-
fi nity to sst
2 
than octreotide, which explains the similar effect of 250μg 
SOM230 and octreotide 100μg in this category of acromegalic patients. 
The second pattern of response, illustrated by patient 12 in which SOM230 
is far more effi cacious compared to octreotide in suppressing GH lev-
els, was observed in three patients. A pivotal role for sst
5 
in mediating 
suppression of GH release is probable. The in vitro data of patient 12 
show relatively low mRNA expression levels for sst
2
 and higher expres-
sion levels for sst
5
. The median inhibitory concentration (IC
50
) for sst
5
of SOM230 is 0.16 nmol/L and that of octreotide is 40-times higher (6.3 
nmol/L), pointing to the higher affi nity of SOM230 for the sst
5
 subtype. 
These observations, together with the the in vitro signifi cant inhibition 
by the native SRIF on the primary culture of adenoma cells, suggest that 
both SRIF and SOM230 exert their potent effects in this particular tumor 
via sst
5
 subtype. So far, the role of sst
5
 in mediating GH release was only 
investigated in studies with primary cultures of pituitary adenoma cells 
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obtained from acromegalic patients (19, 20). Saveanu and his group found 
a 30-fold higher expression of sst
5
 compared to sst
2
 mRNA in four adeno-
mas poorly responsive to octreotide. The addition of the sst
5
 specifi c ana-
log BIM23268 to the medium achieved a maximal GH suppression. This 
suggests a “rescue” through sst
5
 when tumors are only partial sensitive to 
octreotide (14). SOM230 induced a 3-fold stronger inhibition than octreo-
tide on GH release by cultured rat pituitary cells and a pronounced inhibi-
tion of plasma IGF-I levels in rodents after 18 weeks of treatment, which 
again is suggestive for sst
5
 involvement (15). We present the fi rst clinical 
evidence that the sst
5
 subtype may indeed play an essential role in mediat-
ing the in vivo suppressive actions by SOM230 on GH concentrations in 
three acromegalic patients, which were (partially) unresponsive to octreo-
tide. Since SOM230 is able to lower GH levels in both subgroups of pa-
tients, coupled to sst
2
 and sst
5
 subtype physiology, respectively, this novel 
SRIF-analog has a clear advantage over octreotide and might increase the 
number of patients which can be biochemically controlled during long-
term medical treatment. Furthermore, in patient 12, 100μg and 250μg of 
SOM230 suppressed GH levels equally. In this particular case, increasing 
the SOM230 dosage by a factor 2.5 did not result in a further increase in 
GH inhibition. This phenomenon is already known for patients who are 
sensitive to octreotide treatment: a similar GH suppression is found upon 
s.c. injections with octreotide dosages in the range of 100-1500 μg/day 
(21, 22). This could indicate that the density of the predominantly ex-
pressed sst determines the response to a SRIF-analog: in GH-secreting 
adenomas expressing sst
2
 in high density, octreotide is able to suppress 
GH levels signifi cantly. However, if sst
2
 is almost not expressed on the 
pituitary adenoma, sst
5
 mediates the GH-suppressive effects of SRIF and 
SRIF-analogs. The dose-response curves of octreotide and SOM230 seem 
to reach the plateau at low levels when high densities of sst
2
 and sst
5
, re-
spectively, are expressed. In vivo and in vitro data from this trial empha-
size that the inhibitory effects on GH release by SRIF and its analogs are 
primarily mediated via sst
2
, as seen in the group of 8 equal responders 
to octreotide and SOM230. However, when sst
2
 over sst
5
 mRNA levels 
are being expressed below a certain threshold as in patient number 12, a 
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suppressive action upon GH concentrations via sst
5
 receptors becomes 
visible. In addition, heterodimeric effects of different sst subtypes are 
suggested to play a role in receptor physiology (23, 24) and as discussed 
before, the BIM23244 bispecifi c sst
2+5
 analog has already shown to be 
more active than the combination of a sst
2
 specifi c analog combined with 
a sst
5
 specifi c analog on GH release (14, 25), indicating that a heterodi-
meric effect by SOM230 on sst
2 
and sst
5
 subtypes cannot be ruled out.
The third response was observed in one patient, who only tran-
siently responded to SOM230, whereas octreotide was far more ef-
fi cacious in lowering GH levels. The most likely explanation is the 
presence of a relatively high sst
2
 and a low sst
5
 mRNA expression 
level, resulting in a high sensitivity for octreotide. Whether high-
er dosages of SOM230 would indeed induce similar lowering ac-
tions on GH concentrations as seen by octreotide, remains uncertain.
Since SRIF and its analogs inhibit the secretion of insulin, impaired post-
prandial glucose tolerance was observed after the acute administration 
of octreotide (26). Similar elevations of glucose concentrations were ob-
served after SOM230. However, the elevated glucose levels seem not be 
caused by an inhibitory action on insulin release, since after SOM230 
administration at 09:00 a.m. an almost identical insulin response was 
observed after lunch as on the control day. At present, the mechanism 
of this transient increase in glucose levels remains uncertain. Several 
studies support a role for sst
5
 to control insulin secretion in rats, mice 
and humans, whereas sst
2
 mediates glucagon secretion from the pancre-
atic α-cells (27-30). On the basis of the SOM230 and octreotide affi nity 
profi les for sst
2
 and sst
5
, it seems unlikely that octreotide, binding 40-
fold less to sst
5 
compared to SOM230, would exert such a strong and 
long lasting insulin inhibition via sst
5 
subtype whereas SOM230 treat-
ment resulted in barely any inhibition. Therefore, these opposed effects 
of octreotide and SOM230 on insulin levels, suggest a pivotal role for 
sst
2 
subtype in regulating human insulin secretion. In cynomolgus mon-
keys, insulin, glucagon and glucose levels remained unchanged during 
seven days of high-dose infusion with SOM230. Furthermore, during 
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an 18-week treatment with pharmacological doses of SOM230 plasma 
glucose levels were not changed, indicating that SOM230 is well toler-
ated in rats and monkeys with regard to glucose homeostasis (15, 31). 
The promising pharmokinetic properties of SOM230 found in vivo in 
rats, accounting for a terminal elimination half-life of 27 hrs compared 
to 2 hrs for octreotide (15), did not result in a longer duration of action 
of SOM230 than that of octreotide. Probably, serum SOM230 concentra-
tions drop sooner below a certain therapeutical level, leading to a dura-
tion of action on GH levels comparable to that of octreotide treatment.
In conclusion, our data suggest that SOM230 has the potency to increase 
the number of acromegalic patients which can be biochemically controlled 
during long-term medical treatment, since it’s additional suppressive ef-
fects on GH secretion via sst
5
. However, the subtype sst
2 
seems to be the 
dominant receptor in controlling hypersecretion in acromegaly. No seri-
ous side effects occurred during SOM230 treatment. The subtle increase 
in glucose levels after SOM230 injection needs further attention and can 
not be explained by sst
5
 or sst
2 
mediated action on insulin secretion. Fu-
ture studies will also address the question whether SOM230 can control 
pituitary adenoma size in acromegaly better than octreotide (8). Besides 
sst
2
 and sst
5
, sst
1
 and sst
3
 also seem to be involved in cell proliferation 
and in the induction of apoptosis (32-35). This suggests that the universal 
SRIF-analog SOM230, with good affi nity for both sst
1
 and sst
3
, might 
have possible antiproliferative and tumor size reducing effects as well.
References
1. Brazeau P, Vale W, Burgus R, et al. 1973 Hypothalamic polypeptide that 
inhibits the secretion of immunoreactive pituitary growth hormone. Science 
179:77-9.
2. Lamberts SW, Uitterlinden P, Verschoor L, et al. 1985 Long-term treatment 
of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 
313:1576-80.
3. Lamberts SW, Oosterom R, Neufeld M, et al. 1985 The somatostatin analog 
SMS 201-995 induces long-acting inhibition of growth hormone secretion 
without rebound hypersecretion in acromegalic patients. J Clin Endocrinol 
Metab 60:1161-5.
4. Newman CB, Melmed S, George A, et al. 1998 Octreotide as primary therapy 
88
Chapter III-2
for acromegaly. J Clin Endocrinol Metab 83:3034-40.
5. Caron P, Beckers A, Cullen DR, et al. 2002 Effi cacy of the new long-
acting formulation of lanreotide (lanreotide Autogel) in the management of 
acromegaly. J Clin Endocrinol Metab 87:99-104.
6. Chanson P, Boerlin V, Ajzenberg C, et al. 2000 Comparison of octreotide 
acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol 
(Oxf) 53:577-86.
7. Lancranjan I, Atkinson AB 1999 Results of a European multicentre study 
with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. 
Pituitary 1:105-14.
8. Bevan JS, Atkin SL, Atkinson AB, et al. 2002 Primary medical therapy 
for acromegaly: an open, prospective, multicenter study of the effects of 
subcutaneous and intramuscular slow- release octreotide on growth hormone, 
insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87:4554-
63.
9. Colao A, Ferone D, Marzullo P, et al. 2001 Long-term effects of depot long-
acting somatostatin analog octreotide on hormone levels and tumor mass in 
acromegaly. J Clin Endocrinol Metab 86:2779-86.
10. Hofl and LJ, Lamberts SW 2003 The pathophysiological consequences of 
somatostatin receptor internalization and resistance. Endocr Rev 24:28-47.
11. Shimon I, Taylor JE, Dong JZ, et al. 1997 Somatostatin receptor subtype 
specifi city in human fetal pituitary cultures. Differential role of SSTR2 and 
SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin 
regulation. J Clin Invest 99:789-98.
12. Panetta R, Patel YC 1995 Expression of mRNA for all fi ve human somatostatin 
receptors (hSSTR1-5) in pituitary tumors. Life Sci 56:333-42
13. Schaer JC, Waser B, Mengod G, et al. 1997 Somatostatin receptor 
subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-
pancreatic and mammary tumors: comparison of mRNA analysis with receptor 
autoradiography. Int J Cancer 70:530-7.
14. Saveanu A, Gunz G, Dufour H, et al. 2001 Bim-23244, a somatostatin receptor 
subtype 2- and 5-selective analog with enhanced effi cacy in suppressing growth 
hormone (GH) from octreotide-resistant human GH-secreting adenomas. J 
Clin Endocrinol Metab 86:140-5.
15. Bruns C, Lewis I, Briner U, et al. 2002 SOM230: a novel somatostatin 
peptidomimetic with broad somatotropin release inhibiting factor (SRIF) 
receptor binding and a unique antisecretory profi le. Eur J Endocrinol 146:707-
16.
16. Lewis I, Bauer W, Albert R, et al. 2003 A novel somatostatin mimic with 
broad somatotropin release inhibitory factor receptor binding and superior 
therapeutic potential. J Med Chem 46:2334-44.
17. Oosterom R, Blaauw G, Singh R, et al. 1984 Isolation of large numbers of 
dispersed human pituitary adenoma cells obtained by aspiration. J Endocrinol 
Invest 7:307-11.
18. Ferone D, Pivonello R, Van Hagen PM, et al. 2002 Quantitative and 
89
Effi cacy of SOM230 in active Acromegaly
functional expression of somatostatin receptor subtypes in human thymocytes. 
Am J Physiol Endocrinol Metab 283:E1056-66.
19. Shimon I, Yan X, Taylor JE, et al. 1997 Somatostatin receptor (SSTR) 
subtype-selective analogues differentially suppress in vitro growth hormone 
and prolactin in human pituitary adenomas. Novel potential therapy for 
functional pituitary tumors. J Clin Invest 100:2386-92.
20. Jaquet P, Saveanu A, Gunz G, et al. 2000 Human somatostatin receptor 
subtypes in acromegaly: distinct patterns of messenger ribonucleic acid 
expression and hormone suppression identify different tumoral phenotypes. J 
Clin Endocrinol Metab 85:781-92.
21. Ezzat S, Redelmeier DA, Gnehm M, et al. 1995 A prospective multicenter 
octreotide dose response study in the treatment of acromegaly. J Endocrinol 
Invest 18:364-9.
22. Vance ML, Harris AG 1991 Long-term treatment of 189 acromegalic patients 
with the somatostatin analog octreotide. Results of the International Multicenter 
Acromegaly Study Group. Arch Intern Med 151:1573-8.
23. Rocheville M, Lange DC, Kumar U, et al. 2000 Subtypes of the somatostatin 
receptor assemble as functional homo- and heterodimers. J Biol Chem 
275:7862-9.
24. Pfeiffer M, Koch T, Schroder H, et al. 2001 Homo- and heterodimerization 
of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by 
heterodimerization with sst(2A). J Biol Chem 276:14027-36.
25. Shimon I 2003 Somatostatin receptors in pituitary and development of 
somatostatin receptor subtype-selective analogs. Endocrine 20:265-70.
26. Lamberts SW, Uitterlinden P, del Pozo E 1987 SMS 201-995 induces a 
continuous decline in circulating growth hormone and somatomedin-C levels 
during therapy of acromegalic patients for over two years. J Clin Endocrinol 
Metab 65:703-10.
27. Strowski MZ, Parmar RM, Blake AD, et al. 2000 Somatostatin inhibits 
insulin and glucagon secretion via two receptors subtypes: an in vitro study of 
pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 
141:111-7.
28. Strowski MZ, Kohler M, Chen HY, et al. 2003 Somatostatin receptor subtype 
5 regulates insulin secretion and glucose homeostasis. Mol Endocrinol 17:93-
106.
29. Mitra SW, Mezey E, Hunyady B, et al. 1999 Colocalization of somatostatin 
receptor sst5 and insulin in rat pancreatic beta-cells. Endocrinology 140:3790-
6.
30. Kumar U, Sasi R, Suresh S, et al. 1999 Subtype-selective expression of the 
fi ve somatostatin receptors (hSSTR1- 5) in human pancreatic islet cells: a 
quantitative double-label immunohistochemical analysis. Diabetes 48:77-85.
31. Weckbecker G, Briner U, Lewis I, et al. 2002 SOM230: a new somatostatin 
peptidomimetic with potent inhibitory effects on the growth hormone/insulin-
like growth factor-I axis in rats, primates, and dogs. Endocrinology 143:4123-
30.
90
Chapter III-2
32. Zatelli MC, Tagliati F, Piccin D, et al. 2002 Somatostatin receptor subtype 
1-selective activation reduces cell growth and calcitonin secretion in a human 
medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 297:828-
34.
33. Reisine T, Bell GI 1995 Molecular biology of somatostatin receptors. Endocr 
Rev 16:427-42.
34. Benali N, Ferjoux G, Puente E, et al. 2000 Somatostatin receptors. Digestion 
62:27-32.
35. Ferone D, van Hagen MP, Kwekkeboom DJ, et al. 2000 Somatostatin 
receptor subtypes in human thymoma and inhibition of cell proliferation by 
octreotide in vitro. J Clin Endocrinol Metab 85:1719-26.
Chapter III-3
The somatostatin analog 
SOM230, compared with 
octreotide, induces differential 
effects in several metabolic 
pathways in acromegalic patients
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Abstract
OBJECTIVE Recently, our fi rst clinical study with the novel multi-
ligand somatostatin (SRIF) analog SOM230 in acromegalic patients 
showed that SOM230, due to its benefi cial inhibitory effects on GH 
levels compared with octreotide (OCT), might increase the number 
of patients that can be biochemically controlled. Since SRIF-analogs 
are also known to interact with other metabolic pathways, assessment 
of IGF-I, IGFBP-1, glucose and insulin concentrations on the con-
trol day (CD) and on treatments days following a single s.c. injection 
SOM230 100 and 250μg, compared with OCT 100μg, was performed.
DESIGN AND PATIENTS Randomized, cross-over, double-blind-
ed proof-of-concept trial in 12 patients with active acromegaly.
RESULTS Total IGF-I levels, compared with predose, were not affected. 
Free IGF-I levels were suppressed after 24h by OCT, SOM230 250 and 
100μg, whereas at 48h only both SOM230 dosages still induced these 
inhibitory effects. Circulating IGFBP-1 levels (AUC; 08.30-14.30h) 
compared with CD, increased sharply after OCT (from 48 to 237 µg/
Lh; p<0.001 vs CD), while SOM230 250 and 100μg elicited a lower and 
dose-dependent effect (163 and 90 µg/Lh, resp; p<0.05 vs CD and OCT). 
Neither insulin nor GH levels showed statistically signifi cant correla-
tion with IGFBP-1 levels either after SOM230 or OCT. An early rise 
in glucose levels 1h post-injection with SOM230 250μg compared with 
OCT and CD was observed 8.3±0.8, 4.4±0.5 and 4.9±0.4 mmol/L, resp: 
p<0.05). SOM230 250μg (19±4 vs 46±3 mU/L on CD: p<0.05), although 
clearly less potent than OCT (5.4±0.4 mU/L: p<0.01 vs CD), inhibited 
insulin release. Since these corresponding absolute insulin levels cannot 
entirely explain this hyperglycaemic effect of SOM230, other mecha-
nisms seem involved in this glucose rise. If SOM230 would infl uence 
glucose homeostasis in peripheral target tissues of insulin action, expres-
sion of SRIF-receptors (sst) seems a logical necessity. In normal human 
liver tissues, analyzed by quantitative PCR, the average sst
1
 mRNA ex-
pression level appeared signifi cantly higher compared with sst
2
 (n=6, 
relative copy number 161±46 vs 57±6; p<0.05). Fat tissue expressed 
both sst
1
 and sst
2
 mRNA, whereas in muscle only sst
2 
mRNA was found. 
CONCLUSION Both dosages SOM230 inhibit free IGF-I more sustained 
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as compared with OCT, implying longer duration of action. The superior 
action of OCT compared with SOM230 in stimulating IGFBP-1 levels, 
suggests direct regulation of IGFBP-1 by SRIF-analogs via sst
2
. Finally, 
expression of only sst
1
 and sst
2 
in target tissues of insulin action, might point 
towards additional modulatory effects by SOM230 on glucose homeostasis.
Introduction
Acromegaly is a rare disease characterized by chronic hypersecretion of 
growth hormone (GH), which is almost exclusively caused by a GH-se-
creting pituitary adenoma. The clinical manifestations of acromegaly are 
due to the peripheral actions of excess GH and insulin-like growth factor-
I (IGF-I). Successful medical treatment of acromegaly with the current 
clinically available somatostatin (SRIF) analogs octreotide (OCT) and 
lanreotide is due to the expression of high-affi nity (density) SRIF recep-
tors on the adenoma cells, mainly SRIF receptor subtype (sst) 2, which 
is one of the fi ve known SRIF receptor subtypes (1-4), sst
1
-sst
5
, and the 
selective high-affi nity binding of these analogs to sst
2
 (Table I). Several 
Table I. Binding affinity of OCT and SOM230 for the five human sst, 
sst
1-5.
compound sst1 sst2 sst3 sst4 sst5
OCT 280 ± 80 0.38 ± 0.08 7.1 ± 1.4 > 1000 6.3 ± 1.0 
SOM230 9.3 ± 0.1 1.0 ± 0.1 1.5 ± 0.3 > 100 0.16 ± 0.01 
Data are reproduced with permission (11). Results are the mean ± sem; IC50 are ex-
pressed in nanomolar concentration.
studies with this generation of octapeptide SRIF analogs have demon-
strated that long-term therapy, administered subcutaneously (s.c.) or as a 
long-acting depot preparation, induces clinical and biochemical “cure” in 
up to 65% of patients (5-8). Because approximately one third of patients 
with acromegaly seem (partially) resistant to OCT and/or lanreotide ad-
ministration, improved compounds to treat acromegaly are required. The 
recently identifi ed novel synthetic SRIF-peptidomimetic SOM230 forms 
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a serious candidate to obtain such therapeutic signifi cance in acromegaly 
(9). Compared with OCT, SOM230 has a 30, 5 and 40 times higher binding 
affi nity to sst
1
, sst
3
 and sst
5
, respectively, and 2.5 times lower affi nity to sst
2
(Table I).  Preclinical studies showed that SOM230 potently and dose-de-
pendently suppressed GH and IGF-I levels for prolonged periods of time 
up to 120 days in rats, dogs and rhesus monkeys (10, 11). Additional char-
acteristics of SOM230 include a favourable terminal elimination half-life 
of 24 h in humans as well as the preliminary evidence that glucose levels 
in rats and dogs remain normal during long-term administration of the 
compound (10). Clinical evaluation of SOM230, by assessing its effi cacy 
compared with OCT, was recently performed in a single dose proof-of-
concept trial in acromegaly (12). It was concluded that SOM230, due to 
its benefi cial effects on circulating GH levels compared with OCT, might 
increase the number of patients that can be biochemically controlled dur-
ing long-term medical treatment. The advantage of SOM230 compared 
with the current clinically available sst
2
-preferring analogs, likely result-
ed from its sst
5
-mediated suppressive effects on GH levels in a subgroup 
of patients that were (partially) unresponsive to OCT administration.
However, since SRIF and its analogs inhibit the secretion of insulin 
(13), impaired postprandial glucose tolerance was observed after the 
acute administration of OCT (12). Comparable elevations of glucose 
concentrations were observed after SOM230, whereas SOM230 did not 
alter the meal-induced insulin response (12). Therefore, the elevated 
glucose levels seem not to be caused by an inhibitory action on insulin 
release. Still, the mechanism of this early transient increase in glucose 
levels remains uncertain. In order to obtain more insight with respect 
to the acute effects of SOM230 on carbohydrate metabolism in active 
acromegaly, additional analysis of insulin, glucose and insulin-like 
growth factor binding protein (IGFBP) 1 levels of the 12 acromegalic 
patients that participated in the proof-of-concept trial, was conducted. 
Furthermore, we present the fi rst clinical data regarding the effects of 
a single dose SOM230 on total and free IGF-I levels in acromegaly.
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Methods
Patients
Twelve patients with active acromegaly were recruited at the Erasmus MC 
Rotterdam, The Netherlands. Patient characteristics have been described 
in detail previously (12). All subjects had biochemically active disease, 
with a mean serum GH concentration greater than 5 μg/L during a 5-hour 
profi le and elevated circulating IGF-I levels (age- and sex-adjusted). GH 
concentration failed to suppress below 1 μg/L after a 2-hour 75-g oral glu-
cose tolerance test (oGTT). Seven patients had been treated before (see 
below). In those patients who have been medically treated previously, a 
wash-out period after the last dose of medication had to be at least 1 month, 
1 week, 4 months and 1 month for dopamine agonists, subcutaneous for-
mulations of octreotide, depot formulations of long-acting somatostatin 
analogs and growth hormone receptor antagonists, respectively. One pa-
tient had been previously treated by surgery, medical treatment and irra-
diation. One patient was treated only with surgery. Two patients had only 
been medically treated and three patients were treated with surgery and 
medical treatment. Five patients were newly diagnosed. Pituitary func-
tion was preserved in 8 patients. Gonadal steroid-, glucocorticoid- as well 
as thyroxin-replacement therapy was initiated in 3 patients before start 
of the study, whereas 1 patient was treated with only gonadal steroids, 
Patients with compression of the optic chiasm causing any visu-
al fi eld defect or those requiring surgical intervention for relief of 
any sign or symptom possibly associated with tumor compression, 
were excluded. The local ethical committee of the Erasmus MC ap-
proved the study and all patients gave written informed consent.
Treatment protocol
Patients were hospitalized on the control day for 24 h for the assessment 
of baseline effi cacy parameters. On study day 1, 8 and 15, each patient 
received at 09:00 a.m. a single s.c. injection of OCT 100μg, SOM230 
100μg or SOM230 250μg in a randomized, double-blinded, crossover de-
sign with a minimum 6 days of washout between drug treatments. All pa-
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tients received standardized meals, served at 08:30 a.m., 12:30 p.m. and 
17:30 p.m. In addition to the recently published data (12), blood samples, 
initially centrifuged and immediately frozen at -20°C, for the assessment 
of insulin, glucose and IGFBP-1 concentrations were collected at the fol-
lowing time points: 30 minutes and one minute before, and every hour for 
2 h after drug administration. Furthermore, blood samples for IGFBP-1 
assessment were collected 30 minutes and one minute before, and every 
half hour for 2 h after lunch. Finally, for the assessment of total and free 
IGF-I levels, blood samples were collected 30 minutes before, 24 and 48 
h after s.c. injection. These procedures were repeated on all study days.
Assays
Insulin (mU/L; 1 mU/L = 7.175 pmol/L) levels were determined by use of 
a non-isotopic, automatic chemiluminescence immunoassay system (Im-
mulite, DPC Inc., Los Angeles, CA). The intra- and inter-assay coeffi cients 
of variation (CV) for insulin were 4.4% and 5.9%, respectively. Glucose 
(mmol/L; 1 mmol/L = 18.015 mg/dl) was measured with an automatic 
hexokinase method (Roche, Almere, the Netherlands). Serum total IGF-I 
(nmol/L), free IGF-I (pmol/L) and IGFBP-1 (µg/L) were determined with a 
commercially available non-extraction IRMA (Diagnostic Systems Labo-
ratories, Inc., Webster, Texas). All assays were carried out in a blinded man-
ner, and quality-control samples were included within assay runs. Interas-
say coeffi cients of variation for total IGF-I, free IGF-I, and IGFBP-1 were 
4.2%, 5.1 and 6.0%, respectively. Intraassay coeffi cients of variation for 
total IGF-I, free IGF-I and IGFBP-1 were 3.9, 5.1 and 4.6%, respectively.
RNA isolation
Sst mRNA expression in peripheral insulin-targeted tissues was analyzed. 
Per-operatively obtained human liver biopsies from 6 patients diagnosed 
with hepatocellular carcinoma (n=3), colorectal carcinoma (n=2) or he-
mangioma (n=1), were collected. Collected liver tissues were directly 
frozen and stored at –80 °C until pathological examination confi rmed 
that the biopsies showed normal liver tissue histology. Visceral adipose 
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tissue was obtained from two organ-transplant donors, directly frozen 
and stored at –80 °C, who were initially admitted at Leiden University 
Medical Center, The Netherlands. The protocols were in accordance with 
the Helsinki Doctrine on Human Experimentation. Informed consent was 
obtained from the patient or from the closest family member. Collected 
tissues were grinded to powder on dry ice using a mortar and total RNA 
was isolated using either a High Pure RNA Tissue Kit for tissue sam-
ples (Roche Diagnostics GmbH, Mannheim, Germany) or a RNeasy
Lipid Tissue Mini Kit for adipose tissue samples (QIAGEN, Westburg 
B.V., Leusden, The Netherlands) according to manufacturers protocol. 
cDNA from two skeletal muscle (rectus abdominis) biopsies was kind-
ly provided by Dr. van den Berghe (Department of Intesive Care Med-
icine, Catholic University of Leuven, Belgium) from two critically ill 
patients that participated in a large randomized, controlled study on in-
tensive insulin treatment in Intensive Care Unit patients, of which the 
major clinical outcome have been published in detail elsewhere (14, 15).
Quantitative RT-PCR
Quantitative RT-PCR was performed as previously described (16). Brief-
ly, poly A+ mRNA was isolated during Dynabeads Oligo (dT)
25
 (Dynal 
AS, Oslo, Norway). cDNA was synthesized using the poly A+ mRNA 
captured on the Dynabeads Oligo (dT)
25
 as a solid phase and fi rst prim-
er. One-twentieth of the cDNA library was used for quantifi cation of sst 
subtype mRNA levels. A quantitative PCR was performed by TaqMan® 
Gold nuclease assay (The Perkin-Elmer Corporation, Foster City, CA) 
and the ABI PRISM® 7700 Sequence Detection System (The Perkin-
Elmer Corporation) for real-time amplifi cation, according to the man-
ufacturer’s instructions. The assay was performed using 15μl TaqMan®
Universal PCR Master Mix (Applied Biosystems, The Netherlands), 
500 nM forward primer, 500 nM reverse primer, 100 nM probe and 10μl 
cDNA template, in a total reaction volume of 25μl. After an initial heat-
ing at 95° C for 8 minutes, samples were subjected to 40 cycles of de-
naturation at 95° C for 15 seconds and annealing for 1 minute at 60° C. 
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The primer and probe sequences that were used for the detection of 
sst
1
, sst
2
, sst
3
, sst
5
 and hypoxanthine phosphoribosyl transferase (HPRT) 
mRNA’s have been described previously (16). In addition, we also 
evaluated sst
4
 mRNA expression in the present study using the follow-
ing primers and probe: sst
4
 forward 5’-CTGCGCCAACCCTATTCTCT-
3’; sst
4
 reverse 5’-ACCCGCTGGAAGGATCG-3’; sst
4
probe 5’-
FAM-TGGCTTCCTCTCCGACAACTTCCG-TAMRA-3’. Primers 
and probes were purchased from Biosource (Nivelles, Belgium).
The relative amount of sst subtype mRNA was determined using a stan-
dard curve generated from known amounts of human genomic DNA. 
For the determination of the amount of HPRT mRNA, a standard curve 
was obtained by including dilutions of a pool of cDNAs from a hu-
man cell line known to express HPRT. The relative amount of sst sub-
type mRNA was calculated relative to the amount of HPRT mRNA 
and is given in arbitrary units. Each sample was assayed in duplicate.
Statistical analysis
The assumption of normality was investigated by use of a Kolmogo-
rov-Smirnov test. When this hypothesis was not rejected, a paired Stu-
dent t-test was used for assessing the statistical signifi cance compared 
with the control day. The Wilcoxon’s signed rank test, a non-paramet-
ric analog to the paired t-test, was used when data did not represent a 
random sample from normal distribution. Correlation analysis was per-
formed by the use of Spearman’s rank correlation test. IGFBP-1 levels 
were also analyzed as area under the curve (AUC) values. Quantita-
tive RT-PCR data were analyzed by ANOVA to determine overall dif-
ferences between sst subtype mRNA expression. When signifi cant 
differences were found by ANOVA, a multiple comparison sst sub-
types was made using the Newman-Keuls test. Data are expressed 
as mean ± sem. A P value less than 0.05 was considered signifi cant.
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Results
IGF-I concentrations
Total IGF-I levels, compared with predose, were not affected 24 and 
48 h after OCT and SOM230 treatments (Fig. 1 upper panel). However 
free IGF-I levels were suppressed after 24 h by OCT 100μg, SOM230 
100µg and 250μg (-30 ± 5%, -23 ± 5% and -30 ± 7%, respectively: 
p<0.01 to predose), whereby at 48 h only after both SOM230 dosages 
these inhibitory effects persisted (p<0.01 to predose; Fig. 1 lower panel).
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Figure 1. Total and free IGF-I levels (upper and lower panel, respectively) on treatment 
days after s.c injection with the study drugs. Data are expressed as mean ± sem (n=12). 
# P < 0.05 vs predose (pd).
IGFBP-1 concentrations
As shown in fi gure 2, OCT induced a higher response with respect to cir-
culating IGFBP-1 levels. IGFBP-1 concentrations (AUC; 08.30-14.30 h) 
compared with CD, increased sharply after OCT (from 48 to 237 µg/Lh; 
p<0.001 vs CD), while SOM230 250 and 100μg elicited a lower dose-
dependent effect as well (to 163 and 90 µg/Lh, respectively; p<0.05 vs 
CD: OCT vs SOM230 250 and 100μg, p<0.05). Neither insulin nor GH 
levels showed statistically signifi cant correlation with serum IGFBP-1 
concentrations either after both dosages SOM230 or OCT (Table II).
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Figure 2. Serum Insulin-like Growth Factor Binding Protein 1 (IGFBP-1) concentra-
tions following a s.c. injection with the study drugs in comparison with a control day. 
Values represent mean ± sem [n=11, one patient was excluded because of insulin-treat-
ed type II diabetes, (12)]. Symbols display control day (■), OCT 100μg (*), SOM230 
250μg (▲) and SOM230 100μg (○).
Table II. Spearman rank correlation coefficients (rs) of IGFBP-1 with 
GH and insulin levels in 11 patients with active acromegaly.
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s.c. injection 
lunch 12.30pm 
breakfast
8.30-9.00am 
Metabolic parameter 
GH Insulin Treatment 
rs p-value rs p-value
SOM230 100µg -0.18 0.71 -0.31 0.39 
SOM230 250µg -0.5 0.27 -0.36 0.31 
OCT 100µg -0.04 0.96 -0.32 0.37 
Carbohydrate metabolism
The effects of SOM230 and OCT on carbohydrate metabolism during 
lunch have been described already extensively (12). Briefl y, glucose lev-
els were slightly elevated after all drug treatments compared with control 
day. Lunch was accompanied by a physiological increase in glucose lev-
els on the control day and all treatment days. OCT inhibited insulin levels 
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until 2 h after lunch, whereas both dosages SOM230 did not statistically 
signifi cantly affect insulin levels. An early raise in glucose levels 1 h post-
injection with SOM230 250μg compared with SOM230 100μg, OCT and 
CD (8.3 ± 0.8, 6.4 ± 0.7, 4.4 ± 0.5 and 4.9 ± 0.4 mmol/L, resp: p<0.05) 
was seen (Fig. 3A). Two hours after s.c. injection glucose levels were 
raised during OCT treatment as well (6.3 ± 0.4 vs 4.4 ± 0.3 mmol/L on 
CD: p<0.05). At both time points OCT already suppressed insulin levels, 
whereas only at 1 h post-injection SOM230 100 and 250μg (18 ± 4 and 19 
± 4 vs. 46 ± 3 mU/L on CD: both p<0.05), although clearly less potent than 
OCT (5.4 ± 0.4 mU/L: p<0.01 vs CD), inhibited insulin release (Fig. 3B). 
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Figure 3. Mean (± sem) serum glucose (A) and insulin (B) profiles of 11 patients [one 
patient was excluded because of insulin-treated type II diabetes, (12)] during control 
day (■) and on treatment days after s.c. injection of OCT 100μg (*), SOM230 250μg 
(▲) and SOM230 100μg (○).Assessment of metabolic parameters in the subgroup of 8 
patients, responding equally effective to 100µg OCT and 250µg SOM230 with respect 
to circulating GH concentrations
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In order to homogenise the metabolic responses for the effects of both 
SS-analogs on circulating GH concentrations, we have also analysed all 
metabolic parameters in the subgroup of 8 acromegalic patients that re-
sponded to a similar extent to 100µg OCT and 250µg SOM230 with re-
spect to circulating GH levels (12). Total IGF-I concentrations, compared 
with predose, were slightly attenuated only after 24h by 100µg OCT and 
250µg SOM230 (-11 ± 2% and -9 ± 2%, resp: p<0.05) but not by 100µg 
SOM230 (-4 ± 3%). The lowering of circulating free IGF-I concentra-
tions by OCT and both dosages SOM230 in the subgroup of 8 patients, 
appeared similar as compared with the total group of 12 patients, i.e.
100µg OCT, 100µg and 250µg SOM230 suppressed free IGF-I levels 
24h after s.c. injection (-30 ± 6%, -26 ± 7% and -35 ± 6%, resp: p<0.05) 
whereby at 48 h only after 100µg and 250µg SOM230 these inhibitory 
effects persisted (-28 ± 8% and -26 ± 6%, resp: p<0.05). The differential 
effects of OCT and both dosages SOM230 on circulating IGFBP-1 and 
glucose homeostasis in the total group of 12 patients, as described above, 
were also observed when IGFBP-1, glucose and insulin concentrations 
were analyzed in the subgroup of 8 patients that responded in a similar ex-
tent to OCT and SOM230 with respect to circulating GH concentrations.
Sst mRNA expression in human liver, muscle and visceral 
adipose tissue
As described above, the observed raise in glucose levels after s.c admin-
istration of 250 µg SOM230 (and to a lesser extent by 100µg SOM230) 
was not accompanied by a profound inhibitory action of the compound 
on insulin secretion by pancreatic β-cells. Therefore, other (extra-pancre-
atic) mechanisms could be responsible for the detoriated carbohydrate 
metabolism after SOM230 administration. It is generally well known 
that liver, muscle and fat are peripheral tissues predominantly involved 
in the regulatory actions of insulin to control plasma glucose levels. If 
SOM230 infl uences glucose homeostasis in these target tissues direct-
ly, expression of SRIF receptors seems a logical necessity. Therefore, 
we evaluated by quantitative PCR, for the fi rst time the presence of sst
1
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and sst
2
 mRNA in human liver, muscle and fat tissues (Figure 4). The 
other sst subtypes, sst
3-5
, were not expressed. In liver, the average sst
1
mRNA expression level was signifi cantly higher compared with sst
2
(n=6, relative copy number 161 ± 46 vs 57 ± 6; p < 0.05). Visceral fat 
tissue expressed both sst
1
 (n=2, relative copy number 705 and 182) and 
sst
2 
(n=2, relative copy number 403 and 263) mRNA, whereas in mus-
cle only sst
2 
mRNA (n=2, relative copy number 106 and 64) was found.
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Figure 4. Quantitative analysis of RT-PCR showing the relative amounts of two SRIF 
receptor subtypes, sst
1-2
, mRNA in three peripheral target tissues of insulin, calculat-
ed relative to the amount of HPRT and given in arbitrary units. A) Visceral adipose 
fat, n=2: B) Skeletal muscle, n=2 and C) Liver, n=6; # p < 0.05. nd; not detectable.
Discussion
This report is unique due to the fact that SOM230 is the fi rst multili-
gand SRIF-analog administered in vivo to acromegalic patients. Up 
till now, only sst
2
 preferring analogs, i.e. OCT and Lanreotide have 
been used clinically. Our study is in support of the clinical poten-
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tial of novel multiligand SRIF-analogs in acromegaly, but tantalis-
ing novel insights in sst subtype physiology are demonstrated as well.
No effects on total IGF-I levels after single doses of SOM230 and OCT 
were observed in our series of 12 acromegalic patients, which might be 
related to its long half-life. However, in the subgroup of 8 acromegalic 
patients that responded equally to OCT and 250µg SOM230 with respect 
to circulating GH concentrations (12), total IGF-I concentrations were 
lowered to a small extent 24h after s.c. injection with 100µg OCT and 
250µg SOM230. The latter observation could indicate the GH-dependent 
inhibition of total IGF-I. However, the temporal, short-term feedback be-
tween GH secretion and the circulating IGF-I system in normal subjects, 
is recently suggested to be regulated more importantly due to changes in 
free IGF-I levels instead of total IGF-I levels (17). Interestingly, both in 
the total group of 12 patients as well as in the GH-equal responder group 
of 8 patients, single dose administrations of 100 and 250µg SOM230 
persistently inhibited free IGF-I levels signifi cantly after 48 h, whereas 
OCT was only effective for 24 h. This could be explained by intracel-
lular dynamics of sst
2
 and sst
5
 at the central level of the pituitary (18), 
combined with the 40-fold higher sst
5
-binding affi nity and the longer half 
life of SOM230 compared with OCT. Stroh and coworkers demonstrated 
that sst
2
 seems to be rapidly internalized after ligand binding, but sst
5
showed early recycling after internalization, with massive re-recruitment 
from intracellular stores (back) to the membrane (19). On the other hand, 
two other reports recently reported that sst
2
 can be rapidly recycled to 
the membranes as well (20, 21), SOM230 might induce this sustained 
inhibition of free IGF-I levels via sst
2
 as well because of its long half life 
as compared with OCT. In addition, there is compelling evidence that 
SRIF analogs act to suppress IGF-I by inhibiting pituitary GH release 
(22, 23) but whether SRIF analogs act on peripheral target tissues of GH 
to reduce GH-induced IGF-I production as well remains to be further 
clarifi ed. Melmed’s group recently demonstrated in rat hepatocytes and 
perfused rat livers, expressing sst
2
 and sst
3
, that SRIF and OCT dose-
dependently inhibited GH-induced IGF-I production at the level of the 
hepatocyte (24). In respect to the sustained free IGF-I suppression by 
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SOM230 in our acromegalic patients, the question regarding the sst sub-
type responsible for these peripheral inhibitory effects is of importance. 
Based on sst binding affi nity profi les of SOM230 and OCT (Table I), 
combined with our present data showing only sst
1
 and sst
2
 mRNA expres-
sion in human liver tissues, both sst subtypes might mediate peripheral 
IGF-I production; 1) sst
1 
may be involved because SOM230, compared 
with OCT, has a 30-fold higher sst
1
-binding affi nity and 2) SOM230’s 
favorable half-life of nearly 24 h induces prolonged activation of sst
2
. 
SRIF has been implicated in the regulation of IGFBP-1 (25), that blocks 
availability of IGF-I (26). OCT induced a potent increase in serum IGFBP-
1 levels in the acromegalic patients, within 2-3 h following injection, a 
time course in agreement with earlier reports (27-29). Even though 100 
and 250µg SOM230 administration signifi cantly and dose-dependently 
increased IGFBP-1 levels, OCT treatment remained more potent with 
respect to IGFBP-1 release. Furthermore, we could not demonstrate a 
signifi cant relation between the course of either circulating insulin or GH 
levels and IGFBP-1 concentrations, which has been reported previously, 
arguing against a direct regulatory effect of GH on IGFBP-1 production in 
acromegaly (27, 30, 31). Several studies have shown a statistical signifi -
cant inverse correlation between serum insulin and IGFBP-1 concentra-
tions in acromegaly and patients with insulin dependent diabetes mellitus, 
suggesting a regulatory effect of insulin on circulating IGFBP-1 levels 
(31-34), whereas others did not (27, 30). The absence of any statistically 
signifi cant correlation between insulin and IGFBP-1 levels after both OCT 
and SOM230 administration might support a direct role for SRIF-analog 
induced release of IGFBP-1 in acromegaly. Evidence for a direct induction 
of IGFBP-1 mRNA by OCT has been observed in human hepatoma cells, 
but this effect was noted only after 12 h of OCT-incubation (35). Consid-
ering the superior action of OCT compared with SOM230 in stimulating 
IGFBP-1 levels in acromegaly, combined with the higher sst
2
-binding af-
fi nity by OCT (Table I), these data point towards a modulatory role of sst
2
in the direct regulation of IGFBP-1 levels by SRIF-analogs in acromegaly.
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In general, the effects of SRIF-analogs on glucose homeostasis appeared 
to be minor and a mild deterioration occurred only in those without im-
paired glucose tolerance (36). Indeed, compared with OCT, comparable 
elevations of glucose concentrations during lunch were observed after 
SOM230 administration early in the morning in acromegalic patients (12). 
In addition, 250µg SOM230 elicited an acute raise of glucose levels 1 h 
post-injection (fi gure 3). SOM230-mediated inhibitory effects on insulin 
secretion cannot explain these elevated glucose levels. Several studies 
support a role for sst
5
 to control insulin secretion in rats, mice and humans, 
(37-40). On the basis of SOM230 and OCT binding affi nity profi les for 
sst
5
 (Table I), it seems unlikely that OCT, binding 40-fold less to sst
5 
com-
pared with SOM230, would exert such a strong and long lasting insulin 
inhibition via sst
5 
subtype whereas SOM230 treatment resulted in barely 
any inhibition. Therefore, these seemingly discrepant effects of OCT and 
SOM230 on insulin levels, which represent in vivo novel insights in the 
role of sst subtypes in human pancreatic insulin secretion, clearly suggest 
a dominant role for sst
2 
in regulating human insulin secretion. Support for 
this hypothesis comes from recent experiments performed with isolated 
perifused human pancreas tissues, which showed inhibitory effects of 
OCT or a specifi c sst
2 
agonist in low near “physiological” concentrations 
on insulin secretion, while an sst
5 
agonist inhibited insulin secretion only 
in “pharmacological” doses (41). As glucagon release appeared far less 
sensitive for SOM230 as compared with octreotide (44-fold) in several 
in vivo animal models and peripheral glucagon measurement does not 
represent pancreatic glucagon (gastro-intestinal glucagon is measured as 
well) concentrations, the effects of SOM230 and OCT on glucagon levels 
have not been analyzed. Recent immunohistochemical observations in 
human pancreatic tissue have shown a wide occurrence of both sst
2
 and 
sst
5
 in α-cells (42, 43), indicating that it is not clear yet whether SOM230 
mediates glucagon release differently as compared with OCT in humans. 
Because SOM230 administration did not result in a dramatic attenua-
tion of absolute insulin concentrations, we hypothesize a potential local 
role of SOM230 in regulating glucose homeostasis in insulin-targeted 
tissues. Bousquet and coworkers elegantly demonstrated in CHO-K1 
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cells, stably expressing sst
2
, that addition of the sst
2
-preferential analog 
RC-160 to insulin resulted in a higher and more sustained increase of 
the tyrosine phosphatase SHP-1 association to the insulin receptor (IR) 
directly correlated with an inhibition of phosphorylation of IR and in-
sulin receptor substrate 1 (IRS-1) (44). Also, activation of sst
1
 subtype 
enhances PTP activity as well (45). The expression of sst
1
 and sst
2 
in tar-
get tissues of insulin action, might point towards potential modulatory 
effects by SOM230 on insulin signaling. It should also be stated that our 
skeletal muscle mRNA data were derived from critically ill patients, and 
we cannot rule out any sst mRNA expression alteration due to the patho-
logical state of these patients (15). SOM230, via sst
1
 activation, might 
increase PTP activation, which subsequently could result in IR- or IRS-
dephosphorlyation; plasma glucose levels might remain elevated due to 
impaired glucose metabolism in peripheral target tissues. It should be 
noted that OCT administration did not result in a glucose peak 1 h post-
injection, whereas the elevated glucose levels around lunch can be ex-
plained by inhibition on insulin secretion. Based on sst
1
 and sst
2
 binding 
affi nity differences between SOM230 and OCT, i.e. a 30-fold higher and 
2.5-fold lower affi nity, respectively, in combination with the selective ex-
pression of sst
1
 and sst
2
 in liver and adipose tissue, we hypothesize that 
sst
1
 might be involved in SOM230-mediated effects on insulin signaling.
In conclusion, the results show that both dosages SOM230 inhibit free 
IGF-I more sustained as compared with OCT, which could be regulated 
centrally and peripherally at the level of the pituitary and liver, respec-
tively. The superior action of OCT compared with SOM230 in stimulat-
ing IGFBP-1 levels suggests a modulatory role of sst
2
 in the direct regu-
lation of IGFBP-1 levels.. Finally, the acute elevation of glucose levels 
after SOM230 administration, which cannot be explained by concomitant 
suppressive effects on insulin concentrations; suggest that extra-pancre-
atic mechanisms might be involved. The expression of sst
1
 and sst
2 
in 
target tissues of insulin action, might point towards modulatory effects 
by SOM230 on glucose homeostasis. Further in vivo and in vitro stud-
ies with the promising multiligand SRIF-analog SOM230 will be neces-
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sary, not only to further explore its potential benefi cial role in the medical 
treatment of sst-positive neuroendocrine tumours, but also to retrieve ad-
ditional insights regarding its side effects on carbohydrate metabolism. 
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Somatostatin receptors in 
peripheral target tissues of insulin 
action: implications for glucose 
homeostasis during somatostatin 
analog treatment?
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Abstract
It is well documented that Octreotide (OCT), which is used for the medi-
cal treatment of several neuro-endocrine diseases including acromegaly, 
can suppress insulin secretion by the pancreas and, subsequently, induce 
a transient raise in glucose level. The novel somatostatin (SRIF) mul-
tiligand SOM230, has been demonstrated to have the potential to be-
come a novel therapeutic tool for acromegalic patients, particularly for 
those patients being partial responsive to OCT. As expected, SOM230 
lowered insulin secretion as well but to a much lesser extent compared 
with OCT. Surprisingly, only SOM230 induced an acute raise in glucose 
levels, which cannot be explained by insulin suppression. Therefore, it 
is suggestive that SOM230 alters insulin signaling, i.e. reduces insu-
lin sensitivity. The presence of SRIF receptor subtype (sst) 1 and sst
2 
in insulin-target tissues favoured this hypothesis. In a series of visceral 
omental fat biopsies, we confi rm previous fi ndings that only sst
1 
and sst
2 
mRNA are expressed. In the human hepatoma cell line, Huh-7, sst
1 
and 
sst
2
 mRNA was detected as well. When we co-treated Huh-7 cells with 
insulin, a dose-dependent increase in insulin receptor (IR) autophosphor-
ylation at tyrosine residues 1162 and 1163 was observed. However, nei-
ther SOM230 nor OCT was able to alter IR-autophosphorylation, neither 
in the presence or in the absence of insulin. Whether SRIF-analogs can 
infl uence insulin sensitivity more downstream of the IR, i.e. at the level 
of the insulin receptor substrates, remains to be studied in more detail.
Introduction
The novel multiligand somatostatin (SRIF) analog SOM230 has recently 
been demonstrated to have the potential to increase the number of acrome-
galic patients can be biochemically controlled during long-term medical 
treatment. SOM230, compared with the current clinically available SRIF-
analog OCT, can lower circulating growth hormone (GH) concentrations 
effectively via SRIF receptor subtype (sst) 2 and sst
5
, while OCT (at physi-
ological concentrations) can only mediate GH suppression in vivo via sst
2
. 
However, as SRIF and SRIF-analogs modulate the secretion of insulin and 
glucagon via the sst subtype expression within the endocrine pancreas, a 
reduced glucose tolerance and even overt hyperglycaemia were initially 
expected during long-term therapy of acromegaly. In general, the effects 
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of SRIF-analogs on glucose homeostasis appeared to be minor and a mild 
deterioration occurred only in those without impaired glucose tolerance 
(1). Indeed, compared with OCT, comparable post-prandial elevations of 
glucose concentrations after lunch were observed after SOM230 admin-
istration (2). In addition, 250µg SOM230 elicited an acute rise of glucose 
levels 1 h post-injection (3). SOM230-mediated inhibitory effects on in-
sulin secretion cannot explain these elevated glucose levels. While glu-
cagon release appeared far less sensitive for SOM230 as compared with 
OCT (44-fold) in several animal models in vivo, and because peripheral 
glucagon measurement does not represent pancreatic glucagon (gastro-
intestinal glucagon is measured as well) concentrations, the effects of 
SOM230 and OCT on glucagon levels were not analyzed. Since SOM230 
administration did not result in a dramatic attenuation of absolute insu-
lin concentrations, we hypothesize a potential local role of SOM230 in 
regulating glucose homeostasis in insulin-targeted tissues. The expres-
sion of only sst
1
 and sst
2 
in target tissues of insulin action (3), might point 
towards potential modulatory effects by SOM230 on insulin sensitivity. 
Therefore, we carried out additional experiments in a series of visceral 
omental fat tissues as well as in Huh-7 cells, to further explore whether sst 
expression and activation can alter the insulin receptor signaling cascade. 
Methods
Patients and RNA isolation
Sst mRNA expression in visceral (omental) fat tissue was analyzed. Per-
operative obtained human omental fat biopsies from 6 patients were col-
lected. All patients underwent a Whipple procedure because of chronic 
fi brosing pancreatitis (n=1), Vater’s papilla carcinoma (n=2) or pancreas 
carcinoma (n=3). The collected omental tissues were directly snap frozen 
and stored at -80 °C. The protocols were in accordance with the Helsinki 
Doctrine on Human Experimentation, and were performed according to 
the rules of the hospital medical ethical committee. Informed consent 
was obtained from all patients. Collected tissues were grinded to powder 
on dry ice using a mortar and total RNA was isolated using RNeasy
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Lipid Tissue Mini Kit for adipose tissue samples (QIAGEN, Westburg 
B.V., Leusden, The Netherlands) according to manufacturers protocol. 
Cell culture
Huh-7 cells, a human hepatoma cell line, were routinely passaged by tryp-
sinization as described in detail previously (4). The cells were maintained in 
75 cm2 fl asks in Dulbecco’s Minimal Essential Medium (DMEM), supple-
mented with non essential amino acids, sodium pyruvate (1 mmol/L), 10% 
fetal calf serum (FCS), penicillin (1x105 U/L), fungizone (0.5 mg/L), L-
glutamine (2 mmol/L), and sodium bicarbonate (2.2 g/L), pH 7.6. The cells 
were cultured at 37° C in a CO
2
-incubator. Media and supplements were ob-
tained from GIBCO Bio-cult Europe (Invitrogen, Breda, The Netherlands).
Quantitative PCR
Quantitative PCR was performed as described previously (5). Messen-
ger RNA was isolated using Dynabeads Oligo (dT)
25
 (Dynal AS, Oslo, 
Norway) from 1.0 X 106 cells Huh-7 cells or isolated visceral omental 
adipocyte tissue. The cells were lysed for 2 min in an ice-cold Tris-buf-
fer (100 mM Tris-HCl, pH 8, 500 mM LiCl, 10 mM EDTA, 1% LiDS, 5 
mM DTT and 5 U/100µl RNAse inhibitor (HT Biotechnology Ltd., Cam-
bridge, UK). The mixture was centrifuged at 14,000 rpm for 1 min to re-
move cell debris. After adding 40 µl pre-washed Dynabeads Oligo (dT)
25
to the supernatant, the mixture was incubated for 5 min on ice. Thereafter, 
the beads were collected with a magnet, washed three times with a Tris-
buffer (10 mM Tris HCl, pH 8, 0.15 M LiCl, 1 mM EDTA, 0.1% LiDS), 
and once with a similar buffer from which LiDS was omitted. Messenger 
RNA was eluted from the beads in 2 x 20 µl H
2
O for 2 min at 65 °C. Com-
plementary DNA (cDNA) was synthesized using the poly A+ mRNA in a 
Tris-buffer (50 mMTris-HCl, pH 8.3, 100 mM KCl, 4 mM DTT, 10 mM 
MgCl
2
) together with 1 mM of each deoxynucleotide triphosphate, 10 U 
RNAse inhibitor, and 2 U AMV Super Reverse Transcriptase (HT Bio-
technology Ltd., Cambridge, UK) in a fi nal volume of 40 µl. This mixture 
was incubated for 1 h at 42 °C. One tenth of the cDNA library was used 
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for quantifi cation of sst subtype mRNA levels. The assay was performed 
using 15 µl TaqMan Universal PCR master mix (Applied Biosystems, 
Capelle aan de IIssel, The Netherlands), 500 nM forward primer, 500 nM 
reverse primer, 100 nM probe and 10 µl cDNA template, in a total reac-
tion volume of 25 µl. The reactions were carried out in a ABI 7700 se-
quence detector (The Perkin-Elmer Corporation, Foster City, CA). PCR 
amplifi cation started with a fi rst step for 2 min at 50 °C, followed by 
an initial heating at 95 °C for 10 min and, subsequently, samples were 
subjected to 40 cycles of denaturation at 95 °C for 15 sec and annealing 
for 1 min at 60 °C. To ascertain that no detectable genomic DNA was 
present in the poly A+ mRNA preparation, since sst genes are intron-less, 
the cDNA reactions were also performed without reverse transcriptase. 
The detection of hypoxanthine-phosphoribosyl-transferase (hprt) mRNA 
served as a control and was used for normalization of the sst subtype 
mRNA levels.  The primer sequences that were used have been described 
in detail previously (6). In addition, the relative amount of sst subtype 
mRNA was determined using a standard curve generated from known 
amounts of human genomic DNA. For determination of the amount of 
hprt mRNA, a standard curve was generated of a pool of cDNAs from a 
human cell line known to express hprt (6). The relative amount of sst sub-
type mRNA was calculated by normalization to the amount of hprt mRNA 
and is given in arbitrary units. Each sample was assayed in duplicate.
Insulin receptor (IR) autophosphorylation assay
After trypsinizing confl uent 75 cm2 fl asks, Huh-7 cells were dispersed 
in 6 well plates (500.000 cells/well). The following day, culture medium 
was removed and cells were maintained for 1 hr in Krebs buffer (pH 
7.4). Subsequently, Krebs buffer was refreshed and Huh-7 cells were in-
cubated with different concentrations of insulin (10nM-1pM) and 10nM 
SOM230 or OCT (as indicated in Figure legends). Washing the cells with 
ice-cold PBS terminated incubation. Huh-7 were collected in PBS and 
centrifuged. Supernatant was removed and the cell pellet lysed for 30 
minutes, on ice, in 1mL of Cell Extraction Buffer [10mM Tris, pH 7.4; 
119
SRIF Receptors and Insulin Signaling
100mM NaCl; 1mM EDTA; 1mM EGTA; 1mM NaF; 20mM Na
4
P
2
O
7
; 
2mM Na
3
VO
4
; 1% Triton X-100; 10% glycerol; 0.1% SDS; 0.5% deoxy-
cholate; 1mM PMSF and Protease inhibitor cocktail (Sigma, cat. no P-
2714, 250µl per 5mL cell extraction buffer)]. Cell extract was centrifuged 
for 10 min at 4°C at 13,000 rpm and clear lysates were stored at -80°C. 
100µl clear lysate was diluted 10-fold and used, according to the manu-
facturer’s protocol, in a solid phase sandwich Enzyme Linked-Immuno-
Sorbent Assay (ELISA), designed to detect and quantify the levels of IR 
that are phosphorylated at tyrosine (Tyr) residues 1162 and 1163 of IR 
(Biosource, Nivelles, Belgium). Briefl y, during the fi rst 2 hr incubation 
the IR antigen binds to a monoclonal antibody specifi c for IR (β-sub-
unit), which has been coated on the wells. After washing, an antibody 
specifi c for IR phosphorylated at Tyr1162 and Tyr1163 is added to the 
wells for 1 hr. After removal of excess detection antibody, a horseradish 
peroxidase (HRP)-labeled anti-rabbit IgG is added for 30 min, complet-
ing the four-member sandwich. After washing to remove excess anti-
rabbit IgG-HRP, a substrate solution was added for 30 min in the dark, 
which is acted upon the bound enzyme to produce colour. After addition 
of a stop solution, wells were stirred and absorbance (optical density) 
was detected at 450 nm. The intensity of the colored product is direct-
ly proportional to the concentration of IR [pYpY1162/1163] present in 
the original specimen. 1 Unit of standard is equivalent to the amount 
of IR [pYpY1162/1163] derived from 0.6 ng of IR in CHO cells, trans-
fected with human IR, stimulated with 100 nM insulin. The intra- and 
inter-assay coeffi cients of variation were 4.85% and 5.98%, respectively.
Statistical analysis
The statistical signifi cance of the difference between the effects of 10nM-
1pM insulin and 10 nM SRIF-analogs in the IR-autophosphorylation ELI-
SA assay was determined by using one-way analysis of variance (ANOVA). 
When signifi cant overall effects were obtained by this method, comparisons 
were made using Newman-Keuls multiple comparisons test. Data are re-
ported as means ± SEM of the indicated n values, unless otherwise specifi ed.
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Results
Sst mRNA expression
In all six visceral omental adipocyte tissues, both sst
1 
and sst
2
 were 
expressed (Fig. 1A: relative copy number 435 ± 103 and 841 ± 151, 
respectively, p<0.01). The other sst subtypes, sst
3-5
, were not ex-
pressed. As depicted in Figure 1B, Huh-7 cells expressed sst
1 
(rela-
tive copy number 201 ± 22) and sst
2 
(relative copy number 357 ± 
44; p<0.01 vs sst
1
), while sst
3-5
 mRNA expression was not found.
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Figure 1. Quantitative analysis of RT-PCR showing the relative amounts of the five 
SRIF receptor subtypes, sst
1-5
, mRNA in visceral omental fat tissue (A) and Huh-7 cells 
(B), calculated relative to the amount of HPRT and given in arbitrary units. A) Data 
represent the mean ± S.E. of 6 visceral fat specimens, of which each individual pa-
tient sample was assayed in duplicate. B) Data represent the mean ± S.E. of three in-
dependent experiments, performed in duplicate. nd; not detectable. #, p<0.01 vs sst
1
.
IR-autophosphorylation in Huh-7 cells
First, we explored the insulin-induced concentration-dependent auto-
phosphorylation of the IR in Huh-7 cells during different incubation pe-
riods, i.e. 2, 5 and 30 minutes. After all three incubation periods, a dose-
dependent increase of IR-autophosphorylation by insulin was observed 
(Fig. 2). After 2 minutes of insulin treatment, depicted in fi gure 2A, a 
signifi cant 3 to 4-fold increase in IR-autophosphorylation in Huh-7 cells 
by 10 and 1 nM insulin was observed. In addition, after 5 minutes of 
insulin treatment (Fig. 2B), 0.1 and 0.01 nM insulin also signifi cantly 
increased IR-autophosphorylation in Huh-7 cells compared with non-
stimulated cells. At 30 minutes of insulin treatment, the increase in IR 
autophosphorylation was reduced compared with the 2 and 5 minutes 
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Figure 2. Concentration-dependent induction of IR-autophosphorylation by insulin. 
Huh-7 cells were dispersed in 6-wells plates, treated for 2 (A), 5 (B) and 30 (C) min-
utes with insulin (10 nM – 0.001 nM range) in Krebs buffer (ph 7.4). A solid phase 
sandwich ELISA, was used to detect and quantify the levels of IR that are phosphory-
lated at tyrosine residues 1162 and 1163 of IR in the lysates (Biosource, Nivelles, Bel-
gium). Data are expressed as Units/mL IR, and represent the mean ± S.E. of separate 
experiments, performed in duplicate. #, p<0.01 vs. non-stimulated Huh-7 cells (con-
trol). When error bars are not apparent the S.E. values were smaller than symbol size.
incubation periods, although a 2-fold increase by 10 and 1nM insulin 
compared with non-stimulated Huh-7 cells was still observed (Fig. 3C). 
On the basis of these ‘control’ experiments, we chose a 3-minute incuba
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Figure 3. Effect of SOM230 and OCT on IR-autophosphorylation. Huh-7 cells 
were dispersed in 6-wells plates, treated for 3 minutes with 10 nM SOM230 or 
10 nM OCT in Krebs buffer (pH 7.4). Data are expressed as Units/mL IR, and rep-
resent the mean ± S.E of two individual experiments, performed in duplicate.
tion period with physiological concentrations of 1 and 0.1 nM insulin, to 
evaluate whether co-treatment with 10 nM SOM230 or OCT can alter in-
sulin-induced IR-autophosphorylation in sst
1
+sst
2
 expressing Huh-7 cells.
The incubation of Huh-7 cells with either 10 nM SOM230 or 10 nM 
OCT did not induce any change in IR-autophosphorylation (Fig. 3). 
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Figure 4. Effect of SOM230 and OCT on insulin-induced IR-autophosphorylation. Huh-7 
cells were dispersed in 6-wells plates, treated for 3 minutes with insulin in the presence or 
absence of a SRIF-analog in Krebs buffer (pH 7.4). (A) 1nM insulin +/- 10 nM SOM230, 
(B) 0.1nM insulin +/- 10 nM SOM230, (C) 1nM insulin +/- 10 nM OCT and (D) 0.1nM 
insulin +/- 10nM OCT. Data are expressed as Units/mL IR, and represent the mean ± S.E 
of 2 separate experiments, performed in triplicate. □, insulin; ■, insulin + SRIF-analog.
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When Huh-7 cells were treated for 3 minutes with 1 and 0.1 nM insu-
lin either alone or in combination with 10 nM SOM30, IR-autophos-
phorylation was not affected (Fig. 4A+B). As depicted in fi gure 4C 
and 4D, comparable results as for SOM230 were observed when Huh-
7 cells were co-treated with insulin (1 and 0.1 nM) and 10 nM OCT. 
Discussion
SOM230 administration in acromegalic patients does not result in a dra-
matic attenuation of absolute insulin concentrations that can totally ex-
plain the acute rise in glucose levels (3). Therefore, we hypothesized that 
SOM230 might induce altered insulin signaling in major target tissues such 
as liver, skeletal muscle and adipose tissue, i.e. the acute s.c administration 
of SOM230 in acromegaly seems to attenuate insulin sensitivity. During 
a single-dose Phase I study with SOM230, the increase in serum glucose 
levels was enhanced post-prandially as well and appeared dose-dependent, 
while similar observations were reported in multiple-dose studies (7).
Crucial for a potential role of SRIF-analogs, in particular SOM230, in 
modulating the insulin signaling cascade, is the presence of sst in these 
insulin-target tissues. The sst mRNA expression pattern observed in all 
individual 6 specimens from visceral omental fat tissue, i.e. only sst
1 
and 
sst
2 
mRNA, are in agreement with previously reported mRNA data in vis-
ceral fat tissue (3). The insulin receptor (IR) is a tetrameric glycoprotein 
consisting of two α and two β subunits linked by disulfi de bonds. The 
intracellular β subunit is a tyrosine kinase that is activated when insulin 
binds to the extracellular α-subunit. The tyrosine kinase autophosphory-
lates the insulin receptor and initiates subsequent intracellular phosphor-
ylations that mediate the multiple actions of insulin (8). The predominant 
downstream signal after IR autophosphorylation is activation of the insu-
lin receptor substrate (IRS) proteins (9). IRS-1 and other recently cloned 
IRS proteins (IRS-2, -3, -4) are phosphorylated upon insulin stimulation 
and have adaptor functions between the IR and other cellular substrates 
(10). Insulin increases glucose uptake in muscle and fat, inhibits hepatic 
glucose production and promotes the storage of substrates in fat, liver and 
muscle, and inhibits lipolysis, glycogenolysis and protein breakdown (11). 
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Insulin action can be attenuated by protein tyrosine phosphatases (PTP), 
which catalyse the rapid dephosphorylation of the receptor and the IRS 
substrates (8, 12). The fi ve SRIF receptors are known to mediate a vari-
ety of signal transduction pathways, including protein dephosphorylation 
through PTP activation (13-15). Several in vitro studies using sst-express-
ing tumor cells already demonstrated that SRIF-receptors can activate 
tyrosine phosphatases, thereby slowing tumor cell growth stimulated by 
tyrosine kinases (16-18). In particular, Bousquet and coworkers elegantly 
demonstrated in CHO-K1 cells, stably expressing sst
2
, that addition of the 
sst
2
-preferential analog RC-160 to insulin resulted in a higher and more 
sustained increase of the tyrosine phosphatase SHP-1 association to IR, 
that was directly correlated with an inhibition of phosphorylation of IR 
and IRS-1 (19). Also, activation of sst
1
 subtype enhances PTP activity as 
well (20). The expression of sst
1
 and sst
2 
in target tissues of insulin action, 
might form the molecular target point for effects by SOM230 on insulin 
signaling. SOM230, via sst
1
 and/or sst
2
 activation, might increase PTP 
Table I. Binding selectivity of SRIF-analogs for the five sst subtypes.
Binding affinity (IC50, nM) 
Compound 
sst1 sst2 sst3 sst4 sst5
Somatostatin-14 2.3 0.2 1.4 1.8 1.4 
Octreotide 280 0.4 7.1 >1000 6.3 
SOM230 9.3 1.0 1.5 >100 0.2 
Data are from radioligand binding assays to membranes from transfected CHO-K1 
cells and African green monkey kidney cells expressing the different human sst sub-
types (28).
activation, which subsequently could result in IR- or IRS-dephosphory-
lation. Eventually, by attenuating the insulin-signaling cascade, plasma 
glucose levels might remain elevated due to impaired glucose metabo-
lism in peripheral target tissues. Based on sst
1
 and sst
2
 binding affi nity 
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differences between SOM230 and OCT, i.e. a 30-fold higher and 2.5-fold 
lower affi nity, respectively (Table I), we hypothesize that sst
1
 alone, or in 
combination with sst
2
, might be involved in SOM230-mediated effects on 
insulin signaling. This would also explain why OCT 100µg did not induce 
a profound glucose release, because this OCT dosage is by far not enough 
to activate sst
1
 due to its very low sst
1
 binding affi nity (EC
50
 >100 nM).
However, our experiments in Huh-7 cells, which were shown to express 
only sst
1 
and sst
2
 at the mRNA level which, do not demonstrate that sst
1 
or sst
2
 activation can attenuate tyrosine phosphorylation at the IR itself. 
We selected Tyr1162and Tyr1163, since the catalytic loop of the tyrosine 
kinase domains of the IR involves a three-tyrosine motif corresponding to 
Tyr1158, 1162 and 1163 (21). It is generally believed that autophosphory-
lation within the activation loop proceeds a progressive manner initiating 
at the second tyrosine (1162), followed by phosphorylation at the fi rst 
tyrosine (1158), then the last (1163), upon which the IR becomes fully 
active (21). The 10 nM concentration of both SRIF-analogs should have 
been suffi ciently high to activate sst
1 
(only by SOM230) or even sst
2
. Pos-
sibly, attenuation of insulin signaling by SOM230 could also take place 
at the level of IRS-1or IRS-2 proteins. Both IRS-1 and IRS-2 knockout 
mice exhibit insulin resistance (22-25) while IRS-3 and IRS-4 knockout 
mice have a normal metabolic profi le (26). Therefore, it will be interest-
ing to evaluate whether phosphorylation of IRS-1 and/or IRS-2 can be al-
tered via sst
1 
and/or sst
2
 activation by SOM230. It should also be notifi ed 
that the Huh-7 cells have not been thoroughly screened regarding their 
IR-pharmacology; other human hepatoma cell lines or, preferentially, hu-
man primary cell cultures should be investigated as well to evaluate the 
IR-autophosphorylation involvedness in more detail. Moreover, human 
primary adipocytes and myocytes have to be investigated as well, since 
these two represent the other target organs of peripheral insulin action 
throughout the human body. In vivo analysis of IR-autophosphorylation 
in mice can also form a potential target to investigate the role of sst in 
insulin signaling, although interspecies variation can be a burden for 
translating data from mice to men. Still, mice lacking PTP1B are hyper-
responsive to insulin, and liver specifi c re-expression of PTP1B in these 
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PTP1B knock-out mice led to marked attenuation of their enhanced insu-
lin sensitivity (27). This observation was probably caused by preferential 
dephosphorylation of Tyr1162/1163 residues of the IR by PTP1B in vivo.
SOM230
sst2
sst2sst1
sst2
sst1
sst2
PTP
IRS
IR
P
I
� insulin sensitivity
&
� glucose uptake
serum [glucose]
I secretion
X
+
+
+
Figure 5. Schematic overview of possible physiological pathways involved in the 
hyperglycaemic effect induced by SOM230. I, Insulin; IR, Insulin receptor; IRS, In-
sulin receptor substrate; P, phosphorylated state of the receptor/protein; PTP, pro-
tein tyrosine phosphatase and sst, SRIF-receptor subtype. Solid lines represent the 
proposed primary metabolic route of SOM230-induced hyperglycaemia via altera-
tion of insulin sensitivity in peripheral target organs of insulin action; dashed lines 
form the minor involvement of SOM230-mediated suppression of insulin secretion.
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In fi gure 5, we have summarized our data with respect to the potential 
physiological pathways involved in the hyperglycaemic effect induced 
by SOM230. Our data in 12 acromegalic patients demonstrated that 
SOM230 lowers insulin secretion from pancreatic β-cells. The inhibi-
tion of insulin secretion seems to be mediated via sst
2 
while OCT, with 
a 2.5 fold higher sst
2
 binding affi nity as SOM230, inhibited insulin se-
cretion more pronounced as compared with SOM230. In addition, only 
SOM230 injection resulted in an acute raise in glucose levels. There-
fore, we hypothesized that SOM230 might alter insulin signaling, i.e. 
SOM230 lowers insulin sensitivity. The sst
1 
and sst
2
 mRNA expression 
in peripheral target tissues of insulin action, namely liver, visceral fat 
and muscle, form a crucial factor that might point towards a role of sst in 
the insulin signaling cascade. Based on the binding affi nities of SOM230 
and OCT for sst
1 
and sst
2
, and the observation that only SOM230 caused 
an acute raise in glucose levels, we suggest that sst
1 
alone or in com-
bination with sst
2
, might be responsible for attenuating insulin signal-
ing. SOM230, may activate PTPs, leading to dephosphorylation of IRS 
proteins but not the IR, as no alteration of the IR-autophosphorylation 
by SOM230 or OCT in Huh-7 cells was observed. Eventually, this 
would increase insulin resistance, which, together with a subtle sup-
pression of insulin secretion, results in elevated serum glucose levels.
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Abstract
Although recent insights demonstrate that somatostatin (SRIF) receptor 
subtype (sst) 5, compared with sst
2
, is highly expressed in the majority of 
growth hormone (GH-) secreting pituitary adenomas, it has been suggest-
ed that the sst
2
 is the (pre-) dominant receptor in regulating GH release 
by GH-secreting pituitary adenoma cells in vivo and in vitro, whereas sst
5
receptors may mediate an inhibitory effect on GH secretion as well. The 
objective of the present study was to investigate whether a functional 
interplay occurs between sst
2
 and sst
5
. Therefore, a cAMP Response Ele-
ment-Luciferase Reporter Gene Assay and [125I-Tyr11]-SRIF-14 radioli-
gand binding studies were used in several series of transiently co-trans-
fected HEK 293 cells expressing a constant level of sst
2
 mRNA and sst
5
mRNA varying from low (sst
2
>>sst
5
) to high (sst
2
<<sst
5
). The effi cacy 
of the sst
2
-preferring SRIF-analog Octreotide (OCT) appeared not to be 
affected by the different sst
2
/sst
5
 expression ratios, whereas the sst
5
-pre-
ferring SRIF-analog BIM-23206 was only maximally effective if the sst
5
expression level was superior to sst
2
 expression. The same pattern as for 
BIM-23206, although to a lesser extent was observed for the multiligand 
SOM230. In conclusion, these results demonstrate a functional interplay 
between the key-players in the regulation of human GH release. The sst
2
appears to function in a dominant manner over sst
5
, while sst
5 
itself can 
only serve at maximal potency when sst
5 
expression far exceeds that of sst
2
.
Introduction
Somatostatin (SRIF) exerts its biological effects via fi ve distinct high af-
fi nity membrane receptor subtypes (sst) that belong to the family of G-
protein-coupled receptors (GPCR) (1). These sst are particularly densely 
and homogenously distributed over the growth hormone (GH-) secreting 
pituitary tumors of acromegalic patients (2-4). Most GH-secreting pitu-
itary adenomas predominantly express mRNA and protein for sst
2 
and sst
5
, 
while sst
1
 and sst
3
 are moderately expressed and sst
4
 are not found (5-7). 
SRIF binds with high affi nity to all fi ve sst subtypes (8), whereas currently 
available SRIF-analogs octreotide (OCT) and lanreotide display a high, 
moderate and low affi nity to sst
2
, sst
3+5 
and sst
1+4
, respectively (9). The 
sst
2
-preferring SRIF analogs have been demonstrated to control hormonal 
hypersecretion successfully in about two-thirds of acromegalic patients 
136
Chapter IV-1
(10-12). In acromegalic patients only partially responsive to OCT or lan-
reotide, a relatively low expression of sst
2
 receptors in the GH-secreting 
pituitary adenomas of these patients likely explains the partial sensitivity 
to these SRIF-analogs (13). Recent insights show that sst
5
 receptors are 
highly expressed in the majority of GH-secreting pituitary adenomas (13, 
14). Novel SRIF-analogs targeting both sst
2
 and sst
5
 seem more potent 
in suppressing GH release, compared with sst
2
 selective SRIF-analogs 
(15). A fi rst proof-of-concept clinical trial testing a single s.c. adminis-
tration of SOM230, a SRIF-analog with a more universal binding to sst 
(16, 17), showed a signifi cant suppression of circulating GH levels in 11 
of 12 patients, suggesting that novel SRIF-analogs with binding affi nity 
to both sst
2
 and sst
5
 have the potency the increase the number of patients 
that can be controlled biochemically during long-term medical treatment 
(18). GH inhibition from GH-secreting pituitary adenomas by OCT cor-
relates, in vitro as well as in vivo, with quantitative expression of sst
2
mRNA but not for sst
5
 mRNA (13, 14). Surprisingly, although SOM230 
shows a very high binding affi nity for sst
5
 receptors, no signifi cant corre-
lation was found between the in vitro GH suppression by a maximally ac-
tive concentration of SOM230 and sst
5
 mRNA levels, whereas a positive 
correlation was found between the effects of SOM230 and sst
2
 mRNA 
levels (14). Therefore, it has been suggested that the sst
2
 seems the (pre-
) dominant receptor in regulating GH release by GH-secreting pituitary 
adenoma cells, whereas sst
5
 receptors may mediate an inhibitory effect 
on GH secretion as well. A direct proof for this hypothesis is currently 
lacking, however. Therefore, the objective of the present study was to use 
different sst subtype selective and universal SRIF-analogs in HEK293 
cells, transfected with variable quantities of human sst
2 
and sst
5
 receptors 
to investigate whether a functional interplay occurs between sst
2
 and sst
5
.
Materials and Methods
Cell line culture and sst constructs
HEK 293 cells (kind gift of Dr. A.P.N. Themmen, Internal Medicine, 
Erasmus MC Rotterdam, the Netherlands) were routinely passaged by 
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trypsinization as described in detail previously (19). The cells were main-
tained in 75 cm2 fl asks in DMEM/F-12 medium, supplemented with non 
essential amino acids, sodium pyruvate (1 mmol/L), 10% fetal calf serum 
(FCS), penicillin (1*105 U/L), streptomycin (50 mg/L), fungizone (0.25 
mg/L), L-glutamine (2 mmol/L), and sodium bicarbonate (2.2 g/L), pH 
7.6. The cells were cultured at 37° C in a CO
2
-incubator. Before transfec-
tion, the cells were seeded at 40% confl uence in 75 cm2 fl asks and trans-
fected the next day using the calcium phosphate precipitation method.
In order to create a series of different sst
2
/sst
5
 ratios being expressed, HEK 
293 cells were transiently transfected with various concentrations of human 
sst
2 
and sst
5 
cDNA [human sst
2
 or sst
5
 cDNA in pBluescript (pBS) (a kind 
gift of G.I. Bell, Howard Hughes Medical Institute Chicago, Illinois) was 
excised from pBS and inserted into the Nhe-1/Sal1 or EcoRI/XbaI cloning 
site, respectively, of the mammalian expression vector pCi-neo (Promega 
Benelux, Leiden, the Netherlands)]. Media and supplements were ob-
tained from GIBCO Bio-cult Europe (Invitrogen, Breda, the Netherlands). 
Forskolin-induced cAMP Response Element-Luciferase Re-
porter Gene Assay
The functional responses of the SRIF-analogs in the various cell systems 
were determined using a cAMP-responsive reporter construct that con-
tains six cAMP response elements in tandem in front of the cDNA en-
coding the luciferase (LUC) reporter enzyme [pCRE6lux (20)]. HEK293 
cells were co-transfected with pCRE6Lux (20) and pRSVlacZ, to con-
trol for transfection effi ciency (21) (maximum of 10 µg sst-expression 
construct, 2 µg pRSVlacZ, 2 µg pCRE6Lux, and 6 µg carrier DNA per 
ml precipitate). Three days after transfection the SRIF-analog dependent 
CRE-LUC response was determined in 48-well tissue culture plates (Co-
star, Cambridge, MA) by incubating the cells for 6 h in culture medium 
containing 0.1% BSA with 1 µM forskolin (FSK) and increasing con-
centrations of SRIF-analog (range 100 nM – 0.01 pM) and, in another 
series of experiments, also in the absence or presence of 50 nM BIM-
23454 (sst
2
-antagonist). Subsequently, the media were aspirated, the cells 
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lysed and luciferase activity was measured using a TopCount luminom-
eter after adding luciferin (22). β-Galactosidase activity of the lysates 
was determined to correct for transfection effi ciency (21). The CRE-LUC 
response produced by 1 µM FSK in each experiment was set at 100%. 
Radioligand binding studies
Scatchard Analysis
To determine the binding affi nity (Kd) and total receptor number (Bmax), 
HEK293 cells were transfected with different amounts of sst
2 
and sst
5 
DNA 
(maximum of 14µg total sst-expression construct and 6 µg carrier DNA 
per ml precipitate). Three days after transfection, Scatchard analysis using 
[125I-Tyr11]-SRIF-14 binding experiments was performed. The method of 
membrane isolation and the reaction conditions were previously described 
(23). Briefl y, membrane preparations (corresponding to 50 µg protein) of 
transiently transfected HEK 293 cells, were incubated in a total volume 
of 100 µl at room temperature for 45 min with increasing concentrations 
of [125I-Tyr11]-SRIF-14 and with or without excess (1 µM) of unlabeled 
Tyr11-SRIF-14, respectively, in Hepes buffer (10 mM Hepes, 5 mM MgCl
2
and 0.02 g/L bacitracin, pH 7.6) containing 0.2% BSA. After the incuba-
tion, 1 mL ice-cold Hepes buffer was added to the reaction mixture, and 
membrane-bound radioactivity was separated from unbound by centrifu-
gation during 2 min at 14,000 rpm in a Eppendorf microcentrifuge. The 
remaining pellet was washed twice in ice-cold Hepes buffer, and the fi nal 
pellet was counted in a γ-counter. Specifi c binding was taken to be total 
binding minus binding in the presence of 1 µM unlabeled Tyr11-SRIF-14. 
Competition experiments
In competition experiments, membrane preparations of transiently trans-
fected HEK 293 cells, as described above, were incubated in a total volume 
of 100 µl at room temperature for 45 min with 25 µl [125I-Tyr11]-SRIF-14 
(40.000cpm) and either 25 µl binding assay buffer (total binding) or 1 nM 
OCT, SOM230, BIM-23206 or OCT and BIM-23206, in Hepes buffer (10 
mM Hepes, 5 mM MgCl
2
 and 0.02 g/L bacitracin, pH 7.6) containing 0.2% 
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BSA. After the incubation, 1 mL ice-cold Hepes buffer was added to the 
reaction mixture, and membrane-bound radioactivity was separated from 
unbound by centrifugation during 2 min at 14,000 rpm in an Eppendorf 
microcentrifuge. The remaining pellet was washed twice in ice-cold Hepes 
buffer, and the fi nal pellet was counted in a γ-counter. Experiments were 
conducted in triplicate for each separate co-transfection of sst
2
 and sst
5.
Quantitative PCR
Quantitative PCR was performed as described previously (24). Messen-
ger RNA was isolated using Dynabeads Oligo (dT)
25
 (Dynal AS, Oslo, 
Norway) from transiently transfected (72 h) HEK 293 cells. The cells 
were lysed for 2 min in an ice-cold Tris-buffer (100 mM Tris-HCl, pH 
8, 500 mM LiCl, 10 mM EDTA, 1% LiDS, 5 mM DTT and 5 U/100µl 
RNAse inhibitor (HT Biotechnology Ltd., Cambridge, UK). The mixture 
was centrifuged at 14,000 rpm for 1 min to remove cell debris. After 
adding 40 µl pre-washed Dynabeads Oligo (dT)
25
 to the supernatant, the 
mixture was incubated for 5 min on ice. Thereafter, the beads were col-
lected with a magnet, washed three times with a Tris-buffer (10 mM Tris 
HCl, pH 8, 0.15 M LiCl, 1 mM EDTA, 0.1% LiDS), and once with a 
similar buffer from which LiDS was omitted. Messenger RNA was eluted 
from the beads in 2 x 20 µl H
2
O for 2 min at 65 °C. Complementary DNA 
(cDNA) was synthesized using the poly A+ mRNA in a Tris-buffer (50 
mMTris-HCl, pH 8.3, 100 mM KCl, 4 mM DTT, 10 mM MgCl
2
) together 
with 1 mM of each deoxynucleotide triphosphate, 10 U RNAse inhibi-
tor, and 2 U AMV Super Reverse Transcriptase (HT Biotechnology Ltd., 
Cambridge, UK) in a fi nal volume of 40 µl. This mixture was incubated 
for 1 h at 42 °C. One tenth of the cDNA library was used for quantifi ca-
tion of sst subtype mRNA levels. The assay was performed using 15 µl 
TaqMan Universal PCR master mix (Applied Biosystems, Capelle aan de 
IJssel, The Netherlands), 500 nM forward primer, 500 nM reverse primer, 
100 nM probe and 10 µl cDNA template, in a total reaction volume of 25 
µl. The reactions were carried out in a ABI 7700 sequence detector (The 
Perkin-Elmer Corporation, Groningen, The Netherlands). PCR amplifi -
cation started with a fi rst step for 2 min at 50 °C, followed by an initial 
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heating at 95 °C for 10 min and, subsequently, samples were subjected to 
40 cycles of denaturation at 95 °C for 15 sec and annealing for 1 min at 60 
°C. To ascertain that no detectable genomic DNA was present in the poly 
A+ mRNA preparation, since sst genes are intron-less, the cDNA reactions 
were also performed without reverse transcriptase. The detection of hypo-
xanthine-phosphoribosyl-transferase (hprt) mRNA served as a control and 
was used for normalization of the sst subtype mRNA levels. The primer 
sequences that were used have been described in detail previously (14). 
Dopamine D2 receptor(D2R)  assay
In order to create both D2R-expressing as well D2R and sst
2
+sst
5
 co-
expressing HEK 293 cells, transient transfections were carried out with 
human D2R cDNA (commercially available at UMR cDNA resource 
center; www.cDNA.com) in the absence and presence of human sst
2
+sst
5 
cDNA, respectively. Quantitative RT-PCR for the detection of D2R 
mRNA expression was carried out as above, whereby the concentration 
of forward primer, reverse primer and probe were 300 nM, 300 nM and 
200 nM, respectively. The D2R-primer sequences that were used were; 
Forward: 5’- GCCACTCAGATGCTCGCC-3, 
Reverse: 5’- ATGTGTGTGATGAAGAAGGGCA-3’ and 
Probe:   5 ‘FAM - TTGTTCTCGGCGTGTTCATCATCTGC-TAMRA-3
Test-substances
Octreotide (OCT, Sandostatin®) was obtained from Novartis Phar-
ma A.G., (Basel, Switzerland). SOM230 was synthesized by Novar-
tis Pharma A.G. Somatostatin-14 was purchased from Sigma Chemi-
cal Co. (St. Louis, MO). BIM-23206, a sst
5
-subtype specifi c analog, 
and BIM-23454, a sst
2
 antagonist, were synthesized by IPSEN (Mas-
sachusetts, USA). Sst binding affi nities are depicted in Table I. [125I-
Tyr11]-SRIF-14 was purchased from Amersham (Houten, The Nether-
lands). Cabergoline was obtained from Pharmacia-Pfi zer (Rome, Italy).
Statistical analysis
The statistical signifi cance of the difference between the effects of 1 nM 
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SRIF-analog in the CRE-LUC Reporter Gene Assay and radioligand 
competition experiments were determined by using one-way analysis 
of variance (ANOVA). When signifi cant overall effects were obtained 
by this method, comparisons were made using Newman-Keuls multiple 
comparisons test. Calculation of IC
50
 values for inhibition of FSK-in-
duced cAMP response was made using GraphPad Prism version 3.02 (San 
Diego, CA). The unpaired Student t-test was chosen to analyze differ-
ences in concentration-effect curves. Pearson correlation coeffi cient was 
used for correlation analysis between concentration-effect curves and the 
sst
5 
mRNA expression levels (both Log-transformed). Data are reported 
as means ± SEM of the indicated n values, unless otherwise specifi ed.
Table I. Binding selectivity of SRIF-analogs for the five human sst re-
ceptor subtypes used in this study.
Binding affinity (IC50, nM) 
Compound 
sst1 sst2 sst3 sst4 sst5
SRIF-14a 1.1 0.2 1.4 0.5 1.4 
Octreotide 280 0.4 7.1 >1000 6.3 
SOM230 9.3 1.0 1.5 >100 0.2 
BIM-23206 >1000 166 1000 >1000 2.4 
BIM-23454 � ND 31.6 ND ND 138.7 
Data are from radioligand binding assays to membranes from transfected CHO-K1 cells 
(16, 28) and African green monkey kidney cells (16) expressing the different human sst 
subtypes. Values are from IPSEN (Culler, M.D.), and from Lewis and coworkers (16). 
Data for SRIF-14 are summarized from Refs (17, 25-28). ≠, sst2 antagonist; ND, not done.
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Results
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Figure 1. Dose-dependent inhibition of FSK-induced cAMP response by OCT (▲), 
SOM230 (□) and BIM-23206 (●) in transiently transfected HEK 293 cells, express-
ing only sst
2
 (A) or sst
5
 (B). cAMP response was determined with the use of six cop-
ies of a cAMP response element (CRE)-luciferase reporter gene construct (CRE-LUC). 
β-Galactosidase activity of the lysates was determined to correct for transfection ef-
ficiency. The cAMP (CRE-LUC) response produced by 1 µM FSK in each experiment 
was used as 100% (average stimulation by 1 µM FSK; 5 ± 2 fold over control). The val-
ues represent the means ± S.E. from at least 2 experiments performed in quadruplicate. 
Expression of sst
2
 (C) and sst
5 
(D) mRNA levels in a series of transiently co-transfected 
HEK 293 cells, with a fixed concentration sst
2
 cDNA plasmid (10 μg) and increasing con-
centrations of sst
5 
cDNA plasmid (0.1-4 μg). Sst and hprt mRNA levels were quantified 
by a TaqMan assay and results are depicted as bars, representing the means ± S.E. from 
2 separate experiments performed in duplicate, and are adjusted for HPRT expression. 
First, in order to validate the CRE-LUC assay, functional properties of the 
SRIF-analogs to inhibit FSK-stimulated cAMP response in transiently 
transfected HEK 293 cells, expressing only sst
2
 or sst
5
, were explored. In 
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wild type HEK 293 cells, no inhibitory effects of the SRIF-analogs to inhibit 
FSK-stimulated cAMP response was observed (data not shown). As depict-
ed in fi gure 1A, in sst
2
-expressing HEK 293 cells, a concentration-depen-
dent inhibition of cAMP response was seen for OCT (IC
50
 0.02±0.08 nM) 
and SOM230 (IC
50
 0.6±0.12 nM), while BIM-23206 suppressed FSK-in-
duced cAMP response only at 10-100 nM (IC
50
 13±0.11 nM). FSK-induced 
cAMP response in HEK293 cells, expressing sst
5
 (Fig.1B) was dose-de-
pendently inhibited by SOM230 (IC
50
 0.09±0.09 nM) and BIM-23206 (IC
50
0.24±0.10 nM), while OCT appeared the least potent (IC
50
 4.6±0.12 nM). 
To evaluate whether sst
2
 and sst
5
 receptor expression can infl uence the 
functional properties of each receptor subtype, we compared the poten-
cies of the SRIF-analogs at the physiological 1 nM concentration to in-
hibit FSK-induced cAMP response in a series of transiently transfected 
HEK 293 cells, in which a constant sst
2 
mRNA expression level was main-
tained together with increasing sst
5
 mRNA expression levels (Fig. 1C 
and 1D). As shown in fi gure 2A, OCT suppressed FSK-induced cAMP 
response to a similar extent independent of the ratio sst
2
/sst
5
 transfected 
and, moreover, equalled its potency to suppress cAMP response in sst
2
-
expressing HEK 293 cells only. On the other hand, the inhibitory effects 
of BIM-23206 (1 nM) signifi cantly increased with increasing sst
5
 expres-
sion, i.e. from 9 ± 5% to 38 ± 8% and fi nally 56 ± 7% (p < 0.05; Fig.2B). 
Moreover, only when sst
5 
expression was greater than sst
2
 expression, 
the inhibitory potency of 1nM BIM-23206 was not signifi cantly differ-
ent as compared with inhibition of FSK-induced cAMP response in the 
sst
5
 mono-transfected HEK 293 cells. Although 1 nM SOM230 already 
suppressed FSK-induced cAMP response by 51 ± 6% in sst
2
-expressing 
HEK 293 cells, a similar pattern of inhibitory potency as for BIM-23206 
was observed for the multiligand SOM230, i.e. inhibition of FSK-induced 
cAMP response improved when sst
5 
expression was increased (Fig. 2C). 
Subsequently, in order to evaluate whether IC
50
 values of the inhibitory 
effects of OCT, BIM-23206 and SOM230 on FSK-induced cAMP re-
sponse would be infl uenced by different sst
2 
and sst
5
 mRNA expression 
levels, full concentration-response experiments were performed. The IC
50
value for OCT in all sst
2
/sst
5
 transfectants was comparable to the IC
50
 of 
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Figure 2. SRIF-agonist (1 nM) induced inhibition of FSK-induced cAMP response in 
a series of transiently transfected HEK 293 cells, expressing only sst
2 
or sst
5 
as well as 
co-expressing both sst subtypes in different ratios. Bars represent the means ± S.E. from 
2 separate experiments performed in quadruplicate. A) 1 nM OCT; *, p<0.01 sst
5 
vs. all 
other groups: B) 1 nM BIM-23206; #, p<0.05 vs. all other groups and C) 1 nM SOM230; 
$, p<0.05 sst
2 
vs. 1:1, sst
2
 < sst
5 
and sst
5
; +, p<0.05 sst
2
 > sst
5
 vs. sst
2
 < sst
5
 and sst
5
.
Concentration-dependent inhibition of FSK-induced cAMP response by OCT (D), BIM-
23206 (E) and SOM230 (F) in a series of transiently co-transfected HEK 293 cells, with 
a fixed concentration sst
2 
cDNA plasmid (10 μg) and enhanced concentrations of sst
5
cDNA plasmid (0.1-4 μg). The data points represent the mean ± S.E. from separate mea-
surements performed in quadruplicate. IC
50 
values are indicated in the results section.
OCT in HEK 293 cells only expressing sst
2
 (Fig. 2D). In contrast, in-
creasing sst
5
 expression, while sst
2
 expression remained at a similar level, 
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induced the concentration-response curve of BIM-23206 to shift to the 
left, indicating increased potency. The IC
50
 shifted 40-fold from 15 ± 0.14 
nM without sst
5
 to 0.37 ± 0.09 nM in the presence of the highest expres-
sion of sst
5 
(p<0.05; Fig. 2E). Apparently, only when sst
5
 level exceeds 
sst
2
 expression, the concentration-response curve was comparable to the 
dose-dependent inhibitory effects of BIM-23206 on FSK-induced cAMP 
response in HEK 293 cells only expressing sst
5
. The concentration-re-
sponse curve of SOM230 shifted 8-fold to the left as well, although the 
difference was not statistically signifi cant (Fig. 2F). Its corresponding 
IC
50 
value of 0.10 ± 0.05 nM at the lowest sst
2
/sst
5
 ratio, i.e. the highest 
sst
5
 expression, was the only IC
50 
value that reached a comparable value 
as for the sst
5
 mono-transfectant for which SOM230 has a superior mem-
brane binding affi nity. On the other hand, in all sst
2
/sst
5
 ratio levels tested, 
IC
50 
values of SOM230 were below 1 nM. In addition, a signifi cant nega-
tive correlation was observed for the IC
50
 of BIM-23206 in relation to 
the amount of sst
5
 mRNA expressed in this series of co-transfected HEK 
293 cells (r=-0.89, p=0.02). The correlation coeffi cient for SOM230 was 
-0.69 (p=0.13), while no correlation was observed when the IC
50 
value 
of OCT was correlated with sst
5 
mRNA expression (r=0.42, p=0.41)
Radioligand binding studies
First, saturation binding experiments in a series of transiently transfect-
ed HEK 293 cells with different sst
2 
and sst
5 
cDNA concentrations were 
performed and compared with the corresponding mRNA data (Fig. 3). 
In wild type HEK 293 cells, saturation binding revealed no expression 
of sst receptors (data not shown). When HEK293 cells expressed more 
sst
2 
than sst
5
 mRNA or when these cells co-expressed an approximate-
ly 1:1 mRNA ratio, as can be seen in fi gure 3E and 3F (B
max 
428±127 
fmol/mg protein, Kd 0.19±0.1 nM and B
max 
277±19 fmol/mg protein, Kd 
0.16±0.03 nM, respectively), scatchard analysis showed one set of sst 
membrane binding sites. As depicted in fi gure 3G, two sets of sst mem-
brane binding sites, however, were visualized if HEK 293 cells were 
transfected with superior concentration of sst
5
 cDNA compared with 
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Figure 3. Quantification of mRNA expression levels and Scatchard analysis of [125I-
Tyr11]-SRIF-14 binding in a series of transiently co-transfected HEK 293 cells, with 
different expression ratios of sst
2
 and sst
5.
 A-D) Sst
2
 (black bars) and sst
5
 (open bars) 
mRNA levels, together with hprt mRNA levels, were quantified by a TaqMan assay and 
results are depicted as bars, representing the means ± S.E. from 2-3 separate experiments 
performed in duplicate, and are adjusted for hprt expression. E-H) Scatchard analysis 
using [125I-Tyr11]-SRIF-14 was performed to determine the binding affinity (Kd) and 
total receptor number (Bmax). Each figure is a representative of 2-3 individual experi-
ments. The calculated (mean ± S.E.) Kd and Bmax of each co-transfectant, are described 
in detail in the Results section. ■, “sst
2
-like” binding sites; □, “sst
5
-like” binding sites.
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sst
2
 cDNA (“sst
2
-like”, B
max 
98±16 fmol/mg protein and Kd 0.09±0.02 
nM; “sst
5
-like”, B
max 
202±30 fmol/mg protein and Kd 0.3±0.09 nM), 
which appeared even more pronounced when sst
5
 cDNA concentration 
was enhanced (Fig. 3D and 3H: “sst
2
-like”, B
max 
124±25 fmol/mg pro-
tein and Kd 0.10±0.08 nM; “sst
5
-like”, B
max 
287±35 fmol/mg protein 
and Kd 0.35±0.10 nM). The difference in Kd for the “sst
2
-like” binding 
sites compared with the Kd for “sst
5
-like” membrane binding sites seem 
well in agreement with the reported (slightly) better membrane binding 
affi nity of SRIF-14 for sst
2
 compared with sst
5
 [Table I; (17, 25-28)].
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Figure 4. Competition experiments for [125I-Tyr11]-SRIF-14 specific binding sites on iso-
lated cell membranes from sst
2
 (A), sst
5 
(B) and from four different sst
2
/sst
5
 ratio-express-
ing (C-F) HEK 293 cells. 50 μl of membrane preparations of transiently transfected HEK 
293 cells were incubated in a total volume of 100 µl at room temperature for 45 min with 
25 µl [125I-Tyr11]-SRIF-14 (40.000cpm) and either 25 µl binding assay buffer (total bind-
ing = 100%) or with 1 nM OCT, SOM230, BIM-23206 or OCT and BIM-23206. After the 
incubation, 1 mL ice-cold Hepes buffer was added to the reaction mixture, and membrane-
bound radioactivity was separated from unbound by centrifugation during 2 min at 14,000 
rpm in a Eppendorf microcentrifuge. The remaining pellet was washed twice in ice-cold 
Hepes buffer, and the final pellet was counted in a γ-counter. Bars represent the means ± 
S.E. from 2-3 separate experiments performed in triplicate for each transfection with sst
2 
or sst
5
. When error bars are not apparent the S.E. values were smaller than symbol size.
148
Chapter IV-1
Competition experiments for [125I-Tyr11]-SRIF-14 binding sites on isolat-
ed cell membranes from HEK293 cells expressing four different sst
2
/sst
5
ratios (Fig. 3A-D) by the SRIF-analogs at the physiological concentration 
of 1 nM were compared with their potencies in the sst
2
 and sst
5
 mono-
transfectants. Figure 4A, in agreement with the receptor binding affi nities 
of the SRIF-analogs for sst
2
, demonstrates that the order of potency to 
displace [125I-Tyr11]-SRIF-14 binding sites in sst
2
-expressing HEK 293 
cells was: OCT =/> OCT+BIM-23206 > SOM230 > BIM-23206. When 
the same analysis was carried out for the sst
5
-expressing cells (Fig. 4B), 
the order of potency to displace [125I-Tyr11]-SRIF-14 binding sites ap-
peared: SOM230 > BIM-23206 = OCT+BIM-23206 > OCT, which was 
in accordance with the sst
5
-binding affi nities of the SRIF-analogs. As for 
the co-transfectants, OCT at 1 nM remained the most potent SRIF-ana-
log throughout all four situations to displace [125I-Tyr11]-SRIF-14 binding 
sites (Fig. 4C-F) and showed the same displacement effi cacy as of OCT 
in the sst
2
 mono-transfectant. On the other hand, 1 nM BIM-23206 dem-
onstrated displacement of [125I-Tyr11]-SRIF-14 binding  similar to the sst
5
mono-transfectant (-45 ± 3%) only when sst
5
 expression was superior 
compared with sst
2
 expression ( -19 ± 2%, fi g. 4C; -19 ± 2%, fi g. 4D; 
-32 ± 2%, fi g. 4E and -47 ± 2%, fi g. 4F; p<0.05). As already demon-
strated for the cAMP response experiments, SOM230 showed a compa-
rable pattern as BIM-23206 in the radioligand competition experiments 
although to a considerably lesser extent. Moreover, 1 nM SOM230 was 
most potent to displace [125I-Tyr11]-SRIF-14 binding sites when sst
5
 had 
the highest expression level (Fig. 4F, -57 ± 2%) and once more, only in 
this latter co-transfectant the effi cacy of SOM230 equalled its effi cacy 
in the sst
5
 mono-transfectant (-57 ± 3%) as well as the effi cacy of OCT 
(-59 ± 1%). Co-treatment with OCT and BIM-23206 at a fi nal concen-
tration of 1 nM was as effi cacious as 1 nM OCT in all co-transfectants.
The sst
2 
antagonist BIM-23454 in sst
2
+sst
5
 expressing HEK 
293 cells
We also evaluated the functional responses of the SRIF-analogs in the 
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sst
2
/sst
5
 co-transfected HEK293 cells, when sst
2
 expression was function-
ally blocked. Therefore, we used the sst
2 
antagonist BIM-23454 in the 
CRE-LUC assay. We used a 50 nM concentration for the sst
2
-antago-
nist, which is suffi cient to bind sst
2 
but not sst
5
, because the binding af-
fi nity is 32 nM and 138 nM, respectively. As depicted in fi gure 5, 50 
nM BIM-23454 did not alter FSK-induced CRE-LUC gene activation, 
both in sst
2
 (Fig. 5A) and in sst
5
 (Fig. 5B) expressing HEK 293 cells. 
In the presence of BIM-23454, the dose-dependent inhibition of FSK-
induced cAMP response by OCT in sst
2
-expressing HEK 293 cells, 
shifted 40-fold to the right, indicating decreased potency (Fig. 5C). How-
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Figure 5. Control experiments for BIM-23454 in HEK-293 cells, only expressing 
sst
2
 or sst
5
. Effect of 50 nM BIM-23454 on FSK (1µM)-induced activation of CRE-
LUC reporter gene construct, corrected for RSVlacZ (21) expression in sst
2
 (A) or 
sst
5
 (B) expressing HEK 293 cells. Control, open bars; FSK, black bars and FSK+ 
50 nM BIM-23454, hatched bars. Bars represent mean ± SE from two individual ex-
periments, performed in quadruplicate. Concentration-effect curves of OCT and 
BIM-23206 on FSK-induced cAMP response in sst
2 
(C) or sst
5 
(D) expressing HEK 
293 cells, respectively, in the presence (□) or absence (■) of 50 nM BIM-23454. 
Each graph is representative for two individual experiments, run in quadruplicate.
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ever, the dose-dependent inhibition of FSK-induced cAMP response by 
BIM-23206 in sst
5
-expressing HEK 293 cells was not affected (Fig. 5D)
Subsequently, in a series of transiently transfected HEK 293 cells, in 
which mRNA expression levels were comparable for sst
2
 and sst
5
, the 
dose-dependent inhibition of FSK-induced cAMP response by OCT shift-
ed 45-fold to the right, indicating decreased potency (Fig. 6A; IC
50
 0.04 ± 
0.09 nM in the absence and 1.8 ± 0.1 nM in the presence of 50 nM BIM-
23454). The inhibition of FSK-induced cAMP response by 1 nM OCT was 
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Figure 6. Effect of BIM-23454 on concentration-effect curves of OCT (A), BIM-23206 
(B) and SOM230 (C) on FSK-induced cAMP response in HEK 293 cells, express-
ing equal amounts of sst
2 
(10.1 ± 1.3 copies sst
2
/HPRT) and sst
5
 (10.3 ± 1.1 copies 
ss
t5
/HPRT) mRNA. Each graph is representative for two individual experiments, run 
in quadruplicate. (■) Control curve and (□) + 50 nM BIM-23454. (D) Dose-depen-
dent inhibition of FSK-induced cAMP response by Cabergoline in transiently trans-
fected HEK 293 cells, expressing D2R (●) or D2R and sst
2
+sst
5
 (○; 9.2 ± 4.4 copies 
D2R/HPRT, 6.5 ± 5.1 copies sst
2
/HPRT and 3.5 ± 2.3 copies sst
5
/HPRT). The values 
represent the means ± S.E. from at least 2 separate experiments run in quadruplicate.
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signifi cantly lowered in the presence of BIM-23454 (89 ± 1% vs 30 ± 3% 
suppression, p<0.05). However, the dose-dependent inhibition of FSK-
induced cAMP response by BIM-23206 shifted 15-fold to left when HEK 
293 cells were co-treated with BIM-23454 (Fig. 6B; IC
50
 from 1.5 ± 0.05 
nM to 0.1 ± 0.3 nM), indicating increased potency. Also, the inhibition 
of FSK-induced cAMP response by 1 nM BIM-23206 was signifi cantly 
enhanced in the presence of BIM-23454 (31 ± 5% vs 78 ± 2% suppres-
sion, p<0.05). The corresponding IC
50 
for the dose-dependent inhibition 
of FSK-induced cAMP response in sst
5
+sst
5
 expressing HEK 293 cells 
by SOM230 remained 0.1 nM in the presence of BIM-23454, while the 
inhibition at 1 nM SOM230 of FSK-induced cAMP response was almost 
80% in the presence as well as in the absence of BIM-23454 (Fig. 6C).
Cabergoline, a dopamine D2 receptor (D2R) agonist in 
sst
2
+sst
5
+D2R expressing HEK 293 cells
To evaluate whether the bio-availability of G-proteins could be a 
limitation in our experimental design, we set up a fi nal series of ex-
periments in which we introduced the Dopamine D2 receptor into 
co-transfected the D2R with sst
2
 and sst
5
.  As shown in fi gure 6D, the 
concentration dependent inhibition of FSK-induced cAMP response 
by Cabergoline, a D2R-agonist, was not affected when D2R was co-
expressed with both sst
2
 and sst
5
 (IC
50
 of CAB in the presence and ab-
sence of sst
2
+sst
5
 was 0.01 ±  0.09 nM vs 0.01 ± 0.06 nM, respectively).
Discussion
In the present study, the pharmacological profi les of several SRIF-analogs 
as determined by inhibition of FSK-induced cAMP response and radioli-
gand binding in HEK 293 cells expressing different sst
2
/sst
5
 ratios, provide 
quantitative evidence to support the concept that the sst
2
 is a functional 
dominant receptor subtype. While several reports have evaluated the in-
hibitory effi cacy of sst
2 
and sst
5 
activation in the regulation of GH secretion 
by use of primary cultures of GH-secreting pituitary adenomas (15, 28-
30), this report is the fi rst that investigated in a basic experimental design, 
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whether these two sst subtypes have a functional interplay with each other. 
The CRE-LUC assay, a reporter gene to quantify cAMP release, has been 
used frequently to analyze functional responses of different GPCR’s in 
transfected cell systems (20, 31, 32). Our observed functional responses 
(IC
50
) of the SRIF-analogs in the HEK 293 cells, only expressing sst
2 
or 
sst
5
, are well in agreement with the sst membrane binding affi nities of 
the different SRIF-analogs reported in literature (9, 27), i.e. OCT pref-
erentially acts via sst
2
, SOM230 is bi-selective for sst
2
 and sst
5
 but has 
superior (binding and functional) affi nity properties for sst
5
, and BIM-
23206 is 100-fold more sst
5
-specifi c as compared with sst
2
 (Table 1). Sub-
sequently, by evaluating the functional responses and the displacement 
of [125I-Tyr11]-SRIF-14 binding sites by OCT, BIM-23206 and SOM230 
in a series of sst
2
/sst
5
 co-transfectants , it is suggested that sst
5
 activation 
by sst
5
-specifi c SRIF analogs can only occur if sst
5
 subtype expression 
signifi cantly exceeds that of sst
2
 expression. Apparently, a substantial part 
of available BIM-23206 is bound to sst
2
, which explains its attenuated ef-
fi cacy to suppress FSK-induced cAMP response. SOM230, with a nano-
molar binding affi nity for sst
2
 but with a superior sub-nanomolar binding 
affi nity for sst
5
 is already effi cacious when sst
2 
expression is higher than 
sst
5 
expression but induces optimal functional responses when sst
2
/sst
5
expression ratios are low. Strikingly, a dominant sst
2
-mediated suppres-
sion, illustrated by OCT, is suggested as well as by the superior activity of 
OCT at low sst
2
/sst
5
 expression ratios with respect to inhibition of FSK-
induced cAMP release, as well as displacement of [125I-Tyr11]-SRIF-14 
binding sites. OCT-mediated effects are not sensitive for the degree of 
sst
5 
expression, as demonstrated by the absence of a correlation between 
the IC
50
 values of OCT and the expression levels for sst
5
, while the com-
pletely opposite is seen for BIM-23206. Therefore, our data support the 
observation that individual sst receptors in transfected cell systems have 
a good correlation between membrane binding affi nity and functionality 
(33), but when two sst subtypes are co-expressed, a functional interplay, 
i.e. dominance by sst
2
 over sst
5
, is observed. Finally, scatchard analysis 
of the co-transfectants, forms a third part of evidence in support of our 
hypothesis. The density of endogenous sst expression in receptor-rich tis-
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sues such as brain, pituitary and pancreas measured with a non-selec-
tive sst radioligand 125I-LTT-SRIF-28 (which detects all fi ve sst subtypes) 
ranges between 220 and 360 fmol/mg in rats (34, 35). Because receptor 
over-expression might form an artefact in interpreting functional relation-
ship between sst receptors (36), the total sst subtype expression obtained 
in our co-transfectants, 277-428 fmol/mg protein with a transfection ef-
fi ciency of approximately 35%, is within the range (107-2500 fm/pro-
tein) of sst receptor densities used in numerous reports that investigated 
SRIF receptor function (37-42). While scatchard analysis to calculate Kd 
and Bmax of the high sst
2
/sst
5
 and 1:1 ratio co-transfectants resulted in 
a single class of sst-binding sites, two distinct sets of binding sites be-
came apparent only when sst
5 
expression was superior to sst
2
 expression. 
In the latter co-transfectants, the lower Bmax with the lower and thus 
better Kd, may represent the “sst
2
-like” subtype, while enhanced “sst
5
-
like”expression is supported by higher Bmax values and a slightly higher 
Kd, which is well in agreement with the mRNA status of the co-transfec-
tants. So, two sets of sst-binding sites are found only when sst
5
 mRNA 
expression is expressed at superior level compared with sst
2
 mRNA. 
By the use of sst subtype selective SRIF-analogs, it has been demon-
strated that both sst
2
 and sst
5
 selective agonists suppress GH secretion 
(28, 29) in primary cell cultures from normal anterior pituitaries, as well 
as from GH-secreting pituitary adenomas. In agreement with the lat-
ter, sst
2
 and sst
5
 receptors are the predominantly expressed SRIF recep-
tor subtypes, both at the mRNA (7, 13, 14) and the protein level (6) in 
primary cultures of GH-secreting pituitary adenomas. The current clini-
cally used sst
2
-preferring SRIF analogs, OCT and lanreotide, have been 
successful in the treatment of acromegaly because of the high percent-
age of tumors expressing a signifi cant amount of sst
2
. In addition, while 
several groups demonstrated that the sst
5 
subtype seems to be expressed 
at a higher level as compared with sst
2
, only sst
2
 mRNA expression in 
GH-secreting pituitary adenomas shows a positive correlation with the 
in vivo GH suppression induced by an acute test using a single injec-
tion of 200µg OCT (13), as well as with the in vitro and in vivo respon-
siveness to OCT in another series of patients (14). Surprisingly, although 
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SOM230 shows a very high affi nity for sst
5
 receptors, no signifi cant 
correlation was found between the in vitro GH suppression by a maxi-
mally active concentration of SOM230 and sst
5
 mRNA levels, whereas 
a positive correlation was found between the effects of SOM230 and 
sst
2
 mRNA levels (14). Although these data were unexpected, a previ-
ous study by Jaquet and coworkers in fact already made the same obser-
vation using SRIF-14 (13). Moreover, Cervia and coworkers showed in 
AtT-20 cells, endogenously expressing sst
2
 and sst
5
 subtypes that most 
SRIF-analogs will act via sst
2
 receptors, even if they are capable of act-
ing via sst
5
 receptors (43). These observations are well in agreement with 
our data in transiently sst
2
+sst
5
 transfected HEK 293 cells and support 
the hypothesis that the sst
2
 receptor is functionally dominant over sst
5
.
Functional association of sst
2
 and sst
5
 has been suggested to mediate ad-
ditive GH inhibition, at least in human fetal pituitary cell cultures (30). 
In this study Ren and coworkers used a sst
2
 selective antagonist that was 
capable of reversing the GH suppressive effects of 10 nM of sst
2
/sst
5
 bi-
selective agonists, or that of sst
2
 and sst
5
 agonists (10 nM) in combi-
nation. Our results with SOM230, as well as with the co-treatment of 
OCT and BIM-23206 at the physiological concentration of 1 nM do not 
show an enhanced functionality to inhibit adenylyl cyclase, nor to dis-
place sst membrane binding sites. If SOM230 would induce functional 
association of both subtypes, maximal effects would have occurred in 
other co-transfectants than the lowest sst
2
/sst
5 
ratio co-transfectant as 
well. Previous studies already demonstrated that SOM230 inhibits GH 
release in a higher number of GH-secreting pituitary adenomas compared 
with OCT, both in vitro (14, 44) and in vivo (18), but not with a better 
effi cacy in terms of maximal GH-suppressive effect or lower IC
50
 value. 
Nevertheless, although sst
2 
seems the dominant receptor subtype as new 
SRIF-analogs with enhanced sst
2
 binding affi nities inhibit GH secretion 
more potently compared to OCT, SOM230 is able to lower GH levels 
in both OCT-responders (via sst
2
) and partial responders (via sst
5
) and, 
therefore, SRIF analogs bispecifi c for sst
2
 and sst
5
 have a clear advan-
tage over OCT and might increase the number of acromegalic patients 
that can be biochemically controlled during long-term medical treat-
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ment. Our experiments with the sst
2 
antagonist BIM-23454, demonstrate 
indeed that SOM230 can still be effective when sst
2 
availability is low 
(as in those acromegalic patients in which OCT is ineffective). In the 
presence of BIM-23454, both OCT and BIM-23206 drift towards their 
sst
5 
binding affi nity and their IC
50
 values are comparable with the IC
50
values observed in the sst
5
-transfectants. These data confi rm that OCT 
is not effective when sst
2
 is expressed at a low level, i.e. cannot lower 
GH in the subgroup of acromegalic patients that are (partially) non-re-
sponders for OCT, but SOM230 can still be effi cacious to lower FSK-
induced cAMP response because it now can function via sst
5
 receptors.
A critical refl ection regarding our observations, reveals that up till now, no 
intracellular regulatory mechanism is investigated that can account for the 
functional dominance of sst
2
. Studies which describe GPCR signal trans-
duction, especially with respect to individual sst subtype binding to G-
proteins, seem crucial to understand the physiological rationale behind the 
sst
2
 dominance hypothesis. However, the results with Cabergoline (CAB), 
a dopamine agonist which has superior binding affi nity for the G-protein 
coupled D2 receptor (45), show that the effi cacy of CAB is not affected 
when sst
2
+sst
5
 receptors are being co-expressed together with the G-pro-
tein coupled D2R. These data strongly suggest that the amount of G-pro-
tein available in our experimental design is not a limiting factor causing the 
observed functional interplay between sst
2
 and sst
5
. Nevertheless, a further 
understanding of the stoichiometry of ligand-receptor and G-protein com-
plex by GTPγS binding-, co-immunoprecipitation- and/or fl uorescence 
tagged receptor- studies can be of experimental help in this matter (46-48).
In conclusion, our report is the fi rst that investigated the functional in-
terplay between the key-players in the regulation of human GH re-
lease, i.e. the sst
2
 and sst
5 
subtype. The sst
2
 appears to function in 
a dominant way over sst
5
, while sst
5 
itself can only serve at maxi-
mal potency when sst
2
/sst
5 
expression ratio is low. The multiligand 
SOM230 can mediate GH inhibition via both sst
2 
and sst
5
, which make 
SRIF-analogs targeting both sst subtypes suitable candidates to in-
crease the number of acromegalic patients biochemically controlled.
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RNA interference as a novel tool 
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Abstract
Short interfering RNAs (siRNAs) resulting into silencing of specifi c 
genes by double-stranded RNA (dsRNA), have been developed for sys-
tematically deciphering the functions of protein coding genes of the hu-
man genome. We have used the mammalian expression vector pSUPER, 
that directs the synthesis of siRNA-like transcripts, to suppress soma-
tostatin receptor subtype (sst) 2 and sst
5
 gene expression in mammalian 
cell lines. Two designed siRNAs for the sst
2 
gene potently lowered mRNA 
expression levels in stably sst
2
-expressing CHO-K1 cells (74-75% sup-
pression, p<0.05 vs control and scrambled). The siRNA-sst
5 
plasmid, 
transiently transfected in sst
5
-expressing HEK 293 cells, potently sup-
pressed sst
5
 mRNA expression levels (>75%). In conclusion, we have 
demonstrated that the synthesized siRNA constructs for the sst
2 
and sst
5 
gene have the merit to become an interesting novel tool to evaluate the 
individual role of endogenously expressed sst receptors in primary cells.
Introduction
Studies on protein function through the inhibition of their action have 
been critical for our understanding of many normal and abnormal bio-
logical processes. Numerous approaches, ranging from small molecule 
antagonists to knockout animals, have resulted into substantial advances 
in our understanding of the function of many proteins. Still, a lack of 
specifi city or restricted applicability has limited their utility. The dis-
covery that long double-stranded RNA molecules (dsRNA) can induce 
sequence-specifi c silencing of gene expression in primitive organisms, 
such as Caenorhabditis elegans and Drosophila melanogaster, revealed 
a previously unknown mechanism of gene regulation which is highly 
conserved throughout multicellular organisms (1, 2). This process is 
called RNA interference (RNAi) which mediates gene silencing via two 
main steps: (i) the dsRNA is initially recognised by an enzyme of the 
RNAse III family of nucleases, named Dicer (the enzyme that normal-
ly produces siRNA in vivo), and processed into small double-stranded 
molecules, termed siRNA and (ii) the siRNAs are bound by the RNA-
induced silencing complex (RISC), which is a multi-protein complex 
(with RNase activity) that guides the targeted RNA to degradation (3). 
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However, in most mammalian cells the introduction of dsRNA pro-
vokes a strong cytotoxic response (4, 5). By synthesizing short interfer-
ing RNAs (siRNA) this non-specifi c effect can be circumvented and a 
transient reduction in gene expression can be observed. To overcome 
the limitation in the duration of the effect, a new mammalian expres-
sion vector that directs the synthesis of siRNA-like transcripts [pSUPER] 
was designed (6). It was demonstrated that siRNA expression mediated 
by this vector caused effi cient and specifi c down-regulation of gene ex-
pression, resulting in functional inactivation of the targeted genes (6).
Somatostatin (SRIF), a cyclic peptide produced in the hypothalamus, 
throughout the central nervous system, as well as in most major peripheral 
organs, inhibits hormone release from the anterior pituitary gland, pancreas 
and the gastro-intestinal tract (7, 8). Five different SRIF receptor subtypes 
(sst
1-5
) have been identifi ed (9, 10). These receptor subtypes are variably 
expressed in the SRIF-target tissues (11, 12). Sst bind with varying affi n-
ity to the different SRIF-analogs, which were synthesized for clinical ap-
plication (13, 14) as well as for basic science (15, 16), thereby providing 
a tool to unravel the (patho-) physiological function of the fi ve sst’s. We 
have used the pSUPER vector to suppress sst
5
, transiently transfected in 
mammalian cells, in order to evaluate if RNAi can be of use to study the 
individual role of  sst
2 
and sst
5
 in the regulation of growth hormone (GH) 
release from primary cultures of GH-secreting pituitary adenoma cells.
Methods
Cell culture
For expression of sst
2
 and sst
5
 in Chinese hamster ovaries (CHO)-K1 
cells, human sst
2
 and sst
5
 cDNA in pBluescript (pBS) (a kind gift of G.I. 
Bell, Howard Hughes Medical Institute Chicago, Illinois) was excised 
from pBS and inserted into the Nhe-1/Sal1 or EcoRI/XbaI cloning site, 
respectively, of the retroviral expression vector pCi-neo. Selection was 
made by the geneticine resistance gene (G418). This vector was used to 
stably transfect (using DOTAP) CHO-K1 cells. Stably transfected CHO-
K1 cells were selected and cultured in nutrient mixture F12 (HAM) me-
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dium [supplemented with penicillin (100 U/mL), streptomycin (100 μg/
mL), fungizone (0.25 μg/mL) and 10% FCS + geneticine (0.5 mg/mL)]. 
HEK 293 cells (kind gift of Dr. A.P.N. Themmen, Internal Medicine, 
Erasmus MC Rotterdam, the Netherlands) were cultured in DMEM/F-
12 medium, supplemented with 10% fetal calf serum (FCS), penicillin 
(1*105 U/L), streptomycin (50 mg/L), fungizone (0.25 mg/L) and L-
glutamine (2 mmol/L). The cells were maintained in 75 cm2 fl asks at 
37°C in a CO
2
-incubator and routinely passaged by trypsinization as de-
scribed in detail previously (17). Media and supplements were obtained 
from GIBCO Bio-cult Europe (Invitrogen, Breda, the Netherlands). 
Preparation of siRNA
Three different siRNAs for sst
2
, one siRNA for sst
5
 and one scrambled 
control were designed. The predicted structures of the synthetic siRNA 
constructs are depicted in Figure 1. The 19nt target sequence for sst
5 
(H-
219) and sst
2
 (H-121) were fl anked in the mRNA with AA at the 5’ end of 
the sense strand. Regions at the mRNA to select all the 19nt from were 
within the coding region: 100 bp from start and termination of translation. 
GC richness of all 19nt targeting sequence was more than 30%. To pre-
vent premature termination of the transcript, the 19nt that were selected 
must not contain a stretch of four or more Adenines or Thymidines. Fur-
thermore, two siRNA constructs for sst
2
, H-523 and H-573, were selected 
for a high Adenine and/or Thymidine content at the 5’ end of the antisense 
strand (18). Coding sequences for siRNA were analyzed by BLAST re-
search at the National Center for Biotechnology Information against all 
human sequences deposited in the GenBank and RefSeq data-bases and 
were not found to have signifi cant homology to genes other than the targets.
Oligonucleotides were synthesized by Sigma (Zwijndrecht, The Neth-
erlands). Double-stranded siRNA was prepared as described previ-
ously (6). Briefl y, single stranded oligonucleotides were annealed 
with corresponding complementary single-stranded DNA oligonucle-
otides, separated by a short hairpin spacer. The resulting transcript 
is predicted to fold back on itself to form a 19-base pair stem loop 
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(Fig.1). The resultant dsDNA hairpin was inserted into Bgl II-Hin-
dIII site of pSUPER-H1 to generate siRNA plasmids. DH5α compe-
tent cells were transformed with the resultant plasmids. Plasmid DNA 
was purifi ed using a commercial DNA purifi cation kit (QIAGEN).
UUUUUCUGAUGGAGGUGGAGA
AAAGACTACCTCCACCTCT U
U
C
A
A
G
A
G
A
3’-
5’
SiRNA sst5 H-219
UUACGUCAGGAGUGUAAGUAG
TGCAGTCCTCACATTCATC U
U
C
A
A
G
A
G
A
3’-
5’
UUCGUCGACGUGGUAGUUGAC
GCAGCTGCACCATCAACTG U
U
C
A
A
G
A
G
A
3’-
5’
UUGGCAGUGGUUGUAGAUGUA
CCGUCACCAACAUCUACAU U
U
C
A
A
G
A
G
A
3’-
5’
UUGAACGGGUAGUACUAUAUA
CTTGCCCATCATGATATAT U
U
C
A
A
G
A
G
A
3’-
5’
Scrambled
SiRNA sst2 H-121
SiRNA sst2 H-573
SiRNA sst2 H-523
A
C
B
D
E
Figure 1. Structure of synthetic siRNA constructs. The numbers in italic indicate 
the nucleotide position at which the 5’ end of the sense strand of the siRNA match-
es the sst gene reference sequence. The scrambled construct was created on a ran-
dom basis. In general, the 19nt sequences from the target transcript are separated by 
a short spacer from the reverse complement of the same sequence, predicted to fold 
back on itself to form a 19 base pair stem loop structure, i.e. short hairpin siRNA (6).
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Transfection of sst
2
-expressing CHO-K1 cells and mRNA 
analysis
Batches of 1x106 stably sst
2
-expressing CHO-K1 cells were used in 
each transfection experiment with the NucleofectorTM (AMAXA Bio-
systems, Germany). Harvested cells were spin down at 1800 rpm for 5 
min, and the medium removed. Cells were then resuspended in 100μl 
NucleofectorTM solution T (AMAXA Biosystems) at room temperature 
followed by addition of 2 μg RNAi H-121, RNAi H-523, RNAi H-573, 
scrambled or pSUPER cDNA. The mixture of cells, solution and cDNA 
was transferred to a 2 mm electroporation cuvette (AMAXA Biosys-
tems) inserted in the NucleofectorTM and program U-23 (>90% transfec-
tion effi ciency) used for transfecting the cells. Immediately after trans-
fection, 500μl of medium was added to the cells to reduce damage of 
the cells. Finally, 1x105 transfected cells were resuspended in a total 
volume of 1mL in 24-well plates. After 72 hr of incubation, cells were 
lysed and collected for quantitative RT-PCR of sst
2
, as described below.
Transfection and quantitave RT-PCR in HEK 293 cells
Before transfection, wild-type HEK 293 cells were seeded at 40% confl u-
ence in 75 cm2 fl asks and transfected the next day using the calcium phos-
phate precipitation method. HEK 293 cells were transiently transfected 
with various concentrations of human sst
5 
cDNA as well as 5μg RNAi 
cDNA or carrier cDNA. Quantitative PCR was performed as described 
previously (19). Messenger RNA was isolated using Dynabeads Oligo 
(dT)
25
 (Dynal AS, Oslo, Norway) from transiently transfected (72hr) 
wild-type HEK 293 cells. The cells were lysed for 2 min in an ice-cold 
Tris-buffer (100 mM Tris-HCl, pH 8, 500 mM LiCl, 10 mM EDTA, 1% 
LiDS, 5 mM DTT and 5 U/100µl RNAse inhibitor (HT Biotechnology 
Ltd., Cambridge, UK). The mixture was centrifuged at 14,000 rpm for 
1 min to remove cell debris. After adding 40 µl pre-washed Dynabeads 
Oligo (dT)
25
 to the supernatant, the mixture was incubated for 5 min on 
ice. Thereafter, the beads were collected with a magnet, washed three 
times with a Tris-buffer (10 mM Tris HCl, pH 8, 0.15 M LiCl, 1 mM 
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EDTA, 0.1% LiDS), and once with a similar buffer from which LiDS was 
omitted. Messenger RNA was eluted from the beads in 2 x 20 µl H
2
O for 
2 min at 65 °C. Complementary DNA (cDNA) was synthesized using the 
poly A+ mRNA in a Tris-buffer (50 mMTris-HCl, pH 8.3, 100 mM KCl, 
4 mM DTT, 10 mM MgCl
2
) together with 1 mM of each deoxynucleo-
tide triphosphate, 10 U RNAse inhibitor, and 2 U AMV Super Reverse 
Transcriptase (HT Biotechnology Ltd., Cambridge, UK) in a fi nal volume 
of 40 µl. This mixture was incubated for 1 h at 42 °C. One tenth of the 
cDNA library was used for quantifi cation of sst subtype mRNA levels. 
The assay was performed using 15 µl TaqMan Universal PCR master mix 
(Applied Biosystems, Capelle aan de IIssel, The Netherlands), 500 nM 
forward primer, 500 nM reverse primer, 100 nM probe and 10 µl cDNA 
template, in a total reaction volume of 25 µl. The reactions were car-
ried out in a ABI 7700 sequence detector (The Perkin-Elmer Corporation, 
Foster City, CA). PCR amplifi cation started with a fi rst step for 2 min 
at 50 °C, followed by an initial heating at 95 °C for 10 min and, subse-
quently, samples were subjected to 40 cycles of denaturation at 95 °C for 
15 sec and annealing for 1 min at 60 °C. To ascertain that no detectable 
genomic DNA was present in the poly A+ mRNA preparation, since sst 
genes are intron-less, the cDNA reactions were also performed without 
reverse transcriptase. The detection of human hypoxanthine-phosphoribo-
syl-transferase (hprt) mRNA in HEK293 cells served as a control and was 
used for normalization of the sst subtype mRNA levels. The primer se-
quences that were used have been described in detail previously (20, 21). 
Statistical analysis
The statistical signifi cance was determined by using one-way analysis of 
variance (ANOVA). When signifi cant overall effects were obtained by the 
ANOVA method, comparisons were made using Newman-Keuls multiple 
comparisons test. Data are reported as means ± SEM of the indicated n values. 
Results
First, three siRNA-sst
2 
plasmids were tested, compared with scrambled, in 
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stably expressing sst
2
-CHO-K1 cells that were transfected via electropora-
tion by the NucleofectorTM technology. As can be seen in fi gure 2, silencing 
at the mRNA level occurred with varying effi cacy (24-75% suppression 
of sst
2
/HPRT mRNA expression), while both the empty pSuper-H1 vector 
and the scrambled construct did not alter sst
2
/HPRT mRNA expression.
  
siRNA effi cacy was for sst
5
 explored on sst
5
 mRNA expression with various 
concentrations of sst
5 
cDNA. When 5μg sst
5 
cDNA was used, the siRNA-
sst
5 
plasmid suppressed sst
5 
mRNA expression by 75% in transiently trans-
fected sst
5
-HEK293 cells (Fig. 3A). moreover, when the concentration of 
sst
5 
cDNA, co-transfected in HEK 293 cells, was lowered 10-fold, siRNA 
at the mRNA level showed a 92% reduction of sst
5
 expression (Fig. 3B). 
control pSuper scrambled H-121 H-523 H-573
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Figure 2. Expression of sst
2 
mRNA levels in a series of sst
2
-expressing CHO-K1 cells 
transiently transfected (72hr, by NucleofectorTM) with three different siRNA constructs 
for sst
2
 (2µg). Sst and HPRT mRNA levels were quantified by a TaqMan assay and 
results are depicted as bars, representing the means ± S.E. from two experiments per-
formed in quadruplicate, and are adjusted for HPRT expression.  #, p<0.05 compared 
with control and scrambled.
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Figure 3. Quantification of sst
5
 gene expression and analysis of sst
5
 recep-
tor mRNA in transiently (72 hr) co-transfected HEK 293 cells with (A) 5µg sst
5  
or 
(B) 0.5µg sst
5 
plasmid and 5µg siRNA plasmid. Sst
5
 and HPRT mRNA expres-
sion levels were quantified by a TaqMan assay and results are depicted as bars, 
representing the means ± S.E. from two experiments performed in quadrupli-
cate. Control group is transfected with 5µg pSuper vector. ■, siRNA ; □, control.
Discussion
Over the past years RNAi has been introduced as a new approach to ma-
nipulate gene expression in mammalian systems. On the basis of a new 
mammalian expression vector that directs the synthesis of short hairpin 
siRNA-like transcripts [pSUPER] (6), which have been demonstrated to 
trigger gene silencing (22, 23), we synthesized a siRNA constructs for sst
2
and sst
5 
and evaluated its effi cacy to down-regulate sst gene expression. 
Effective silencing of the sst
2 
and sst
5 
mRNA expression in sst-transfected 
CHO-K1 cells and HEK 293 cells, respectively, by use of our RNAi con-
structs was successful. It is generally believed that the siRNA needs to be 
double stranded in order to be effi ciently recognized and bound to RISC, 
the two siRNA strands must unwind before RISC becomes active (24). 
Several studies revealed that only the antisense strand of the siRNA is in-
corporated into the enzymatic machinery of the RISC complex and effec-
tive siRNA exhibited decreased stability of the 5’ strand of the antisense 
strand (18, 25, 26). It should therefore be desirable to design the siRNA 
duplex in a way that the antisense strand is the one to be preferentially used 
by RISC. This prompted us to synthesize two additional sst
2 
targeted siR-
NA constructs (H-523 and H-573) which enrolled these guidelines (18). 
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Thermodynamic profi les, the standard Gibbs free energies, which refl ect 
the stability of pentamer sequences, would favour the H-523 construct as 
being effi cacious to silence the sst
2
 gene as it contains a rich A/T region 
at the 5’ end of the antisense strand. However, H-523 was not effective to 
down-regulate sst
2 
mRNA expression in our model, while the other two 
constructs suppressed sst
2 
expression with approximately 75%. It should 
be noted that highly effective siRNA sequences can be found that do not 
adhere these criteria and that some siRNAs that adhere to the criteria do 
not function well (26). Interestingly, in retrospect, the synthesized siRNA-
sst
5 
construct appeared to follow several of these guidelines, i.e. rich A/T 
area at 5’ of the antisense strand, a rich C/G area at the 5’ end of the sense 
strand and the absence of any GC stretch of more than 9nt in length (18). 
A vital assumption in the application of siRNA-mediated RNAi as a func-
tional genomics tool is that the knockdown of a targeted gene is specifi c 
both at the RNA and protein level. Additional experiments will have to 
be done to demonstrate that the siRNA constructs for sst we have de-
veloped are also capable to reduce the function of the receptor as well. 
Studies that involve specifi c sst-membrane binding with the use of ra-
diolabeled SRIF-14 or studies which evaluate SRIF-induced inhibition 
of adenylate cyclase activity, seem of interest for future experiments.
In conclusion, we have demonstrated that the siRNA constructs for the sst
2
and sst
5 
gene we have synthesized merit to become novel tools to eventu-
ally evaluate the individual role of sst
2
 and sst
5 
receptors endogenously 
expressed in primary cells, such as GH-secreting pituitary adenomas. At 
present, the transfectability of cells is one of the limiting steps in siRNA-
mediated gene silencing, especially in primary cells which are notorious 
for having low transfection effi ciencies when plasmid DNA is used. Fur-
thermore, several aspects of RNAi, i.e. non-specifi c silencing effects (27) 
and activation of the interferon response (4) may occur when endogenous 
(sst-) expressing mammalian cell systems are used. As of now, it is not 
clear how often siRNAs trigger the interferon pathway and which condi-
tions favour this response to these RNAs. Chemical features of dsRNAs, 
as well as their expression levels and delivery routes, may determine 
whether they become visible to the interferon response machinery (4, 28). 
172
Chapter IV-2
References
1. Sharp PA 1999 RNAi and double-strand RNA. Genes Dev 13:139-41
2. Fire A, Xu S, Montgomery MK, et al. 1998 Potent and specifi c genetic 
interference by double-stranded RNA in Caenorhabditis elegans. Nature 
391:806-11
3. McManus MT, Sharp PA 2002 Gene silencing in mammals by small 
interfering RNAs. Nat Rev Genet 3:737-47
4. Bridge AJ, Pebernard S, Ducraux A, et al. 2003 Induction of an interferon 
response by RNAi vectors in mammalian cells. Nat Genet 34:263-4
5. Hunter T, Hunt T, Jackson RJ, et al. 1975 The characteristics of inhibition of 
protein synthesis by double-stranded ribonucleic acid in reticulocyte lysates. J 
Biol Chem 250:409-17
6. Brummelkamp TR, Bernards R, Agami R 2002 A system for stable 
expression of short interfering RNAs in mammalian cells. Science 296:550-3
7. Brazeau P, Vale W, Burgus R, et al. 1973 Hypothalamic polypeptide that 
inhibits the secretion of immunoreactive pituitary growth hormone. Science 
179:77-9.
8. Patel YC 1999 Somatostatin and its receptor family. Front Neuroendocrinol 
20:157-98.
9. Patel YC, Greenwood MT, Panetta R, et al. 1995 The somatostatin receptor 
family. Life Sci 57:1249-65
10. Benali N, Ferjoux G, Puente E, et al. 2000 Somatostatin receptors. Digestion 
62:27-32.
11. Reubi JC, Waser B, Schaer JC, et al. 2001 Somatostatin receptor sst1-
sst5 expression in normal and neoplastic human tissues using receptor 
autoradiography with subtype-selective ligands. Eur J Nucl Med 28:836-46
12. Hofl and LJ, Lamberts SW 2003 The pathophysiological consequences of 
somatostatin receptor internalization and resistance. Endocr Rev 24:28-47.
13. Lamberts SW, van der Lely AJ, de Herder WW, et al. 1996 Octreotide. N 
Engl J Med 334:246-54.
14. Lamberts SW, van der Lely AJ, Hofl and LJ 2002 New somatostatin analogs: 
will they fulfi l old promises? Eur J Endocrinol 146:701-5.
15. van der Hoek J, Hofl and LJ, Lamberts SW 2005 Novel subtype specifi c and 
universal somatostatin analogues: clinical potential and pitfalls. Curr Pharm 
Des 11:1573-92
16. Weckbecker G, Lewis I, Albert R, et al. 2003 Opportunities in somatostatin 
research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 
2:999-1017.
17. Hofl and LJ, van Koetsveld PM, Waaijers M, et al. 1995 Internalization of 
the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and 
human pituitary tumor cells: increase by unlabeled octreotide. Endocrinology 
136:3698-706
18. Ui-Tei K, Naito Y, Takahashi F, et al. 2004 Guidelines for the selection of 
highly effective siRNA sequences for mammalian and chick RNA interference. 
173
RNAi in sst Gene Expression and Function
Nucleic Acids Res 32:936-48
19. Ferone D, Pivonello R, Van Hagen PM, et al. 2002 Quantitative and 
functional expression of somatostatin receptor subtypes in human thymocytes. 
Am J Physiol Endocrinol Metab 283:E1056-66.
20. van der Hoek J, Waaijers M, van Koetsveld PM, et al. 2005 Distinct 
Functional Properties of Native Somatostatin Receptor Subtype 5 Compared 
with Subtype 2 in the Regulation of Acth Release by Corticotroph Tumour 
Cells. Am J Physiol Endocrinol Metab
21. Hofl and LJ, van der Hoek J, van Koetsveld PM, et al. 2004 The novel 
somatostatin analog SOM230 is a potent inhibitor of hormone release by 
growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin 
Endocrinol Metab 89:1577-85
22. Yu 2002 RNA interference by expression of short-interfering RNAs and hairpin 
RNAs in mammalian cells. PNAS
23. Paddison 2002 Short hairpin RNAs (shRNAs) induce sequence-specifi c 
silencing inmammalian cells. Genes Dev
24. Khvorova 2003 Functional siRNAs and miRNAs exhibit strand bias. 
25. Bantounas I, Phylactou LA, Uney JB 2004 RNA interference and the use of 
small interfering RNA to study gene function in mammalian systems. J Mol 
Endocrinol 33:545-57
26. Dillon CP, Sandy P, Nencioni A, et al. 2005 Rnai as an experimental and 
therapeutic tool to study and regulate physiological and disease processes. 
Annu Rev Physiol 67:147-73
27. Scacheri 2004 Short interfering RNAs can induce unexpected and divergent 
changes in the levels of untargeted proteins in mammalian cells. 
28. Sledz 2003 Activation of the interferon system by short-interfering RNAs. Nat 
Cell Biol

Chapter V
SOMATOSTATIN RECEPTOR SUBTYPE 
5 IN CUSHING’S DISEASE; IN VITRO 
SUPPORT FOR NOVEL THERAPEUTIC 
OPPORTUNITIES

Chapter V-1
The multiligand somatostatin 
analog SOM230 inhibits ACTH 
secretion by cultured human 
corticotroph adenomas via 
somatostatin receptor subtype 5
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Abstract
Objective: Currently, there is no effective medical treatment in pa-
tients with pituitary dependent Cushing’s disease. A novel somatostatin 
(SRIF)-analog, named SOM230, with high binding affi nity to sst
1
, sst
2
, 
sst
3
, and sst
5
 was recently introduced. We compared the in vitro effects 
of the sst
2
-preferring SS-analog octreotide (OCT) and the multiligand 
SOM230 on ACTH release by human and mouse corticotroph tumor cells. 
Methods: By quantitative RT-PCR the sst subtype expression level 
was determined in human corticotroph adenomas. In vitro, the inhibi-
tory effect of OCT and SOM230 on ACTH release by dispersed hu-
man corticotroph adenoma cells and mouse AtT20 corticotroph 
adenoma cells was determined. In addition, the infl uence of dexa-
methasone on the responsiveness to OCT and SOM230 was studied.
Results: Corticotroph adenomas expressed predominantly sst
5
 mRNA (6/6 
adenomas), whereas sst
2
 mRNA expression was detected at signifi cantly 
lower levels. In a 72 h incubation with 10nM SOM230, ACTH release was 
inhibited in 3 out of 5 cultures (range -30 to -40%). 10nM OCT slightly 
inhibited ACTH release in only 1 of 5 cultures (-28%). In AtT20 cells, ex-
pressing sst
2
, sst
3
 and sst
5
, SOM230 inhibited ACTH secretion with high 
potency (IC
50
;0.2nM). Dexamethasone (10nM) pre-treatment did not infl u-
ence the sensitivity of the cells to the inhibitory effect of SOM230, suggest-
ing that sst
5
 is relatively resistant to negative control by glucocorticoids. 
Conclusions: The selective expression of sst
5
 receptors in corticotroph ade-
nomas and the preferential inhibition of ACTH release by human corticotroph 
adenoma cells by SOM230 in vitro, suggest that SOM230 may have poten-
tial in the treatment of patients with pituitary dependent Cushing’s disease.
Introduction
The fi rst choice of treatment of patients with pituitary-dependent Cush-
ing’s disease is surgery. If surgery fails, radiotherapy, alone or in com-
bination with steroidogenic inhibitors, may be used (1, 2). These sec-
ondary options are primarily due by the absence of an effective medical 
treatment option (3, 4). Some preliminary data suggest a potential use of 
dopamine (DA) agonists, alone or in combination with ketoconazole, in 
selected cases of Cushing’s disease or Nelson’s syndrome (2). The ex-
pression of somatostatin (SRIF) receptors (sst) in adrenocorticotropin 
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(ACTH)-secreting pituitary adenomas has been studied in vivo and in vi-
tro. In vivo, none of a series of eight corticotroph microadenomas showed 
an increased uptake of 111In-DTPA-octreotide, whereas sst scintigraphy 
was positive in two invasive ACTH-secreting macroadenomas and two 
cases of Nelson’s tumors (5). The current generation of sst
2
-preferential 
SRIF-analogs have no suppressive effect on ACTH level in patients with 
untreated Cushing’s disease, who have elevated cortisol levels (6). How-
ever, the SRIF-analog octreotide (OCT) suppressed pathological ACTH 
release in patients with Nelson’s syndrome and ACTH and cortisol se-
cretion in patients with Cushing’s syndrome caused by ectopic ACTH 
secretion (7-9). Overall, these data suggest that in corticotroph adenomas 
of untreated patients with Cushing’s disease sst
2
 levels, one of the fi ve 
known sst subtypes to which OCT binds preferentially, are low, and that 
this receptor subtype may be down-regulated when circulating cortisol 
levels are high. The fact that ectopic ACTH secreting tumours express 
suffi cient sst numbers allowing their in vivo visualization by sst scintigra-
phy and responsiveness to octreotide, even in the presence of a high corti-
sol level, can be explained by their relative resistance to glucocorticoids, 
compared with corticotroph adenomas (10). Additional in vitro evidence 
for a sst downregulation by hypercortisolaemia comes from studies us-
ing primary cultures of human corticotroph adenomas, in which it was 
shown that glucocorticoids down-regulated the response of corticotro-
phin releasing hormone (CRH)-induced ACTH secretion to octreotide 
(11). Little is know yet about the quantitative expression levels of the fi ve 
sst subtypes (sst
1-5
) in normal and tumoral corticotroph cells. By double 
labelling in situ hybridization analysis for sst
2
 and sst
5
 mRNA, Day et 
al. (12) showed that normal rat corticotrophs expressed preferentially 
sst
5
 mRNA. In a few selected cases expression of sst subtype mRNA 
transcripts was studied in human corticotroph adenomas. In these stud-
ies it was found that the highest frequency of expression of sst mRNA 
transcripts was found for sst
2
 and sst
5
, and to a lesser extent sst
1
 (13-16). 
Although sst
2
 mRNAs can be found in corticotroph adenomas, their lev-
els of expression are apparently low since octreotide has no effect on 
ACTH secretion in patients with pituitary  dependent Cushing’s disease. 
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However, at present the role of the other frequently expressed sst sub-
type, sst
5
, on ACTH secretion by corticotroph adenoma cells is unclear.
Recently, a novel multiligand SRIF-analog SOM230 has been synthe-
sized. Compared with octreotide, SOM230 has a 30-, 5- and 40-times 
higher binding affi nity to sst
1
, sst
3
 and sst
5
 receptors, respectively, and 2.5 
times lower affi nity to sst
2
 (17). The very high affi nity of this SRIF-ana-
log for sst
5
 probably forms the basis for the higher potency of SOM230 
in reducing IGF-I concentrations in rats, primates and dogs (18). More-
over, the very favourable elimination half-life of SOM230, which is 23 h 
(17), makes this novel compound suitable for clinical application as well. 
The present study was carried out to further explore the poten-
tial functional signifi cance of sst subtypes expressed in human cor-
ticotroph adenomas. We evaluated the effect of the SRIF-ana-
log SOM230 on ACTH secretion by primary cultures of human 
corticotroph adenomas and mouse AtT20 corticotroph tumor cells. 
Materials and Methods
Patients
Pituitary tumor samples were obtained by transsphenoidal operation from 
11 patients with Cushing’s disease due a corticotroph adenoma as de-
scribed in detail previously (19). ACTH-dependent hypercortisolism was 
biochemically established by the absence of cortisol diurnal rhythm, an 
increased 24 h free cortisol excretion, insuffi cient suppression of plasma 
cortisol concentrations after administration of 1 mg of dexamethasone and 
normal to increased plasma ACTH concentrations. MRI of the pituitary 
showed a microadenoma in 7 patients, a macroadenoma in 1 patient and 
no adenoma in 3 patients. In these latter patients pituitary ACTH overpro-
duction was determined by sinus petrosus inferior sampling. Histological 
examination showed adenomatous tissue (n=9; case no. 1 and no.’s 4-11) or 
hyperplasia (n=2; case no.’s 2 and 3) with immunohistochemically expres-
sion of ACTH. All patients gave their informed consent for the use of tumor 
material for research purposes. After surgery, 7 of 11 patients were cured. 
In six cases (no. 1-6) the tissue was directly snap-frozen on dry ice 
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and stored at -80 C until analysis. Adenoma tissue from the 5 addi-
tional patients (culture no. 7-11) was directly used for cell culturing. 
Quantitative PCR
Quantitative PCR was performed as described previously (20). Briefl y, 
poly A+ mRNA was isolated from adenoma tissue using Dynabeads Oligo 
(dT)
25
 (Dynal AS, Oslo, Norway). cDNA was synthesized using the poly 
A+ mRNA, which was eluted from the beads in 40 µl H
2
O for 2 min 
at 65 °C, using Oligo (dT)
12-18
 Primer (In Vitrogen, Breda, The Nether-
lands). One-twentieth of the cDNA library was used for quantifi cation 
of sst subtype mRNA levels. A quantitative PCR was performed by Taq-
Man® Gold nuclease assay (Perkin Elmer Corporation, Foster City, CA, 
USA) and the ABI PRISM® 7700 sequence Detection System (Perkin 
Elmer, The Netherlands) for real-time amplifi cations, according to man-
ufacturer’s protocol. The assay was performed using 15µl TaqMan® Uni-
versal PCR Master Mix (Applied Biosystems, The Netherlands), 500 nM 
forward primer, 500 nM reverse primer, 100 nM probe and 10µl cDNA 
template, in a total reaction volume of 25 µl. After an initial heating at 
95° C for 8 min, samples were subjected to 40 cycles of denaturation 
at 95° C for 15 seconds and annealing for 1 min at 60° C. The primer 
and probe sequences that were used are indicated below. The detection 
of hypoxantine-phosphoribosyl-transferase (hprt) mRNA served as a 
control and was used for normalisation of the sst subtype mRNA levels.
The primer and probe sequences that were used for the detection 
of sst
1
, sst
2
, sst
3
, sst
5
 and hprt mRNA’s have been described previ-
ously (20). In addition to these primers and probes, we also evalu-
ated sst
4
 mRNA expression in the present study using the following 
primers and probe: Sst
4
 forward 5’-CTGCGCCAACCCTATTCTCT-
3’; Sst
4
 reverse 5’-ACCCGCTGGAAGGATCG-3’; Sst
4
 probe 5’-
FAM-TGGCTTCCTCTCCGACAACTTCCG-TAMRA-3’. Prim-
ers and probes were purchased from Biosource (Nivelles, Belgium).
The relative amount of sst subtype mRNA was determined us-
ing a standard curve generated from known amounts of human ge-
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nomic DNA. For determination of the amount of HPRT mRNA, a 
standard curve was generated of a pool of cDNAs from a human 
cell line known to express HPRT. The relative amount of sst sub-
type mRNA was calculated relative to the amount of HPRT mRNA 
and is given in arbitrary units. Each sample was assayed in duplicate.
Poly A+ mRNA from AtT20/D16V cells was isolated as de-
scribed above. PCR analysis to determine the expression of 
mouse sst
1-5
 mRNAs was performed as described elsewhere (21).
Cell dispersion and cell culture 
Pituitary adenoma tissue
Single cell suspensions of the pituitary adenoma tissues were prepared 
by enzymatic dissociation with dispase as described in detail previously 
(19). For short-term incubation of monolayer cultures, the dissociated 
cells were plated in 48-well plates (Corning BV Life Sciences, Schiphol-
Rijk, The Netherlands) at a density between 10,000 to 50,000 cells per 
well per 1 ml culture medium. After 3 - 4 days the medium was changed 
and 4, 24 or 72 h incubations without or with test-substances were initi-
ated. At the end of the incubation the medium was collected and stored 
at –20 C until hormone determination. The cells were cultured at 37 C 
in a CO
2
-incubator. The culture medium consisted of Minimum Essen-
tial Medium with Earle’s salts (MEM) supplemented with non essential 
amino acids, sodium pyruvate (1 mmol/L), 10% fetal calf serum (FCS), 
penicillin (1x105 U/L), fungizone (0.5 mg/L), L-glutamine (2mmol/L), 
and sodium bicarbonate (2.2 g/L), pH 7.6. Media and supplements were 
obtained from In Vitrogen (Breda, The Netherlands). Unfortunately, not 
enough tumor material was obtained to test the adenoma cells at all time-
points and on the dose-dependency of the effects by the indicated drugs.
Mouse corticotroph adenoma cells
AtT20/D16V mouse corticotroph tumor cells (Dr. J. Tooze; Europe-
an Organization Molecular Biology) were routinely passaged by tryp-
sinization as described in detail previously (22). The cells were main-
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tained in 75 cm2 culture fl asks in Dulbecco’s Minimal Essential Medium 
(DMEM), supplemented with non essential amino acids, sodium pyru-
vate (1 mmol/L), 10% fetal calf serum (FCS), penicillin (1x105 U/L), 
fungizone (0.5 mg/L), L-glutamine (2mmol/L), and sodium bicarbonate 
(2.2 g/L), pH 7.6. For experiments, the cells were seeded at a density 
of 20,000 cells per well in 1 ml of culture medium. After 72 h, the me-
dium was changed and 4, 24 or 72 h incubations without or with OCT, 
SOM230 or SRIF were initiated. In addition, the acute effect of SRIF, 
OCT and SOM230 was evaluated in a 3h incubation without or with 
10nM CRH. In order to evaluate the effect of glucocorticoids on SRIF-
analog induced inhibition of ACTH release, the cells were pre-treated 
in some experiments for 48h with the synthetic glucocorticoid dexa-
methasone (10nM). Thereafter, the medium was changed and a 3 h in-
cubation without or with octreotide (10nM) or SOM230 (10nM) in the 
presence of CRH (10nM) was performed. After the indicated time peri-
ods, the medium was collected and stored at -200C until determination 
of ACTH concentrations. For determining the effects of the compounds 
on cell growth, 3H-thymidine incorporation, as well as the DNA con-
tent of the wells, was measured as described in detail elsewhere (23). 
Hormone determinations
Human ACTH concentrations were determined by a non-isotopic, auto-
matic chemiluminescence immunoassay system (Immulite, DPC Inc.). 
Intra- and interassay CV’s were 5.6% and 7.8%, respectively. Human 
GH, PRL, LH and FSH concentrations in the media were determined, 
in order to exclude the presence of contaminating normal pituitary cells 
in the cultures. GH, PRL, LH and FSH concentrations were determined 
by a non-isotopic, automatic chemiluminescence immunoassay system 
as well (Immulite, DPC Inc., Los Angeles, CA). Intra- and interassay 
CV’s for GH, PRL, LH and FSH were 6.0%, 5.7%, 5.7%, 6.4% and 
6.2%, 6.4%, 12.3%, 7.5%, respectively. Except for the expected hor-
mone ACTH, none of the other hormones were detectable (not shown).
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Test-substances
Octreotide (OCT; Sandostatin) was obtained from Novartis Pharma A.G. 
(Basle, Switzerland). SOM230 was a gift from Novartis Pharma A.G. 
Somatostatin-14 (SRIF) was purchased from Sigma Chemical Co. (St. 
Louis, MO). Binding affi nities of SRIF, OCT and SOM230 to the fi ve sst 
are shown in table I. Dexamethason was obtained from the Erasmus MC 
Pharmacy (Rotterdam, The Netherlands). Corticotropin-releasing hor-
mone (CRH) was purchased from Ferring (Hoofddorp, The Netherlands). 
Table I. Binding affinity of SRIF, OCT and SOM230 for sst
1-5.
Compound hsst1 hsst2 hsst3 hsst4 hsst5
SRIF 0.93 ± 0.12 0.15 ± 0.02 0.56 ± 0.17 1.5 ± 0.4 0.29 ± 0.04 
OCT 280 ± 80 0.38 ± 0.08 7.1 ± 1.4 >1000 6.3 ± 1.0 
SOM230 9.3 ± 0.1 1.0 ± 0.1 1.5 ± 0.3 >100 0.16 ± 0.01 
Data are reproduced with permission (17). Results are the mean ± SE, IC
50
 values are 
expressed in nM.
Statistical analysis of the data
All data on hormone release are expressed in mean ± SE, n=4 wells 
per treatment group. All data were analyzed by analysis of vari-
ance (ANOVA) to determine overall differences between treatment 
groups. When signifi cant differences were found by ANOVA, a mul-
tiple comparison between treatment groups was made using the New-
man-Keuls test. Calculation of IC
50
 values for inhibition of hor-
mone release were made using GraphPad Prism (San Diego, CA).
Results
Somatostatin receptor subtype mRNA expression
In 6 out 6 human corticotroph adenomas (no’s 1-6), sst
2
 mRNA was 
detectable. However, the relative copy numbers were low (varying be-
tween 8 and 141 copies/hprt). The relative sst
2
 copy number was con-
siderably lower compared with the majority of GH-secreting pituitary 
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Figure 1. SRIF  receptor subtype mRNA expression level in human corticotroph adenoma. 
mRNA levels were determined by real time PCR of cDNA obtained from six human cortico-
troph adenomas (no. 1-6). Values are expressed as the number of copies relative to hprt mRNA.
adenomas, as recently reported (20). Sst
5
 mRNA was detectable at much 
higher levels in 6/6 adenomas (relative copy number between 277-1217). 
In the two cases in which histological analysis of the tissue revealed 
hyperplasia of ACTH-producing cells (case no.’s 2 and 3), sst
5
 mRNA 
level were relatively high. On the other hand, one ACTH-secreting pi-
tuitary adenoma (case no. 1), expressed the highest level of sst
5
 mRNA 
in the series. Sst
1
, sst
3
 and sst
4
 mRNA was detectable at low levels in 
only 1/6, 2/6 and 2/6 samples, respectively. This is shown in fi gure 1. 
In agreement with the results of RT-PCR analysis of the corticotroph adeno-
mas, the sst subtype mRNAs expressed in ACTH-secreting mouse AtT20 cor-
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ticotroph pituitary tumor cells were sst
2
, sst
3
 (low abundance) and sst
5
 (fi g. 2).
500
200
Mw hprt 1 2 3 4 5
+ RT
- RT
sst subtype
500
200
Figure 2. Expression of sst subtypes in mouse AtT20 pituitary tumor cells. Poly A+ 
mRNA was reverse transcribed and cDNA was amplified by PCR. PCR products of the 
sst
1–5 
were separated on 1% agarose gel and stained with ethidium bromide. Left panel 
represents cDNA synthesis in the presence of reverse transcriptase (+RT); right panel 
represents negative control of cDNA synthesis in the absence of RT (-RT) to exclude the 
presence of genomic DNA contamination. Only bands of sst
2, 
sst
3 
and sst
5
 PCR products 
with the expected molecular weight (Mw) were detected. hprt: house-hold keeping gene 
hypoxantine-phosphoribosyl-transferase.
Effect of SRIF, octreotide and SOM230 on basal and CRH-
induced ACTH secretion by primary corticotroph adenoma 
cells
Since not suffi cient tissue was obtained to carry out both mRNA- and cul-
ture studies on the same tissue, cell culture experiments were performed 
using adenoma tissue from 5 additional patients (no.’s 7-11). In a 72 h incu-
bation, SOM230 (10nM) signifi cantly suppressed ACTH secretion in 3/5 
primary cultures of human corticotroph adenomas (between 30 and 40% 
suppression). In contrast, OCT (10nM) suppressed basal ACTH release in 
only 1/5 cultures (28% suppression). This is shown in fi gure 3A and 3B. 
From one corticotroph adenoma (no.8) suffi cient cells were obtained to 
perform a time course study of the effects of SRIF, OCT and SOM230 on 
basal ACTH release. As shown in fi gure 4A (4, 24 and 72 h incubation), 
statistically signifi cant (P<0.01 vs untreated control cells) suppression of 
ACTH release was observed only after 72 h of incubation with SOM230 
(10nM) and SRIF (10nM). 10nM OCT did not signifi cantly inhibit basal 
ACTH release at any time point. A comparable time-course experiment 
188
Chapter V-1
Figure 3. Effect of 10nM OCT (A) and 10nM SOM230 (B) on basal ACTH release 
from five cultured human corticotroph adenomas (no. 7-11). The cells were incubated 
in the absence or presence of octreotide (panel A) or SOM230 (panel B) during 72 h 
after which the medium was collected for ACTH determination. Values are expressed as 
% of control (CON; untreated cells). Basal ACTH concentrations in the culture media 
were 239 ± 5.0, 28800 ± 1159, 25100 ± 2150, 218 ± 12 and 3228 ± 153 fmoles/well, for 
cultured adenomas no. 7, 8, 9, 10 and 11, respectively. *p<0.05 and **p<0.01 vs control.
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Figure 4. Time-dependent effect of OCT, SOM230 and SRIF (10 nM) on basal ACTH 
release from cultured human corticotroph adenoma no.8 (A) and mouse AtT20 tumor 
(B) cells. The cells were incubated for 4, 24 or 72 h in the absence or presence of the 
indicated compounds after which medium was collected for ACTH determination. Val-
ues are expressed as the % of ACTH release by control (untreated) cells at the indicated 
time-points. For the human corticotroph adenoma cells, basal ACTH values were 3505 
± 232 (4 h), 9778 ± 946 (24 h) and 28800 ± 1159 (72 h) fmoles/well. *p<0.01 vs control.
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was performed in mouse AtT20 cells. In agreement with the observations 
in primary human corticotroph adenoma cultures, SOM230 and SRIF, 
but not OCT, all tested at 10nM, suppressed basal ACTH production (fi g. 
4B). The effect of SOM230 on basal ACTH release by AtT20 cells was 
dose-dependent with an IC
50
 value of 0.2 nM (fi g. 5A), corresponding to 
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Figure 5. Dose-dependent effect of SOM230 and OCT on basal ACTH release (pan-
el A) and cell proliferation as measured by [3H]-thymidine incorporation (panel B) 
by mouse AtT20 pituitary tumor cells. AtT20 cells were incubated during 72h with-
out or with increasing concentrations of OCT (open circles) or SOM230 (closed 
circles) after which the medium was collected for ACTH determination. Values are 
expressed as the % of control (untreated) cells. *p<0.05 and **p<0.01 vs control.
the binding affi nity of SOM230 for sst
5
. In contrast, OCT inhibited ACTH 
release with much lower potency with a slight suppression at 100nM 
(fi g. 5A), which did not reach statistical signifi cance, however. Taken 
together, these data suggest that the effect of SOM230 on basal ACTH 
release is most likely mediated via sst
5
. OCT and SOM230 did not in-
hibit AtT20 cell proliferation as measured by 3H-thymidine incorporation 
(fi g. 5B), and had no effect on the DNA content of the cells (not shown).
In contrast to the absence of an effect of OCT on basal ACTH release by 
AtT20 cells, OCT (10nM) signifi cantly suppressed CRH (10nM)-induced 
ACTH release by 52% and SRIF by 47% in a 3 h incubation. SOM230 
was signifi cantly more potent and inhibited CRH-induced ACTH re-
lease by 76% (fi g. 6). The effect of SRIF on CRH-induced ACTH-re-
lease by AtT20 cells is in agreement with previous reports (24-26). 
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Figure 6. Effect of OCT, SRIF and SOM230 on CRH-stimulated ACTH re-
lease by mouse AtT20 pituitary tumor cells. AtT20 cells were incubated for 3 
h in the absence or presence of CRH and SRIF, OCT or SOM230 after which 
the medium was collected for ACTH determination. Values are expressed as 
the % of control (untreated) cells. *p<0.01 vs control, #p<0.01 vs CRH alone.
Effect of glucocorticoid pre-treatment
In order to evaluate whether pre-treatment of the cells with glucocorti-
coids infl uenced the sensitivity to the effects of OCT and SOM230, mouse 
AtT20 cells were pre-treated with 10 nM dexamethasone (DEX) during 
48 h, after which a 3 h incubation without or with CRH (10 nM), OCT 
(1 nM) and/or SOM230 (1 nM) was performed. Figure 7 shows that pre-
treatment of AtT20 cells with 10 nM DEX had no effect on the inhibitory 
effect of SOM230 on CRH-induced ACTH release. On the other hand, 
the inhibitory effect of 1 nM OCT was completely abolished by Dex pre-
treatment. In the presence of Dex, SOM230 almost completely abolished 
CRH-induced ACTH release (fi g. 7, lower panel). Finally, Dex-pretreat-
ment did not change the inhibitory effects of 10nM OCT or SOM230 on 
CRH-induced ACTH release (data not shown), suggesting that at OCT at 
10nM, induced its inhibitory effect via interaction with sst
5
., to which it 
0
100
100
120
140
160
180
200
220
A
C
T
H
 s
ec
re
ti
on
(%
 c
on
tr
ol
)
0
100
100
120
140
160
180
200
220
A
C
T
H
 s
ec
re
ti
on
(%
 c
on
tr
ol
)
0
100
100
120
140
160
180
200
220
CON CRH
(10nM)
CON CRH
+
OCT (10nM)
CRH
(10nM)
CON CRH
(10nM)
*
#* ,
CRH
+
SRIF (10nM)
CRH
+
SOM230 (10nM)
*
#* ,
#* ,
(-47%) (-52%)
(-76%)
*
191
Role of SOM230 in Human Corticotroph Adenomas
has signifi cant lower affi nity compared with SOM230 (Table I). More-
over, in one primary culture of corticotroph adenoma cells (case no. 4), 
which was unresponsive to OCT, DEX (10nM) pre-treatment did not re-
duce the inhibitory effect by SOM230 on CRH (10 nM)-induced ACTH 
release as well (-21% without DEX vs -33% in the presence of DEX).
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Figure 7. Effect of glucocorticoids on OCT and SOM230 mediated inhibition of CRH-
stimulated ACTH release by mouse AtT20 pituitary adenoma cells. AtT20 cells were 
pre-incubated during 48 h without or with 10nM dexamethasone (Dex). After 48 h, the 
medium was refreshed and the cells were incubated for 3 h in the absence or presence 
of Dex, CRH (10nM) and OCT (1 nM) or SOM230 (1 nM) after which the medium 
was collected for ACTH determination. *p<0.01 vs control, #p<0.01 vs CRH alone.
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Discussion
Currently, there is no effective medical treatment option in patients with 
pituitary-dependent Cushing’s disease (3, 4). Therefore, in the present 
study we evaluated the effects of the recently developed multiligand stable 
SRIF-analog SOM230 (17, 18, 27), which has high binding affi nity to sst
1
, 
sst
2
, sst
3
 and sst
5 
on ACTH release by human corticotroph tumors in vitro. 
The role of SRIF in the regulation of normal ACTH release is equivocal. 
Previous in vitro studies showed no inhibitory effect of SRIF on basal- 
and CRH-induced ACTH release by normal rat anterior pituitary cells (28) 
and perifused normal rat pituitary halves (29). On the other hand, SRIF 
inhibited CRH-stimulated ACTH release by fragments of pituitary glands 
(30), as well as arginine vasopressin-induced ACTH release by cultured 
pituitary cells from long-term adrenalectomized rats (31). The latter study 
suggests that normal corticotrophs only respond to SS in the presence of 
very low cortisol concentrations. Confi rming this hypothesis, we dem-
onstrated that SRIF inhibits CRH-stimulated ACTH secretion by normal 
rat anterior pituitary cells only when the cells are cultured in the absence 
of glucocorticoids in the culture medium (32). In addition, pre-incuba-
tion of the cells with the progesterone-glucocorticoid receptor-blocking 
compound RU 38486, increased the sensitivity of ACTH secretion to the 
inhibitory effect by SS and pre-treatment with dexamethasone made the 
cells insensitive to SRIF (32). The high levels of cortisol in patients with 
pituitary dependent Cushing’s disease can thus be responsible for the ob-
served lack of inhibition of ACTH release by SRIF and/or OCT in these 
patients (6, 11, 33). Moreover, in patients with Nelson syndrome and ad-
renal insuffi ciency of different origin, SRIF and/or OCT lower ACTH 
secretion (6, 9, 34, 35). In cultured corticotroph adenomas, SRIF and/or 
OCT inhibit ACTH secretion in part of the cultures (11, 36-38). Stalla et 
al. (11) showed that hydrocortisone treatment in vitro abolished the inhibi-
tory effect of octreotide on ACTH secretion, possibly due to a down-regu-
lation of sst on the corticotrophs. In agreement with this hypothesis, corti-
sol reduced [125I-Tyr1]SRIF binding on mouse AtT20/D16 pituitary tumor 
cells by 20-40% (39), although the subtype sst was not characterized. 
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Little is known with respect to sst subtype expression in pituitary corti-
cotrophs. In rat pituitary cells, co-localization of all fi ve sst with ACTH 
expressing cells has been reported  (40). In another study, sst
5
 mRNA 
was found in 38% of normal corticotrophs, and sst
2
 in only 3%. More-
over, the average number of grains per cell was also higher for sst
5
 than 
sst
2 
(12). This suggests that under normal physiological conditions, sst
5
is predominantly more expressed in rat corticotrophs than sst
2
. As far 
as known, no data on the quantitative expression of sst mRNA in hu-
man corticotroph adenomas are available. In the present study we found 
that at the mRNA level, sst
5
 was the predominantly expressed receptor 
type in human corticotroph adenomas. In the small series of tissues (n=6) 
analyzed in this study, two cases of hyperplasia of corticotroph cells, ex-
pressed a relatively high sst
5
 mRNA level. On the other hand, one cor-
ticotroph adenoma expressed the highest sst
5
 mRNA level in this series. 
The number of cases is too low, however, to establish whether there is a 
difference in sst
5
 mRNA expression between hyperplasia of ACTH-pro-
ducing cells and ACTH-secreting adenoma. Sst
2
 mRNA was expressed 
in all cases as well, although at a much lower level. The high frequency 
of expression of sst
2
 and sst
5
 in corticotroph adenomas is well in agree-
ment with other reports. mRNA expression in human corticotroph tumors 
shows the overall presence of sst
1
 in 5/8 (63%), sst
2
 in 7/8 (88%), sst
3
 in 
3/9 (33%), sst
4
 in 1/8 (12%), and sst
5
 in 6/7 (86%) cases (13-15, 41, 42). 
The low expression levels of sst
2
 may explain the lack of effi cacy of the 
sst
2
-preferring agonist OCT in lowering circulating ACTH and cortisol 
levels in untreated patients with pituitary-dependent Cushing’s disease 
(6, 11). In vitro we found a statistically signifi cant inhibition of basal 
ACTH release by OCT in only 1/5 cases. The higher number of cultures 
(3/5) responding to a maximally active concentration of 10 nM SOM230, 
which has very high binding affi nity to sst
5
, is in agreement with the 
higher expression levels of sst
5
 mRNA. Unfortunately, not enough tis-
sue was obtained to perform both mRNA analysis and cell culture stud-
ies. In one adenoma, which had an intermediate sst
5
 mRNA level (case 
no. 4), SOM230 already inhibited ACTH secretion, whereas OCT had 
no effect. It should be noted that only mRNA levels were studied. Future 
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studies should demonstrate whether sst
5
 receptors are expressed in corti-
cotroph adenomas at a high protein level as well. The importance of sst
5
in regulating ACTH release was further confi rmed by our observation 
that SOM230 was also much more potent compared with OCT in inhibit-
ing basal ACTH release by mouse AtT20/D16V corticotroph tumor cells. 
The pattern of inhibition, e.g. a higher potency of SOM230 vs OCT, is in 
line with the sst binding profi le of both SRIF-analogs. Recently, Cervia 
et al. (43) showed that sst
2
 is the predominant functional receptor subtype 
in AtT20 cells, while sst
5
 is also able to mediate inhibition of ACTH re-
lease when the ligand is not able to activate sst
2
 receptors. Interestingly, 
while SOM230 was much more potent in inhibiting basal ACTH release 
by AtT20 cells, we found that OCT also potently inhibited CRH-induced 
ACTH release. However, maximal inhibition of ACTH by SOM230 was 
signifi cantly higher compared with OCT. These data suggest that expres-
sion of sst
2
 in our AtT20 line is relatively low, compared with sst
5
. The 
involvement of both sst
2
 and sst
5
 in the regulation of ACTH release is 
further underlined by the observation that sst
2
- and sst
5
-specifi c agonists 
potently inhibit ACTH release and cAMP production by AtT20 cells (44). 
As indicated above, glucocorticoids may down-regulate sst on AtT20 
corticotrophs and lower responsiveness of ACTH to the inhibitory effect 
of SRIF and/or octreotide. Therefore, we also studied whether pre-treat-
ment of the cells with the synthetic glucocorticoid dexamethasone (10nM) 
reduced responsiveness of the cells to inhibition of ACTH release by 
SOM230. We found that glucocorticoid pre-treatment did not infl uence 
the inhibitory effect of SOM230 on CRH-induced ACTH release, sug-
gesting that the expression of functional sst
5
 receptors is relatively resis-
tant to glucocorticoids. This may also explain the higher expression levels 
of sst
5
 mRNA we found in human corticotroph adenomas from untreated 
patients with pituitary-dependent Cushing’s disease. These data suggest 
that glucocorticoids may have differential regulatory effects on sst
2
 and 
sst
5
 expression, respectively. An intriguing observation is that SOM230 
and SRIF only inhibit basal ACTH secretion after prolonged in vitro ex-
posure. SOM230 did not inhibit AtT20 cell proliferation. Therefore, other 
mechanisms, e.g. inhibition of POMC synthesis and/or increased ACTH 
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breakdown, as has been shown for the effect of OCT on GH-secreting pi-
tuitary adenomas (45, 46) may form additional explanations for the inhibi-
tory of SOM230 and SRIF on basal ACTH secretion. Interestingly, recent 
evidence suggests that sst
5
 is also important in the control of ACTH secre-
tion in vivo. Sst
5
 knock out mice were shown to have signifi cantly elevat-
ed ACTH and corticosterone levels, compared with wild type mice (47).
While our data suggest that the novel SRIF-analog SOM230 may be 
useful in the medical management of patients with pituitary-dependent 
Cushing’s disease, several issues will have to be clarifi ed. First, pro-
longed treatment of AtT20 cells with SRIF results in desensitization 
of its inhibitory effect on ACTH secretion and cAMP formation (48, 
49). In addition, prolonged agonist exposure of AtT20 cells with SRIF-
14 or SRIF-28 was shown to down-regulate sst receptors (50). How-
ever, these studies only evaluated the acute inhibitory effects of SRIF 
on AtT20 cells. Moreover, the effects of SOM230 are most likely sst
5
-
mediated and sst
5
 receptors have shown to be rapidly recycled and re-
cruited from intracellular storages after agonist activation. This combi-
nation of recycling and recruitment of spare sst
5
 receptors may protect 
from long-term down-regulation through sequestration and, therefore, 
facilitate extended SRIF-signaling (51). We observed that the inhibito-
ry effects of SOM230 on basal ACTH secretion became only apparent 
after prolonged exposure. This observation already suggests that endog-
enously expressed sst
5
 receptors may be more resistant to desensitization 
and/or downregulation. Nevertheless, the in vivo effect of SOM230 on 
ACTH secretion by corticotroph adenomas needs to be further evaluated. 
In conclusion, the selective expression of sst
5
 receptors in human cortico-
troph adenomas, in combination with the inhibitory effect of SOM230 on 
basal and CRH-induced ACTH secretion, suggest that SOM230 may have 
potential in the medical treatment of pituitary-dependent Cushing’s disease.
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Abstract
In a series of human corticotroph adenomas, we recently found pre-
dominant mRNA-expression of somatostatin (SRIF) receptor subtype 
(sst) 5. After 72h, the multiligand SRIF-analog, SOM230, which has a 
very high sst
5 
binding affi nity, but not Octreotide (OCT), signifi cantly 
inhibited basal ACTH release. To further explore the role of sst
5
 in the 
regulation of ACTH release, we conducted additional studies with mouse 
AtT-20 cells. SOM230 showed a 7-fold higher ligand binding affi nity 
and a 19-fold higher potency in stimulating GTPγS binding in AtT-20 
cell membranes as compared with OCT. SOM230 potently suppressed 
CRH-induced ACTH release, which was not affected by 48h dexame-
thasone (DEX) pre-treatment. However, DEX attenuated the inhibitory 
effects of OCT on ACTH release, whereas it increased the inhibitory 
potency of BIM-23268, a sst
5
-specifi c analog, on ACTH release. Quan-
titative-PCR analysis showed that DEX lowered sst
2A+2B
 mRNA expres-
sion signifi cantly after 24 and 48h, whereas sst
5 
mRNA levels were not 
signifi cantly affected by DEX treatment. Moreover, Scatchard analy-
ses showed that DEX suppressed maximum binding capacity (Bmax) 
by 72% when [125I-Tyr3]-Octreotide was used as radioligand, whereas 
Bmax declined only by 17% when AtT-20 cells were treated with [125I-
Tyr11]-SRIF-14. These data suggest that the sst
5
 protein, compared with 
sst
2
, is more resistant to glucocorticoids. Finally, after SRIF-analog 
pre-incubation, compared with OCT, both SOM230 and BIM-23268 
showed a signifi cant higher inhibitory effect on CRH-induced ACTH re-
lease. In conclusion our data support the concept that the sst
5
 receptor 
might be a target for new therapeutic agents to treat Cushing disease.
Introduction
Cushing’s disease, the pituitary-dependent form of Cushing’s syn-
drome, is the hypercortisolemic state secondary to excess or dysregu-
lated ACTH secretion caused by an ACTH-secreting pituitary adenoma 
(1). The signifi cant associated morbidity, such as increased tissue fragil-
ity, poor wound healing, hypertension and diabetes mellitus, demands 
a proper medical intervention (2). Trans-sphenoidal surgery is currently 
the fi rst line of treatment, while secondary options consist of irradia-
tion therapy either alone or in combination with adrenolytic agents (3-
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6). Unfortunately, none of the current treatment modalities ensure a full 
and permanent cure, as evidenced by the number of patients develop-
ing recurrent Cushing’s disease (7). The absence of an effective medi-
cal treatment has prompted physicians to explore new medical strategies, 
preferably based on fundamental and (patho-) physiological pathways, 
in the hope of increasing the curation chances in this group of patients.
The physiological role of somatostatin (SRIF) in the regulation of anterior 
pituitary function (8-11), its equivocal effects on ACTH release (12, 13), 
and the current use of SRIF-analogs in patients with anterior pituitary 
tumours (14), has led to the exploration of SRIF-analogs in patients with 
(recurrent) Cushing’s disease. To date, fi ve G-protein coupled SRIF-recep-
tors have been cloned (sst
1
-sst
5
) and six gene products are currently known 
(10, 15). The receptor subtypes sst
1-5 
produce single gene products, while 
sst
2A
 (long form) and sst
2B 
(short form) originate from a common precursor 
mRNA which is spliced at the carboxy terminus (16).  While in vitro data 
demonstrate the presence of sst expression in corticotroph adenomas, the 
sst
2
-preferential analog octreotide (OCT) appears to inhibit ACTH release 
in Nelson’s syndrome and in some patients harboring ectopic ACTH-pro-
ducing tumours, but rarely in patients with Cushing’s disease (17, 18). 
These observations are in agreement with the observation that almost all 
ACTH-secreting pituitary adenomas, i.e. patients with untreated Cush-
ing’s disease, cannot be visualized by SRIF-receptor (sst) scintigraphy 
using 111In-diethylenetriamine pentaacetic acid (DTPA) octreotide (19, 
20), whereas 111In-DTPA scintigraphy is positive in patients with Nelson’s 
syndrome (19, 21). Apparently, ACTH release from corticotrophinomas is 
only sensitive to OCT in the absence of peripheral feedback regulation by 
glucocorticoids, suggesting that the sst
2
 might be down-regulated when 
cortisol levels are high. Additional in vitro evidence for this hypothesis 
comes from studies using primary cultures of human corticotroph adeno-
mas, in which glucocorticoids down-regulated the response of cortico-
trophin releasing hormone (CRH)-induced ACTH secretion to OCT (22). 
To explore the possible role of novel SRIF-analogs in the medical treat-
ment of Cushing’s disease, we have further evaluated the potential signif-
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icance of sst subtypes expressed in human corticotroph adenomas and de-
termined the effects of the novel multiligand SRIF-analog, SOM230, on 
ACTH release in primary cultures of human corticotroph adenomas (23). 
SOM230, compared with OCT, has a 30-, 5- and 40-times higher affi nity 
to sst
1
, sst
3
 and sst
5 
receptors, respectively, and 2.5 times lower affi nity to 
sst
2
 (24). Its elimination half-life of 23 hours makes this compound suitable 
for clinical application (25, 26). On the basis of the observed selective ex-
pression of the sst
5
 receptor in this series of human corticotroph adenomas, 
the very high affi nity of SOM230 for sst
5 
receptors, and the inhibition by 
SOM230 of basal ACTH release by human corticotroph adenoma cells, 
even when the cells were pretreated with DEX, it was hypothesized that 
this multiligand SRIF-analog may become a new medical treatment mo-
dality in a subgroup of patients with pituitary dependent Cushing’s disease.
The present study was carried out to further evaluate the role of sst
5 
in suppressing ACTH secretion from pituitary corticotrophs, with par-
ticular emphasis on the role of glucocorticoids in regulating sst
2 
and/
or sst
5
-mediated ACTH suppression. Studies were carried out by us-
ing the mouse ACTH-producing AtT-20 corticotroph tumour cell line, 
which is known to express mainly sst
2A+2B 
and sst
5
 subtypes (16, 27, 28). 
Methods
Cell culture
AtT-20/D16V mouse tumour cells (Dr. J. Tooze; European Organization 
Molecular Biology) were routinely passaged by trypsinization as de-
scribed in detail previously (29). The cells were maintained in 75 cm2
fl asks in Dulbecco’s Minimal Essential Medium (DMEM), supplemented 
with non essential amino acids, sodium pyruvate (1 mmol/L), 10% fetal 
calf serum (FCS), penicillin (1x105 U/L), fungizone (0.5 mg/L), L-glu-
tamine (2 mmol/L), and sodium bicarbonate (2.2 g/L), pH 7.6. The cells 
were cultured at 37° C in a CO
2
-incubator. Media and supplements were 
obtained from GIBCO Bio-cult Europe (Invitrogen, Breda, The Nether-
lands). For crude cell membrane preparations, AtT-20 cells were scraped 
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and centrifuged at 4°C for 5 min at 1000g. The cell pellet was either stored 
at -80°C or used directly. For ACTH release studies, the cells were seeded 
at a density of 20,000 cells per well in 1mL of culture medium. After 
72 h, the medium was changed and a 2 h incubation without or with the 
SRIF-analogs in the presence of CRH (10 nM) was performed. In order 
to evaluate the effect of glucocorticoids or SRIF-analogs on SRIF-analog 
[SRIF-14, OCT, SOM230 and BIM-23268 (Table 1)] induced inhibition 
of ACTH release, the cells were pre-treated for 48 h with the synthetic 
glucocorticoid DEX (10 nM) or 72 h with SRIF-14, OCT or SOM230 
(all 10 nM), respectively. After this preincubation, the medium was 
changed and the effect of SRIF-analogs on CRH-induced ACTH secre-
tion was evaluated as described above. At the end of the incubations the 
medium was collected and stored at -20° C until hormone determination.
Table 1. Binding selectivity of SRIF-analogs for the five human sst.
Binding affinity (IC50, nM) 
Compound 
sst1 sst2 sst3 sst4 sst5
Somatostatin-14 2.3 0.2 1.4 1.8 1.4 
Octreotide 280 0.4 7.1 >1000 6.3 
SOM230 9.3 1.0 1.5 >100 0.2 
BIM-23268 18 15 62 16 0.4 
Data are from radioligand binding assays to membranes from transfected CHO-K1 cells 
(25, 61) and African green monkey kidney cells (25) expressing the different human sst 
subtypes. Values are from IPSEN (Culler, M.D.), Shimon (61) and from Bruns et al. (25).
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Radioligand binding assay
As previously described (28), the cells were resuspended in binding 
assay buffer (0.5% (w/v) bovine serum albumin (BSA), 10 mM N-[2-
hydroxyethyl]piperazine-N’-[2-ethanesulphonic acid] (HEPES), pH 
7.5) by homogenisation with a Polytron homogeniser (Kinematica AG) 
at 50 Hz for 30 s. 150 µl of cell homogenate (ca. 10000-25000 cells) 
was incubated with 50 µl of [125I]LTT-SRIF-28 (2175 Ci/mmol, 25-75 
pM fi nal concentration) in binding assay buffer containing MgCl
2
 (5 
mM) and bacitracin (20 µg/ml), and either 50 µl binding assay buffer 
alone (total binding), supplemented with 1 µM SRIF-14 (non specifi c 
binding) or with increasing concentrations of SOM230 or OCT. Ex-
periments were conducted in triplicate. Incubation was terminated af-
ter 1 h at room temperature by vacuum fi ltration through glass fi bre 
fi lters pre-soaked in 0.25% (w/v) polyethyleneimine. The fi lters were 
washed 3 times with ice-cold 10 mM Tris-HCl buffer containing 154 
mM NaCl (pH 7.4) and dried. Bound radioactivity was measured in a 
Packard TopCount using liquid scintillation (65% counting effi ciency).
[35S]GTPγS binding assay
As previously described (30), the cell pellet was re-suspended in 10 
mM HEPES, pH 7.5, by Polytron homogenisation at 50 Hz for 30 s, and 
centrifuged at 4°C for 30 min at 15000g. The microsome pellets were 
re-suspended in assay buffer (10 mM HEPES, 100 mM NaCl, 5 mM 
MgCl
2
, 0.1 mM EDTA, 10 µg/ml bacitracin, pH 7.4), and either stored 
at -80°C or directly used. 100 µl per well of the microsome prepara-
tion (ca. 75000 cells) were incubated in 96-well plates with [35S]GTPγS 
(1030 Ci/mmol, 100-200 pM fi nal concentration) in assay buffer con-
taining 1 µM GDP and triplicates of either: assay buffer (basal), 10 µM 
GTPγS, SOM230 or OCT at increasing concentrations. After 5 min pre-
incubation, 1.5 mg per well of wheatgerm agglutinin (WGA) scintilla-
tion proximity assay (SPA) beads (Amersham) were added (beads in 
50 mM Tris-HCl, 0.1% (w/v) sodium azide, pH 7.4), the plates sealed, 
incubated for 30 min at room temperature, and centrifuged for 10 min 
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at 1000g. During assay incubation cell membranes bind to WGA, ef-
fectively immobilizing the receptor-bearing membranes on to the SPA 
bead. The binding of [35S]GTPγS to such immobilized receptors brings 
the isotope into close proximity with the scintillant, which is incorpo-
rated within the bead. This allows the emitted radiation to stimulate the 
scintillant to emit light, which was measured (cpm) in a Packard Top-
Count. Percent stimulation of specifi c basal [35S]GTPγS binding was 
calculated as: 100 x [(experimental - basal)/(basal - non-specifi c)].
Quantitative PCR
Quantitative PCR was performed as previously described (31). Briefl y, 
poly A+ mRNA was isolated during Dynabeads Oligo (dT)
25
 (Dynal AS, 
Oslo, Norway) from AtT20/D16V cell pellets containing 0.5x106 cells 
per sample. cDNA was synthesized using the poly A+ mRNA, which was 
eluted from the beads in 40 µl H
2
O for 2 minutes at 65° C, using Oligo 
(dT)
12-18
 Primer (Life Technologies). One-twentieth of the cDNA library 
was used for quantifi cation of the sst subtype mRNA levels. A quantita-
tive RT-PCR was performed by TaqMan® Gold nuclease assay (The Per-
lin-Elmer Corporation, Foster City, CA) and the ABI PRISM® 7700 Se-
quence Detection System (The Perkin-Elmer) for real-time amplifi cation, 
according to the manufacturer’s instructions. The assay was performed 
using 15 µl TaqMan® Universal PCR Master Mix (Applied Biosystems, 
the Netherlands), 300 nM forward primer, 300 nM reverse primer, 200 
nM probe and 10 µl cDNA template, in a total reaction volume of 25 µl. 
The detection of pro-opiomelanocortin (POMC) mRNA was performed 
as a control for the negative feedback regulation by glucocorticoids on 
POMC gene expression. The detection of hypoxanthine phosphoribosyl 
transferase (HPRT) mRNA served as a control and was used for normali-
sation of the POMC and sst subtype mRNA levels. The specifi c mouse 
primer sequences (Biosource, Nivelles, Belgium) that were used included:
HPRT forward 5’-TGAAGAGCTACTGTAATGATCAGTCAAC-3’
HPRT reverse 5’-AGCAAGCTTGCAACCTTAACCA-3’
POMC forward 5’-ACCTCACCACGGAGAGCAAC-3’ 
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POMC reverse 5’-GCGAGAGGTCGAGTTTGCA-3’
Sst
2A
forward 5’-TGAGTGGTACGGAGGATGGG-3’
Sst
2A
reverse 5’-CTCCGTGGTCTCATTCAGCC-3’
Sst
2B
forward 5’-CAAGGCAGACAATTCACAATCC-3’
Sst
2B
reverse 5’-GTTTCTGCCGGGCAGCT-3’
Sst
5
 forward 5’-GCGCTCAGAACGCAAGGT-3’
Sst
5
reverse 5’-CAGCAGCCCACGAACACC-3’
The probe sequences that were used included:
HPRT 5’-FAM-TGCTTTCCCTGGTTAAGCAGTACAGCCC-TAMRA-3’
POMC 5’-FAM-TGCTGGCTTGCATCCGGGC-TAMRA-3’
Sst
2A
5’-FAM-AGAGGAGCGACAGTAAGCAGGACAAATCC-TAMRA-3’
Sst
2B
 5’-FAM-ATTGCCTGGGTGTGACCTGGTGGA-TAMRA-3’
Sst
5
5’-FAM-ACTCGCATGGTGGTGGTAGTGGTGC-TAMRA-3’
The relative amount of POMC, sst
2
 and sst
5
 mRNA was determined by means 
of a standard curve generated in each experiment from known amounts 
of mouse genomic DNA. For the determination of the amount of HPRT 
mRNA, a standard curve was obtained by including dilutions of a pool cD-
NAs known to contain HPRT. The amount of POMC, sst
2
 and sst
5
 mRNA 
was calculated relative to the amount of HPRT and is given in arbitrary units.
Sst membrane binding studies
The method of membrane isolation and the reaction conditions were pre-
viously described (32). Briefl y, membrane preparations (corresponding to 
30-50 µg protein) of cultured AtT-20 cells, in the presence or absence of 
10nM DEX (48 h), were incubated in a total volume of 100 µl at room tem-
perature for 60 min with increasing concentrations of [125I-Tyr11]-SRIF-14 
or [125I-Tyr3]-Octreotide with and without excess (1 µM) of unlabeled 
SRIF-14 or Octreotide, respectively, in Hepes buffer (10 mM Hepes, 5 
mM MgCl
2
 and 0.02 g/L bacitracin, pH 7.6) containing 0.2% BSA. After 
the incubation, 1 mL ice-cold Hepes buffer was added to the reaction mix-
ture, and membrane-bound radioactivity was separated from unbound by 
210
Chapter V-2
centrifugation during 2 min at 14,000 rpm in a Eppendorf microcentrifuge. 
The remaining pellet was washed twice in ice-cold Hepes buffer, and the 
fi nal pellet was counted in a γ-counter. Specifi c binding was taken to be total 
binding minus binding in the presence of 1 µM unlabeled SRIF-14 or Oc-
treotide. As a control for binding, rat brain cortex membranes were used. 
Hormone determination
Mouse immunoreactive (ir-) ACTH concentrations were determined by a 
non-isotopic, automatic chemiluminescence immunoassay system (Immu-
lite, DPC Inc.), as described previously for the detection of rodent ir-ACTH 
(33). The intra- and inter-assay coeffi cients of variation (CV) for ACTH 
were 5.6% and 7.8%, respectively. Under the conditions employed, the assay 
detects 1 fmol/tube of ir-ACTH. Dilution curves of the samples were par-
allel with those of the standard, and in addition, biological specifi city of the 
results was in agreement with hypothalamic-pituitary-adrenal physiology.
Test-substances
Octreotide (OCT, Sandostatin®) was obtained from Novartis Pharma 
A.G., (Basel, Switzerland). SOM230 was synthesized at Novartis Phar-
ma A.G. Somatostatin-14 was purchased from Sigma Chemical Co. (St. 
Louis, MO). BIM-23268, an sst
5
-subtype specifi c analog, was synthe-
sized at IPSEN (Massachusetts, USA). Dexamethasone was derived from 
the pharmacy department of the Erasmus MC (Rotterdam, the Nether-
lands). Corticotropin-releasing hormone (CRH) was purchased from 
Ferring (Hoofddorp, the Netherlands). [125I]LTT-SRIF-28 was custom 
synthesised by ANAWA (Wangen, Switzerland). [125I-Tyr11]-SRIF-14 
was purchased from Amersham (Houten, The Netherlands). The SRIF-
analog [Tyr3]-Octreotide was iodinated with 125I by the chloramine-T 
method and purifi ed by HPLC, as described previously in detail (34). 
Specifi c radioactivity of all radioligands yielded approximately 2000 Ci/
mmol. [35S]GTPγS was purchased from Amersham (Freiburg, Germany).
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Statistical analysis
The statistical signifi cance of the difference between mean values regarding 
the effects of the SRIF-analogs on ACTH release was determined by using 
one-way analysis of variance (ANOVA). When signifi cant overall effects 
were obtained by this method, comparisons were made using Newman-
Keuls multiple comparisons test. The unpaired Student t-test was chosen 
to analyze for statistical signifi cance in the experiments determining the 
effects of DEX treatment on POMC and sst mRNA expression levels. pKd, 
EC
50
 and IC
50
 values were determined by non-linear regression curve anal-
ysis of the concentration-effect responses using the computer programs 
ActivityBase and GraphPad Prism. The unpaired Student t-test was cho-
sen to analyze differences in concentration-effect curves. Data are report-
ed as means ± SEM of the indicated n values, unless otherwise specifi ed. 
Results
Radioligand and [35S]GTPγS binding assays
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Figure 1. Inhibition of radioligand binding in AtT-20 cell membranes (A). Crude mem-
brane preparations were incubated with [125I]LTT-SRIF-28, and increasing concen-
trations of SOM230 (●) and OCT (○). Data are expressed as percentage of specific 
binding. The data points represent the mean ± SEM (bars) of data from 3-8 different 
experiments run in triplicate. (B). Stimulation of [35S]GTPγS binding in AtT-20 cell 
membranes. Dose-Response effects of SOM230 (●) and OCT (○). Data are expressed 
as percentage stimulation of specific basal [35S]GTPγS binding. The data points repre-
sent the mean ± SEM (bars) of data from 3-12 different experiments run in triplicate
The binding properties of SOM230 and OCT at [125I] Leu8 Trp22 Tyr25
SRIF-28 (LTT-SRIF-28) labeled sites in AtT-20 cell membranes were es-
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tablished in competition experiments. As shown in fi gure 1A, SOM230 
had a 7-fold higher ligand binding affi nity than OCT for [125I]LTT-SRIF-
28 labeled sites in AtT-20 cell membranes [IC
50
 0.18 nM (pKd 9.74 ± 0.08, 
n=8) vs. 1.2 nM (pKd 8.92 ± 0.03, n=3), respectively;  p<0.0001]. In micro-
some preparations from AtT-20 cells, both SOM230 and OCT produced a 
concentration-dependent increase in [35S]GTPγS binding (Fig. 1B). Inter-
estingly, SOM230 showed a clear 19-fold higher potency in stimulating 
GTPγS binding as compared with OCT [EC
50
 8.71 nM (pKd 8.09 ± 0.11, 
n=12) and 169.8 nM (pKd 6.78 ± 0.07, n=3), respectively; p<0.0001]. 
Effect of SRIF-14 and SRIF-analogs on CRH-induced ACTH 
secretion in AtT-20 corticotroph cells, with or without gluco-
corticoid pre-treatment.
Full dose-response curves were performed to ascertain which concentra-
tion of DEX and CRH should be used in our experiments. As can be seen 
in Figure 2, DEX concentration-dependently suppressed POMC mRNA 
expression in AtT-20 cells, after 24 h (Fig. 2A) and 48 h (Fig. 2B), where-
by 10nM was most effective. CRH induced ACTH release by AtT-20 cells 
in a dose-dependent way as well, which reached its maximum effect  at 
10 nM CRH (Fig. 2C). Because of the physiological negative feedback 
loop within the hypothalamus-pituitary-adrenal axis, the effect of 48 h 
DEX (10 nM) pre-treatment was assessed (Fig. 2D). ACTH release by 
AtT-20 cells was decreased when cultured for 48 h with DEX (from 1213 
± 32 to 75 ± 1.8 fmol/L*well; p<0.0001). Nevertheless, DEX-treated 
AtT-20 cells remained responsive to CRH (10 nM) stimulation (Fig. 2D). 
In order to evaluate the effects of DEX pre-treatment on CRH-induced 
ACTH release in AtT-20 cells, we fi rst investigated the inhibitory poten-
cies of the SRIF-analogs on CRH-induced ACTH-release in AtT-20 cells, 
under basal conditions. Each SRIF-analog (100 nM) potently inhibited 
CRH-induced ATCH release varying between 58% and 75% suppression 
(BIM-23268, p<0.05 vs OCT and SRIF-14; SOM230 vs OCT, p<0.05). 
The dose-dependent inhibition of ACTH release by SRIF-14 (Fig. 3A) and 
SOM230 (Fig. 3B) was not affected by 48h DEX (10nM) and the corre-
sponding IC
50
 values for SRIF-14 (1.3 nM without vs. 0.7 nM with DEX; 
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Figure 2. Effect of glucocorticoids and CRH on POMC mRNA and ACTH release in 
AtT-20 corticotroph tumour cells. Cells were pre-incubated during 24 (A) and 48h (B) 
with dexamethasone (range 0.01-10 nM DEX). Subsequently, Poly A+-mRNA was 
isolated, which was used to determine the expression levels of POMC by quantitative 
PCR (corrected for HPRT). Values represent percent change of POMC mRNA tran-
scripts under DEX treatment compared with control, and are the mean ± SEM of two 
independent experiments. #, p<0.001 vs control, 0.1 and 0.01nM DEX; *, p<0.05 vs 
control, 0.1 and 0.01nM DEX. C) Concentration effect curve of 3 h incubation with 
CRH (0.01-1000 nM) on ACTH release in AtT-20 cells. Values represent percent change 
of ACTH release compared with control, and are the mean ± SEM of two indepen-
dent experiments run in quadruplicate. D) Effect of Dexamethasone (10 nM; 48 h) on 
CRH-induced ACH release in AtT-20 cells. After 48 h, the medium was refreshed and 
the cells were incubated for 2 h in the absence or presence of DEX and CRH (10nM) 
after which the medium was collected for ACTH determination. Values are expressed 
as mean ± SEM of four wells per treatment group. The left part depicts CRH induced 
ACTH release in the absence of DEX (no Dex); the right part of the graph depicts 
CRH-induced ACTH release after 48h 10nM DEX-treatment. #, p<0.0001 com-
pared with basal ACTH release in the absence of  DEX; *, p<0.001 CRH vs basal.
p=ns) and SOM230 (0.06 nM without vs. 0.07 nM with DEX; p=ns) re-
mained unchanged. Interestingly, the concentration-response curve for the 
inhibitory effects of BIM-23268 on CRH-induced ACTH release showed 
a shift to the left, indicating increased potency, when pre-treated with 
DEX, with the IC
50 
value shifting 34-fold from 3.4 to 0.1nM in the pres-
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ence of DEX (p<0.05; Fig. 3C). In contrast, DEX pre-treatment caused 
the concentration-response curve of OCT to shift to the right, indicating 
decreased potency. The IC
50
 indicates a 20-fold shift from 0.2 nM without 
DEX to 4.3 nM in the presence of DEX (p<0.05; Fig. 3D). Both 100 nM 
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Figure 3. Effect of glucocorticoids on concentration-dependent inhibition of CRH-in-
duced ACTH release in mouse corticotroph tumour cells by different SRIF-analogs. 
AtT-20 cells were pre-incubated during 48 h with 10 nM DEX. After 48 h, medium 
was collected and exchanged for new medium containing 10 nM CRH and differ-
ent concentrations of SRIF (A), SOM230 (B), BIM-23268 (C) or OCT (D). Incuba-
tion was performed for an additional 2 h and the medium was collected for ACTH 
determination. Calculation of the IC
50
 values was performed using the GraphPad 
Prism (San Diego, CA) computerized program and the unpaired Student t-test was 
chosen to analyze differences in IC
50
 values. Control □, DEX 10nM ■. #, p<0.05.
BIM-23268 and 100 nM SOM230 showed signifi cantly enhanced sup-
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pressive effects on CRH-induced ACTH release in the presence of DEX 
(p<0.01 and p<0.05 vs without DEX, respectively). No differences in the 
maximal inhibitory effects were observed when the cells were incubated 
with 100 nM OCT without or with DEX; however, as shown in fi gure 4, 
the inhibitory effect of 1 nM OCT on CRH-induced ACTH release was 
almost completely abolished by DEX treatment (-39 ± 2% without vs. -9 
± 6% with DEX; p<0.05). In contrast, DEX treatment enhanced the abili-
ty of 1 nM BIM-23268 (Fig. 4: -15 ± 1% without vs. -60 ± 7% with DEX; 
p<0.01) to suppress CRH-induced ACTH release.  DEX did not affect the 
inhibitory effects of 1 nM SOM230. Both SOM230 and BIM-23268 were 
signifi cantly more effi cacious than OCT in suppressing ACTH release 
under DEX treatment, not only at supra physiological but also at physi-
ological concentrations (p<0.05, BIM-23268 and SOM230 vs OCT). 
Figure 4. Effect of glucocorticoids on SRIF and SRIF-analog mediated inhibi-
tion of CRH-induced ACTH release by AtT-20 cells. Cells were pre-incubated with 
or without 10nM DEX. After 48 h, the medium was refreshed and the cells were in-
cubated for 2 h in the absence or presence of 10nM DEX, CRH (10nM) and the in-
dicated compounds at a concentration of  1nM. Subsequently, medium was collect-
ed for ACTH determination. Values are expressed as mean ± SEM of four wells per 
treatment group. Control □, DEX 10nM ■. # , p<0.05 SOM230 and BIM-23268 vs 
OCT. +, p<0.05 OCT vs BIM-23268. *, p<0.05, SOM230 vs OCT and BIM23268.
Effect of glucocorticoid treatment on sst
2 
+ sst
5
 mRNA levels 
To determine whether glucocorticoids display a regulatory role on both 
sst
2
 isoforms and/or sst
5 
mRNA expression levels, AtT-20 cells were ex-
posed to 10 nM DEX for 24 and 48 h. As shown in fi gure 5, DEX signifi -
cantly suppressed POMC mRNA levels after 24 and 48 h (-55 ± 2% and 
-74 ± 2%, respectively: both p<0.001 to control). Sst
2A
 and sst
2B 
mRNA 
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levels were potently suppressed after 24 h of DEX treatment by 30 ±
6% and 45 ± 4%, respectively (Figure 5, left panel: p<0.001), which re-
mained signifi cantly lower after 48 h (Figure 5, right panel). In contrast, 
sst
5
 mRNA expression remained constant after 24 h of DEX and was 
not signifi cantly affected  (20 ± 8%; p = ns) after 48 h DEX treatment.
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Figure 5. Effect of glucocorticoids on sst mRNA expression levels in AtT-20 pituitary 
adenoma cells. AtT-20 cells were pre-incubated for 24 h (left panel) and 48 h (right 
panel) without or with 10nM DEX. Poly A+-mRNA was isolated from untreated and 
treated AtT-20 cells, which was used to determine the expression levels of POMC or sst 
mRNA by quantitative PCR (corrected for HPRT). Values represent percent change of 
the different mRNA transcripts under DEX treatment compared with control, and are the 
mean ± SEM of three independent experiments. Control □, DEX 10nM ■. *, p<0.001.
Effect of glucocorticoid treatment on sst binding sites
To determine whether glucocorticoids display a regulatory role on sst
2
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and/or sst
5 
at the protein level as well, AtT-20 cells were cultured in the 
presence or absence of 10nM DEX for 48 h and subsequently collected 
for cell membrane binding assays with two different radiolabeled so-
matostatin analogs: [125I-Tyr3]-Octreotide, displaying superior binding 
affi nity for only sst
2
, and [125I-Tyr11]-SRIF-14, which can bind to both 
sst
2 
and sst
5
 with good affi nity. Maximum binding capacity (Bmax) was 
dramatically suppressed by 72% in the presence of 10nM DEX when 
[125I-Tyr3]-Octreotide was used as radioligand (Fig. 6A; Bmax 1404 to 
390 fmol/mg in the absence and presence of DEX, respectively). As de-
picted in Figure 6B, DEX attenuated radioligand binding only by 17% 
when [125I-Tyr11]-SRIF-14 was used as radioligand (Bmax 1581 and 
1315 fmol/mg in the absence and presence of 10nM DEX, respectively). 
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Figure 6. Sst membrane binding studies. A) Scatchard analysis of [125I-Tyr3]-Oc-
treotide binding to cell membranes of AtT-20 cells, cultured in the absence (Kd= 
0.1 nM, n= 1404 fmol/mg) or presence of 10 nM DEX (48 h; Kd= 0.7 nM, n= 390 
fmol/mg). B) Scatchard analysis [125I-Tyr11]-SRIF-14 binding to cell membranes 
of AtT-20 cells, cultured in the absence (Kd= 0.1, n= 1581 fmol/mg) or presence 
of 10 nM DEX (48 h; Kd= 0.1 nM, n= 1315 fmol/mg).  Control □, DEX 10nM ■.
Effect of SRIF-analog pre-treatment
First, it should be noted that SRIF-analog pre-treatment lowered the in-
hibitory effects of all SRIF-analogs (10 nM) on CRH-induced ACTH 
release (from 47-69% to 18-54% range of suppression). In order to 
evaluate the effect of continued exposure of AtT-20 cells to a maximal 
inhibitory concentration of the different SRIF-analogs, AtT-20 cells 
218
Chapter V-2
were preincubated for 72 h with either SRIF-14, OCT or SOM230 (10 
nM), followed by 2 h incubation with CRH (10 nM) and either SRIF-
14, OCT, SOM230 and/or BIM-23268 (all 10 nM). As depicted in 
Figure 7A, the inhibitory effects of SOM230 (-48%) and BIM-23268 
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Figure 7. Effect of prior SRIF-analog treatment on the SRIF-analog mediated inhibi-
tion of CRH-induced ACTH release by AtT-20 cells. Cells were pre-incubated with 
10nM SRIF (A), OCT (B) or SOM230 (C). After 72 h, the medium was refreshed 
and the cells were incubated for 2 h in the absence or presence of 10nM SRIF-ana-
log, CRH (10nM) and the indicated compounds (10nM), after which the medium 
was collected for ACTH determination. Values are expressed as mean ± SEM of four 
wells per treatment group. *, p<0.01 vs OCT and SRIF; #,p<0.05 vs OCT and SRIF.
(-54%) appeared to be two fold more effi cacious as compared with 
OCT (-22%; *p<0.01 vs SOM230 and OCT) when AtT-20 cells were 
treated for 72h with SRIF-14. Comparable superior suppressive ef-
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fects by SOM230 and BIM-23268, compared with OCT, were observed 
when cells were pre-treated with OCT (Fig. 7B) or SOM230 (Fig. 7C).
Discussion
Because purifi ed populations of corticotrophs are diffi cult to pre-
pare and require substantive amounts of pituitary tissue, we based our 
study on the mouse pituitary corticotroph (AtT-20/D16V) cell line after 
fi rst confi rming by quantitative RT-PCR the expression of sst
2A
, sst
2B
and sst
5
 mRNA. Although it is appreciated that cell lines are not nec-
essarily representative of their parent cell types, we reasoned that this 
clonal population, which has been studied intensively as a well-ac-
cepted cellular model for corticotrophs (35), would provide a useful 
model in which to explore fundamental mechanisms of the effects of 
SRIF (-analogs) on ACTH release and the role of sst subtypes herein. 
In the present study predominance of sst
2 
and sst
5 
was found as both OCT 
and SOM230 showed high affi nity binding. These observations are well 
in agreement with recent extensive pharmacological studies that indicated 
sst
2
 and sst
5
 are mainly expressed with no or negligible presence of sst
1
, sst
3
and sst
4
 in AtT-20 cells (28). The inhibitory effects of SRIF-14, SOM230, 
OCT and BIM-23268 on CRH-induced ACTH release in AtT-20 cells, are 
well in agreement with the concept that both sst
2 
and sst
5
-binding SRIF-
analogs potently inhibit CRH-induced ACTH release by AtT-20 cells 
(36). Moreover, the maximal inhibitory effect of the two SRIF-analogs 
that bind with very high affi nity to sst
5
, i.e. SOM230 and BIM-23268, 
was signifi cantly higher as compared with OCT. This apparent function-
al superiority of sst
5
 over sst
2
 seems to confi rm recent observations by 
Cervia and coworkers (30), as well as our membrane and GTPγS bind-
ing results showing the superior profi le of SOM230 compared to OCT. 
In the present study we found that glucocorticoid treatment induced 
remarkable differences with respect to the role of sst
2
 and sst
5 
in regu-
lating ACTH release. We observed a profound difference in effi cacy 
between the sst
2
 specifi c analog, OCT, and the multiligand SRIF-ana-
log, SOM230, and the sst
5 
preferring analog, BIM-23268. Since both 
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SOM230 and BIM-23268 still potently inhibited CRH-induced ACTH 
release under DEX treatment whereas the suppressive effects of OCT 
were almost completely blocked in the “physiological” nanomolar range, 
it is suggested that sst
2
 is down-regulated by glucocorticoids treatment 
while sst
5
 is more resistant. The intriguing differences in the functional 
properties of sst
2 
and sst
5 
in mediating ACTH release under DEX pres-
sure is further supported by our observations that both the IC
50
 values 
for OCT and BIM-23268 during DEX treatment shift toward their sst
5
binding affi nity, i.e. a 20-fold decrease and 34-fold increase in their po-
tency to suppress ACTH release, respectively. Our data not only confi rm 
earlier observations that glucocorticoid treatment abolishes the inhibitory 
effect of OCT on ACTH release in vitro (22) but also seem well in agree-
ment with other reports which demonstrate that SRIF only suppressed 
ACTH release by rat pituitary cells from long-term adrenalectomized 
rats (37) or when the cells were cultured in the absence of glucocorti-
coids (11, 38), One group did observe ACTH suppression by SRIF-28, 
which is known to have preferable binding affi nity for sst
5
, in a primary 
cell culture from a Nelson’s tumour and from an ACTH-secreting pitu-
itary adenoma (39, 40). However, in patients with Nelson’s syndrome 
and adrenal insuffi ciency of different origin, both SRIF and OCT lower 
ACTH secretion (14, 41-43), again suggesting that glucocorticoids infl u-
ence the sensitivity of the corticotroph cells for SRIF and OCT.  Because 
glucocorticoids are also well known to mediate biologic effects through 
regulation of gene expression, it was of interest to test the effects of glu-
cocorticoids on sst
2
 and sst
5
 gene expression in AtT-20 cells. The primary 
transcript of the sst
2
 gene is alternatively spliced in a long (sst
2A
) and a 
short (sst
2B
) form (16, 27, 44-46). The current mRNA data again support 
the concept that glucocorticoid treatment differentially infl uences sst
2A+2B 
expression as compared with sst
5
. It is known that the mouse sst
2
 gene 
promoter sequence is the only sst receptor that has been shown directly 
to be transcriptionally regulated by glucocorticoids (47, 48), whereas the 
mouse sst
5
 gene possesses multiple glucocorticoid responsive elements 
half-sites (49). Therefore, the immediate and powerful suppression of 
both sst
2A+2B 
suggests a direct effect of DEX at the transcriptional level, 
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whereas sst
5 
could be regulated in a different way. Support for transcrip-
tional down-regulation of sst subtype
1+2+3
 mRNA expression by glucocor-
ticoids comes from studies in rat pituitary GH
4
C
1 
cells (50). Infl uencing 
mRNA stability, could be involved as well since the addition of a RNA 
synthesis inhibitor produces no disruption of the ability of DEX to sup-
press either sst
2
 or sst
3
 mRNA levels in cultured rat pituitary cells (51). 
Our observation that sst
2 
and sst
5 
receptors might be regulated differently 
by glucocorticoids was also recently observed by Park and coworkers: 
in a rat model, DEX inhibited sst
2
 mRNA expression both in vivo and 
in vitro, but enhanced sst
5
 mRNA expression (51). Moreover, earlier ob-
servations already demonstrated that glucocorticoids lower [125I-Tyr11]-
SRIF-14 binding in AtT-20 cells, but sst receptors were not characterized 
(52). Our data confi rm that [125I-Tyr11]-SRIF-14 binding is attenuated in 
AtT-20 cells after DEX treatment. However, [125I-Tyr3]-Octreotide bind-
ing, i.e. the presence of only sst
2 
receptor subtypes, was reduced by al-
most 75% by DEX, indicating that sst
2
 at the protein level is dramatically 
decreased. Since [125I-Tyr11]-SRIF-14 binding displays both sst
2 
and sst
5
binding affi nity and is only slightly lowered by DEX, it becomes sugges-
tive that this universal radioligand represents predominantly sst
5
 recep-
tors when AtT-20 cells are treated by glucocorticoids. These experiments 
clearly support our mRNA data and demonstrate at the protein level that 
sst
5
, compared with sst
2
, seems less sensitive to DEX treatment as well.
The down regulation of sst
2A+2B
 mRNA and protein levels in AtT-20 cells 
by glucocorticoids, may be an explanation for the lack of effi cacy of 
OCT in lowering ACTH and cortisol levels in patients with untreated 
Cushing’s disease (18). Thus, the observed ability of sst
5
 to suppress 
ACTH release in AtT-20 cells, which appears to be relatively resistant 
to glucocorticoids, might be a new target for therapeutical agents that 
could lower ACTH and cortisol levels in a subgroup of patients with 
Cushing’s disease. Furthermore, we propose that sst
2 
+ sst
5
 preferring 
SRIF-analogs, such as SOM230, might become of therapeutic interest 
in Cushing’s disease as well. The suppression of ACTH levels by ac-
tivation of sst
5
 in patients with Cushing’s disease might lower cortisol 
levels. Since cortisol inhibits sst
2
 expression, these suppressive effects 
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might subsequently be (partially) abrogated. In this relative hypocor-
tisolemic state, enhanced ACTH inhibition via restored sst
2 
expression 
becomes suggestive. Therefore, SOM230 may be able to lower ACTH 
levels in Cushing’s disease even more, because it could now function 
via both sst
5 
and sst
2 
receptor subtypes. Nevertheless, it should be kept 
in mind that this tantalizing hypothesis needs further studies to confi rm 
its rationale. These studies should be confi rmed in primary cultures of 
rodent corticotroph cells and in living animals as well, before a a well de-
signed clinical trial in patients with Cushing’s disease can be performed.
Internalization of receptor-ligand complexes has been shown to play a role 
in desensitization (53), leading to tachyphylaxis of the inhibitory effect of 
sst
2
-preferring analogs on hormone secretion in a subgroup of neuroendo-
crine tumours (54, 55). Prolonged treatment of AtT-20 cells with SRIF-14 
results in desensitization of its inhibitory effect on ACTH secretion and 
cAMP formation (56), and prolonged exposure of AtT-20 cells to SRIF-14 
and SRIF-28 has been shown to down-regulate SRIF-14 receptors (57). 
Interestingly, we recently observed that prolonged SOM230 treatment, 
but not OCT, inhibited basal ACTH release both from primary cultures of 
ACTH-producing pituitary and from AtT-20 cells (23) suggesting that sst
2
and sst
5 
appear to respond differently after continued ligand activation. 
The ability of the sst
5
-preferring analogs to continue to suppress ACTH 
levels, independent of prior 72 h SRIF-analog exposure and the decreased 
effi cacy of OCT, supports other data that sst
2
 desensitizes on continued 
ligand activation and suggests that the sst
5
 receptor may be more resistant 
to desensitization. It has already been demonstrated that sst
5
 receptors 
are rapidly recycled and restored from intracellular storage after agonist 
activation, which might protect this particular receptor from long-term 
down-regulation (58). In addition, it was recently demonstrated in live 
transfected AtT-20 cells that only fl uorescein protein  (FP-) tagged sst
2
 sub-
type, but not FP-sst
5
, internalized upon ligand activation (59). The FP-sst
5
subtype remained localized to the membrane during treatment with either 
a sst
5
 preferring agonist, a sst
2+5 
biselective agonist, SRIF-14 or SRIF-28.
In summary, this study demonstrates that sst
5
 receptors display intriguing 
functional properties in regulating ACTH release in mouse corticotroph 
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tumour cells. Moreover, the recent observation that in sst
5
 knockout mice 
serum ACTH and cortisol levels were elevated compared with wild type 
mice supports the concept that sst
5
 receptors are important in the regula-
tion of ACTH release in mice (60). Based on the potent suppressive effects 
on ACTH release by sst
5
 preferring analogs, the relative resistance of sst
5
expression and action to DEX suppression as well as to prolonged SRIF-
analog exposure, and our recent observation that sst
5 
is the predominant sst 
expressed in human corticotroph adenomas (23), we propose that sst
5
 may 
become a new therapeutic target for the control of ACTH and cortisol hyper-
secretion in untreated patients with pituitary dependent Cushing’s disease.
Grants
This work was supported in part by EC contract QLG3-CT-1999-00908 
and Swiss Grant BBW 00-0427. 
References
1. Nieman LK 2002 Diagnostic tests for Cushing’s syndrome. Ann N Y Acad Sci 
970:112-8
2. Arnaldi G, Angeli A, Atkinson AB, et al. 2003 Diagnosis and complications 
of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 
88:5593-602
3. Morris D, Grossman A 2002 The medical management of Cushing’s syndrome. 
Ann N Y Acad Sci 970:119-33
4. Colao A, Di Sarno A, Marzullo P, et al. 2000 New medical approaches in 
pituitary adenomas. Horm Res 53 Suppl 3:76-87
5. Miller JW, Crapo L 1993 The medical treatment of Cushing’s syndrome. 
Endocr Rev 14:443-58
6. Orrego JJ, Barkan AL 2000 Pituitary disorders. Drug treatment options. 
Drugs 59:93-106
7. Pereira AM, van Aken MO, van Dulken H, et al. 2003 Long-term predictive 
value of postsurgical cortisol concentrations for cure and risk of recurrence in 
Cushing’s disease. J Clin Endocrinol Metab 88:5858-64
8. Brazeau P, Vale W, Burgus R, et al. 1973 Hypothalamic polypeptide that 
inhibits the secretion of immunoreactive pituitary growth hormone. Science 
179:77-9.
9. Patel YC, Greenwood MT, Panetta R, et al. 1995 The somatostatin receptor 
family. Life Sci 57:1249-65
10. Reisine T, Bell GI 1995 Molecular biology of somatostatin receptors. Endocr 
Rev 16:427-42.
224
Chapter V-2
11. Lamberts SW 1988 The role of somatostatin in the regulation of anterior 
pituitary hormone secretion and the use of its analogs in the treatment of human 
pituitary tumors. Endocr Rev 9:417-36
12. Kraicer J, Gajewski TC, Moor BC 1985 Release of pro-opiomelanocortin-
derived peptides from the pars intermedia and pars distalis of the rat pituitary: 
effect of corticotrophin-releasing factor and somatostatin. Neuroendocrinology 
41:363-73
13. Brown MR, Rivier C, Vale W 1984 Central nervous system regulation of 
adrenocorticotropin secretion: role of somatostatins. Endocrinology 114:1546-
9
14. Lamberts SW, Krenning EP, Reubi JC 1991 The role of somatostatin and its 
analogs in the diagnosis and treatment of tumors. Endocr Rev 12:450-82.
15. Patel YC 1999 Somatostatin and its receptor family. Front Neuroendocrinol 
20:157-98.
16. Vanetti M, Kouba M, Wang X, et al. 1992 Cloning and expression of a novel 
mouse somatostatin receptor (SSTR2B). FEBS Lett 311:290-4
17. de Herder WW, van der Lely AJ, Lamberts SW 1996 Somatostatin analogue 
treatment of neuroendocrine tumours. Postgrad Med J 72:403-8
18. Lamberts SW, Uitterlinden P, Klijn JM 1989 The effect of the long-acting 
somatostatin analogue SMS 201-995 on ACTH secretion in Nelson’s syndrome 
and Cushing’s disease. Acta Endocrinol (Copenh) 120:760-6
19. De Herder WW, Lamberts SW 1999 Octapeptide somatostatin-analogue 
therapy of Cushing’s syndrome. Postgrad Med J 75:65-6
20. Lamberts SW, Hofl and LJ, de Herder WW, et al. 1993 Octreotide and 
related somatostatin analogs in the diagnosis and treatment of pituitary disease 
and somatostatin receptor scintigraphy. Front Neuroendocrinol 14:27-55
21. De Herder WW, Kwekkeboom DJ, Reijs AEM, et al. 1996 Receptor 
scintigraphy with somatostatin analogues and dopamine antagonists of pituitary 
tumours. In: von Werder K, Fahlbusch R (eds) Pituitary adenomas. From basic 
research to diagnosis and therapy. Elsevier Science BV., Amsterdam, pp 93-
104
22. Stalla GK, Brockmeier SJ, Renner U, et al. 1994 Octreotide exerts different 
effects in vivo and in vitro in Cushing’s disease. Eur J Endocrinol 130:125-
31
23. Hofl and LJ, van der Hoek J, Feelders R, et al. 2005 The multiligand 
somatostatin analog SOM230 inhibits ACTH secretion by cultured human 
corticotroph adenomas via somatostatin receptor subtype 5. Eur J Endocrinol: 
in press
24. Lewis I, Bauer W, Albert R, et al. 2003 A novel somatostatin mimic with 
broad somatotropin release inhibitory factor receptor binding and superior 
therapeutic potential. J Med Chem 46:2334-44.
25. Bruns C, Lewis I, Briner U, et al. 2002 SOM230: a novel somatostatin 
peptidomimetic with broad somatotropin release inhibiting factor (SRIF) 
receptor binding and a unique antisecretory profi le. Eur J Endocrinol 146:707-
16.
225
Regulation of ACTH Release by sst
5
26. Weckbecker G, Briner U, Lewis I, et al. 2002 SOM230: a new somatostatin 
peptidomimetic with potent inhibitory effects on the growth hormone/insulin-
like growth factor-I axis in rats, primates, and dogs. Endocrinology 143:4123-
30.
27. Patel YC, Panetta R, Escher E, et al. 1994 Expression of multiple somatostatin 
receptor genes in AtT-20 cells. Evidence for a novel somatostatin-28 selective 
receptor subtype. J Biol Chem 269:1506-9
28. Cervia D, Nunn C, Fehlmann D, et al. 2003 Pharmacological characterisation 
of native somatostatin receptors in AtT-20 mouse tumour corticotrophs. Br J 
Pharmacol 139:109-21.
29. Hofl and LJ, van Koetsveld PM, Waaijers M, et al. 1995 Internalization of 
the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and 
human pituitary tumor cells: increase by unlabeled octreotide. Endocrinology 
136:3698-706
30. Cervia D, Fehlmann D, Hoyer D 2003 Native somatostatin sst2 and sst5 
receptors functionally coupled to G(i/o)-protein, but not to the serum response 
element in AtT-20 mouse tumour corticotrophs. Naunyn Schmiedebergs Arch 
Pharmacol 367:578-87.
31. Ferone D, Pivonello R, Van Hagen PM, et al. 2002 Quantitative and 
functional expression of somatostatin receptor subtypes in human thymocytes. 
Am J Physiol Endocrinol Metab 283:E1056-66.
32. Hofl and LJ, van Koetsveld PM, Wouters N, et al. 1992 Dissociation of 
antiproliferative and antihormonal effects of the somatostatin analog octreotide 
on 7315b pituitary tumor cells. Endocrinology 131:571-7
33. Lloyd-MacGilp SA, Torielli L, Bechtel S, et al. 2002 Mutations in aldosterone 
synthase gene of Milan hypertensive rats: phenotypic consequences. Am J 
Physiol Endocrinol Metab 282:E608-17
34. Bakker WH, Krenning EP, Breeman WA, et al. 1990 Receptor scintigraphy 
with a radioiodinated somatostatin analogue: radiolabeling, purifi cation, 
biologic activity, and in vivo application in animals. J Nucl Med 31:1501-9
35. Tierney T, Patel R, Stead CA, et al. 2005 Macrophage migration inhibitory 
factor is released from pituitary folliculo-stellate-like cells by endotoxin and 
dexamethasone and attenuates the steroid-induced inhibition of interleukin 6 
release. Endocrinology 146:35-43
36. Strowski MZ, Dashkevicz MP, Parmar RM, et al. 2002 Somatostatin 
receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated 
adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinology 75:339-
46.
37. Voight KH, Fehm HL, Lang RE, et al. 1977 The effect of somatostatin and of 
prolyl-leucyl-glycinamide (MIF) on ACTH release in dispersed pituitary cells. 
Life Sci 21:739-45
38. Lamberts SW, Zuyderwijk J, den Holder F, et al. 1989 Studies on 
the conditions determining the inhibitory effect of somatostatin on 
adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary 
cells. Neuroendocrinology 50:44-50
226
Chapter V-2
39. Shibasaki T, Masui H 1982 Effects of various neuropeptides on the secretion 
of proopiomelanocortin-derived peptides by a cultured pituitary adenoma 
causing Nelson’s syndrome. J Clin Endocrinol Metab 55:872-6
40. Shibasaki T, Nakahara M, Shizume K, et al. 1983 Pituitary adenomas that 
caused Cushing’s disease or Nelson’s syndrome are not responsive to ovine 
corticotropin-releasing factor in vitro. J Clin Endocrinol Metab 56:414-6
41. Tyrrell JB, Lorenzi M, Gerich JE, et al. 1975 Inhibition by somatostatin of 
ACTH secretion in Nelson’s syndrome. J Clin Endocrinol Metab 40:1125-7
42. Fehm HL, Voigt KH, Lang R, et al. 1976 Somatostatin: a potent inhibitor of 
ACTH-hypersecretion in adrenal insuffi ciency. Klin Wochenschr 54:173-5
43. Benker G, Hackenberg K, Hamburger B, et al. 1976 Effects of growth 
hormone release-inhibiting hormone and bromocryptine (CB 154) in states of 
abnormal pituitary-adrenal function. Clin Endocrinol (Oxf) 5:187-90
44. Vanetti M, Vogt G, Hollt V 1993 The two isoforms of the mouse somatostatin 
receptor (mSSTR2A and mSSTR2B) differ in coupling effi ciency to adenylate 
cyclase and in agonist-induced receptor desensitization. FEBS Lett 331:260-6
45. Vanetti M, Ziolkowska B, Wang X, et al. 1994 mRNA distribution of two 
isoforms of somatostatin receptor 2 (mSSTR2A and mSSTR2B) in mouse 
brain. Brain Res Mol Brain Res 27:45-50
46. Patel YC, Greenwood M, Kent G, et al. 1993 Multiple gene transcripts 
of the somatostatin receptor SSTR2: tissue selective distribution and cAMP 
regulation. Biochem Biophys Res Commun 192:288-94
47. Kraus J, Woltje M, Schonwetter N, et al. 1998 Alternative promoter usage 
and tissue specifi c expression of the mouse somatostatin receptor 2 gene. FEBS 
Lett 428:165-70
48. Kraus J, Woltje M, Hollt V 1999 Regulation of mouse somatostatin receptor 
type 2 gene expression by glucocorticoids. FEBS Lett 459:200-4
49. Gordon DF, Woodmansee WW, Lewis SR, et al. 1999 Cloning of the 
mouse somatostatin receptor subtype 5 gene: promoter structure and function. 
Endocrinology 140:5598-608
50. Xu Y, Berelowitz M, Bruno JF 1995 Dexamethasone regulates somatostatin 
receptor subtype messenger ribonucleic acid expression in rat pituitary GH4C1 
cells. Endocrinology 136:5070-5
51. Park S, Kamegai J, Kineman RD 2003 Role of glucocorticoids in the 
regulation of pituitary somatostatin receptor subtype (sst1-sst5) mRNA levels: 
evidence for direct and somatostatin-mediated effects. Neuroendocrinology 
78:163-75
52. Schonbrunn A 1982 Glucocorticoids down-regulate somatostatin receptors on 
pituitary cells in culture. Endocrinology 110:1147-54
53. Hukovic N, Panetta R, Kumar U, et al. 1996 Agonist-dependent regulation of 
cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective 
internalization or upregulation. Endocrinology 137:4046-9.
54. Ferguson SS 2001 Evolving concepts in G protein-coupled receptor 
endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 
53:1-24
227
Regulation of ACTH Release by sst
5
55. Hofl and LJ, Lamberts SW 2003 The pathophysiological consequences of 
somatostatin receptor internalization and resistance. Endocr Rev 24:28-47.
56. Reisine T, Axelrod J 1983 Prolonged somatostatin pretreatment desensitizes 
somatostatin’s inhibition of receptor-mediated release of adrenocorticotropin 
hormone and sensitizes adenylate cyclase. Endocrinology 113:811-3
57. Heisler S, Srikant CB 1985 Somatostatin-14 and somatostatin-28 pretreatment 
down-regulate somatostatin-14 receptors and have biphasic effects on 
forskolin-stimulated cyclic adenosine, 3’,5’-monophosphate synthesis 
and adrenocorticotropin secretion in mouse anterior pituitary tumor cells. 
Endocrinology 117:217-25
58. Stroh T, Jackson AC, Sarret P, et al. 2000 Intracellular dynamics of sst5 
receptors in transfected COS-7 cells: maintenance of cell surface receptors 
during ligand-induced endocytosis. Endocrinology 141:354-65.
59. Ben-Shlomo A, Miklovsky I, Wawrosky K, et al. 2004 Visualization and 
function of pituitary receptor subtypes in live ACTH-secreting AtT20 cells. 
The Endocrine Society Meeting:Abstract P3-244
60. Strowski MZ, Kohler M, Chen HY, et al. 2003 Somatostatin receptor subtype 
5 regulates insulin secretion and glucose homeostasis. Mol Endocrinol 17:93-
106
61. Shimon I 2003 Somatostatin receptors in pituitary and development of 
somatostatin receptor subtype-selective analogs. Endocrine 20:265-70.

THE ROLE OF NOVEL SOMATOSTATIN 
ANALOGS IN THE TREATMENT OF 
NEUROENDOCRINE TUMOURS
Chapter VI

Chapter VI-1
Novel subtype specifi c and 
universal somatostatin analogues: 
Clinical potential and pitfalls
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Recent developments of novel somatostatin analogs
Somatostatin (SRIF, 1) inhibits a variety of physiological processes. 
Initially, its possible therapeutic value in clinical conditions involv-
ing hyperfunction of several (endocrine) organ systems seemed very 
promising. However, the multiple simultaneous effects of SRIF in dif-
ferent organs, the need for intravenous administration (a half-life, 
T
1/2
, in the circulation of less than three minutes), and the post-infu-
sion hypersecretion of hormones (GH, insulin and glucagon) con-
siderably hampered the initial enthusiasm for its clinical use (1). 
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Figure 1. Structures of the natural somatostatin peptide SRIF and two 
current clinically available SRIF-analogues octreotide and lanreo-
tide. Compounds are referred to using bold numbers in the main text
Attempts have been made to synthesize SRIF-analogs that do not have 
these disadvantages. To design a more stable peptide derivative, one 
needs to strengthen the metabolic resistance of the cleavage sequences of 
the native peptide. In the case of SRIF, the most critical cleavage can oc-
cur at amino acid Tryptophan on position 8, because such a rupture leads 
to completely inactive fragments. Essential structural features of SRIF 
include the β-turn comprising amino acids; phenylalanine7 (Phe), trypto-
phan8 (Trp), lysine9 (Lys) and threonine10 (Thr) as well as the cysteine-cys-
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teine (Cys-Cys) bridge between position 3 and terminal position 14 (2, 3). 
SRIF-receptor agonists
The clinically available short synthetic SRIF-analogs octreotide (2) and 
lanreotide (3), encapturing a Cys-Cys bridge, contain the β-turn which has 
been stabilized by incorporation of D-Trp (Fig. 1). Both peptides display 
selective high-affi nity binding to sst
2
 along with lower affi nity binding to 
sst
3
 and sst
5
 and (almost) no binding to sst
1
 and sst
4
. Pharmacokinetic data 
on the metabolism and elimination of octreotide and lanreotide, compared 
to SRIF, were found to show enhanced metabolic stability (T
1/2
 of 2 h and 
less than 1h, respectively), a small volume of distribution and low clearance, 
all resulting in a longer duration of exposure and consequently a longer 
lasting biological activity. Furthermore, rebound hypersecretion of hor-
mones does not occur, making these analogs feasible for clinical use (4, 5).
BioMeasure introduced several peptide sst subtype specifi c SRIF-ana-
logs, which were predominantly directed towards sst
2
 (BIM-23190, BIM-
23197 ) and sst
5 
(BIM-23052, BIM-23268 (4) (6-8) (Table I). Whereas 
the sst
2
 specifi c compounds are classical cyclic analogs, the sst
5
 specifi c 
analog BIM-23052 is a linear peptide, and all three were assembled by 
solid- or liquid-phase synthesis using conventional fl uorenylmethyloxy-
carbonyl methods. BIM-23268 (4) harbours a unique structure and differs 
from other cyclic octapeptides in that the characteristic disulphide bridge 
of this cyclic peptide begins and ends at the NH
2
 and COOH terminals, 
rather than positions 2 and 7 (Fig. 2). These sst
2
 and sst
5
 analogs appeared 
highly potent in suppressing human GH and TSH in cultures of human 
fetal pituitaries, whereas PRL secretion in fetal human lactotroph cultures 
was reduced via sst
2
 selective compounds alone. BIM-23926 and BIM-
23745, both proposed sst
1
 specifi c agonists have been introduced in vitro
as well, but no insights have been released about their pharmacological 
development (9-11). However, only biodistribution of BIM-23190 and 
BIM-23197 was determined in rats (12). Even though these two analogs 
seemed to achieve longer in vivo stability, higher plasma and tissue levels 
compared to lanreotide (3), these BIM compounds have not been used in 
a clinical setting yet. The main reason seems to be a lack of additivity of 
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these BIM analogs regarding lanreotide and octreotide, as their sst bind-
ing affi nity profi le is comparable and further clinical effi cacy would not 
be expected. Another explanation might be the new insights into SRIF-
receptor physiology, as already discussed in the previous section. As a 
consequence of the demonstrated molecular cross-talk not only between 
different members of the sst subfamily but also between different related
Table I. Binding selectivity of SRIF-agonists to all sst subtypes.
Receptor subtype binding affinity (IC50 in nM) 
Agonist
sst1 sst2 sst3 sst4 sst5
SS-14 (1) 2.3 0.2 1.4 1.8 0.9 
octreotide (2) >1000 0.6 34.5 >1000 7 
lanreotide (3) >1000 0.8 107 >1000 5.2 
BIM-23926 3.6 >1000 >1000 833 788 
BIM-23745 42 >1000 >1000 >1000 >1000 
BIM-23197 >1000 0.2 26.8 >1000 9.8 
BIM-23268 (4) 18.4 15.1 61.6 16.3 0.4 
BIM-23244 >1000 0.3 133 >1000 0.2 
BIM-23A387 293 0.1 77 >1000 >1000 
�-peptide (5)a 4.73 4.48 4.85 7.83 4.73 
compound 6 >1000 807 750 0.84 633 
�-peptide (7)a 6.26 5.17 6.00 5.92 5.87 
SOM230 (8) 9.3 1 1.5 >100 0.16 
PTR-3173 (9) >1000 3 >100 7 6 
KE108 (10) 2.6 0.9 1.5 1.6 0.65 
cyclic urea (11)b n.i. 8.5 >1000 n.i. >1000 
L-797,591b 1.4 >1000 >1000 170 >1000 
L-779,976b >1000 0.05 729 310 >1000 
L-796,778b >1000 >1000 24 >1000 >1000 
L-803,087b 199 >1000 >1000 0.7 >1000 
L-817,818 (12)b 3.3 52 64 82 0.4 
Data are derived from Refs. 6-11, 16-17, 19-20, 22-25 and 27. n.i., not investigated.
a  Values represent pKD values (–log10 concentration constant).
b  Values represent Ki values in nM.
G-protein coupled receptor families, the BioMeasure company recently 
developed two SRIF-analogs, of which no pharmacological insights in 
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the chemical structure of these two compounds have been published yet. 
BIM-23244 is the new bispecifi c analog with high affi nity and selectivity 
for both sst
2
 and sst
5
 (13) (Table I). This peptide can activate both recep-
tors, and because of the heterogeneous expression of sst
2
 and sst
5
 in neu-
roendocrine tumours, this analog has the potency to achieve a better con-
trol of hormonal hypersecretion. The second compound, BIM23A387, 
contains the ability to bind in nmol/L range both to sst
2
 and the D2 recep-
tor (14) (Table I). This chimeric SRIF-Dopamine (“dopastatin”) hybrid 
molecule, clearly provides a tool to further elucidate and unravel the oligo
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Figure 2. Structures of somatostatin receptor subtype specific ago-
nists. Compounds are referred to using bold numbers in the main text.
meric interactions among different members of the GPCR family (15). As 
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will be outlined in the next chapter, the practical consequences of these 
new compounds, demonstrating possible novel receptor complexes with 
enhanced functional activity, have recently been demonstrated in vitro.
Another promising new compound series are the β-peptides, still encaptur-
ing the pharmacophore D-Trp/L-Lys, which are easily adapted to second-
ary structures and have the advantage of total stability against proteolytic 
degradation. Nunn and coworkers demonstrated this strategy indeed to 
have potentials, when they characterised the fi rst β-peptide sst
4
 selective 
compounds (5) (16). So far, these compounds displayed only moderate 
affi nities in recombinant human and mouse sst
4
 receptors (Table I). More 
recently, based on rather simple amino acid substitutions, the group of 
Reubi launched several sst
4
 specifi c analogs as well. On the basis of their 
observations that amino acid position 7 in SRIF is important for selective 
sst
4
 binding, which was confi rmed by alanine scanning of SRIF (17), they 
used their ODT-8 (H-c[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-OH) octa-
peptide scaffold as a template for optimizing specifi c binding and selec-
tivity for sst
4
 (18). When the L-Trp isomer, suggested to be more selective 
to sst
4
 whereas D-Trp tends to increase potency to all receptors, was in-
corporated at position 8 and alanine at position 7, an unexpected high sst
4
affi nity and selectivity was observed (compound 6). Tyrosine substitution 
at the N-terminus of the compound did not negatively impact either af-
fi nity or selectivity and radiolabeling with 125I demonstrated sst
4
 specifi c 
binding as well (19). Although the sst
4
 subtype is poorly expressed in 
human tissues, these compounds still could serve as a tool to elucidate its 
(patho-) physiological role and distribution throughout the human body. 
Moreover, as an extension of the β-peptide approach, a series of sim-
ple γ-dipeptide (7) derivatives were synthesized for sst binding affi n-
ity (20). These derivatives have the Trp side chain in the γ2-position of 
the fi rst amino acid and the Lys moiety at the γ4-position of the sec-
ond amino acid. So far, one of the synthesized γ-dipeptides showed only 
very moderate (submicromolar) affi nity for sst
1 
and sst
3. 
 Apparently, a 
14 amino acid cyclic disulphide hormone, can be mimicked by a simple, 
designed, low molecular weight, open-chain γ-dipeptide derivative that 
contains only three amide bonds and they promise a potential of γ-dipep
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Figure 3. Structures of universal somatostatin receptor analogues. 
Compounds are referred to using bold numbers in the main text.
tides for the development of peptidase-resistant peptidomimetic drugs.
Unlike most previous studies to develop subtype-selective SRIF-analogs, 
more universal binding SRIF-analogs have been characterised and intro-
duced recently as well (Fig. 3).  The search for SRIF-analogs with a high 
affi nity binding profi le to all fi ve subtypes was only started a few years 
ago, when it became clear that differential expression of the fi ve sst sub-
types in pathological SRIF targets hampers successful treatment with the 
current clinically available sst
2
 preferring SRIF-analogs. Therefore, uni-
versal SRIF-analogs could offer a therapeutic advantage in the treatment 
of tumours expressing multiple sst subtypes. In this respect, the Novartis 
company has recently introduced SOM230 (8) (17). By using alanine 
scanning technology, the essential functional groups of the SRIF peptide, 
comprising the β-turn, responsible for the high affi nity to all fi ve sst sub-
types were detected (Table I). The incorporation of Lys4 in the form of 
a novel basic trans-(L)-hydroxyproline aminoethyl-urethane extension, 
phenyglycine, O-benzyl-tyrosine, and D-Trp to corresponding positions 
NH
NH
O
NH
NH2
N
H
O
N
H
O
O
N
H
N
H
OH
O
N
H
N
O
NH2 O
NH
O
O
PTR-3173  (9)
N
O
NH
NH2
N
H
O
N
H
O
N
H
O
NH
NH2NH
NH
O
N
H
OH
N
H
O
O
N
H
N
H
O
NH2
OH
O
KE-108  (10)
NH
O
NH
NH2
N
H
O
N
H
O
ON
H
O
N
O
N
HNH2
O
O
N
H
O
SOM230 (8)
239
Potential and Pitfalls of novel Somatostatin Analogs
resulted in SOM230 (8). This stable cyclohexapeptide binds with a high 
affi nity to sst
1
, sst
2
, sst
3
 and sst
5
, and with low affi nity to sst
4. 
In rats, dogs 
and monkeys SOM230 potently and dose-dependently decreases GH and 
Insulin-like Growth Factor I (IGF-I) levels, which appeared more effi ca-
cious compared to octreotide (21, 22). No desensitization of the suppress-
ing effect of SOM230 on IGF-I levels was observed, which is in contrast 
to what has been seen with octreotide in rodents. Potential explanations for 
this marked IGF-I lowering effects of SOM230, compared to octreotide, 
include: 1) a more pronounced GH-dependent lowering of IGF-I; and 2) 
a postulated direct inhibitory effect of SOM230, independent of pituitary 
effects and exerted at the level of the liver (21). Finally, an additional very 
favourable characteristic of SOM230 is a half-life of nearly 24 hours.
Another long acting SRIF-analog, (c[GABA-Phe-Trp-D-Trp-Lys-Thr-
Phe-GlyC3-NH2], PTR-3173 (9), has been recently described (23). PTR-
3173 (Fig. 3) is a novel cyclic-backbone based SRIF-analog, derived from 
libraries of backbone cyclic SRIF-analogs which were tested following 
their synthesis by solid phase, multiple parallel synthesis, using F-moc 
chemistry. The backbone cycling building, possessing in vivo endocrine 
effi cacy and selectivity, were protected on their ω-carboxy by allyl/al-
loc protecting group, which was removed before on resin cyclization. 
This peptide showed 1000- and 10,000 fold more potent in vivo inhibition 
of GH release compared with inhibition of insulin and glucagon secre-
tion, respectively. PTR-3173 bound with high affi nity for sst
2
, sst
4
, and 
sst
5
 and is reported to be the fi rst SRIF-analog that demonstrates selec-
tive in vivo (in rats) inhibition between GH and insulin release (Table I).
Also, Reubi and coworkers presented, based on a nonapeptide scaffold, 
another universal SRIF-analog, [Tyr0-(cyclo-D-Dab-Arg-Phe-Phe-D-Trp-
Lys-Thr-Phe), KE108 (10)], which compared to SRIF-28, encaptured 
equivalent affi nity for sst
1
 but 2 to 4 times higher affi nity for sst
2-5
 (24) 
(Table I). Moreover, KE108 (Fig. 3) showed agonistic properties for the 
fi ve sst’s, which was demonstrated by inhibition of forskolin stimulated 
cAMP production in CHO-K1 cells, stably expressing all fi ve sst sub-
types. Again, these inhibitory properties of KE108 (its structural deter-
minants for the universal profi le are at present unknown) were within the 
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same levels and concentrations as SRIF-28. Two additional features of 
this peptide seem interesting as well. First, during a 24 h incubation of 
the compound in human serum, HPLC detection revealed a major peak 
corresponding to the intact peptide for several hours. Second, because of 
its Tyr in position zero, this universal SRIF-analog can be easily labelled 
with radioactive iodine and could be used as a tracer in vitro and in vivo
to identify tissues expressing SRIF receptors other than sst
2
. Therefore, 
the in vivo characterization of KE108, such as its stability, metabolism, 
biodistribution and toxicology, have to be the next necessary steps be-
fore clinical applications, i.e. phase I clinical trials, can be considered.
During the late 90s, the fi rst data upon non-peptide SRIF analogs were 
published, possibly not only providing new tools to unravel the physi-
ological role of the individual sst subtypes but it might eventually result 
in developing an orally active agent capable of crossing the blood-brain 
barrier as well. Rohrer and coworkers combined an integrated approach 
of combinatorial chemistry and high-throughput receptor binding tech-
niques to rapidly identify subtype-selective compounds (25). A cyclic 
hexapeptide SRIF agonist (L-363,377) was used as a probe, in which the 
β-turn forming amino acids were given priority in their search. The com-
pound L-264,930 which contains a tripartite in structure with an aromatic 
moiety, a tryptophan moiety and a diamine moiety, appeared to be the 
most potent and became the original lead structure (26), to which the fi ve 
non-peptide sst selective analogs were related to (Table I). An important 
pharmacokinetic improvement was achieved by urea backbone cycliza-
tion of acyclic urea precursors, which resulted in a non-peptide sst
2
 ago-
nist (11) with high affi nity for sst
2
 and high bioavailability in rats (27). 
Currently, no recent new non-peptide SRIF-agonists, displaying high af-
fi nity to sst subtypes, have been identifi ed. Therefore, the fi ve subtype 
selective agonists, L-797,591 (sst
1
), L-779,976 (sst
2
), L-796,778 (sst
3
), 
L-803,087 (sst
4
) and L-817,818 (12, sst
5
) (Fig. 2), are still frequently used 
for defi ning the physiological functions of each individual sst subtype.
SRIF-receptor antagonists
However, in order to elucidate conclusively the physiological effects of 
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Figure 4. Structures of somatostatin receptor antagonists. Com-
pounds are referred to using bold numbers in the main text.
individual sst subtypes, the combined use of both agonists and antagonists 
(Fig. 4) seems interesting as well. BIM-23454 and BIM-23627 (13), both 
sst
2 
specifi c open-chain octapeptide antagonists, as well as BIM-23056, a 
sst
5
 specifi c linear octapeptide specifi c antagonist, all three incorporated 
with an aromatic β-naphtoyl moiety, have been released by BioMeasure 
in order to retrieve answers within the sst receptor physiology (28). Their 
role will be discussed in the next section.A family of octapeptide deriva-
tives of SRIF-cyclized via a disulphide bridge that showed high affi nity 
and selectivity for the human sst
3
 was identifi ed (18). Binding affi nity for 
sst
3
 appeared equal to that of SRIF-28, whereas affi nity towards the other 
4 receptor subtypes appeared 1000-fold less than SRIF-28. Compound 
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sst
3
-ODN-8 (14), in which the conformation-restricting N-methyl-amino-
2-naphtoyl aminoglycine replaced Trp in the β-turn, potently reversed 
SRIF induced forskolin-stimulated cAMP production as well as SRIF-in-
duced stimulation of phospholipase C activity, making this peptide a spe-
cifi c and selective sst
3
 antagonist (Table II) (18). Since the tyrosine at po-
sition 7 could be radioiodinated as well, this antagonist seems of special 
interest regarding the study of sst
3
-mediated (patho-) physiological condi-
tions in areas of the lymphoreticular system and cell growth (apoptosis).
CYN 154806 (15), another cyclic octapeptide fi rst reported in 1996, dis-
plays nanomolar affi nity for sst
2
, and L-Tyr8 and D-Tyr8 isoforms have 
been shown to possess antagonism at sst
2
 receptors (Table II) (29, 30). 
Recently, it has been shown that both isoforms of this antagonist also 
displayed high affi nity for sst
5
 and agonist like properties as well. In 
Table II. Binding selectivity of SRIF-antagonists to all sst subtypes.
Receptor subtype binding affinity (IC50 in nM) 
Antagonist
sst1 sst2 sst3 sst4 sst5
BIM-23454 >1000 31 50.5 301 139 
BIM-23627 (13) >1000 6.4 44 423 86.5 
BIM-23056 337 132 177 234 12.1 
sst3-ODN-8 (14) >10.000 >10.000 6.7 >10.000 >10.000 
CYN 154806 (15)a 5.7 8.14 6.23 6.5 7.65 
SRA-880 (16)a 8.1 4.7 5.4 5.3 5.9 
BN-81674 (17)b >10.000 >10.000 0.92 >10.000 >10.000 
Data are derived from Refs. 6, 18, 28-29, 31 and 33-34.
a  Values represent pKD values (–log10 concentration constant).
b  Values represent Ki values in nM.
CHO cells transfected with sst
2
, concentration-dependent inhibition of 
forskolin stimulated adenylyl cyclase activity was found (31). There-
fore, CYN 154806 seems not totally sst subtype selective and it harbours 
intrinsic activity at sst
2
 as well, and should be used with caution as an 
sst
2
 selective antagonist. Agonist properties of other putative small-mol-
ecule sst
2
 antagonists has been demonstrated as well (32), which might 
hamper the use of these SRIF-tools in the fi eld of SRIF-physiology.
SRA-880 (16) is a novel non-peptide sst
1
 antagonist (IC
50
= 9.1 nM) based 
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on a octahydrobenzo[g]quinoline backbone (33). SRA-880, tested in vivo
using a mouse model, is at least active in the neuro-psychiatric fi eld of 
anxiety, depression and bipolar disorders. The development of selective 
sst
3
 non-peptide antagonists, BN-81674 (17) is a tetrahydro-β-carboline 
derivative showing a pKd value of 8.69 nM for human sst
3
 receptor along 
with a 400-fold greater sst
3
 selectivity compared to the other sst sub-
types, enables functional investigation of the sst
3
 regarding cell growth 
and apoptosis (34). Such compounds might eventually combine the ad-
vantages of oral bioavailability with various therapeutic opportunities.
Clinical potential
Somatostatin analogs in the medical treatment of hormone-secreting 
pituitary adenomas and GEP tumours
The clinical introduction of the long acting SRIF-analogs octreotide (2) 
and lanreotide (3) in the early 1980s added a new dimension to the ther-
apy of GH-secreting pituitary adenomas (35, 36). Throughout the past 
two decades several clinical trials with these SRIF-analogs, administered 
either by subcutaneous (s.c.) or as a long-acting depot preparation by 
intramuscular injection, repeatedly turned out to be effective in around 
60-70% of patients in controlling GH and IGF-I levels (4). However, 
approximately 35% of acromegalic patients appear not to be sensitive 
enough for this treatment, since in this group of partial responders GH 
levels can not be controlled to “safe” levels. In addition, notable shrink-
age also occurs in some patients, based on a decrease in the size of in-
dividual pituitary tumour cells, which no longer synthesize and secrete 
hormones (37, 38). The effi cacy of SRIF-analogs in non-GH-secreting 
pituitary adenomas has still to be proven in clinically non-functioning 
adenomas, besides the well-known expression of sst subtypes in these 
tumours, whereby sst
3
 seems to be the predominant subtype (39).  The 
large majority of patients with TSH-secreting pituitary adenomas respond 
very well to treatment with either octreotide or lanreotide, although long-
term data are still limited (40, 41). Prolactin- and ACTH-secreting pitu-
itary adenomas generally respond weakly to treatment with the current 
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clinically available SRIF-analogs, while in vitro experimental results 
show a high PRL-suppressive effect of agonists selective for sst
5 
(42).
In most patients with metastatic carcinoid disease and islet cell tumours, 
octreotide therapy also improves clinical symptoms (43). Control of 
fl ushing attacks and diarrhoea, caused by an overproduction of serotonin 
or tachykinin(s), was reported in 70-90% of patients with metastatic car-
cinoid tumours (5, 44). Results from studies also suggest a temporary 
stabilization of tumour growth during SRIF-analog therapy in 30-60% 
of patients with carcinoids or GEP tumours (45). However, as will be 
shortly discussed in the Pitfalls section, an important aspect of the long-
term successful control of hormone secretion and tumour cell growth dur-
ing SRIF-analog treatment is a loss of effect (tachyphylaxis). Frequently, 
newly developed SRIF-analogs are primarily being explored within GH-
secreting pituitary adenomas (7). The signifi cant percentage of GH-se-
creting pituitary tumours relatively resistant to octreotide (2) and lanre-
otide (3), may be explained in part by a variable tumoural expression or 
reduced receptor density of sst subtypes on the adenomas of these pa-
tients. Saveanu and coworkers compared the in vivo sensitivity of GH re-
lease for octreotide in nine acromegalic patients with the tumour mRNA 
expression for sst
2
 and sst
5
 subtypes (13). It was observed that sst
2 
mRNA 
expression was lower and sst
5
 mRNA was higher in adenomas that were 
partially sensitive to octreotide, compared with octreotide sensitive ad-
enomas. In the group of partially octreotide sensitive tumours, both the 
sst
5
-preferential analog BIM-23268 (4), but especially the sst
2
 and sst
5
bi-specifi c compound BIM-23244, were quite effective in suppressing 
GH secretion. Indeed, enhanced suppression (73%) of GHRH stimulated 
GH secretion from fetal pituitary cells using combined sst
2
 and sst
5
 se-
lective agonists, compared with the use of these analogs alone (32% for 
sst
2
 and 34% for sst
5
) was demonstrated.  These data indicate that due 
to the heterogeneous expression of sst
2
 and sst
5
 subtypes in GH-secret-
ing adenomas, a bispecifi c analog, such as BIM-23244 that can activate 
both receptors possibly because this bivalent ligand mediates receptor 
heterodimerization, may achieve a better control of GH hypersecretion of 
GH-producing pituitary tumours than octreotide. Also, Melmed’s group 
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recently showed that the sst
2
 antagonist BIM-23454 completely blocked 
GH release in primary fetal pituitary cultures treated either simultane-
ously with sst
2
 (BIM-23197) and sst
5
 agonists (BIM-23268) or with 
BIM-23244 (46). These data again suggested that both receptors need a 
functional interaction before enhanced suppression of GH release is es-
tablished.Furthermore, the hybrid ‘dopastatin’ molecule, BIM-23A387, 
has an enhanced inhibitory effect on in vitro PRL and GH release from 
human pituitary adenoma cells (14). This dimer molecule appeared more 
potent than either sst
2
 or D2 selective analogs alone and interestingly, no 
additivity was even found when the sst
2
 and D2 selective analogs were 
added simultaneously to the primary cultured GH-secreting pituitary ad-
enoma cells. This signifi cant potency of BIM-23A387 (EC
50
 was 50 times 
lower than that of the individual sst
2
 and D2 agonists as well), however, 
could not be explained on the basis of the binding affi nity of the com-
pounds for sst
2
 and D2 receptors. In addition, only the combined addition 
of the sst
2
 antagonist BIM-23454 and D2 antagonist sulpiride completely 
blocked the effects of BIM-23A387, indicating that signaling properties 
of the receptors may be dependent on having the binding requirements 
for each receptor within the same molecule. In contrast, performing the 
same kind of experiments in primary cultured human fetal pituitary and 
human GH/PRL secreting pituitary adenoma cells, Melmed’s group did 
fi nd complete blockade only after sulpiride, but not after BIM-23454 
treatment (47). The observed difference between the two study groups 
could be explained because the latter study used BIM-23A387 at su-
pramaximal concentrations (4 nmol/L), whereas Saveanu and coworkers 
used a 50% effective dose (1 pmol/L) (14). At lower doses, BIM-23A387 
ligand-induced heterodimerization of sst
2
 and D2 receptors may not be 
suffi cient to saturate the chimeric molecule, so that free BIM-23A387 
is still available for banding sst
2
 or D2 receptors alone (47). Still, col-
lectively these results suggest that GH suppression by BIM-23A387, is 
not mediated through either individual sst
2
 or D2 receptors, but requires a 
functional interaction between the two receptors in which the D2 receptor 
might have a dominant role. Therefore, the intriguing in vitro data with 
both BIM-23244 and BIM-23A387, fully in line with the new insights in 
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SRIF-receptor physiology, indicate that processes like heterooligomeriza-
tion of G-protein coupled receptors could indeed create a novel receptor 
with distinct functionality, that might have functional and clinical impli-
cations in the treatment of neuroendocrine tumours. Recently, using the 
sst
1
 specifi c analog BIM-23926, GH and PRL secretion was signifi cantly 
inhibited in primary cultures of GH/PRL-secreting pituitary adenomas 
(10). BIM-23745, another sst
1 
specifi c analog, showed suppressive ac-
tions on GH release in primary cultured GH-secreting pituitary adeno-
mas as well, even in a subgroup of adenomas that partially responded to 
octreotide or lanreotide (11). Since the sst
1
 receptor appears monomeric 
upon receptor activation even if it can be recruited in heterodimer forma-
tion by an activated sst
5
 (48), SRIF analogs with enhanced affi nity for 
sst
1
 may have potential as a pharmacological tool for the treatment of 
this type of pituitary adenoma. The latest insights in new medical treat-
ment options for pituitary and GEP tumours come from the fi rst clini-
cal trial with SOM230 (8) in patients with active acromegaly, which has 
been extensively described and discussed in Chapter III of this thesis. 
Somatostatin analog therapy in oncology 
Biological and clinical effects of SRIF and SRIF-analogs
In contrast to the antisecretory properties of SRIF, its possible antipro-
liferative effects were documented largely through use of the long act-
ing analogs for the treatment of hormone hypersecretion from pancreatic, 
intestinal, and pituitary tumours (43). It was noted that SRIF not only 
blocked hormone hypersecretion from these tumours but also caused 
variable tumour shrinkage possibly through an additional antiprolifera-
tive effect, which appeared not limited to endocrine tumours. Several pre-
clinical data and clinical advances have brought the potential use of SRIF 
analogs in the treatment of patients with cancer much closer to reality. 
The presumed potential antiproliferative effects of SRIF and SRIF-ana-
logs can be a result of a decrease in both tumour cell growth and tumour 
angiogenesis as well as an increased incidence of (cancer) cell apoptosis. 
As has been reviewed extensively, these inhibitory effects at the cellu-
lar level can be based on direct and indirect mechanisms (49, 50). In 
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general, all fi ve sst subtypes have been shown to modulate antiprolifera-
tive second messenger pathways, such as protein tyrosine phospatases, 
SHP-1, SHP-2, MAP/ERK1/2 kinases and the subsequent induction of 
cyclin-dependent kinase inhibitors such as p21 and p27Kip1 (51-53). In-
direct mechanisms of cell growth may include inhibition of secretion of 
growth-promoting hormones and growth factors, i.e. IGF-I, EGF-I and 
PDGF. Also, SRIF inhibits tumour angiogenesis via sst
2
 (54), whereby 
sst
3
 as well might inhibit endothelial nitric oxidase and the following at-
tenuation of nitric oxide, a second messenger that plays a pivotal role in 
angiogenesis (55). Evidence further suggests that SRIF may infl uence 
the immune system, since SRIF-receptors are expressed in human lym-
phoid organs and can regulate various immune functions as well (56-58). 
Finally, sst
3
 and to a lesser extent sst
2
 seem to be involved in mediating 
cell growth arrest by the induction of apoptosis in normal and tumour 
cells (53, 59). Still, no specifi c evidence of a pro-apoptotic role of SRIF-
analogs in cancer has been documented so far. Despite promising in vitro 
data, attempts to use these analogs for therapy of human cancers have 
produced few benefi cial effects (44). Recent trials still show disappoint-
ing results when lanreotide (3), vapreotide (2x) and octreotide (2) were 
administered respectively to patients with advanced hepatocellular carci-
noma, advanced prostatic cancer, metastatic breast cancer and again ad-
vanced hepatocellular carcinoma (60-63). Hejna and co-workers elegantly 
reviewed the clinical application of SRIF-analogs in malignant diseases 
(64). While SRIF-analogs are highly effective in the symptomatic man-
agement of patients with neuroendocrine tumours, the antiproliferative 
effects of SRIF-analogs as judged by objective tumour regression has 
not been convincingly demonstrated. An explanation comes likely from 
the fact that in various cancers there is a loss of gene expression for sst
2
, 
which is the preferred subtype of these analogs. However, the expression 
of sst
1 
(prostate), sst
5 
and sst
3
 should make possible the therapy with novel 
SRIF-analogs. Again, SOM230 can also further help in elucidating and 
resolving these issues if sst
1
- and sst
3
-mediated antiproliferative effects 
might have a clinically benefi cial effect. Moreover, the long-term and 
sustained suppression of IGF-I might also have new, important clinical 
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signifi cance in the control of tumour growth in a variety of IGF-I re-
sponsive solid cancers. The promising β-casomorphin derived cyclopen-
tapeptide SRIF-analog, Tyr-c[D-Orn-Tyr(Bzl)-Pro-Gly] (cCD-2), has 
been developed by conventional solution methods (65), which appears 
interesting especially regarding the consequences of the demonstrated 
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Figure 5. Structure of two frequently used chelators for radiolabeling SRIF-analogues, as 
well as the molecular structure of the cytotoxic hybrid SS-analogue AN-238. To achieve 
tight binding of therapeutically used radioisotopes, bifunctional chelators are used. In such 
bifunctional chelators, all coordination sites are free to bind the metal ion and the peptide 
is connected to the chelator at a site that does not interfere with the metal ion binding site.
molecular cross-talk between members of the SRIF- and opioid-receptor 
family (66). Using different human tumour cell lines, cDC-2 inhibited 
cell growth by activation of sst
1
 or sst
2 
and subsequent downstream PTP, 
MAPK and cyclin dependent kinase inhibitor p21 activation. The addi-
tion of specifi c opioid-receptor antagonists, as opioid agonists are known 
to decrease cell proliferation via μ-, κ-, and δ-receptors (67), did not at-
tenuate the cell growth inhibition, indicating that only sst subtypes can 
be responsible. Furthermore, whereas cDC-2 itself only has a very low 
affi nity to μ-receptors, this compound was able to increase the agonist 
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binding to μ-receptors in vitro and to potentiate the analgesic effect of the 
μ-receptor agonist morphine in vivo, indicating some kind of μ-receptor 
sensitization by cCD-2. However, SRIF-receptor binding affi nity of cDC-
2 was very moderate (IC
50 
= 250 nM), and might be too low for possible 
clinical use. Nevertheless, the combination of two therapeutically inter-
esting properties, such as inhibition of tumour cell growth and stimula-
tion of analgesic potency of morphine within the structure of a single 
pentapeptide might be useful in the development of new anticancer drugs.
Somatostatin-receptor targeted radio- and chemotherapy
The demonstration of the effi cient internalization of receptor-ligand com-
plexes into sst-positive cells, as already previously described, formed the 
basis for the concept of targeted sst-mediated chemo- or radiotherapy of 
sst-expressing metastatic human cancer (3, 68-71). Internalization brings 
the cytotoxic SRIF-analog or the radionuclide-coupled analog closer to 
the nucleus of the cell, resulting in prolonged cellular retention and ex-
posure to radioactivity or cytotoxic agent. Human sst-positive tumours 
show a high uptake of 111In-diethylenetriamine pentaacetic acid (DTPA, 
Fig. 5) octreotide (Octreoscan) at sst-scintigraphy (72, 73). Recently, it 
was demonstrated by using an in vivo sst
2
 knock-out mouse model, that 
the sst
2
 predominantly determines uptake of both [111In-DTPA0]octreotide 
and [111In-DTPA0]SRIF in sst-positive organs (the 0 indicates that the che-
lator is attached to the amino acid in the fi rst position of the peptide). A 
possible explanation for the observation that also uptake of the universal 
radioactive ligand and [111In-DTPA0]SRIF appeared only in the wild-type 
mice, could be that sst
2
 has a modulatory effect upon sst-mediated in-
ternalization of the other sst subtypes (74). Furthermore, as soon as the 
success of the Octreoscan became clear, the next logical step was to la-
bel these peptides with radionuclide emitting α- or β-particles, including 
Auger (radiotoxicity of Auger electrons is very high if the DNA of the 
cell is within the particle range, probably resulting into an effect upon 
tumour cell proliferation) or conversion electrons, and to perform pep-
tide receptor radionuclide therapy (PRRT). Indeed, high dosages of [111In-
DTPA0]octreotide showed anti-tumour effects in vitro and in patients with 
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Table III. Physical characteristics of different radionuclides.
.
 T1/2 (days E� (keV) Range in tissue (�m) Advantage
111In 2.8 (only �) 0.02-0.10 emits Auger electrons 
90Y 2.6 2,270 4-12*103
high maximum energy; 
suitable for large tumours 
177Lu 6.7 500 0.5-2*103
�-emission (scintigraphy & dosimetry); 
high tumoural uptake; 
low renal toxicity; 
radiological bystander effect; 
suitable for smaller tumours 
64Cu 0.5 
655 (�+)
573 (�-)
1-2*103
effective accumulation in nucleus and 
mitochondria; 
radiological bystander effect; 
therapy (�+) and diagnostics(�-)
Data have been documented from Refs. 76, 82, 87 and 104.
neuroendocrine tumours (75, 76). The disadvantage of 111In for PRRT is 
the short particle range and consequently small tissue penetration. There-
fore, other radionuclides, like 90Y and 177Lu (Table III), were coupled to 
tetra-azacyclododecane tetracetic acid (DOTA) conjugated SRIF-analogs 
(Fig. 5), such as [DOTA0,Tyr3]octreotide and [DOTA0,Tyr3]octreotate (in 
which the C-terminal threoninol is replaced with threonine) (77). 90Y is a 
β-particle emitter, has a mean range of several millimetres in tissue, and 
coupled to [DOTA0,Tyr3]octreotide (90Y-SMT)  induces partial remissions 
in 10-25% of patients with GEP tumours combined with an improvement 
in clinical status (78, 79). 177Lu is a β-particle emitter with a mean tis-
sue range of approximately 1mm, but it is also a γ-emitter that enables 
visualisation with a gamma camera and thus tumour dosimetry and stag-
ing. Pharmacodynamic properties of [177Lu-DOTA0,Tyr3]octreotate show, 
compared to [111In-DTPA0]octreotide and [90Y-DOTA0,Tyr3]octreotide, 
a 3- to 4-fold higher tumoural uptake of radioactivity and a 9-fold in-
crease in sst
2
 affi nity, respectively (80). Also, labelled with 177Lu, this 
compound was very successful in achieving tumour regression and sur-
vival in a pancreatic tumour bearing rat model (81). Because of these ad-
251
Potential and Pitfalls of novel Somatostatin Analogs
vantages, a study was conducted to compare this radiolabeled compound 
to [111In-DTPA0]octreotide in patients with sst-positive tumours. Kwek-
keboom and coworkers found that the uptake of radioactivity, expressed 
as a percentage of the injected dose [177Lu-DOTA0,Tyr3]octreotate, was 
comparable to that after [111In-DTPA0]octreotide for kidneys, spleen and 
liver, but was three- to fourfold higher for four of the fi ve tumours (82). 
They concluded that [177Lu-DOTA0, Tyr3]octreotate potentially represents 
an important improvement because of (a) the higher absorbed doses that 
can be delivered to most tumours with about the equal doses to poten-
tially dose-limiting organs and (b) the lower tissue penetration range of 
177Lu as compared to 90Y, which may be especially important for small 
tumours. Recently, the fi rst data on the anti-tumoural effects of 177Lu-
octreotate therapy in 35 patients with GEP tumours have been described 
(83). The investigators observed tumour shrinkage in 38% of patients, 
but this could be an underestimation because only 46% of included pa-
tients showed signs of progressive disease (as this percentage was around 
80% in studies with the former mentioned radiolabeled SRIF-analogs), 
whereby it is well known that rapidly growing tumours are the most sen-
sitive ones to PRRT or chemotherapy. Still, long-term effi cicacy needs 
to be determined, but this study provokes to treat patients with 177Lu-oc-
treotate not only when progressive disease has been diagnosed but also 
already during an early stage of metastatic disease, as in this last group 
of patients tumour load appeared more frequently limited. Finally, com-
bination therapy with 90Y-labelled and 177-Lu labelled octreotate, tackling 
larger and smaller tumours, respectively, may be tried in the near future 
as well (84, 85). This might hopefully result into better clinical responses. 
These promising results have triggered researchers to synthesize and test 
new SRIF-analogs labelled with various radiometals, such as 64Cu (Table 
III) (86). When this radiometal was labelled to tetraazacyclotetradecane-
octeotide (64Cu-TETA-octreotide), an increase of 64Cu localization to the 
cell nucleus and mitochondria after the addition of 64Cu-TETA-octreotide 
to intact AR42J rat pancreatic tumour cells over time was observed (87). 
These data indicate that still considerable progress is being made, which 
should eventually result in better non-invasive strategies in the treatment 
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of GEP tumours and cancer. Like targeted radiotherapy, SRIF receptor-
targeted chemotherapy represent an appealing approach to the treatment 
of sst expressing tumours. By synthesizing conjugates of SRIF-analogs 
and cytotoxic drugs (such as methotrexate or doxorubicin), selective ac-
cumulation of cytotoxic radicals in sst positive tumour cells would be pos-
sible (88, 89). The adverse reactions in patients with advanced metastatic 
tumours treated with chemotherapeutic agents are caused by the severe 
toxicity of these agents to normal cells (90). Experimental studies have 
actually shown that these derivatives are indeed less toxic and seem more 
effective than the parent cytotoxic drugs in inhibiting tumour growth in 
vitro and in vivo in preclinical tumour models. The ‘magic bullet’ approach 
of developing targeted hybrids directed against sst was studied extensive-
ly by Schally and coworkers, who synthesized AN-238 (18, Fig. 5), made 
by coupling one molecule 2-pyrrolino-DOX-14-o-hemiglutarate to the 
NH
2
 terminus of [lys(fl uorenylmethoxycarbonyl)5]RC-121, followed by 
deprotection and purifi cation (89). Treatment with AN-238 (18) in vari-
ous human experimental tumours such as prostate, breast, ovarian, renal, 
brain, lung, pancreatic and colorectal cancer appeared to induce an aver-
age growth inhibition of more than 50-70% (88, 91). Recently, three nude 
mice in vivo gastric carcinoma models confi rmed the potency of AN-238, 
which appeared correlated to the expression of sst
2 
and sst
5
 as well (92). 
The next step in the further development of this strategy is under way, since 
clinical trials with this compound are being planned for the near future.
Pitfalls
General considerations
The success of a newly developed SRIF-analog is predominantly based 
upon its bioavailability or metabolic stability, which is the main ther-
apeutic limitation of SRIF itself (T
1/2
 2-3 min). Therefore, short-chain 
peptides can be built, which are metabolically stable, typically showing 
selectivity for one (or two) of the sst subtypes (for example octreotide 
(2); T
1/2
 2 hrs). Interestingly, these reduced sized SRIF-analogs can be 
further structurally modifi ed ultimately leading to (near) universal bind-
ing to sst subtypes (for example SOM230 (8); T
1/2
 nearly 24 hrs). Another 
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strategy involves characterizing larger SRIF-analogs that bind to the ma-
jority of sst subtypes, but requires metabolic stabilization through sub-
sequent chemical modifi cation involving the incorporation of D-amino 
acids or N-methylated amino acids (for example KE108 (10); T
1/2
 not 
known yet). Moreover, mixing octreotide with microspheres of biode-
gradable glucose polymers, made it possible to deliver therapeutic oc-
treotide levels for at least 28 days after intramuscular injection (initial 
s.c. administration was 3 times a day) (93, 94). Also, lanreotide (3) is 
prepared in microspheres of biodegradable lactide/glycolide copolymers 
as well and is administered by i.m. injection every 7-14 days, whereas 
the slow-release s.c. autogel formulation is active for 28 days (95). Apart 
from differences in the affi nity profi les of unlabelled SRIF-analogs due 
to structural differences, whereby nanomolar affi nity is strongly pre-
ferred regarding future clinical possibilities, radiolabeling or coupling of 
chemotherapeutic compounds of such analogs has major effects on bind-
ing affi nity for the different human sst subtypes as well. Several char-
acteristics of SRIF-analogs developed for radiotherapy, such as small 
structural modifi cations, chelator substitution, or type of radioisotope, 
considerably affect binding affi nity which will have major implications 
for their effi cacy and subsequent potentials for clinical use (76, 80).
Side-effects
The current sst
2
-preferring SRIF octapeptide analogs are generally well 
tolerated and well documented. The most common side effects are gastro-
intestinal symptoms such as diarrhea, abdominal discomfort, and nausea. 
Early side effects occur in approximately 50% of patients but improve 
within 10-14 days, probably as a consequence of local adaptation within 
the gastrointestinal tract, and generally persist in <10% of patients. Dur-
ing long-term therapy, gall-stone development has been reported in 20-
30% of patients and can be managed similar to gallstones in the general 
population (95). As SRIF and SRIF-analogs modulate the secretion of 
insulin and glucagon combined with sst subtype expression within the 
endocrine pancreas, reduced glucose tolerance and even overt hyperg-
lycaemia were initially expected during long-term therapy. On the con-
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trary, the effects on glucose homeostasis appeared to be minor and a mild 
deterioration occurred only in those without impaired glucose tolerance 
(5). Still, the proposed predominant role of sst
5
 in mediating suppression 
of insulin secretion from rodent β-cells, could be a possible pitfall for 
newly developed sst
5
 specifi c analogs as well as for universal SRIF-ana-
logs (96, 97). Indeed, compared to octreotide (2), similar elevations of 
glucose concentrations were observed after SOM230 (8) administration 
in acromegalic patients (98). However, the elevated glucose levels seem 
not be caused by an inhibitory action on insulin release by SOM230. No 
data regarding the effects of SOM230 and octreotide on glucagon levels 
in acromegalics have been analyzed. At present, the mechanism of this 
transient increase in glucose levels remains uncertain. On the basis of the 
SOM230 and octreotide affi nity profi les for sst
2
 and sst
5
, it seems unlikely 
that octreotide, binding 40-fold less to sst
5 
compared to SOM230, would 
exert such a strong and long lasting insulin inhibition via sst
5 
subtype 
whereas SOM230 treatment resulted in barely any inhibition. Therefore, 
these opposed effects of octreotide and SOM230 on insulin levels, sug-
gest a role for sst
2 
subtype in regulating human insulin secretion. Support 
for this hypothesis comes from recent experiments performed with iso-
lated perfused human pancreas tissues, which showed inhibitory effects 
on insulin secretion when treated with octreotide or a specifi c sst
2 
agonist 
in physiological concentrations, while an sst
5 
agonist only inhibited in-
sulin secretion at pharmacological doses (99). With immunoneutraliza-
tion of endogenous somatostatin, the sst
2
 agonist was still specifi c for 
inhibiting insulin secretion, while the sst
5
 agonist had no signifi cant ef-
fect on insulin secretion, suggesting again that sst
2
 could play a role in 
regulating insulin secretion. Still, in cynomolgus monkeys, insulin, glu-
cagon and glucose levels remained unchanged during seven days of high-
dose infusion with SOM230. Furthermore, during an 18-week treatment 
with pharmacological doses of SOM230 plasma glucose levels were not 
changed, indicating that SOM230 is well tolerated in rats and monkeys 
with regard to glucose homeostasis (22). Nevertheless, the variable ex-
pression of sst subtypes throughout the body and their role in normal 
physiology, forms a potential pitfall as complete selectivity of newly de-
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veloped SRIF-analogs towards pathological processes seems to be elusive.
Tachyphylaxis/Resistance
Octreotide controls hormone secretion effectively in most acromegalics 
for many years, and escape from therapy has not been observed. In strik-
ing contrast, the initial rapid improvement of clinical symptoms in the 
fi rst weeks to months of SRIF-analog therapy in patients with GEP tu-
mours gradually escapes, in spite of a an increase in the dose adminis-
tered (45). The underlying mechanisms for the observed difference in 
developing tachyphylaxis to SRIF-analog treatment between GH-secret-
ing pituitary adenomas on the one hand, and other types of sst-positive 
tumours have not been elucidated yet, but could involve the differen-
tial expression of sst subtypes, a tissue-specifi c desensitization, and/or 
homo-heterologous down-regulation of sst-subtypes, or alternatively, tis-
sue-specifi c upregulation of SRIF-analog responsive sst subtypes by pro-
longed agonist treatment resulting in continued responsiveness. This has 
recently been thoroughly and extensively reviewed (68). Furthermore, as 
much of the current (pre-) clinical knowledge about tachyphylaxis is built 
upon sst
2
-mediated mechanisms and sst
2
-preferring analogs, possible 
diffi culties regarding the behaviour of other sst subtypes in this matter, 
could come up during the further development of new non-sst
2
 specifi c 
SRIF-analogs. The antiproliferative effects of SRIF-analogs as judged 
by objective tumour regression, however, are not likely to be promising. 
While activity has initially been claimed in almost all tumour entities in-
vestigated so far, the review by Hejna and co-workers has clearly shown 
that most series have been performed with a non-randomized approach 
in patients with highly disseminated disease, and the results reported 
are not consistent (64). Interpretation of the observed results is further 
complicated because sst status of the included patients is hard to obtain, 
making it diffi cult to judge whether the activity seen in some series of 
patients is due to a receptor-ligand interaction, indirect effects such as 
decreasing various growth factors or simply refl ects an improvement of 
patients’ well being due to suppression of paraneoplastic syndromes. Fur-
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thermore, the discrepancy between the promising in vitro data and poor 
in vivo response could be provided by three other possible explanations 
(44): (1) most human cancers comprise a mixture of stromal tissue and 
different clones of epithelial tumour cells that no uniformly express sst. 
This contrasts sharply to experimental mostly monoclonal tumour mod-
els in animals, which, in most instances, homogeneously express sst on 
all tumour cells; (2) sst expression in parts of breast, prostate and colonic 
cancers often indicates loss of differentiation of the tumours. In general, 
these undifferentiated tumours with neuroendocrine cell differentiation 
have a poor prognosis at that stage of development. As discussed already, 
the synthesis of new bivalent peptides (15) and subsequent concomitant 
expression of several different peptide receptors in neuroendocrine tu-
mours (100), provide promising perspectives to eventually tackle these 
diffi culties in the treatment of neuroendocrine and malignant tumours; 
and (3) because of the nature of new clinical trials in oncology, often it 
is mainly those patients who are late in the onset of their disease who 
are included in the studies. In addition, there is preliminary evidence 
that chemotherapy might decrease the number of sst. Should this ob-
servation be verifi ed in vivo, this would have widespread consequences 
for further planning of therapeutical trials to rule out negative (sched-
ule-dependent) interaction between chemotherapy and SRIF-analogs.
Toxicity
Using the radiolabeled SRIF-analogs, critical organs for PRRT, such as 
[111In-DTPA0]octreotide, [90Y-DOTA0, Tyr3]octreotide and [177Lu-DOTA0, 
tyr3]octreotate, are the kidneys and bone marrow. The corresponding 
maximal tolerated doses for external radiation of these tissues are 23 
and 2 Gy, respectively (76). Using 90Y-DOTA0, Tyr3]octreotide, stud-
ies have reported hematological and renal toxicity in 17% of patients; 
pancytopenia in 5%; grade III or IV lymphoctyopenia in 23%, grade III 
anaemia in 3% and grade II renal insuffi ciency in 3% of patients (101-
103), whereas no endocrine dysfunction of the pituitary axis (thyroid, 
adrenal, gonads) and no diabetes mellitus were seen (104). Interestingly, 
the novel DOTA-tagged SRIF-analog 177Lu-octreotate showed grade III 
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anaemia, leucocytopenia and thrombocytopenia in 0%, 1% and 1% of 
administrations, respectively (83). Also, serum creatinin and creatinin 
clearance did not alter signifi cantly, making this PRRT directed drug 
again suitable for clinical application in the near future. However, a 80% 
decrease in inhibin-B with a concurrent rise in FSH suggests a nega-
tive effect on spermatogenesis in men by [90Y-DOTA0, Tyr3]octreotide 
and by [177Lu-DOTA0, Tyr3]octreotate (82). Finally, the renal uptake 
of small radiopeptides, mediated through reabsorption in the proximal 
tubular cell of the kidney, can be reduced by the intravenous infusion 
of basic amino acids lysine and arginine, before, during and after the 
injection of the radioligand, thereby reducing renal toxicity (82, 105).
Conclusion
So far, only three SRIF-receptor ligands are approved for clinical use: 
SRIF itself and the metabolically stabilized octapeptide SRIF-analogs 
octreotide and lanreotide, both registered for medical treatment of acro-
megaly and GEP tumours. After their clinical introduction in 1987, the 
current limited number of proven indications for the use of SRIF-ana-
logs in clinical medicine, has encouraged researchers for many years to 
unravel the (patho-) physiological role of SRIF throughout the human 
body. The identifi cation of fi ve distinct SRIF-receptor subtypes, being ex-
pressed on fi ve different chromosomes, suggested different functions in 
different organs and provided specifi c targets for SRIF-analog chemistry 
and creating new therapeutic opportunities. In a very short time, not only 
sst subtype selective ligands and universal binding ligands have been 
discovered but also promising sst antagonists were introduced, whereby 
each group of compounds signifi cantly participated to the current knowl-
edge in the exciting fi eld of SRIF-physiology. Subsequently, distinct, but 
overlapping patterns in function and the expression of these different 
sst subtypes in different (pathological) tissues have been demonstrated. 
Moreover, new observations on the physiology and interaction of vari-
ous sst subtypes and other G-protein coupled receptors, i.e. homo-and 
heterooligomerization, might make the long-term use of new SRIF-ana-
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logs with a different affi nity profi le in the treatment of (neuro-) endocrine 
tumours and cancer more successful. Also, sst-targeted radio- or chemo-
therapy of inoperable sst-positive cancer is an exciting new possibility, 
with promising early clinical observations. Still, the careful clinical eval-
uation of new SRIF-analogs (and antagonists) remains crucial, regarding 
their pitfalls, such as bioavailability, tachyphylaxis as well as potential 
adverse effects, since their novel pharmacological properties have usu-
ally been characterized in preclinical models only. Nevertheless, 30 years 
of tremendous efforts still provokes chemists, biologists and physicians 
to seek for better tools to fully understand the precise basic physiological 
role of SRIF and its receptors, thereby directly providing new medical 
treatment options for a variety of challenging diseases, including cancer.
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Abstract
It is well documented that in a subgroup of neuroendocrine tumors, the 
potent inhibitory responses to Octreotide (OCT) treatment diminish with 
continued exposure to this somatostatin (SRIF) analog. This phenomenon 
is know as adaptation or tachyphylaxis of inhibition of hormone secre-
tion by SRIF-analogs. This report investigated the susceptibility of the 
SRIF receptor subtype (sst) 2 and sst
5
, expressed either alone or together 
in HEK 293 cells, for tachyphylaxis to various SRIF-analogs. Pre-treat-
ment during 24 h with 10 and 100 nM OCT resulted in a nearly total 
loss of responsiveness of the sst
2
 receptor. The multiligand SOM230 (10 
and 100 nM), induced a loss of responsiveness of sst
2
 that can be classi-
fi ed as partial tachyphylaxis of SRIF-analog induced inhibition of adeny-
lyl cyclase activity. Comparable partial tachyphylaxis was observed if 
sst
2
-expressing cells were pre-treated with the sst
2
-specifi c analog BIM-
23120 (10 nM). In addition, sst
5
 also seems less susceptible to tachy-
phylaxis compared with the sst
2 
subtype, since SOM230 pre-treatment 
(10 and 100 nM) in sst
5
-expressing cells resulted in a lower induction 
of tachyphylaxis compared with the (almost) complete tachyphylaxis in-
duced by OCT in sst
2
-expressing cells. Interestingly, no loss of sensitiv-
ity of sst
5 
was found if sst
5
-expressing cells were pretreated with OCT. 
Finally, the potencies and effi cacies of SOM230 and OCT after pre-treat-
ment with either OCT or SOM230 in the sst
2 
+ sst
5
 co-transfected cells 
refl ected the resultant of the SRIF-analog induced tachyphylaxis in the 
mono-transfected state. In conclusion, we demonstrate that the prolonged 
activity of agonists with very good binding affi nity for sst
2 
and/or sst
5 
differentially elicit tachyphylaxis of both the sst
2 
and the sst
5
 receptor, 
presumably due to distinct agonist-induced receptor conformations. 
Introduction
The biological actions of somatostatin (SRIF) are mediated via fi ve G-pro-
tein coupled receptors (GPCR), named sst
1
, sst
2
, sst
3
, sst
4
 and sst
5
. The high 
density of sst on human neuro-endocrine tumors originating from normal 
SRIF-target tissues has been used clinically to treat symptoms of hormon-
al hypersecretion in patients with growth hormone (GH)- or thyrotropin 
(TSH)-secreting pituitary adenomas, as well as in patients harbouring is-
let cell or carcinoids tumors, with SRIF-analogs (1). Moreover, the pres-
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ence of sst
2
 is a prerequisite for sensitivity of inhibition of tumour-related 
hormonal hypersecretion to treatment with octapeptide SRIF-analogs, i.e. 
Octreotide (OCT) and Lanreotide, as has been extensively demonstrated 
in patients with GH-secreting pituitary adenomas and islet cell tumours 
(2, 3). These currently clinically available octapeptides display a high 
membrane binding affi nity for sst
2
, a moderate affi nity for sst
3
 + sst
5
 and 
no affi nity for sst
4
. However, in patients with islet cell or carcinoid tumors 
these initially potent inhibitory responses diminish with continued expo-
sure (1, 4). Quite remarkably, this adaptation or tachyphylaxis of inhibition 
of hormone secretion by OCT and Lanreotide is not observed in patients 
with GH-secreting pituitary adenomas (5, 6). Continuous exposure to 
SRIF or SRIF-analogs may be associated with processes as receptor phos-
phorylation, G-protein uncoupling, receptor internalization, and degrada-
tion/down-regulation (7). As much of the current clinical knowledge with 
respect to tachyphylaxis is built upon sst
2
-mediated mechanisms, howev-
er, possible novel therapeutical directions might become possible regard-
ing targeting other sst subtypes, such as sst
1 
and sst
5
, since cumulating 
reports demonstrate their presence in neuro-endocrine tumors as well (5). 
The recently developed SRIF multiligand, SOM230 (8), seems of interest 
for the medical treatment of patients harbouring OCT-resistant neuroen-
docrine tumors. SOM230, in striking contrast to OCT, showed signs of 
only partial loss of its inhibitory effects on IGF-I levels during a period of 
126 days continuous infusion in rats (9). The superior binding affi nity of 
SOM230 for sst
5
, compared with OCT, could well account for this enhanced 
IGF-I suppression (9). This would suggest, however, that sst
5
 is not or less 
susceptible to tachyphylaxis by prolonged treatment with SRIF-analogs.
In the present study, various SRIF-analogs, sst
2
- or sst
5
-specif-
ic, as well as universal, were studied in HEK 293 cells, transfect-
ed with sst
2
, sst
5
 alone or in combination, for their ability to in-
duce tachyphylaxis of SRIF-analog mediated inhibition of forskolin 
(FSK)-induced cAMP release. Prolonged SRIF-analog treatment of 
sst-expressing HEK 293 cells, a model cell line that has been used ex-
tensively for studies of GPCR function, indicates that, there is ligand-
specifi c induction of tachyphylaxis of the sst
2
 and sst
5
 receptor subtypes. 
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Methods
Cell line culture and sst constructs
HEK 293 cells (kind gift of Dr. A.P.N. Themmen, Internal Medicine, 
Erasmus MC Rotterdam, the Netherlands) were routinely passaged by 
trypsinization as described in detail previously (10). The cells were main-
tained in 75 cm2 fl asks in DMEM/F-12 medium, supplemented with non 
essential amino acids, sodium pyruvate (1 mmol/L), 10% fetal calf serum 
(FCS), penicillin (1*105 U/L), streptomycin (50 mg/L), fungizone (0.25 
mg/L), L-glutamine (2 mmol/L), and sodium bicarbonate (2.2 g/L), pH 
7.6. The cells were cultured at 37° C in a CO
2
-incubator. Before transfec-
tion, the cells were seeded at 40% confl uence in 75 cm2 fl asks and trans-
fected the next day using the calcium phosphate precipitation method.
In order to create different sst
2
/sst
5
 ratios being expressed, HEK 293 cells 
were transiently transfected with various concentrations of human sst
2 
and sst
5 
cDNA [human sst
2
 or sst
5
 cDNA in pBluescript (pBS) (a kind gift 
of G.I. Bell, Howard Hughes Medical Institute Chicago, Illinois) was ex-
cised from pBS and inserted into the Nhe-1/Sal1 or EcoRI/XbaI cloning 
site, respectively, of the mammalian expression vector pCi-neo (Promega 
Benelux, Leiden, the Netherlands)]. Media and supplements were ob-
tained from GIBCO Bio-cult Europe (Invitrogen, Breda, the Netherlands). 
Forskolin-induced cAMP Response Element-Luciferase 
Reporter Gene Assay
The functional responses of the SRIF-analogs in the various cell systems 
were determined using a cAMP-responsive reporter construct that contains 
six cAMP response elements in tandem in front of the cDNA encoding the 
luciferase (LUC) reporter enzyme [pCRE6lux (11)]. HEK293 cells were 
co-transfected with pCRE6Lux (11) and pRSVlacZ, to control for trans-
fection effi ciency (12) (maximum of 10 µg sst-expression construct, 2 µg 
pRSVlacZ, 2 µg pCRE6Lux, and 6 µg carrier DNA per ml precipitate). Two 
days after transfection, cells were pre-incubated for 24 h (at 37°C in cul-
ture medium) without or with SRIF-analog (10 or 100 nM). Subsequently, 
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media were refreshed and the SRIF-analog dependent CRE-LUC response 
was determined in 48-well tissue culture plates (Costar, Cambridge, MA) 
by incubating the cells for 6 h in culture medium containing 0.1% BSA 
with 1 µM forskolin (FSK) and increasing concentrations of SRIF-analog 
(range 100 nM – 0.01 pM). Thereafter, the media were aspirated, the cells 
lysed and luciferase activity was measured using a TopCount luminom-
eter after adding luciferin (13). β-Galactosidase activity of the lysates 
was determined to correct for transfection effi ciency (12). The CRE-LUC 
response produced by 1 µM FSK in each experiment was set at 100%. 
Quantitative PCR
Quantitative PCR was performed as described previously (14). Messen-
ger RNA was isolated using Dynabeads Oligo (dT)
25
 (Dynal AS, Oslo, 
Norway) from transiently transfected (72 h) HEK 293 cells. The cells 
were lysed for 2 min in an ice-cold Tris-buffer (100 mM Tris-HCl, pH 
8, 500 mM LiCl, 10 mM EDTA, 1% LiDS, 5 mM DTT and 5 U/100µl 
RNAse inhibitor (HT Biotechnology Ltd., Cambridge, UK). The mixture 
was centrifuged at 14,000 rpm for 1 min to remove cell debris. After 
adding 40 µl pre-washed Dynabeads Oligo (dT)
25
 to the supernatant, the 
mixture was incubated for 5 min on ice. Thereafter, the beads were col-
lected with a magnet, washed three times with a Tris-buffer (10 mM Tris 
HCl, pH 8, 0.15 M LiCl, 1 mM EDTA, 0.1% LiDS), and once with a 
similar buffer from which LiDS was omitted. Messenger RNA was eluted 
from the beads in 2 x 20 µl H
2
O for 2 min at 65 °C. Complementary DNA 
(cDNA) was synthesized using the poly A+ mRNA in a Tris-buffer (50 
mMTris-HCl, pH 8.3, 100 mM KCl, 4 mM DTT, 10 mM MgCl
2
) together 
with 1 mM of each deoxynucleotide triphosphate, 10 U RNAse inhibi-
tor, and 2 U AMV Super Reverse Transcriptase (HT Biotechnology Ltd., 
Cambridge, UK) in a fi nal volume of 40 µl. This mixture was incubated 
for 1 h at 42 °C. One tenth of the cDNA library was used for quantifi ca-
tion of sst subtype mRNA levels. The assay was performed using 15 µl 
TaqMan Universal PCR master mix (Applied Biosystems, Capelle aan de 
IJssel, The Netherlands), 500 nM forward primer, 500 nM reverse primer, 
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100 nM probe and 10 µl cDNA template, in a total reaction volume of 25 
µl. The reactions were carried out in a ABI 7700 sequence detector (The 
Perkin-Elmer Corporation, Groningen, The Netherlands). PCR amplifi -
cation started with a fi rst step for 2 min at 50 °C, followed by an initial 
heating at 95 °C for 10 min and, subsequently, samples were subjected to 
40 cycles of denaturation at 95 °C for 15 sec and annealing for 1 min at 60 
°C. To ascertain that no detectable genomic DNA was present in the poly 
A+ mRNA preparation, since sst genes are intron-less, the cDNA reactions 
were also performed without reverse transcriptase. The detection of hypo-
xanthine-phosphoribosyl-transferase (hprt) mRNA served as a control and 
was used for normalization of the sst subtype mRNA levels. The primer 
sequences that were used have been described in detail previously (15). 
Table 1. Binding selectivity of SRIF-analogs for the five sst subtypes.
Binding affinity (IC50, nM) 
Compound 
sst1 sst2 sst3 sst4 sst5
Octreotide 280 0.4 7.1 >1000 6.3 
SOM230 9.3 1.0 1.5 >100 0.2 
BIM-23206 >1000 166 1000 >1000 2.4 
BIM-23120 >1000 0.34 412 >1000 213.5 
Data are from radioligand binding assays to membranes from transfected CHO-K1 cells 
(8, 30) and African green monkey kidney cells (8) expressing the different human sst 
subtypes. Values are from IPSEN (Culler, M.D.), and from Lewis and coworkers (8).
Test-substances
Octreotide (OCT, Sandostatin®) and SOM230 were from Novartis Phar-
ma A.G., (Basel, Switzerland). Somatostatin-14 was purchased from Sig-
ma Chemical Co. (St. Louis, MO). BIM-23206, a sst
5
-subtype specifi c 
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analog, and BIM-23120, a sst
2
-specifi c analog, were synthesized by IP-
SEN (Massachusetts, USA). Sst binding affi nities are depicted in Table I.
Statistical analysis
Calculation of IC
50
 values for inhibition of FSK-induced cAMP response 
was made using GraphPad Prism version 3.02 (San Diego, CA). The 
statistical signifi cance of the difference between the mRNA expression 
levels after 10 nM SRIF-analog pre-treatment were determined by us-
ing one-way analysis of variance (ANOVA). When signifi cant over-
all effects were obtained by this method, comparisons were made us-
ing Newman-Keuls multiple comparisons test. Data are reported as 
means ± SEM of the indicated n values, unless otherwise specifi ed. 
Results
cAMP response in sst
2 
or sst
5 
transfected HEK 293 cells
It has been demonstrated that the design of experiments involving the 
pre-treatment of cells with high concentrations of SRIF or SRIF-analogs 
followed by measurement of surface receptor numbers by ligand binding 
or functional responses, can have important consequences for interpreting 
the results. The concentration of agonist accumulating in the medium can 
be suffi cient to re-activate the receptor and it has been shown that there 
is a dynamic cycling of both somatostatin agonist ligands and receptors 
between the cell surface and internal compartments both during agonist 
treatment and after surface-bound agonist has been removed, unless steps 
are taken to prevent the re-activation of receptors by recycled agonist 
(16). Therefore, we fi rst evaluated the inhibitory effects of 10 nM OCT to 
inhibit FSK-induced cAMP (CRE-LUC) response in sst
2
-expressing HEK 
293 cells when pretreated overnight (24 hr) with 10 nM OCT. As depicted 
in fi gure 1, compared with control (a rapid removal of the medium fol-
lowed by immediate incubation with 10 nM OCT in the presence of 1μM 
FSK at 37°C for 6 hr), washing the cells once in DMEM or washing the 
cells once in DMEM followed by a 10 min incubation at 37°C in HBSS 
pH 5 (to dissociate cell surface-bound ligand), did not alter the inhibitory 
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Figure 1. Control experiments in sst
2-
expressing HEK 293 cells, to compare three 
commonly used strategies to handle cells that were pre-treated for 24 h with 10 nM 
OCT. cAMP response was determined with the use of six copies of a cAMP re-
sponse element (CRE)-luciferase reporter gene construct (CRE-LUC). β-Galactosi-
dase activity of the lysates was determined to correct for transfection efficiency. The 
cAMP (CRE-LUC) response produced by 1 µM FSK in each experiment was used as 
100%. The values represent the means ± S.E. from separate experiments performed 
in quadruplicate. Each bar is representative for two individual experiments. CT, me-
dium was removed from the wells and immediate incubation with FSK and 10 nM 
OCT in serum free DMEM was initiated; Wash, medium was removed from the 
wells, cells were washed once in DMEM (37°C) followed by incubation with FSK 
+ OCT and Wash + pH 5, medium was removed from the wells, cells were washed 
once in DMEM (37°C) followed by 10 min incubation with HBSS (pH 5) at 37°C. 
Subsequently, HBSS was removed an incubation with FSK + OCT was initiated.
effi cacy of 10 nM OCT to inhibit FSK-induced cAMP response (-29 ± 
7, -19 ± 3 and -30 ± 9%, respectively). In addition, the average cAMP 
response produced by 1 µM FSK in the untreated experiments (5 ± 2 fold 
over control) was not different compared with SRIF-analog pretreated 
experiments (6.5 ± 2.5 fold over control). In subsequent experiments, 
therefore, after pre-treating the cells with a SRIF-analog, rapid removal 
of the medium was followed by immediate incubation with 1μM FSK in 
the presence of a 100 nM - 1 pM range of SRIF analog at 37°C for 6 hr.
To investigate the susceptibility of the sst
2 
receptor to tachyphylaxis, sst
2
-
expressing HEK 293 cells were incubated in the absence or presence of 
three different SRIF-analogs (10 nM) for 20 h at 37°C. In untreated cells, 
OCT and SOM230 inhibited FSK-induced cAMP response with an IC
50 
of 0.02 ± 0.09 and 0.4 ± 0.23 nM, respectively. Maximum inhibition was 
79 ± 1 and 90 ± 1%, respectively. Preincubation of cells with 10 nM OCT, 
1�M FSK CT wash wash+pH 5
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Figure 2. Dose-dependent inhibition of FSK-induced cAMP response by OCT 
(■) and SOM230 (○) in sst
2-
expressing HEK 293 cells, that were untreated (sol-
id lines) or pre-treated for 24 h (dashed lines) with 10 nM OCT (A), SOM230 (B) 
or BIM-23120 (C). cAMP response was determined with the use of six cop-
ies of a cAMP response element (CRE)-luciferase reporter gene construct (CRE-
LUC). The values represent the means ± S.E. from separate experiments performed 
in quadruplicate. Each graph is representative for two individual experiments
as depicted in fi gure 2A, dramatically reduced the effi cacy of maximum 
inhibition by OCT (-22 ± 5%) as well as the potency (IC
50 
= 0.5 ± 0.5 nM). 
In addition, the potency of SOM230 to inhibit the FSK-induced cAMP 
response was completely abolished after pre-treatment with 10 nM OCT 
(IC
50
 = > 1000 nM). Pre-treatment of cells with 10 nM SOM230 resulted in 
different responses. As can be seen in fi gure 2B, the potency of OCT was 
attenuated only 5-fold compared with untreated cells while the maximal 
inhibition was still -67 ± 1%. The same results were observed for SOM230; 
the potency lowered nearly 3-fold while the effi cacy remained at -62 ± 
9% suppression of FSK-induced cAMP response. Finally, sst
2
-expressing 
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cells were pre-treated with 10 nM BIM-23120 (Fig. 2C), a sst
2
-selective 
SRIF analog with comparable binding affi nity (0.34 nM) and functional 
potency to suppress FSK-induced cAMP (0.03 ± 0.20 nM) response as 
OCT. Interestingly, treatment of cells with BIM-23120, increased the IC
50 
for OCT only 4-fold (0.08 ± 0.15 nM), while maximum inhibition re-
mained -71 ± 1%. The IC
50
 of SOM230 after pre-treatment with 10 nM 
BIM-23120 appeared 7.9 ± 0.30 nM while its effi cacy was -69 ± 2%.
In untreated sst
5
-expressing HEK 293 cells OCT and SOM230 inhibited 
FSK-induced cAMP response with an IC
50 
of 8.4 ± 0.10 and 0.05 ± 0.11 
nM, respectively (Fig. 3). Maximum inhibition was 73 ± 31 and 82 ±1%, 
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Figure 3. Dose-dependent inhibition of FSK-induced cAMP response by OCT 
(■) and SOM230 (○) in sst
5
-expressing HEK 293 cells, that were untreated (sol-
id lines) or pre-treated for 24 h (dashed lines) with 10 nM OCT (A), SOM230 (B) 
or BIM-23206 (C). cAMP response was determined with the use of six cop-
ies of a cAMP response element (CRE)-luciferase reporter gene construct (CRE-
LUC). The values represent the means ± S.E. from separate experiments performed 
in quadruplicate. Each graph is representative for two individual experiments.
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respectively. OCT pre-treatment did not affect both the potency as well 
as the effi cacy of both SRIF-analogs to inhibit FSK-induced cAMP re-
sponse (Fig. 3A: OCT, IC
50 
= 9.9 ± 0.20 nM and -68 ± 4%; SOM230, 
IC
50 
= 0.1 ± 0.30 nM and -75 ± 2%). The maximum inhibition by OCT 
was only 15 ± 5% when cells were pretreated with 10 nM SOM230. 
SOM230, on the other hand, suppressed FSK-induced cAMP response 
by 57 ± 5% while its potency was lowered to 1.9 ± 0.18 nM (Fig. 3B). Fi-
nally, sst
5
-expressing cells were pretreated with 10 nM BIM-23206 (Fig. 
3C), a sst
5
-selective SRIF analog with high binding affi nity (2.4 nM) and 
functional potency to suppress FSK-induced cAMP (IC
50 
= 0.20 ± 0.11 
nM). Both the potency and effi cacy of OCT were attenuated (45 ± 0.7 
nM and -31 ± 4%) after pre-treatment with BIM-23206. The potency of 
SOM230, after BIM-23206 pre-treatment, was lowered 2-fold (0.1 ± 0.1 
nM) while its maximum inhibition was partially reduced to -49 ± 6%.
mRNA expression  in sst
2 
or sst
5 
transfected HEK 293 cells
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Figure 4. Expression of sst
2 
(A) and sst
5 
(B) mRNA levels in HEK 293 cells after 24h 
pre-treatment with various SRIF-analogs at 10 nM concentration. Sst and hprt mRNA 
levels were quantified by a TaqMan assay and results are depicted as bars, representing 
the means ± S.E. from 2 separate measurements performed in duplicate, and are adjust-
ed for hprt expression. CT = control untreated cells. #, p<0.05 vs CT; *, p<0.01 vs CT.
As depicted in fi gure 4, all SRIF-analogs signifi cantly suppressed 
sst
2
 mRNA expression levels (Fig. 4A: range of inhibition 31-
59%) as well as sst
5 
mRNA expression levels (Fig. 4B: approxi-
mately 40% inhibition) when sst
2
- or sst
5
-expressing HEK 293 cells 
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were pretreated for 24 h with 10 nM of the individual compounds. 
cAMP response in sst
2 
+ sst
5 
co-transfected HEK 293 cells
Because a signifi cant proportion of human sst-positive neu-
roendocrine tumors simultaneously express multiple sst sub-
types, including sst
2 
and sst
5
 (5), we also evaluated tachyphylax-
is for SRIF-analogs in sst
2 
and sst
5 
co-expressing HEK 293 cells.
When the sst
2
/sst
5 
mRNA expression ratio was high (Fig. 5: sst
2
, 2.87 ± 
0.21 sst/hprt and sst
5
, 0.34 ± 0.01 sst/hprt) in untreated HEK 293 cells, 
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Figure 5. Dose-dependent inhibition of FSK-induced cAMP response by OCT (■) and 
SOM230 (○) in HEK 293 cells, with a high sst
2
/sst
5 
mRNA expression ratio, that were 
untreated (solid lines) or pre-treated for 24 h (dashed lines) with 10 nM OCT (A) or 
SOM230 (B). cAMP response was determined with the use of six copies of a cAMP 
response element (CRE)-luciferase reporter gene construct (CRE-LUC). The values 
represent the means ± S.E. from separate experiments performed in quadruplicate.
the potency in terms of IC
50
 for OCT and SOM230 was 0.01 ± 0.44 and 
0.66 ± 0.17 nM, respectively. Maximum inhibition was -88 ± 4% for 
OCT and -87 ± 3% for SOM230. Preincubation of these cells with 10 
nM OCT (Fig. 5A) attenuated the potency (IC
50
 = 0.16 ± 0.12 nM) and 
effi cacy of OCT inhibition (maximum inhibition = -40 ± 5%) as well 
as the potency (IC
50
 = 10 ± 0.18 nM) and effi cacy of SOM230 inhibi-
tion (maximum inhibition = -55 ± 2%). Treatment of cells with 10 nM 
SOM230, as depicted in fi gure 5B, only attenuated the potency of OCT 
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2 fold (IC
50 
= 0.02 ± 0.24 nM) and maximum inhibition remained -74 ± 
4%. The same results were observed for SOM230: IC
50 
lowered near-
ly 2-fold to 1.14 ± 0.19 nM and maximum inhibition was -74 ± 6%.
Subsequently, the same panel of experiments were carried out in HEK 293 
cells, in which the sst
2
/sst
5 
ratio was low (Fig. 6: sst
2
, 0.71 ± 0.09 sst/hprt 
and sst
5
, 2.02 ± 0.20 sst/hprt). In untreated cells, the potency in terms of IC
50
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Figure 6. Dose-dependent inhibition of FSK-induced cAMP response by OCT (■) and 
SOM230 (○) in HEK 293 cells, with a low sst
2
/sst
5
 mRNA expression ratio, that were 
untreated (solid lines) or pre-treated for 24 h (dashed lines) with 10 nM OCT (A) or 
SOM230 (B). cAMP response was determined with the use of six copies of a cAMP 
response element (CRE)-luciferase reporter gene construct (CRE-LUC). The values 
represent the means ± S.E. from separate experiments performed in quadruplicate.
for OCT and SOM230 was 0.02 ± 0.16 and 0.08 ± 0.04 nM, respectively. 
Maximum inhibition was -93 ± 4% for OCT and -81 ± 1%   for SOM230. 
If the cells were pretreated with 10 nM OCT (Fig. 6A), both the potency 
and effi cacy of OCT to inhibit FSK-induced cAMP were attenuated (IC
50
= 0.51± 0.20 nM, -48 ± 1%). The potency of SOM230 was only lowered 
4-fold (IC
50
 = 0.83 ± 0.25 nM) while its maximum inhibition appeared -76 
± 2%. Pre-treatment of cells with 10 nM SOM230 (Fig. 6B), lowered the 
potency of OCT 4-fold (IC
50
 = 0.08 ± 0.30 nM) and maximum inhibition 
was attenuated to -52 ± 1%, while the potency of SOM230 was unaffected 
(IC
50 
= 0.10 ± 0.33 nM) and maximum inhibition was lowered to -45 ± 3%.
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Pre-treatment of HEK 293 cells at 100 nM SRIF-analog 
concentration
Finally, we investigated the susceptibility of both individual sst sub-
types to tachyphylaxis in the presence of 100 nM OCT or SOM230. 
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Figure 7. Dose-dependent inhibition of FSK-induced cAMP response by OCT 
(A) and SOM230 (B) in sst
2
-expressing HEK 293 cells, that were untreated (■, sol-
id line) or pre-treated (dotted lines) for 24 h with 100 nM OCT (□) or SOM230 (○). 
cAMP response was determined with the use of six copies of a cAMP response el-
ement (CRE)-luciferase reporter gene construct (CRE-LUC). The values represent 
the means ± S.E. from at least 2 separate experiments performed in quadruplicate.
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Figure 8. Dose-dependent inhibition of FSK-induced cAMP response by OCT 
(A) and SOM230 (B) in sst
5
-expressing HEK 293 cells, that were untreated (■, sol-
id line) or pre-treated (dotted lines) for 24 h with 100 nM OCT (□) or SOM230 (○). 
cAMP response was determined with the use of six copies of a cAMP response el-
ement (CRE)-luciferase reporter gene construct (CRE-LUC). The values represent 
the means ± S.E. from at least 2 separate experiments performed in quadruplicate.
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Pre-treatment of sst
2
-expressing cells with 100 nM OCT completely 
abolished the inhibitory effects of OCT and SOM230 on FSK-induced 
cAMP response (Fig. 7A and 7B). On the other hand, pre-treating the 
cells with 100 nM SOM230 lowered the potency of OCT only 10-fold: 
from 0.02 ± 0.08 nM to 0.26 ± 0.16 nM, while maximum inhibition went 
from -84 ± 2% in the absence to -62 ± 4% in the presence of 100 nM 
SOM230. Comparable effects were observed for SOM230: maximum 
inhibition was slightly reduced from -83 ± 4% to -69 ± 1% while the 
IC
50
 for SOM230 was increased from 0.60 ± 0.13 nM to 26 ± 0.16 nM.
Strikingly, no signifi cant alterations in terms of effi cacy and poten-
cy for OCT and SOM230 to inhibit FSK-induced cAMP response 
by sst
5
-expressing cells were observed, when pre-treated for 24 h 
with 100 nM OCT (Fig. 8A and 8B). However,  pre-treatment with 
100 nM SOM230 signifi cantly diminished the inhibitory effects by 
OCT, while SOM230 still induced signifi cant suppressive effects on 
FSK-induced cAMP response in sst
5
-expressing cells: maximum in-
hibition was reduced from -82 ± 2% to -35 ± 6%, while the IC
50
for SOM230 was increased from 0.08 ± 0.09 nM to 1.14 ± 0.50 nM.
Discussion
The clinical observation of tachyphylaxis to SRIF-analog therapy in the 
medical treatment of neuroendocrine tumors, such as carcinoids and in-
sulinomas, has prompted physicians, biologists and chemists to develop 
novel therapeutic tools that can provide other treatment options in this 
subgroup of patients. Before such a pharmacological tool can be designed, 
however, fundamental insights regarding the mechanisms involved in 
tachyphylaxis to SRIF-analogs seem essential. This report evaluated the 
susceptibility of sst
2
 and sst
5
 subtypes, either expressed alone or together 
in HEK 293 cells, for tachyphylaxis to the currently clinically available 
sst
2
-preferring analog OCT, as well as to the recently developed multili-
gand SOM230, which has superior binding affi nity for sst
5
. We demon-
strate that tachyphylaxis is sst subtype specifi c, but moreover, different 
SRIF-analogs differentially induce tachyphylaxis of the same sst subtype.
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To keep in close proximity with the in vivo physiological concentration 
of SRIF and therapeutic levels of OCT, which both are within the one-
nanomolar range (1), we  have chosen 10 nM as the pre-treatment SRIF-
analog concentration in most experiments. Moreover, although we are 
aware of the fact that GPCR-function in terms of G-protein uncoupling 
and/or receptor internalization can be affected within minutes after ac-
tivation, we were primarily interested in prolonged pre-treatment with 
SRIF-analogs because this is more representative for the clinical observa-
tions of SRIF-analog induced tachyphylaxis. In agreement with previous 
reports (16-18), pre-treatment with 10 nM OCT resulted in a nearly total 
loss of responsiveness of the sst
2
 receptor. Interestingly, SOM230, with 
a very high binding affi nity for sst
2
, induced a loss of responsiveness 
of sst
2
 that can be classifi ed as partial tachyphylaxis. Moreover, even a 
100 nM concentration of SOM230, compared with 100 nM OCT, was 
still not able to induce a complete tachyphylaxis of SRIF-analog induced 
inhibition of adenylyl cyclase activity in sst
2
-expressing cells. Striking-
ly, a comparable partial tachyphylaxis was observed when sst
2
-express-
ing cells were pre-treated with 10 nM BIM-23120, a sst
2
-specifi c SRIF 
analog with a superior sst
2 
binding affi nity and functional potency that 
equals the sst
2
-pharmacological properties of OCT. Two interesting con-
clusions can be deduced from these experiments: 1) although SOM230 
binds with good affi nity to sst
2
, this multiligand cannot induce complete 
tachyphylaxis and 2) the differential agonist-induced tachyphylaxis, as 
shown with the three different SRIF-analogs, all having superior binding 
affi nity and functional activity at the sst
2
 subtype, seems in support for the 
concept of for distinct agonist-induced receptor conformations. In agree-
ment with the latter, convincing data have recently demonstrated for the 
fi rst time that the activity of SRIF-analogs to regulate receptor endocyto-
sis and signaling are not tightly linked and compelling evidence for the 
induction of agonist specifi c states of the sst
2 
receptor was provided as it 
was shown that sst
2
-agonists differ in their potency ratios for inhibiting 
adenylyl cyclase and stimulating receptor internalization (19). Taken all 
this evidence together, a reasonable amount of proof is provided for the 
induction of agonist-specifi c conformations of the sst
2 
receptor and it can 
284
Chapter VI-2
be suggested that no single measure of agonist activity is predictive of all 
post-receptor effects induced by agonists (19). Our observations with the 
sst
5
 subtype, moreover, provide the fi rst evidence that the same hypoth-
esis can be transposed to this receptor as well. In addition, considering 
the equally superior binding affi nity of SOM230 and OCT for the sst
5
 and 
sst
2
, respectively, the sst
5
 also seems less susceptible to tachyphylaxis 
compared with the sst
2 
subtype. SOM230 pre-treatment of sst
5
-expressing 
cells resulted in only a partial induction of tachyphylaxis compared with 
the (almost) complete tachyphylaxis induced by OCT in sst
2
-expressing 
cells. Even 100 nM SOM230 pre-treatment showed that SOM230 could 
still inhibit FSK-induced cAMP response in a dose-dependent manner 
in SOM230 pre-treated sst
5
-expressing cells, while tachyphylaxis was 
complete when sst
2
-expressing cells were pre-treated with 100 nM OCT. 
Another striking observation and, in a way, supporting the lower sus-
ceptibility for tachyphylxis, as well as the agonist-specifi c induction of 
tachyphylaxis of sst
5
 may be derived from our observations that both 10 
nM and 100 nM OCT pre-treatment in sst
5
-expressing cells did not result 
in a signifi cant loss of sensitivity of the cells for SRIF-analog induced in-
hibition of adenylyl cyclase activity. Finally, the potencies and effi cacies 
of SOM230 and OCT after pre-treatment with either OCT or SOM230 in 
the sst
2 
+ sst
5
 co-transfected cells refl ect the resultant of the SRIF-analog 
induced tachyphylaxis in the mono-transfected state. In this respect, our 
data seem not supportive for hetero-dimerization by sst
2 
and sst
5 
receptor 
subtypes, as has been demonstrated for sst
2
 and sst
3
. It was shown that 
this newly formed dimer displayed enhanced functional properties such 
as a greater resistance of the sst
2
-sst
3 
dimer to SRIF-14 (1μM for 6 hr) 
induced desensitization compared with SRIF-14 induced desensitization 
of sst
2 
homodimers (20). However, the authors only evaluated whether 
SRIF-14 treatment results in desensitisation of the sst
3 
itself, when adeny-
lyl cyclase inhibition was evaluated with a non-peptidyl agonist for sst
3
. 
Since they also demonstrated that native SRIF-14 had a 10-30 fold greater 
potency for sst
3
 compared with the non-peptidyl agonist, it could well be 
that SRIF-14, on the basis of ligand-induced receptor conformations, can 
still be effective in their co-transfected sst
2
+sst
3 
cells via sst
3 
homodimers.
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It should be emphasized that our results are not being discussed in terms 
of the “classical” densitization. This classical paradigm for signal trans-
duction by GPCR states that the active form of the receptor stimulates 
heterotrimeric G proteins and, subsequently, this receptor is rapidly phos-
phorylated by G-protein-coupled receptor kinases (GRKs), which leads 
to β-arrestin recruitment followed by effective uncoupling of the GPCR 
from the G-protein (21). The receptor is thereby rapidly desensitized, 
and the signaling is stalled. Agonist binding has been shown to stimu-
late sst
2
 receptor phosphorylation, is potentiated by overexpression of 
GRKs (18, 22, 23), and is correlated with receptor internalization (18, 
24). Furthermore, β-arrestin recruitment to the sst
2
 at the plasma mem-
brane is stimulated by SRIF-14 (23, 25). Because a dominant-negative 
β-arrestin failed to inhibit sst
2
 endocytosis (25), it was proposed that β-
arrestin plays a role in desensitization rather than receptor internaliza-
tion. In addition, Liu and coworkers recently demonstrated different 
interactions between sst
2
 and a GFP-tagged β-arrestin-2 after SRIF-14 
treatment or after treatment with the nonpeptide agonist L-779,976 (19). 
Although β-arrestin-2-GFP was also recruited to the plasma membrane 
sst
2
 receptors after L-779,976 binding, the β-arrestin-receptor complex 
dissociated within minutes. This observation indicates that the SRIF-14 
receptor complex binds β-arrestin with higher affi nity than L-779,976-
receptor complex. In addition, the sst
5
 subtype was recently shown to 
exhibit a class A receptor-like traffi cking pattern (23), i.e. a rapid recy-
cling back to the plasma membrane after receptor activation by SRIF-14.
Down-regulation of sst receptors may form another (long-term) cause of 
tachyphylaxis after continuous exposure of sst to agonists (5). Chronic 
exposure of cultured pituitary cells to relatively high concentrations of 
SRIF-14, SRIF-28, or SRIF-analogs reduces the number of sst on AtT20 
and 7135b pituitary tumor cells (26-29). In both sst
2
- and sst
5 
mono-trans-
fected cells we observed a lower quantitative mRNA expression level 
after prolonged SRIF-analog treatment. This supposed sst mRNA down-
regulation was not agonist-specifi c, in contrast to the observed agonist-
specifi c tachyphylaxis of sst
2
 and sst
5
. Furthermore, in another series 
of experiments it was shown that in cells expressing an amount of sst
2
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or sst
5
 mRNA that was comparable to the amount of sst
2
 or sst
5
 mRNA 
which was observed after SRIF-agonist treatment, this amount is still suf-
fi ciently high to produce concentration-dependent inhibition curves com-
parable to (untreated) control curves (unpublished data). Therefore, we 
suggest that sst down-regulation seems partially involved in tachyphy-
laxis, but other cellular mechanisms must be taken into account as well.
What can be the clinical implications of our results? Prolonged OCT 
treatment in neuro-endocrine tumors, expressing both sst
2 
and sst
5
, may 
result in complete tachyphylaxis of the sst
2
 subtype, but the sst
5
 will 
remain functionally active. Therefore, it won’t be of any use for sub-
sequent treatment with a sst
2
-selective or preferring SRIF-analog, but 
adjuvant treatment with SRIF-analogs that can bind with sub-nano-
molar affi nity to sst
5
 might be of interest to elicit once again a thera-
peutic response in these OCT-resistant cases. On the other hand, pro-
longed treatment with SOM230 might result in a longer duration 
of action irrespective of the sst
2
 and sst
5
 expression levels, because 
SOM230 induces only partial tachyphylaxis of both receptor subtypes.
In conclusion, we demonstrate that agonists with a very good binding 
affi nity for sst
2 
and/or sst
5 
differentially elicit tachyphylaxis of both the 
sst
2 
and the sst
5
 receptor. These results provide some new insights in the 
mechanisms involved in tachyphylaxis after prolonged SRIF-analog 
treatment and could be of help for the development of novel therapeutic 
tools for patients that are classifi ed as OCT-resistant. Additional studies, 
however, are inevitable to determine which cellular mechanisms are actu-
ally triggered after the distinct agonist-induced receptor conformation. 
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Chapter VI-3
Functional characterisation of 
the novel tri-selective chimeric 
molecule BIM-23A760 with 
activity at somatostatin receptors 
2 and 5, and the dopamine D2 
receptor
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Abstract
The recent development of novel pharmacological agents targeting both 
somatostatin (SRIF) receptors and the Dopamine (DA) D2 receptor, 
i.e. chimeric SRIF-DA agonists, might lead to novel potential oppor-
tunities in the medical treatment of acromegaly. This report is the fi rst 
that analysed BIM-23A760, a tri-chimeric molecule, both in a series of 
sst
2
+sst
5
+D2R transfected mammalian cells, to retrieve additional in-
sights with respect to the functional explanation for the high potency of 
these chimeric molecules. While the membrane binding affi nity of the 
tri-chimeric molecule BIM-23A760 compared with the internal control 
BIM-23023, for sst
2 
and sst
5
, display a 10-fold difference, respectively, 
no differences to inhibit forskolin (FSK)-induced cAMP response were 
observed in the sst
2
 or sst
5
 mono-transfected HEK 293 cells. Furthermore, 
while BIM-23A760 possesses a similar binding affi nity for the D2R, 
compared with the D2R-targeted internal control BIM-53097, the chi-
mera was even 20-fold more potent to dose-dependently suppress FSK-
induced cAMP response. In various sets of co-expressing sst
2
+sst
5
+D2R 
HEK 293 cells the effi cacy of BIM-23A760 in terms of maximal in-
hibitory effect (100nM) or concentration-dependent inhibition of FSK-
induced cAMP response was not enhanced compared with the combi-
nation of BIM-23023 and BIM-53097 or Cabergoline. In conclusion, 
our results BIM-23A760 are not in favour of oligo-heterodimerization 
between sst
2
, sst
5 
and D2R, but merely suggest that dopastatin chime-
ras can alter ligand-mono-receptor complexes differently, that already 
can result in enhanced potency of these novel pharmacological agents.
Introduction
Recent evidence suggested potential cross-talk of somatostatin (SRIF) 
receptors with other members of the G-protein coupled receptor (GPCR) 
family. Heterodimerization of SRIF receptor subtype (sst) 5 and dopamine 
D2 receptors (D2R) seems to result in the formation of a novel receptor 
with possible enhanced biological activity (1). On the basis of these data, 
including the observation that combined SRIF-analog and dopamine 
(DA) agonist treatment inhibits growth hormone (GH) hypersecretion in 
a signifi cant proportion of acromegalic patients partially resistant to Oc-
treotide (OCT) or Lanreotide (2), Saveanu et al. (3) recently studied the 
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effects of the chimeric molecule BIM-23A387, which selectively binds 
with high affi nity to sst
2
 and D2R receptors, on GH and prolactin (PRL) 
release by 11 cultured GH-secreting pituitary adenomas. In both OCT-
sensitive, as well as in cultures showing partial responsiveness to OCT, 
the maximal inhibition of GH release induced by the individual sst
2
- and 
D2R analogs and by BIM-23A387 was comparable. However, the mean 
IC
50
 for GH suppression by BIM-23A387 (0.2pM) was 50 times lower than 
that of the individual sst
2
 and D2R specifi c compounds. This enhanced 
potency of chimeric molecules, such as BIM-23A387, may therefore 
lead to potential novel medical treatment options in acromegalic patients. 
Recent insights show that sst
5
 receptors are highly expressed in the major-
ity of GH-secreting pituitary adenomas (4, 5). Therefore, in order to further 
extend the concept of SRIF/DA chimeras, recently a novel chimeric analog, 
BIM23A760, which in addition to sst
2
 and D2R activity also has activity 
at the sst
5 
receptor, has been developed (6). This report characterizes the 
novel BIM-23A760 molecule in a functional sst and D2R receptor assay, 
to sort out why chimeric molecules have enhanced potencies compared 
with the combined treatment of SRIF-analogs and Dopamine agonists.
Methods
Cell line culture and sst constructs
HEK 293 cells (kind gift of Dr. A.P.N. Themmen, Internal Medicine, 
Erasmus MC Rotterdam, the Netherlands) were routinely passaged by 
trypsinization as described in detail previously (7). The cells were main-
tained in 75 cm2 fl asks in DMEM/F-12 medium, supplemented with non 
essential amino acids, sodium pyruvate (1 mmol/L), 10% fetal calf serum 
(FCS), penicillin (100 U/ml), streptomycin (100 μg/ml), and fungizone 
(0.25 μg/ml), L-glutamine (2 mmol/L), and sodium bicarbonate (2.2 g/
L), pH 7.6. The cells were cultured at 37° C in a CO
2
-incubator. Before 
transfection, the cells were seeded at 40% confl uence in 75 cm2 fl asks and 
transfected the next day using the calcium phosphate precipitation method.
In order to create a series of different sst
2
/sst
5
/D2R ratios being expressed, 
HEK 293 cells were transiently transfected with various concentrations 
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of human sst
2, 
human sst
5 
cDNA [human sst
2
 or sst
5
 cDNA in pBluescript 
(pBS) (a kind gift of G.I. Bell, Howard Hughes Medical Institute Chicago, 
Illinois) was excised from pBS and inserted into the Nhe-1/SalI and Eco-
RI/XbaI, respectively, cloning site of the mammalian expression vector 
pCi-neo] and human D2R cDNA (commercially available at UMR cDNA 
resource center; www.cDNA.com). Media and supplements were ob-
tained from GIBCO Bio-cult Europe (Invitrogen, Breda, the Netherlands). 
Forskolin-stimulated cAMP Response Element-Luciferase 
Reporter Gene Assay
The functional responses of the SRIF-analogs in the various cell systems 
were determined using a cAMP-responsive reporter construct that con-
tains six cAMP response elements in tandem in front of the cDNA encod-
ing the luciferase (LUC) reporter enzyme [pCRE6lux (8)]. HEK293 cells 
were co-transfected with pCRE6Lux (8) and pRSVlacZ (9) (maximum 
of 10 µg sst-expression construct, 2 µg pRSVlacZ, 2 µg pCRE6Lux, and 
6 µg carrier DNA per ml precipitate). Three days after transfection the 
SRIF-analog dependent cAMP (CRE-LUC) response was determined 
in 48-well tissue culture plates (Costar, Cambridge, MA) by incubating 
the cells for 6 h in culture medium containing 0.1% BSA with 1 µM 
forskolin (FSK) and increasing concentrations of SRIF-analog (range 10 
µM – 0.01 pM). Subsequently, the media was aspirated, the cells lysed 
and luciferase activity was measured using a TopCount luminometer 
after adding luciferin (10). β-Galactosidase activity of the lysates was 
determined to correct for transfection effi ciency (9). The CRE-LUC re-
sponse produced by 1 µM FSK in each experiment was used as 100%. 
Quantitative PCR
Quantitative PCR was performed as described previously (11). Messen-
ger RNA was isolated using Dynabeads Oligo (dT)
25
 (Dynal AS, Oslo, 
Norway) from transiently transfected (72 h) HEK 293 cells or freshly 
isolated pituitary adenoma cell pellets containing 1.0 X 106 adenoma 
cells. The cells were lysed for 2 min in an ice-cold Tris-buffer (100 mM 
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Tris-HCl, pH 8, 500 mM LiCl, 10 mM EDTA pH 8, 1% LiDS and 5 
mM DTT. After adding 40 µl pre-washed Dynabeads Oligo (dT)
25
 to the 
supernatant, the mixture was incubated for 10 min on ice. Thereafter, 
the beads were collected with a magnet, washed three times with a Tris-
buffer (10 mM Tris HCl, pH 8, 0.15 M LiCl, 1 mM EDTA, 0.1% LiDS), 
and once with a similar buffer from which LiDS was omitted. Messenger 
RNA was eluted from the beads in 2 x 20 µl H
2
O for 2 min at 65 °C. 
Complementary DNA (cDNA) was synthesized using the poly A+ mRNA 
in a Tris-buffer (50 mMTris-HCl, pH 8.3, 100 mM KCl, 4 mM DTT, 10 
mM MgCl
2
) together with 1 mM of each deoxynucleotide triphosphate, 
10 U RNAse inhibitor, and 2 U AMV Super Reverse Transcriptase (HT 
Biotechnology Ltd., Cambridge, UK) in a fi nal volume of 40 µl. This 
mixture was incubated for 1 h at 42 °C. One tenth of the cDNA library 
was used for quantifi cation of sst subtype mRNA levels. The sst subtype 
assay was performed using 15 µl TaqMan Universal PCR master mix 
(Applied Biosystems, Capelle aan de IJssel, The Netherlands), 500 nM 
forward primer, 500 nM reverse primer, 100 nM probe and 10 µl cDNA 
template, in a total reaction volume of 25 µl. The forward primer, reverse 
primer and probe concentrations in the D2R assay were 300 nM, 300 nM 
and 200 nM, respectively. The reactions were carried out in a ABI 7700 
sequence detector (The Perkin-Elmer Corporation, Foster City, CA). 
PCR amplifi cation started with a fi rst step for 2 min at 50 °C, followed 
by an initial heating at 95 °C for 10 min and, subsequently, samples were 
subjected to 40 cycles of denaturation at 95 °C for 15 sec and annealing 
for 1 min at 60 °C. To ascertain that no detectable genomic DNA was 
present in the poly A+ mRNA preparation, since sst genes are intron-less, 
the cDNA reactions were also performed without reverse transcriptase. 
The detection of hypoxanthine-phosphoribosyl-transferase (hprt) mRNA 
served as a control and was used for normalization of the sst subtype 
mRNA levels.  The primer sequences that were used have been described 
in detail previously (4). The D2R-primer sequences that were used were; 
Forward: 5’- GCCACTCAGATGCTCGCC-3, 
Reverse: 5’- ATGTGTGTGATGAAGAAGGGCA-3’ and 
Probe:   5 ‘FAM - TTGTTCTCGGCGTGTTCATCATCTGC-TAMRA-3
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Test-substances
BIM-23A760, BIM-23023 and BIM-53097 were synthesized at IPSEN 
(Massachusetts, USA). Sst and D2R binding affi nities are depicted in Table I.
Table I. Human sst and D2R binding affinities of the various DA and 
SRIF analogs. Values are from IPSEN.
Compound sst1 sst2 sst3 sst4 sst5 D2R 
SRIF-14 1.95 0.25 1.2 1.8 1.4 ND 
Octreotide 1140 0.6 34 7030 7 ND 
Cabergoline ND ND ND ND ND 3.0a
BIM-23023 6616 .42 87 2700 4.2 >1000 
BIM-53097 ND ND ND ND ND 22.1 
BIM-23A760 622 0.03 160 >1000 42 15.9 
Values are the 50% inhibitory concentration (nM). ND, Not determined. a, Ref (31)
Statistical analysis
The statistical signifi cance of the difference between the effects of 100-0.1 
nM SRIF-analog in the CRE-LUC Reporter Gene Assay was determined 
by using ANOVA. When signifi cant overall effects were obtained by this 
method, comparisons were made using Newman-Keuls multiple compar-
isons test. Calculation of IC
50
 values for inhibition FRSK-induced cAMP 
accumulation and inhibition of hormone release were made using Graph-
Pad Prism version 3.02 (San Diego, CA). The unpaired Student t-test was 
chosen to analyze differences in concentration-effect curves. Data are re-
ported as means ± SEM of the indicated n values, unless otherwise specifi ed.
Results
cAMP Response
The concentration-dependent inhibition of FSK-induced cAMP response 
in sst
2
-expressing HEK 293 cells, in terms of IC
50
, by BIM-23A760 was 
comparable to its internal control BIM-23023 (0.04 ± 0.02 vs 0.02 ± 
0.01 nM, respectively). The maximal inhibitory effect, induced by 100 
nM of the individual compound, was not statistically different as well 
(Fig. 1A). Corresponding IC
50 
values in sst
5
-expressing HEK 293 cells 
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Figure 1. Dose-dependent inhibition of FSK-induced cAMP response by BIM-
23023 (■), BIM-23A760 (□), BIM-53097 (○) and Cabergoline (●) in transiently 
transfected HEK 293 cells, expressing only sst
2 
(A), sst
5 
(B) or D2R (C). cAMP re-
sponse was determined with the use of six copies of a cAMP response element 
(CRE)-LUC reporter gene construct. β-Galactosidase activity of the lysates was 
determined to correct for transfection efficiency. The CRE-LUC response pro-
duced by 1 µM FSK in each experiment was used as 100%. The values represent 
the means ± S.E. from at least 3 separate experiments performed in quadruplicate.
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for the concentration dependent inhibition of FSK-induced cAMP re-
sponse by BIM-23A760 and BIM-23023 were 6.3 ± 0.1 and 5.6 ± 0.1 
nM, respectively (p=ns), while the inhibitory effects of 100 nM of the 
compounds were not statistically different (Fig. 1B). No statistical dif-
ference at 100nM concentration was observed between BIM-53097 
and BIM-23A760 in D2-expressing HEK-293 cells as well (Fig. 1C). 
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Figure 2. Functional characterisation of BIM-23A760 in transiently co-transfected HEK 
293 cells, that expressed high D2R mRNA levels compared with sst
2
 and sst
5
.  (A) Sst and 
D2R mRNA expression levels were quantified by a TaqMan assay and results are depicted 
as bars, representing the means ± S.E. from a single experiment performed in duplicate, 
and are adjusted for HPRT expression. sst
2
 (open bars), sst
5
 (black bars) and D2R (hatched 
bars) (B) Dose-dependent inhibition of FSK-induced cAMP response by BIM23A760 
and BIM-23023+BIM52097. cAMP response was determined with the use of the CRE-
LUC reporter gene construct. The values represent the means ± S.E. from a single ex-
periment performed in quadruplicate. ■, BIM-23023+BIM-53097; □, BIM-23A760.
However, the concentration-dependent inhibition of FSK-induced 
cAMP response in D2R-expressing HEK 293 cells by BIM-23A760, 
IC
50
 value of 0.02 ± 0.07 nM, shifted 20-fold to the left, indicating in-
creased potency, compared with its internal control BIM-53097 (IC
50
: 
0.4 ± 0.11 nM, p<0.001 vs. BIM-23A760). Cabergoline, the D2R ag-
onist, displayed comparable effi cacy as compared to BIM-23A760 
in D2R-expressing HEK 293 cells (Fig. 1C, IC
50
: 0.02 ± 0.07 nM).
Subsequently, three sets of co-expressing sst
2
+sst
5
+D2R HEK 293 cells 
were synthesized and the effi cacy of BIM-23A760 was compared with 
the combination of BIM-23023 and BIM-53097 or Cabergoline. No 
statistically differences in the maximal inhibitory effect (100nM) or 
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Figure 3. Functional characterisation of BIM-23A760 in transiently co-transfected HEK 
293 cells, that expressed high sst
2
 mRNA levels compared with sst
5
 and D2R.  (A) Sst and 
D2R mRNA expression levels were quantified by a TaqMan assay and results are depicted 
as bars, representing the means ± S.E. from a single experiment performed in duplicate, 
and are adjusted for HPRT expression. sst
2 
(open bars), sst
5
 (black bars) and D2R (hatched 
bars) (B) Dose-dependent inhibition of FSK-induced cAMP response by BIM23A760 
and BIM-23023+Cabergoline. cAMP response was determined with the use of the CRE-
LUC reporter gene construct. The values represent the means ± S.E. from a single ex-
periment performed in quadruplicate. ■, BIM-23023+Cabergoline; □, BIM-23A760.
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Figure 4. Functional characterisation of BIM-23A760 in transiently co-transfected 
HEK 293 cells, that expressed comparable mRNA levels of sst
2
 and D2R and low-
er sst
5 
mRNA expression. (A) Sst and D2R mRNA expression levels were quanti-
fied by a TaqMan assay and results are depicted as bars, representing the means 
± S.E. from a single experiment performed in duplicate, and are adjusted for HPRT 
expression. sst
2
 (open bars), sst
5
 (black bars) and D2R (hatched bars) (B) Dose-
dependent inhibition of FSK-induced cAMP response by BIM23A760 and BIM-
23023+Cabergoline. cAMP response was determined with the use of the CRE-LUC 
reporter gene construct. The values represent the means ± S.E. from a single experi-
ment performed in quadruplicate. ■, BIM-23023+Cabergoline; □, BIM-23A760.
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concentration-dependent inhibition of FSK-induced cAMP response, 
in terms of IC
50
, was observed between treatments, neither when D2R 
mRNA expression was higher than sst
2 
or sst
5
 expression (Fig. 2), nor 
when sst
2
 mRNA expression was higher compared with sst
5 
and D2R 
Fig. 3).  As shown in Figure 4, when sst
2 
equalled D2R mRNA expres-
sion, IC
50 
values were comparable between BIM-23A760 and BIM-
23023+Cabergoline (0.02 ± 0.01 vs. 0.01 ± 0.1 nM, respectively). 
Discussion
Although the clinical introduction of SRIF-analogs has nowadays 
emerged into their use as reference drug for the medical treatment of ac-
romegaly, up to date, no more than approximately two thirds of cases of 
persistent acromegaly respond satisfactory to these agents (12). The re-
cent development of novel pharmacological agents targeting both sst and 
D2R, i.e. chimeric SRIF-DA agonists, might lead to novel potential op-
portunities in the medical treatment of acromegaly. While the increased 
potency of a sst
2
/D2R-interacting chimeric molecule, BIM-23A387, in 
suppressing GH and PRL secretion from human pituitary adenoma cells 
in vitro has been independently reported by two groups (3, 13), the un-
derlying mechanism for this enhanced potency is not known yet. Nev-
ertheless, a next generation of chimeric compounds has already been 
developed. Since cumulating evidence demonstrates high levels of sst
5 
expression in GH-secreting pituitary adenomas (4, 5, 14-16) that might 
be of interest to suppress GH release, in particular if sst
2
-targeted SRIF-
analogs (OCT and Lanreotide) are (partially) ineffective (5, 17-19), the 
newest chimeric compounds display activity at sst
2
+sst
5
 and the dopa-
mine D2 receptor. This report is the fi rst that analysed BIM-23A760, 
a tri-chimeric molecule, to retrieve additional insights with respect to 
the functional explanation for the potency of these chimeric molecules.
On the basis of the sst membrane binding affi nity profi le of the tri-chime-
ric molecule BIM-23A760 and its internal control BIM-23023, for sst
2 
and sst
5
, discrepancies with the functional (CRE-LUC) cAMP responses 
were observed in the mono-transfected HEK 293 cells, expressing only 
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sst
2 
or sst
5
. Although BIM-23A760, compared with BIM-23023, has a 
10-fold higher binding affi nity for sst
2
 and a 10-fold lower binding af-
fi nity for sst
5
, no differences were observed in concentration-dependent 
inhibition as well as in maximum suppression of FSK-induced cAMP 
accumulation. Moreover, while BIM-23A760 possesses a comparable 
binding affi nity for the D2R, compared with the D2R-targeted internal 
control BIM-53097, the tri-chimeric molecule was 20-fold more potent 
to suppress FSK-induced cAMP response in a dose-dependent manner in 
the functional CRE-LUC assay. In addition, in the D2R mono-transfec-
tant Cabergoline and BIM-23A760 showed comparable potency, despite 
the fact that Cabergoline has a fi ve-fold higher binding affi nity for the 
D2R (Table1). On the basis of this discrepancy between receptor bind-
ing and receptor activation seems interesting to speculate whether this 
enhanced functional potency of the mono D2R by BIM-23A760 might 
play a role in the demonstrated enhanced potency of chimeric com-
pounds in vitro (3, 13). Therefore, it could be hypothesized that BIM-
23A760 alters the mono ligand-receptor complex differently compared 
with individual DA or SRIF agonists. For example, receptor traffi cking 
may be infl uenced differently resulting in enhancement of the receptor in 
terms of adenylyl cyclase inhibition. Recently, ligand specifi c-receptor 
traffi cking by various SRIF-agonists for the sst
2
 has been nicely dem-
onstrated (20). It was shown that both cAMP inhibition and endocyto-
sis were affected differently between sst
2
-binding SRIF-analogs. These 
data seem to correspond with our data and, together, support the con-
cept that ligand-receptor complexes within the G-protein coupled re-
ceptor family seem to be uniquely triggered by each individual ligand.
As already shortly outlined above, the hybrid ‘dopastatin’ molecule BIM-
23A387 induced in both OCT-sensitive, as well as in cultures showing 
partial responsiveness to OCT, a comparable maximal inhibition of GH 
release compared with the individual sst
2
 and D2DR analogs. On the 
other hand, the mean IC
50
 for GH suppression by BIM-23A387 (0.2pM) 
was 50 times lower than that of the individual sst
2
 and D2DR specifi c 
compounds. Recently, in a series of primary GH-secreting pituitary ad-
enoma cultures collected from acromegalic patients classifi ed as only 
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partially responsive to OCT, the tri-chimeric molecule BIM-23A760 was 
also demonstrated to have increased effi cacy to suppress GH release by 
the adenoma cells, compared with the individual sst
2+5 
and D2R agonist 
(21). In 6 primary cultures, compared with OCT, BIM-23A760 increased 
maximal inhibition of GH release by 15%. Also, BIM-23A760 produced 
greater maximal suppression (± 13%) of GH secretion than the combina-
tion of the internal controls for sst
2+5 
and D2R, a fi nding that has not been 
reported for BIM-23A387. The higher effi cacy of the chimeric compound 
can be explained, at least in part, by its higher binding affi nity for sst
2
.
Quite surprisingly, no differences in effi cacy between BIM-23A760 and 
the combination of BIM-23023 and BIM-53097 or Cabergoline, in terms 
of maximal suppression and dose-dependent inhibition of FSK-induced 
cAMP response were found when all three receptors where co-trans-
fected at different expression levels in HEK 293 cells. Still, the in vitro 
data with BIM-23A387 and the use of sst
2 
and D2R antagonists do sug-
gest that sst and D2R can form oligo-heterodimers with distinct func-
tional properties (3, 13). Ligand-induced oligomerization of G-protein 
coupled receptors has now been demonstrated for different receptors. 
Both sst
2
 and sst
3
 homodimers underwent agonist induced endocyto-
sis, but the heterodimer of sst
2a
 and sst
3
, both being over-expressed in 
HEK293 cells, dissociated at the cell membrane and only sst
2
 underwent 
agonist induced endocytosis combined with loss of sst
3
 function (22). 
In addition to this communication between receptor subtypes within the 
same GPCR family, sst
2A
 receptor heterodimerization with the μ-opioid 
receptor (MOR1) has also been demonstrated (23). The sst
2A
-MOR1 
heterodimers did not signifi cantly alter the ligand binding or coupling 
properties but promoted cross-modulation of phosphorylation, internal-
ization and desensitization of these receptors. Finally, studies using bio-
luminescence resonance energy transfer assays (BRET) on living cells 
have also indicated that hetero-oligomerization of the sst
5
 and the D2R 
occurs following to agonist binding (1). The “new receptor” formed by 
the heterooligomerization of the D2 receptor and sst
5
 appeared pharma-
cologically distinct from its receptor homodimers, as it was characterized 
by a much greater affi nity for binding both dopamine and SS-agonists, 
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directly associated with enhanced G-protein and effector coupling to ad-
enylyl cyclase. Recently, the fi rst data on heterodimerizaton in vivo has 
been demonstrated. In normal rat astrocytes, sst
2
 and D
2 
receptors formed 
hetero-oligomeric complexes, displaying properties distinct from the 
native receptors (24). Other examples of GPCR heterodimer-formation 
with increase in biological functions with adrenergic (25), opioid (26, 27) 
and γ-aminobutyric acid (28, 29) receptors have been reported as well.
Our data with BIM-23A760 are not in favour of oligo-heterodimeriza-
tion between sst
2
, sst
5 
and D2R, but additional experiments such as the 
use of sst- and D2R-antagonists or confocal microscopy, to confi rm this 
will have to be performed. Cumulating in vitro data are present which 
suggest that heterodimerization leads to a distinct receptor with al-
tered functional properties does not occur. We propose, in addition to 
the current knowledge about GPCR function, that dopastatin chimeras 
can alter ligand-mono-receptor complexes differently, resulting in en-
hanced potency of these novel pharmacological agents. Additional sup-
port for this hypothesis is formed by Jaquet and coworkers. When they 
treated primary GH-secreting pituitary adenoma cells for 30 minutes 
with BIM-23A761, another tri-chimeric dopastatin molecule, a rapid 
GH-suppressive effect that lasted 24h was found. If the adenoma cells 
were co-treated with BIM-23023 and BIM-53097, however, a slower GH 
suppression that was lost already at 12 h was observed (30). In addi-
tion, incubation periods used in several reports with the dopastatin mol-
ecules that demonstrated enhanced potency, were 12 and 20 hr (3, 13). 
In conclusion, novel chimeric dopastatin molecules can become of inter-
est in the medical treatment of GH-secreting pituitary adenomas. Ideally, 
these molecules should have superior binding-affi nity towards the sst
2
, 
sst
5 
and D2R, thus initiating a super-agonist ligand-receptor conformation 
for each individual receptor. Eventually, such a hybrid compound forms 
the ideal pharmacological tool to treat GH hypersecretion, independent 
of the varying sst and D2R expression levels on the pituitary adenomas.
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General Discussion
The patho-physiological role of SRIF receptor subtypes (sst) in neuro-
endocrine diseases has gained enhanced scientifi c interest in the past few 
years. The development of novel, promising SRIF-analogs, both sst-spe-
cifi c and universal ligands, seem promising as a tool to further increase 
fundamental insights in sst function. Eventually, this research should 
result in novel medical therapeutic opportunities in patients suffering 
from neuro-endocrine diseases. In the present thesis we have evaluated 
the functional role of sst in pituitary adenomas, not only from a clinical 
point of view, but also studies were conducted to obtain more insights 
in distinct functional properties of sst in neuroendocrine tumor cells.
Clinical and functional characterisation of SRIF receptor 
subtypes in Acromegaly
Acromegaly is a debilitating disease which is predominantly caused by 
a GH-secreting pituitary adenoma. Following upon the successful clini-
cal introduction of octreotide (OCT) and Lanreotide, two cyclic SRIF-
analogs with comparable characteristics, these stable octapeptides have 
become a mainstay of medical therapy for acromegaly. Twenty years of 
clinical practice show, however, that these clinically available SRIF-ana-
logs achieve clinical and biochemical control in approximately two-third 
of acromegalic patients, both as primary or secondary therapy. The char-
acterisation of the fi ve SRIF receptor subtypes (sst) between 1993 and 
1995 has shed a new light on the pharmacological basis behind the effi ca-
cy of OCT and Lanreotide. All fi ve sst bind natural SRIF-14 with a com-
parable high affi nity, but there are major differences in the binding affi ni-
ties of OCT and Lanreotide. These octapeptides bind with a high affi nity 
to sst
2
, with a moderate affi nity to sst
3 
and sst
5
, but do not bind to sst
1 
and 
sst
4
. The expression of a high density of sst on the adenoma cells, mainly 
sst
2
, forms the basis for successful treatment of acromegalic patients with 
sst
2
-preferring SRIF-analogs such as OCT and Lanreotide. The molecu-
lar rationale for the clinical experience that one-third of patients with 
acromegaly is not adequately controlled by treatment with octapeptide 
SRIF-analogs is probably formed by a variable expression of the fi ve sst 
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in the adenomas of these patients. Indeed, OCT-sensitive GH-secreting 
pituitary adenomas seem to present with a high level of both sst
2 
and sst
5
mRNA expression, two subtypes predominantly involved in the regula-
tion of GH release by human fetal pituitary cells, as well as by GH-se-
creting pituitary adenomas. On the other hand, tumors which are partially 
sensitive to OCT, sst
2 
mRNA expression seems lower, while sst
5 
mRNA 
expression is signifi cantly higher compared with the OCT-sensitive tu-
mors. As described in chapter III-1, we also found a variable expression 
of sst mRNAs, predominantly sst
2
 and sst
5
, in our series of GH-secreting 
pituitary adenomas. Only selected cases expressed sst
1
 and sst
3
 mRNAs, 
suggesting that these sst subtypes are probably of less importance in this 
type of pituitary adenoma. Moreover, in most adenomas, sst
5
 expression 
levels were higher, compared with sst
2
 mRNA levels. Interestingly, how-
ever, a positive correlation was found between sst
2
, but not sst
5 
mRNA 
levels in the adenoma cells and the inhibitory potency of OCT on GH 
release in vivo and in vitro, as well as the effects of SOM230 and SRIF-14 
in vitro. These data demonstrate that the sst
2
 subtype is clearly a predomi-
nant receptor determining responsiveness to SRIF-analogs in acromegalic 
patients in vitro. The advantage of the multiligand SOM230 which binds 
to 4 of the 5 human sst, was clearly demonstrated in one OCT-resistant 
culture. In this particular case, expressing low sst
2
 and high sst
5
, SOM230 
inhibited GH release with comparable effi cacy as SRIF-14, thereby con-
fi rming the importance of the sst
5
 receptor subtype in mediating GH re-
lease, when sst
2
 levels are low. Moreover, compared with OCT, SOM230 
is signifi cantly more potent in suppressing PRL release by mixed GH/
PRL-secreting adenoma and prolactinoma cells, which appeared to be 
related to the expression level of sst
5
, but not sst
2
. However, the potential 
clinical importance of sst
5 
receptors in prolactinomas should be considered 
in view of the very high proportion of patients with prolactinomas that 
respond to DA agonist treatment with a normalization of PRL levels and 
tumor shrinkage. We concluded that SOM230 has a broad profi le of inhi-
bition of tumoral pituitary hormone release in the low nanomolar range, 
probably mediated via both sst
2 
and sst
5 
receptors. The higher number of 
responders of GH secreting pituitary adenoma cultures to SOM230, com-
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pared with OCT, suggest that SOM230 has the potency to increase the 
number of acromegalic patients which can be biochemically controlled. 
A fi rst proof-of-concept trial with SOM230 in patients with active acro-
megaly was performed in our center to further analyse to clinical potential 
of this novel multiligand SRIF-analog. A single s.c. injection of 250 µg 
SOM230 was compared with 100 µg OCT, thereby compensating for the 
2.5 lower binding affi nity for sst
2
. This study showed a comparable effi ca-
cy in suppressing circulating GH concentrations in 8 patients, and showed 
a signifi cant enhanced GH suppression in 3 of 12 acromegalic patients, as 
described in chapter III-2. The observation that SOM230 demonstrated 
potent inhibitory effects upon GH release in patients with GH-secreting 
pituitary adenomas expressing a low amount of sst
2
 and a high amount 
of sst
5
, suggests that the sst
5
 subtype may indeed play an essential role 
in mediating in vivo GH suppressive actions by SOM230 in OCT-partial 
responders. The enhanced effi cacy of SOM230 can be explained by high 
sst
5
 expression in this type of adenomas and its 40-fold higher binding 
affi nity for sst
5
 as compared with OCT. In vivo and in vitro data from our 
trial emphasize that the inhibitory effects on GH release by SRIF and its 
analogs are primarily mediated via sst
2
, as seen in the group of 8 equal 
responders to OCT and SOM230. However, when sst
2
 mRNA over sst
5
mRNA levels are low as demonstrated in one patient, a suppressive ac-
tion upon GH concentrations via sst
5
 receptors becomes evident as well.
Additional evaluation of the effects of SOM230 on the metabolism of 
acromegalic patients has been discussed in chapter III-3. Interestingly, 
single dose administrations of 100 and 250µg SOM230 persistently in-
hibited free IGF-I levels signifi cantly after 48 h whereas OCT was only 
effective for 24 h. Free IGF-I seems seem more important in the tempo-
ral short-term feedback between GH secretion and the circulating IGF-I 
system in normal subjects. The inhibitory effects on free IGF-I could be 
explained by intracellular dynamics of sst
2
 and sst
5
 at the central level of 
the pituitary, combined with the 40-fold higher sst
5
-binding affi nity and 
the longer half life of SOM230 compared with OCT. SOM230 might 
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induce this sustained inhibition of free IGF-I levels via sst
2
 as well be-
cause of its long half life as compared with OCT. Moreover, only in the 
subgroup of those 8 acromegalic patients that responded equally to OCT 
and 250µg SOM230 with respect to circulating GH concentrations, total 
IGF-I concentrations were lowered to a small and similar extent 24h after 
s.c. injection with 100µg OCT and 250µg SOM230. This suggests a GH-
dependent inhibition of total IGF-I, as no effects on total IGF-I levels af-
ter single doses of SOM230 and OCT were observed in the total series of 
12 acromegalic patients. In addition, SRIF-analogs can dose-dependently 
inhibit GH-induced IGF-I production by rat hepatocytes and perfused rat 
livers, expressing sst
2
 and sst
3
. However, it is not known yet whether this 
peripheral regulation of IGF-I levels is functional in the human liver as 
well. It remains unclear why differences in inhibitory effects of free and to-
tal IGF-I concentrations between the two drug treatments were observed. 
SRIF analogs also directly regulate IGFBP-1 levels, which can block 
IGF-1 bioavailability. Even though 100 and 250µg SOM230 adminis-
tration signifi cantly and dose-dependently increased IGFBP-1 levels, 
OCT treatment was more potent. The absence of a statistically signifi -
cant correlation between GH or insulin and IGFBP-1 levels after both 
OCT and SOM230 administration might support a direct role for SRIF-
analog induced release of IGFBP-1 in acromegaly, and, considering the 
superior action of OCT compared with SOM230 in stimulating IGFBP-
1 levels in acromegaly, these data suggest a modulatory role of sst
2
 in 
the direct regulation of IGFBP-1 levels by SRIF-analogs in acromegaly.
In patients with acromegaly, the effects of GH excess on insulin sensitiv-
ity are refl ected by an increased incidence of impaired glucose tolerance, 
and even overt diabetes in untreated patients. Since the human pancreas 
expresses multiple sst on α- and β-cells, a deterioration of glucose home-
ostasis was expected during SRIF-analog treatment. The inhibitory ef-
fects of OCT on insulin secretion are transient, however. In general, the 
effects of octapeptide SRIF-analogs on glucose homeostasis appeared to 
be minor and clinically important effects on carbohydrate metabolism 
during long-term therapy in acromegaly are not routinely observed. Com-
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pared with OCT, we observed comparable elevations of glucose concen-
trations during lunch after SOM230 administration (chapter III-3). On 
the other hand, 250µg SOM230 elicited an acute rise in glucose levels 
already 1 h post-injection. SOM230-mediated inhibitory effects on insu-
lin secretion cannot explain these elevated glucose levels. On the basis of 
SOM230 and OCT binding affi nity profi les for sst
5
, it seems unlikely that 
OCT, binding 40-fold less to sst
5 
compared with SOM230, would exert 
such a strong and long lasting insulin inhibition via sst
5 
subtype. There-
fore, these seemingly discrepant effects of OCT and SOM230 on insulin 
levels, clearly suggest a dominant role for sst
2 
in regulating human insulin 
secretion. As glucagon release appeared far less sensitive for inhibition by 
SOM230 as compared with octreotide (44-fold) in several in vivo animal 
models, and because peripheral glucagon measurement does not repre-
sent pancreatic glucagon (gastro-intestinal glucagon is measured as well) 
concentrations, peripheral circulating glucagon levels were not analyzed 
in our study. Moreover, cumulating data suggest that post-absorptive 
plasma glucose concentrations are maintained within the physiological 
range by insulin alone, whereas glucagon only becomes relevant when 
glucose drifts below the physiological range. Therefore, we hypothesized 
whether SOM230 might alter glucose metabolism via extra-pancreatic 
mechanisms, whereby the expression of sst in target tissues of insulin ac-
tion, i.e. liver, visceral fat and skeletal muscle seems a prerequisite for this 
theory. By quantitative PCR we indeed detected the expression of sst
1
 and 
sst
2
 in these tissues (chapter III-3 and chapter III-4). It is well known 
that insulin increases glucose uptake in muscle and fat. Based on sst
1
 and 
sst
2
 binding affi nity differences between SOM230 and OCT, i.e. a 30-
fold higher and 2.5-fold lower affi nity, respectively, and the differential 
effects of these SRIF-analogs on glucose homeostasis, we hypothesized 
that sst
1
 alone or in combination with sst
2
, may be involved in SOM230-
mediated effects on insulin signaling by activation protein tyrosine phos-
phatases (PTP), which may catalyse the rapid dephosphorylation of the 
insulin receptor (IR) and the insulin receptor substrates (IRS). This would 
also explain why OCT 100µg did not induce a profound glucose release, 
because this OCT dosage is by far not suffi cient to activate sst
1
 because 
314
Chapter VII
of very low sst
1
 binding affi nity (EC
50
 >100 nM). SOM230, via sst
1
 ac-
tivation, might increase PTP activation, which subsequently could result 
in IR- or IRS-dephosphorylation. Via such a mechanism, e.g. attenuating 
the insulin-signaling cascade,  SOM230 may even induce a relative state 
of insulin resistance. However, our experiments in Huh-7 hepatoma cells, 
which were shown to express only sst
1 
and sst
2
 at the mRNA level, do not 
demonstrate that sst
1 
or sst
2
 activation can attenuate tyrosine phosphoryla-
tion at the IR itself. Possibly, attenuation of insulin signaling by SOM230 
could also take place at the level of IRS-1or IRS-2 proteins. Both IRS-1 
and IRS-2 knockout mice exhibit insulin resistance while IRS-3 and IRS-
4 knockout mice have a normal metabolism. Therefore, further studies are 
required to evaluate whether insulin-induced phosphorylation of IRS-1 
and/or IRS-2 can be altered through sst
1 
and/or sst
2
 activation by SOM230.
In conclusion, our in vitro and in vivo data suggest that SOM230 has the 
potency to increase the number of acromegalic patients which can be 
biochemically controlled during long-term medical treatment. While the 
sst
2 
seems to be the dominant receptor in controlling GH-hypersecretion 
in acromegaly, SOM230 can mediate its suppressive actions via sst
2
 and, 
in contrast to OCT, seems also to mediate a GH-suppressive effect via the 
sst
5 
receptor. It should be noted, however, that in one patient OCT was far 
more effi cacious compared with both dosages SOM230 to lower GH lev-
els. Until now, this feature remains to be clarifi ed. Whether higher dosages 
of SOM230 in this particular case would indeed induce similar lowering 
actions on GH concentrations as seen by OCT, remains uncertain. Future 
studies will have to address the question whether SOM230 treatment is 
able to control pituitary adenoma size as well. Besides sst
2
 and sst
5
, also 
sst
1
 and sst
3
 seem to be involved in inhibition of cell proliferation and in 
the induction of apoptosis. This suggests that SOM230, with good affi n-
ity for both sst
1
 and sst
3
, might have potential anti-proliferative and tumor 
size reducing effects as well. Long-term treatment with SOM230 will 
also elucidate whether this drug can endure its advantages over OCT to 
control GH and IGF-I hypersecretion. Moreover, although SOM230 was 
well tolerated and caused no serious side effects, the alteration of glucose 
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homeostasis needs further evaluation. It seems of extreme importance for 
future clinical application of SOM230 to evaluate whether the elevated 
glucose levels will diminish during long-term treatment, and moreover, 
to elucidate the metabolic pathways behind this hyperglycaemic effect.
As already discussed, the inhibitory effects of sst
2 
and sst
5 
activation in 
the regulation of GH secretion in vitro and in vivo in patients with a GH-
secreting pituitary adenoma, are supportive for a dominant role of sst
2 
in the regulation of GH release. The data from the study described in 
chapter IV-1, provide a fi rst quantitative evidence to support the concept 
that sst
2
 is the functional dominant receptor subtype over sst
5
. In these 
studies, a cAMP Response Element-Luciferase Reporter Gene Assay 
and [125I-Tyr11]-SRIF-14 radioligand binding studies were used in HEK 
293 cells transiently co-transfected to express different ratios of sst
2
/sst
5
. 
The effi cacy of OCT appeared not to be affected by the different sst
2
/sst
5
expression ratios, whereas the sst
5
-preferring SRIF-analog BIM-23206 
was only maximally effective if the sst
5
 expression level was superior 
to sst
2
 expression. The multiligand SOM230 appeared far less sensitive 
for the ratio of sst
2
/sst
5
 expression due to its good binding affi nity for 
sst
2
. Apparently, in the transfected cell system a good correlation between 
membrane binding affi nity and functionality for individual sst subtypes 
is found. However, when two sst subtypes are co-expressed, a functional 
interplay, i.e. dominance by sst
2
 over sst
5
, is observed. In addition, the 
presence of the sst
2
 antagonist BIM-23454 the effect of OCT drifts to-
wards its low sst
5 
binding affi nity in sst
2
+sst
5 
expressing cells, whereas a 
subnanomolar binding affi nity is suggested to be physiologically active. 
These data confi rm that OCT is not effective when sst
2
 is expressed at a 
low level, i.e. cannot lower GH in the subgroup of acromegalic patients 
that are (partially) non-responders for OCT. Our experiments with the sst
2 
antagonist BIM-23454, moreover, demonstrate that SOM230 can still be 
effective when sst
2 
availability is low (as in those acromegalic patients in 
which OCT is ineffective), because it can now function via sst
5
 receptors 
for which it endorses a superior sub-nanomolar binding affi nity. A criti-
cal refl ection regarding the studies in HEK 293 cells expressing differ-
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ent ratios of sst
2
/sst
5
, reveals that up till now no intracellular regulatory 
mechanism is known that can account for the functional dominance of 
sst
2
. Studies which describe GPCR signal transduction, especially with 
respect to individual sst subtype binding to G-proteins, seem crucial 
to understand the physiological rationale behind the hypothesis of sst
2
dominance. The availability of G-proteins, however, does not seem to 
be a limiting factor in the experimental design we have used. This is 
supported by the observation that the effi cacy of the G-protein coupled 
Dopamine D2 receptor (D2R) analog Cabergoline to inhibit adenylyl cy-
clase activity is not affected when D2R are being expressed either alone 
or co-expressed with sst
2
 and sst
5 
receptor subtypes in HEK 293 cells. 
Still, further understanding of the stoichiometry of ligand, receptor and 
G-protein, by GTPγS binding-, co-immunoprecipitation- and/or fl uores-
cence tagged receptor- studies can be of experimental help in this matter. 
In recent years, the use of RNA interference has been a new approach to 
manipulate gene expression in mammalian systems. This technique could 
also be potentially very suitable to ultimately investigate further the func-
tional role of the endogenously expressed sst
2 
and sst
5
 in the regulation 
of GH release from primary cultures of GH-secreting pituitary adenoma 
cells. In chapter IV-2, we demonstrated that a synthesized siRNA con-
structs for the sst
2 
and sst
5 
gene have merit to become such novel tools. 
At present, the transfectability of cells is the limiting step in siRNA-
mediated gene silencing, especially in primary cells which are notori-
ous for having low transfection effi ciencies when plasmid DNA is used. 
Furthermore, several aspects of RNAi, i.e. non-specifi c silencing effects 
and activation of the interferon response may occur when endogenous 
(sst-) expressing mammalian cell systems are used. Chemical features of 
dsRNAs, as well as their expression levels and delivery routes, may deter-
mine whether they become visible to the interferon response machinery.
So far, we have confi rmed that the sst
2
-preferring SRIF-analog OCT is ef-
fective in approximately 65% of acromegalic patients to lower circulating 
GH concentrations, but it seems largely dependent upon a certain expres-
sion level of sst
2 
on the pituitary adenoma cells. The multiligand SOM230, 
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with good and superior binding affi nity for sst
2
 and sst
5
, respectively, seems 
less susceptible to the sst expression pattern on the tumor cells. Which 
characteristics should be incorporated when SRIF-analogs are designed 
for the treatment of acromegaly? An optimal SRIF-analog should have a 
very high affi nity for both sst
2
 and sst
5
 receptor subtypes (in particular, the 
analog should have an affi nity close or better than that for sst
2
). If not, for 
example when an analog with a high affi nity for sst
5
 and low affi nity for 
sst
2
, this analog will “suffer” from the presence of the dominant sst
2
 recep-
tor for which it has low affi nity. Future studies should also be performed 
to clarify how the functional dominance of sst
2
 is actually being executed 
at the cellular level. One explanation might be that sst subtypes display 
differential binding affi nities for the available G-proteins within the cyto-
plasm, and that the regulation of the expression and activity of one type 
of G-protein coupled receptor in a given cell type would inevitably affect 
the ligand-sensitivities of other co-existing G-protein coupled receptors. 
Somatostatin receptor subtypes in Cushing’s disease
The endogenous Cushing syndrome is predominantly caused due to excess 
ACTH release from a  ACTH-secreting pituitary adenoma, also known as 
Cushing’s disease (CD). Since signifi cant mortality and morbidity ac-
company this condition, proper medical intervention is necessary. Trans-
sphenoidal surgery is the treatment of choice for pituitary-dependent CD. 
Although transsphenoidal surgery allows cure of CD, the reported success 
rates vary between 50 to 90%. If surgery fails radiotherapy, either alone 
or in combination with adrenolytic agents, may be used. Unfortunately, 
none of the current treatment modalities ensure a full and permanent cure, 
as the rate of recurrence of the disease, depending on the criteria of ini-
tial cure, varies between 5 to 24% in the literature. Therefore, physicians 
have explored new medical strategies, preferably based on fundamental 
and (patho-) physiological pathways, with the hope to increase the chanc-
es of curation in this group of patients. Neuromodulatory agents, such 
as dopamine and SRIF, have been proposed to be of therapeutic interest 
in the medical treatment of CD. The conclusion of various case reports, 
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however, is that the sst
2
-preferring analog OCT is ineffective in treating 
CD. Chapter V is devoted to the functional role of sst in the patho-physi-
ological regulation of ACTH release in CD. In chapter V-2 glucocorti-
coid treatment induced remarkable differences with respect to the role 
of sst
2
 and sst
5 
in regulating ACTH release in mouse corticotroph AtT-20 
cells, predominantly expressing sst
2
 and sst
5
. In the absence of dexameth-
asone (DEX), OCT and SOM230 potently inhibited CRH-induced ACTH 
release, while the sst
5
-specifi c analog BIM-23268 appeared the to be the 
least potent. In the presence of DEX, a physiological nanomolar concen-
tration of SOM230 and BIM-23268 still inhibited CRH-induced ACTH 
release whereas the suppressive effects of OCT were almost completely 
blocked, and in addition, the IC
50
 values for OCT and BIM-23268 during 
DEX treatment shift toward their sst
5
 binding affi nity. The high potency 
for SOM230 was not affected by DEX. These data suggest down-regu-
lation of sst
2 
by DEX, while sst
5 
receptors seem more resistant to DEX. 
This was indeed confi rmed by the mRNA as well as by the sst membrane 
binding studies. These data suggest that in untreated patients with CD 
the expression level of sst
2
 is too low for OCT to lower ACTH and cor-
tisol level. Indeed, as shown in chapter V-1, relatively low levels of sst
2
mRNA in a series of primary human corticotroph adenomas of patients 
with CD were found. On the other hand, we found a predominant expres-
sion of sst
5
 mRNA in corticotroph adenomas. This sst mRNA profi le in 
human corticotroph adenomas, i.e. a low sst
2
 and a signifi cant sst
5
 mRNA 
expression, supports the concept that glucocorticoids down-regulate sst
2 
expression in human corticotroph adenomas while sst
5
 receptors are more 
resistant to glucocorticoid pressure. These observations also support the 
lack of effi cacy of OCT in lowering circulating ACTH and cortisol levels 
in these patients, because sst
2
 expression is too low and sst
5
-membrane 
binding affi nity by OCT is not high enough to make OCT therapeutically 
active in patients with CD. Support is formed by SOM230 induced inhi-
bition of basal and CRH-stimulated ACTH release by the corticotroph 
adenomas, which appeared comparable with the observations in AtT20-
cells (chapter V-2), i.e. signifi cant inhibition by SOM230 compared with 
OCT, even in the presence of DEX. SOM230 did not inhibit AtT20 cell-
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proliferation or POMC synthesis during a 72 hr incubation in vitro. There-
fore, increased ACTH breakdown may form an additional explanation for 
the inhibitory effect of SOM230 (and SRIF) on basal ACTH secretion. 
SOM230
Adrenal cortex
ACTHcortisol
sst5 sst2
Adrenal cortex
+ + 
ACTH
>>
cortisol
sst5
sst2
Figure 1. SOM230 in untreated pituitary-dependent Cushing’s disease. A de novo hu-
man corticotroph adenoma has predominant expression of sst
5
 and low expression of 
sst
2
. The elevated ACTH and cortisol levels down-regulate sst
2
 expression on the tumor, 
making it almost impossible for the current clinically available sst
2
-preferring SRIF-
analogs to inhibit ACTH and cortisol secretion (left panel). SOM230, however, through 
activation of sst
5
, should be able to lower ACTH and cortisol levels. In this relative 
hypocortisolemic state, the down-regulation of sst
2
 by cortisol might be abrogated. Sub-
sequently, because SOM230 also bind with good affinity to sst
2
, enhanced suppression 
of ACTH and cortisol via restored sst
2
 expression becomes suggestive (right panel).
In conclusion, we propose that sst
2 
+ sst
5
 preferring SRIF-analogs, such as 
SOM230, might become of therapeutic interest in CD. The suppression of 
ACTH levels by activation of sst
5
 in patients with CD might lower corti-
sol levels. Since cortisol lowers sst
2
 expression, these suppressive effects 
might subsequently be (partially) abrogated and enhanced ACTH inhibi-
tion via restored sst
2 
expression becomes suggestive. Therefore, prolonged 
treatment with SOM230 may be able to lower ACTH levels in CD even 
more, because it could now function via both sst
5 
and sst
2 
receptor subtypes 
(Fig. 1). An open label phase II trial in nine patients with untreated or re-
current CD has demonstrated promising results with SOM230. After two 
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weeks of SOM230 treatment, 600μg s.c. twice daily, free urinary cortisol 
levels normalized in three patients, while in the remaining six patients 
urinary cortisol levels were suppressed by 17-60%. Prolonged treatment 
shall reveal whether this multiligand can indeed be of clinical potential for 
this serious neuro-endocrine condition. On the other hand, glucose intol-
erance in all patients studied was documented during this short treatment 
period, and one patient even withdrew from the trial due to overt diabetes 
mellitus. Even though patients with CD are already known to suffer from 
glucose intolerance, it seems crucial for the future clinical development 
of SOM230 to retrieve answers with respect to this serious side effect.
Tachyphylaxis and chimeric compounds in neuro-endocrine 
diseases
Chapter VI-1 is a review of the clinical potentials and possible pitfalls of 
novel sst subtype specifi c analogs, as well as universal binding SRIF-pep-
tides in sst-positive neuro-endocrine tumors. Although the current clini-
cally available sst
2
-preferring analogs OCT and Lanreotide effectively 
control hormonal hypersecretion by GH-secreting pituitary adenomas, is-
let cell tumors, and carcinoids, signifi cant differences are observed among 
patients with respect to the effi cacy of treatment. In striking contrast to 
the absence of the occurrence of adaptation or tachyphylaxis of hormone 
secretion by continuous exposure to OCT or Lanreotide in patients with 
GH-secreting pituitary adenomas, are the observations in patients with 
islet cell tumors or carcinoids. In the majority of patients with metastatic 
carcinoids, VIPomas, gastrinomas, insulinomas and glucagonomas, treat-
ment with OCT induces a rapid improvement of clinical symptomatol-
ogy. On the other hand, the majority of the patients show tachyphylaxis of 
the inhibition of the secretion of tumor related hormones by OCT within 
weeks to months. This effect may be initially reversed by increasing the 
dosage of OCT, but eventually the drug becomes ineffective in all pa-
tients. The potential mechanisms responsible for this tachyphylaxis are 
not known at present. Multiple causes may underly the development of 
tachyphylaxis to octapeptide SRIF analogs treatment in patients neuro-
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endocrine gastro-enteropancreatic tumors. These include: 1. Differential 
expression of sst subtypes among tumors. While a preferential expression 
of sst
2 
and sst
5 
is found in GH-secreting pituitary adenomas, expression of 
sst
1 
and sst
3 
in combination with the presence of sst
2 
in other neuro-endo-
crine tumors is observed. 2. Sst receptor induced down- and/or up-regu-
lation; 3. Outgrowth of clones of tumor cells that lack sst receptors and 
4. Mutations in sst genes leading to absence of functional receptor pro-
teins. Since one of the potential mechanisms of OCT-resistance includes 
desensitization and/or down-regulation of sst, we have investigated this 
issue in sst
2 
and sst
5
 over-expressing HEK 293 cells. Much of the current 
(pre-) clinical knowledge about tachyphylaxis is built upon sst
2
-mediated 
mechanisms and sst
2
-preferring analogs. Therefore, it seems of interest 
to compare OCT with novel SRIF-analogs, having a different sst binding 
profi le compared with OCT, to evaluate whether they may be of potential 
interest for the medical treatment of (OCT-resistant-) neuro-endocrine 
tumors. In chapter VI-2, we evaluated tachyphylaxis of sst
2 
and sst
5
 sub-
types expressed alone or together in HEK 293 cells to various SRIF-ana-
logs. Prolonged (24h) pre-treatment with OCT resulted in a nearly total 
loss of responsiveness of sst
2
 receptor expressing cells in terms of inhibi-
tion of adenylyl cyclase activity. This observation may provide one of the 
explanations for the in vivo data in patients with neuro-endocrine tumors 
which are prone for developing unresponsiveness for OCT after pro-
longed treatment. What seems interesting is that SOM230, binding with 
a 2.5 lower binding affi nity to sst
2 
compared with OCT, induces a loss of 
responsiveness of sst
2
 that can be classifi ed as partial tachyphylaxis of 
SRIF-analog induced inhibition of adenylyl cyclase activity. In addition, 
the sst
5
 also seems less susceptible to tachyphylaxis compared with the 
sst
2 
subtype. SOM230 pre-treatment, which has a superior binding affi n-
ity for sst
5 
resulted in a signifi cant lower induction of tachyphylaxis in 
sst
5
-expressing cells compared with the (almost) complete tachyphylaxis 
induced by OCT in sst
2
-expressing cells. Moreover, no loss of sensitivity 
of sst
5 
was found if cells were pretreated with OCT. These data merely 
indicate that the sst
5 
subtype seems less susceptible to tachyphylaxis af-
ter prolonged treatment with a sst
5
-preferring analog, and suggest that 
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the sst
5
 receptor might form a potential new target for the treatment of 
OCT-resistant neuro-endocrine tumors. Also, prolonged treatment with 
SOM230 might result in a longer duration of action, because SOM230 
induces only partial tachyphylaxis of both the sst
2
 and sst
5
. However, as 
already discussed, it should be taken into account that the expression lev-
els of sst
5 
in carcinoid tumors is not as high as in GH-secreting pituitary 
adenomas and that other sst subtypes, for example sst
1
, are profoundly 
expressed in carcinoid tumors as well. Furthermore, the mechanism be-
hind distinct agonist-induced variability of receptor tachyphylaxis re-
mains to be elucidated. Although SRIF-analog induced down-regulation 
of sst
2 
and sst
5 
mRNA expression levels was observed in our experiments, 
which appeared not to be statistically different between various SRIF an-
alogs, we believe that other processes like G-protein uncoupling and/or 
endocytosis might play a role in tachyphylaxis to SRIF-analogs. Addi-
tional studies, therefore, are inevitably required to determine which cel-
lular mechanisms are actually triggered after the distinct agonist-induced 
receptor tachyphylaxis. Finally, the potencies and effi cacies of SOM230 
and OCT after pre-treatment with either OCT or SOM230 in the sst
2 
+ sst
5
co-transfected cells to inhibit adenylyl cyclase activity fully refl ected the 
resultant of the SRIF-analog induced tachyphylaxis in the mono-trans-
fected state. Extrapolating these latter observations to the clinical setting 
of a patient diagnosed with a carcinoid tumor, expressing both sst
2 
and 
sst
5
, prolonged OCT treatment may result in complete tachyphylaxis of 
the sst
2
 subtype, but the sst
5
 will remain functionally active. Therefore, it 
won’t be of any use for subsequent treatment with a sst
2
-selective or pre-
ferring SRIF-analog, but adjuvant treatment with SRIF-analogs that can 
bind with sub-nanomolar affi nity to sst
5
 might be of interest to elicit once 
again a therapeutic response in these OCT-resistant patient. On the other 
hand, prolonged treatment with SOM230 might result in a longer dura-
tion of action irrespective of the sst
2
 and sst
5
 expression levels, because 
SOM230 induces only partial tachyphylaxis of both receptor subtypes. 
As already discussed extensively, acromegalic patients that are clas-
sifi ed as only partially responsive to long-term therapy with OCT and 
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Lanreotide represent approximately 60% of the population. Dopamine 
agonists, however, were the fi rst drugs used in the medical treatment of 
acromegaly. The effi cacy of dopaminergic treatment increased to reach 
35% of patients with the advent of the high affi nity Dopamine D2 recep-
tor (D2R) analog, cabergoline (CAB). In selected acromegalic patients, 
the combination of SRIF- and D2R-analog treatment has been shown to 
be more effective than treatment with the individual analogs. Moreover, 
under experimental conditions sst
5
 and D2R have been demonstrated to 
heterodimerize in the presence of appropriate ligands, which provided a 
rationale for the development of novel molecules which might enhance 
biochemical control during long-term medical treatment of acromegalic 
patients. Indeed, the hybrid ‘dopastatin’ molecule, BIM-23A387 which 
has high binding affi nity for both sst
2 
and D2R, has an enhanced inhibito-
ry effect on in vitro PRL and GH release from human pituitary adenoma. 
This chimeric molecule appeared more potent than either sst
2
 or D2 selec-
tive analogs alone and interestingly, no additivity was even found when 
the sst
2
 and D2 selective analogs were added simultaneously to primary 
cultures of GH-secreting pituitary adenoma cells. This enhanced potency 
of BIM-23A387 (EC
50
 was 50 times lower than that of the individual sst
2
and D2 agonists as well), however, could not be explained on the basis 
of the binding affi nity of the compounds for sst
2
 and D2 receptors. It has 
been suggested that GH suppression by BIM-23A387 is not mediated via 
either individual sst
2
 or D2 receptors, but requires a functional interac-
tion between the two receptors in which the D2 receptor might have a 
dominant role. More recent studies with novel chimeric compounds, with 
differing enhanced activity at sst
2
, sst
5
 and D2R, demonstrated that these 
molecules consistently produced signifi cantly greater suppression of GH 
and PRL than either OCT or single-receptor-interacting ligands in tumors 
from patients classifi ed as only partial responsive to OCT therapy. Al-
though the higher effi cacy of the chimeric compounds targeting sst
2
, sst
5 
and D2R seems to be at least partially linked to their higher effi cacy for 
sst
2
, other mechanisms by which such molecules produce enhanced in-
hibition of GH secretion are lacking. Another explanation for the greater 
potency of the multi-receptor-interacting chimeric molecules may simply 
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be the fact that they can bind and activate multiple receptors. This ability 
increases the chance that once the ligand is released form one receptor it 
will rapidly occupy another receptor. To gain additional insights with re-
spect to the functional explanation for the potency of these novel chimeric 
compounds, BIM-23A760, targeting sst
2,
 sst
5
 and D2R, was evaluated in 
chapter VI-3 for its effi cacy to inhibit forskolin-induced adenylyl cyclase 
activity in sst
2
+sst
5
+D2R transfected mammalian cells. No differences in 
effi cacy between BIM-23A760 and the combination of the sst
2
-preferring 
analog BIM-23023 and the D2R-analog BIM-53097 or CAB, in terms 
of inhibition of adenylyl cyclase was found when all three receptor sub-
types where co-transfected in HEK 293 cells. Moreover, although BIM-
23A760, compared with BIM-23023, has a 10-fold higher binding affi nity 
for sst
2
 and a 10-fold lower binding affi nity for sst
5
, no differences were 
observed in functional activity. In addition, although BIM-23A760 has a 
similar binding affi nity for the D2R, compared with the internal control 
BIM-53097, the tri-chimeric molecule was 20-fold more potent to inhibit 
adenylyl cyclase activity in cells, expressing only the D2R. While it has 
been hypothesized that multiple G-protein coupled receptor ligands can 
induce receptor homo- and heterodimerization, which can result in a dis-
tinct novel G-protein coupled receptor with enhanced functionality com-
pared with the individual receptor subtypes, the data with BIM-23A760 
are not in favour of such an oligo-heterodimerization between sst
2
, sst
5 
and 
D2R. We propose, in addition to the current knowledge about GPCR func-
tion, that dopastatin chimeras can alter ligand-mono-receptor complexes 
differently, allowing prolonged stabilization of its active conformation 
or alteration of the rate of internalization. These molecules should have 
superior binding-affi nity towards the sst
2
, sst
5 
and D2R, thus initiating a 
super-agonist ligand-receptor conformation for each individual receptor. 
Eventually, such a hybrid compound may form an ideal pharmacological 
tool to treat GH hypersecretion, independent of the varying sst and D2R 
expression levels on the pituitary adenomas. Additional experiments, 
with  the use of sst- and D2 receptor analogs and antagonists, have to be 
carried out in order to understand how these chimeric molecules actu-
ally work at the cellular level. Resonance Energy transfer (FRET/BRET) 
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studies,  confocal microscopy and RNAi techniques, seem crucial to un-
derstand how individual, and possibly combined, sst and D2R undergo li-
gand-induced G-protein coupled receptor traffi cking in mammalian cells. 
In summary, the novel multiligand SRIF-analog SOM230 has been 
shown to have potential as a novel medical treatment option for acrome-
galic patients. Whereas OCT mediates its GH-suppressive actions pre-
dominantly via sst
2
, SOM230 can lower hormonal hypersecretion from 
GH-secreting pituitary adenomas via both sst
2
 and sst
5
 and, therefore, it 
has an advantage over OCT which seems benefi cial in the medical treat-
ment of about two thirds of acromegalic patients. With respect to the 
interplay between the two main key players in the regulation of GH-se-
cretion from GH-secreting pituitary adenomas, the sst
2 
subtype seems to 
function in a dominant way over sst
5
 to inhibit adenylyl cyclase activity. 
In mouse ACTH-secreting pituitary adenoma cells the sst
5 
subtype, as 
compared with sst
2
, has been demonstrated to be glucocorticoid resis-
tant, which is supported by the high sst
5 
mRNA and low sst
2
 mRNA 
expression in primary cultures of human ACTH-secreting pituitary ad-
enomas. In addition, SRIF-analogs targeting sst
5 
and/or sst
2
+sst
5
 can 
lower ACTH secretion from mouse and human ACTH-secreting pitu-
itary adenomas more effectively compared with OCT. Since these su-
perior inhibitory effects of sst
5
-targeting analogs on ACTH release re-
main unaffected in the presence of glucocorticoids,  sst
5
-preferring SRIF 
analogs may have merit for the medical treatment of Cushing’s disease.
Evaluating sst
2 
and sst
5
 subtypes, expressed alone or together in HEK 
293 cells, for tachyphylaxis to various SRIF-analogs demonstrated that 
prolonged pre-treatment with OCT results in a nearly total loss of re-
sponsiveness of the sst
2
 receptor to inhibit adenylyl cyclase activity 
What seems interesting is that SOM230 induces a loss of responsive-
ness of sst
2
 that can be classifi ed as partial tachyphylaxis of SRIF-ana-
log induced inhibition of adenylyl cyclase activity. In addition, the sst
5
also seems less susceptible to tachyphylaxis compared with the sst
2 
sub-
type, indicating that the sst
5 
subtype seems less susceptible to tachyphy-
laxis after prolonged treatment with a sst
5
-preferring analog, suggesting 
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that the sst
5
 receptor might form a potential target for the treatment of 
OCT-resistant neuro-endocrine tumors. Finally, one of the latest phar-
maceutical novelties for the medical treatment of sst-expressing neuro-
endocrine tumors, the novel chimeric compound BIM-23A760, target-
ing sst
2,
 sst
5
 and D2R, was not shown to be more effective to inhibit 
adenylyl cyclase activity as compared with the individual receptor-li-
gands. It is suggested, therefore, that dopastatin chimeras can alter li-
gand-mono-receptor complexes differently, allowing prolonged stabiliza-
tion of its active conformation or alteration of the rate of internalization.
Chapter VIII
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The main subject of the current thesis is the role of somatostatin (SRIF) 
receptors subtype 2 and 5 in the patho-physiological regulation of GH 
and ACTH release from human pituitary adenomas. The sst expression 
pattern in both types of pituitary adenomas is evaluated with respect to 
the inhibitory effects by SRIF-analogs on hormone secretion from the 
primary cultured tumor cells. The novel multiligand SOM230, compared 
with the current clinically available SRIF-analog OCT, is evaluated both 
for its clinical potential in the medical treatment of acromegaly, as well 
for in vitro for its potential in the medical treatment in patients with Cush-
ing’s disease. SOM230, together with sst-selective analogs and chimeric 
molecules, targeting the sst
2
, sst
5
 and Dopamine D2 Receptor, are used as 
tools to retrieve insights with respect to the functional interplay between 
sst
2, 
sst
5
 and D2R in the regulation of adenylyl cyclase activity as well the 
susceptibility of sst receptors to undergo ligand-induced adaptation, i.e.
tachyphylaxis, of inhibition of adenylyl cyclase activity by SRIF-analogs. 
In chapters III-1 and III-2, the role of SRIF receptor subtypes in the 
regulation of in vitro and in vivo GH release by acromegalic patients was 
evaluated. The inhibitory effect of the novel multiligand SOM230, which 
binds with high affi nity to four of the fi ve human sst, on hormone release 
by GH-secreting pituitary adenomas are compared with the clinically 
used sst
2
-preferring analog Octreotide (OCT). All GH-secreting pituitary 
adenomas that were studied showed mRNA expression for sst
2
 and sst
5
. 
Whereas the relative sst
5 
mRNA expression level in the GH-secreting pi-
tuitary adenomas was higher compared with sst
2
 mRNA expression, the 
sst
2 
subtype seems to be a dominant receptor regulating in vivo and in vitro
GH secretion in acromegaly. This conclusion is based on the observation 
that the inhibitory effects of OCT and SOM230 on GH release from the 
pituitary adenomas was positively correlated with the levels of sst
2 
mRNA 
expression, but not with sst
5
 mRNA expression, of the tumors. Moreover, 
during the fi rst proof-of-concept study with SOM230, a concentration-
dependent inhibitory effect of SOM230 on circulating GH concentrations 
from patients with acromegaly supports a dominant role of sst
2 
in the 
regulation of GH release, since the 100μg concentration of SOM230 was 
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not as effective as 100μg OCT, to suppress GH release in vivo. Regard-
ing the superior binding affi nity of SOM230 for the sst
5 
subtype and the 
comparable superior binding affi nity of OCT for sst
2 
receptors, it could 
have been expected that 100μg SOM230 acting via sst
5,
 would be as po-
tent as 100μg OCT, exerting its action via sst
2
, to suppress GH release. 
The results demonstrated that only 250μg SOM230, compensating for the 
2.5 lower binding affi nity for sst
2 
compared with OCT, was as effective as 
100μg OCT to suppress GH secretion in acromegalic patients. On the other 
hand. however, only SOM230, in striking contrast to OCT, can lower GH 
concentrations when sst
2
 expression was low and sst
5
 expression was high 
on the adenoma cells. This is likely caused by the sst
5 
binding affi nity of 
SOM230, which is 40-fold higher as compared with OCT. The multiligand 
SOM230, therefore, has a clear advantage over OCT with the potential 
to increase the number of acromegalic patients that can be biochemically 
controlled during long-term medical treatment. SOM230, in contrast to 
OCT, appeared to lower PRL secretion in prolactinomas as well, which 
was clearly related to the level of sst
5
 expression on the adenoma cells.
Additional analysis regarding the effects of SOM230 on several meta-
bolic parameters in acromegalic patients in vivo are described in chap-
ter III-3. Both dosages SOM230 inhibited free IGF-I more sustained 
as compared with OCT. Circulating IGFBP-1 is capable of binding free 
IGF-I, thereby lowering the metabolic actions of free IGF-I. The regu-
lation of IGFBP-1 is suggested to be regulated directly via SRIF-ana-
logs. The superior action of OCT compared with a lower effectiveness of 
SOM230, which has a 2.5 lower affi nity for sst
2,
 in stimulating IGFBP-1 
levels, supported the concept of direct regulation of IGFBP-1 by SRIF-
analogs via sst
2
. Comparable elevations of glucose concentrations during 
lunch were observed after SOM230 and OCT administration. However, 
250µg SOM230 elicited an acute increase in glucose levels 1 h post-
injection. This effect could not be explained by its concomitant slight 
inhibitory effect on insulin secretion. Since absolute insulin concentra-
tions were not dramatically affected by SOM230, it was hypothesized 
that this multiligand negatively infl uences insulin action, i.e. induces 
a state of insulin resistance, in peripheral target tissues such as liver, 
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visceral adipose tissue and skeletal muscle. Subsequently, as shown in 
chapter III-3 and III-4, the observed sst
1
 and sst
2
 mRNA expression pat-
tern in peripheral target tissues of insulin action, forms a prerequisite 
for the involvement of sst subtypes in the regulation of insulin action. 
The evaluation of insulin receptor (IR) auto-phosphorylation in the hu-
man hepatoma cell line HuH-7, endogenously expressing sst
1 
and sst
2
, 
did not demonstrate that SOM230 can attenuate IR autophosphorylation 
by possible activation of protein tyrosine phosphatases. Other causes, for 
instance dephosphorylation of the IRS proteins, which are more down-
stream of the IR, by SOM230 via sst
1
 and/or sst
2 
remains to be clarifi ed
Using [125I-Tyr11]SRIF-14 radioligand binding and functional cAMP re-
sponse studies in transiently transfected HEK 293 cells expressing differ-
ent sst
2
/sst
5 
ratios, chapter IV-1 provides support for a dominant role of 
sst
2 
over sst
5
 in the inhibition of adenylyl cyclase activity. The lowering of 
intracellular cAMP concentrations via inhibition of adenylyl cyclase ac-
tivity is one of the main second messenger systems involved in inhibition 
of GH-secretion. This fundamental approach to evaluate whether a func-
tional interplay between sst
2
 and sst
5
 occurs, is fully in accordance with 
the in vitro and in vivo correlation of sst
2 
mRNA expression levels, but not 
sst
5 
mRNA expression, with the inhibitory effects of OCT and SOM230 
on GH release from GH-secreting pituitary adenomas. Experiments with 
a sst
2
-antagonist, are supporting the clinically observed advantage of 
SOM230 compared with OCT in those acromegalic patients classifi ed 
as (partially) OCT-resistant. In the presence of the sst
2 
antagonist, only 
SOM230 was still effective to suppress adenylyl cyclase activity in sst
2 
+ 
sst
5 
expressing HEK 293 cells. Apparently, when sst
2
 expression is low, 
OCT cannot be suffi ciently effective via sst
5
, because it’s binding affi nity 
for the sst
5
 subtype is 40-fold lower compared with SOM230. In agree-
ment with our hypothesis based on clinical observations, these funda-
mental studies support the concept that SOM230 can be benefi cial in the 
medical treatment of acromegaly, because the multiligand can effectively 
lower GH release, as well as adenylyl cyclase activity, via both sst
2
 and sst
5.
RNA interference seems an interesting methodological novel tool al-
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lowing silencing a specifi c gene of interest. Chapter IV-2 shows that 
the silencing RNA constructs for the sst
2 
and sst
5 
gene, evaluated in 
several mammalian cell lines expressing either sst
2 
or sst
5
, have mer-
it to become novel tools to eventually evaluate further the individu-
al role of sst subtypes in the regulation of hormone (hyper-) secretion 
from endogenously sst-expressing primary pituitary adenoma cells. 
Chapter V describes the sst expression pattern in pituitary adenomas 
from patients with Cushing’s disease (CD), as well as the functional 
characterisation of sst
2 
and sst
5
 in regulating ACTH release. In patients 
with untreated CD, OCT has not been effective to lower circulating 
ACTH and cortisol levels, which has been suggested to be caused by 
down-regulation of sst
2 
receptors by glucocorticoids. In mouse cortico-
troph AtT-20 cells, a down regulation of sst
2
 mRNA and protein levels 
by glucocorticoids was indeed observed, which supports the clinical ob-
servation that OCT is ineffective in lowering ACTH and cortisol levels 
in patients with untreated CD. The suppressive effects on ACTH release 
in AtT-20 cells and primary cultures of human corticotroph adenomas 
and the observation that sst
5
 appeared to be relatively resistant to down-
regulation by glucocorticoids, suggests that this sst subtype plays an 
important role in the regulation of (tumoral) ACTH release. As the sst
5 
seemed the predominantly sst expressed in human corticotroph adeno-
mas, whereas low sst
2
 mRNA expression levels support once more the 
lack of effi cacy of OCT in these tumors, it is hypothesized that SRIF-
analogs targeting sst
5
 and sst
2
, or even universal SRIF-analogs, may be-
come a new medical treatment option to the control of ACTH and cor-
tisol hypersecretion in untreated patients with pituitary dependent CD.
 In chapter VI-1 an overview is given with respect to the role of novel 
SRIF-analogs in the treatment of neuroendocrine tumors. A potential medi-
cal problem during prolonged treatment with the sst
2
-preferring SRIF-an-
alogs OCT and Lanreotide is tachyphylaxis to the initial inhibitory effects 
of different SRIF-analogs. Therefore, this tachyphylaxis of the inhibitory 
effects of SRIF-analogs on adenylyl cyclase activity in a mammalian cell 
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line expressing sst
2
, sst
5
 or co-expressing sst
2
 and sst
5
, is investigated in 
chapter VI-2. HEK 293 cells have been transiently transfected with sst
2 
and/or sst
5 
subtypes and treated for a prolonged period of time with sever-
al SRIF-analogs. Prolonged OCT-treatment, in accordance with the clini-
cal experience in carcinoids tumors, results in a complete tachyphylaxis 
of cAMP formation via  the sst
2 
subtype. In contrast to OCT, SOM230 
and BIM-23023, the latter being a sst
2
-specfi c agonist, induced a loss of 
responsiveness of sst
2
 that can be classifi ed as partial tachyphylaxis of 
inhibition of adenylyl cyclase activity. On the other hand, the sst
5
 was 
demonstrated to be less susceptible to tachyphylaxis compared with the 
sst
2 
subtype. This might indicate that targeting the sst
5 
could form a po-
tential treatment strategy in patients with a neuro-endocrine tumor which 
has become unresponsive after prolonged treatment with current sst
2
-pre-
ferring SRIF-analogs. In addition, on the basis of this agonist-selective 
induction of tachyphylaxis of a single sst subtype, it is suggested that the 
prolonged activity of agonists with very good binding affi nity for sst
2 
and/
or sst
5 
differentially elicit tachyphylaxis of both the sst
2 
and the sst
5
 recep-
tor, presumably due to distinct agonist-induced receptor conformations.
Representing one of the potential novel medical tools for the treatment of 
neuroendocrine tumors including pituitary adenomas, BIM23A760, tar-
geting both sst
2+5
 and dopamine D2 (D2R) receptors has been critically 
evaluated in a series of sst
2
+sst
5
+D2R transfected mammalian cells. This 
is described in chapter VI-3. The functional effi cacy of BIM-23A760 
in the experimental model seems not in favour of oligo-heterodimer-
ization between sst
2
, sst
5 
and D2R. The effi cacy of BIM-23A760, com-
pared with the mono-receptor sst ligands and the D2R agonist Caber-
goline, in mono-transfected cells with one of the three target receptor 
subtypes to inhibit adenylyl cyclase activity is not different as compared 
with their effi cacy in HEK 293 cells transfected with all thee receptor 
simultaneously. Also, even though BIM-23A760 and its D2R-target-
ed internal control BIM-53097 share comparable binding affi nities for 
D2R, a more potent inhibition of adenylyl cyclase activity by BIM-
23A760 was observed. Therefore, it is suggested that the dopastatin 
chimera BIM-23A760 can alter ligand-mono-receptor complexes differ-
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ently compared with the individual mono-receptor ligand, that already 
can result in enhanced potency of this novel pharmacological agent.
In chapter VII the results of the studies reported in this thesis are discussed, 
as well as the possible clinical signifi cance and potential future develop-
ments of using novel sst subtype selective or universal SRIF-analogs.
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Het hoofddoel van dit proefschrift is geweest om meer inzicht te krijgen 
over de rol van somatostatine (SRIF) receptor subtype (sst) 2 and 5 in 
patho-physiologische regulatie van GH en ACTH secretie door humane 
hypofyse adenomen. Het sst expressie patroon in beide type hypofyse 
tumoren is onderzocht met betrekking tot de remmende werking van SRIF-
analogen op de hormoon productie door hypofyse adenoom cellen. Het 
nieuwe multiligand SOM230, afgezet tegen het klinisch beschikbare SRIF-
analoog Octreotide (OCT), is onderzocht voor zowel zijn klinische potentie 
voor de medische behandeling van acromegalie maar tevens ook voor zijn
in vitro potentie voor de medicamenteuze behandeling van patiënten met 
de ziekte van Cushing. SOM230, tezamen met sst-selectieve analogen en 
chimerische moleculen, welke bindingsaffi niteit hebben voor sst
2
, sst
5
 en 
de dopamine D2 receptor (D2R), zijn verder gebruikt als hulpmiddelen 
om nieuwe inzichten te verkrijgen omtrent de functionele interactie tussen 
deze drie receptoren aangaande adenylyl cyclase activiteit alsmede voor het 
ondergaan van ligand-geïnduceerde adaptatie van sst, i.e. tachyphylaxie, 
voor remming van adenylyl cyclase activiteit door SRIF-analogen.
In de hoofdstukken III-1 en III-2 is de rol van SRIF receptor subtypen in 
de regulatie van in vitro en in vivo GH secretie bij acromegalie patiënten 
onderzocht. De remmende werking van het nieuwe multiligand SOM230, 
wat met hoge affi niteit bindt aan vier van de vijf humane sst, op GH 
productie door GH-producerende hypofyse adenomen is vergeleken met 
het klinisch beschikbare sst
2
-prefererende analoog OCT. In alle GH-
producerende hypofyse adenomen is mRNA expressie van sst
2
 en sst
5
aangetoond. De relatieve expressie van sst
5
 mRNA in deze serie hypofyse 
adenomen bleek hoger te zijn dan de expressie van sst
2
 mRNA, echter de 
sst
2 
lijkt dominant over sst
5 
voor wat betreft de in vitro en in vivo regulatie 
van GH secretie in acromegalie. Deze conclusie is gebaseerd op het feit 
dat de remmende werking van OCT en SOM230 op GH secretie door 
hypofyse adenomen positief gecorreleerd is met de mate van sst
2
 mRNA 
expressie, maar niet met de mate van sst
5
 mRNA expressie, van de 
tumoren. De observatie, tijdens de eerste klinische studie met SOM230 in 
acromegalie, dat SOM230 een concentratie-afhankelijk remmend effect 
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had op circulerende GH concentraties, ondersteunt de hypothese dat de 
sst
2 
een dominante rol heeft in de regulatie van GH secretie, omdat 100μg 
SOM230 minder effectief bleek te zijn dan 100μg OCT. Omdat SOM230 
en OCT een superieure bindingsaffi niteit voor respectievelijk sst
5 
en sst
2
hebben, kon verwacht worden dat 100μg van iedere compound, via sst
5 
of 
sst
2
, even effectief zou zijn om GH secretie te remmen. Onze resultaten 
lieten zien dat alleen 250μg SOM230, waarmee gecompenseerd wordt 
voor de 2.5 lagere bindingsaffi niteit van SOM230 voor sst
2
 vergeleken met 
OCT, even effectief was als 100μg OCT om GH secretie in acromegalie 
patiënten te remmen. Aan de andere kant, echter, bleek alleen SOM230 
in staat te zijn om GH concentraties te verlagen als op de adenoom cellen 
de sst
2 
expressie laag en sst
5
 expressie hoog is. Dit wordt waarschijnlijk 
verklaard door de 40-voudige hogere bindingsaffi niteit, vergeleken met 
OCT, van SOM230 voor sst
5. 
De multiligand SOM230 heeft derhalve een 
duidelijk voordeel over OCT, met de potentie om het aantal patiënten dat 
biochemisch gecontroleerd kan worden tijdens langdurige medicamenteuze 
behandeling, te doen vermeerderen. Tevens bleek alleen SOM230, en niet 
OCT, in staat om PRL productie door prolactinoma cellen te remmen, 
wat duidelijk geassocieerd is met sst
5 
mRNA expressie van de tumoren.
Aanvullende analyse aangaande de effecten van SOM230 op verscheidende 
metabole parameters in acromegalie patiënten, zijn beschreven in 
hoofdstuk III-3. Beide doseringen SOM230 bleken vrije IGF-I spiegels 
meer te remmen dan OCT. Circulerend IGFBP-1 is in staat om vrij IGF-I 
te binden, waardoor de metabole werking van IGF-I wordt gereduceerd. 
De regulatie van IGFBP-1 is gesuggereerd direct gereguleerd te zijn 
door SRIF-analogen. De superieure stimulerende werking van OCT op 
IGFBP-1 concentraties, vergeleken met SOM230, ondersteunt het concept 
dat de directe regulatie van IGFBP-1 spiegels door SRIF-analogen is 
gemedieerd via sst
2
. Vergelijkbare stijgingen in bloedsuikerspiegels 
tijdens en na de lunch zijn geobserveerd na SOM230 en OCT toediening. 
SOM230 250μg, echter, induceerde 1 uur na toediening een acute stijging 
van de bloedsuiker concentratie. Dit effect bleek niet verklaard door 
een absolute remming van de insuline spiegel door SOM230. Derhalve 
is geponeerd dat SOM230 mogelijk de werking van insuline negatief 
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beïnvloed, het induceert mogelijk insuline resistentie in perifere doelwit 
organen van insuline werking zoals de lever, skeletspieren en visceraal 
vet. Zoals beschreven in de hoofdstukken III-3 en III-4, is de expressie 
van sst
1 
en sst
2 
mRNA in deze perifere doelwit organen van insuline 
werking een eerste vereiste voor een betrokkenheid van sst in de regulatie 
van insuline werking. De evaluatie van insuline receptor (IR) auto-
phosphorylatie in de humane hepatoom cellijn Huh-7, welke endogeen 
sst
1
 en sst
2
 tot expressie brengt, heeft niet aangetoond dat SOM230 IR 
autophosphorylatie kan doen verlagen via mogelijke activatie van proteïne 
tyrosine phosphatasen. Andere oorzaken, bijvoorbeeld dephosphorylering 
van IRS eiwitten, welke down-stream van IR gelegen zijn, door 
SOM230 via sst
1
 en/of sst
2
 zullen nog opgehelderd moeten worden.
Met behulp van [125I-Tyr11]SRIF-14 radioligand binding en functionele 
cAMP respons studies in transiënt getransfecteerde HEK 293 cellen 
met verschillende expressie niveaus van sst
2
/sst
5, 
wordt in hoofdstuk 
IV-1 aanvullend bewijs aangeleverd dat de sst
2
 een dominante rol heeft 
over sst
5
 om adenylyl cyclase activiteit te remmen. Het verlagen van de 
intracellulaire cAMP concentratie via remming van het adenylyl cyclase 
is een van de belangrijke second messenger systemen welke betrokken 
zijn bij de suppressie van GH secretie. Onze fundamentele benadering om 
de functionele interactie te bestuderen tussen sst
2
 en sst
5
, was volledig in 
overeenstemming met de in vitro en in vivo correlatie tussen sst
2
 mRNA 
expressie niveaus, maar niet met sst
5
 mRNA, en de remmende werking 
van OCT en SOM230 op GH secretie door GH-producerende hypofyse 
adenomen. Experimenten met een sst
2
-antagonist ondersteunden de 
klinische observatie van het voordeel dat SOM230 heeft, vergeleken met 
OCT, in die acromegalen geclassifi ceerd als partiële OCT-responder. In 
de aanwezigheid van de sst
2
-antagonist was alleen SOM230 in staat om 
effectief adenylyl cyclase activiteit in sst
2
 + sst
5
 tot expressie brengende 
HEK 293 cellen te supprimeren. Kennelijk, als de sst
2
 expressie laag 
was, kon OCT niet effectief werken via de sst
5
 omdat OCT een 40-
voudige lagere bindingsaffi niteit dan SOM230 heeft voor de sst
5
. In 
overeenstemming met onze hypothese die gebaseerd op de klinische 
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observaties, ondersteunen de fundamentele experimenten het concept 
dat SOM230 van toegevoegde waarde kan zijn in de medicamenteuze 
behandeling van acromegalie, omdat deze multiligand effectief via sst
2
en sst
5
 zowel GH secretie als adenylyl cyclase activiteit kan remmen.
RNA interferentie is een interessante nieuwe methodologie waarmee 
het mogelijk moet zijn om een specifi ek gen te ‘silencen’. Hoofdstuk 
IV-2 liet zien dat RNAi gen-constructen voor de sst
2
 en sst
5
 mogelijk 
in de toekomst bruikbaar kunnen zijn om de rol van de sst subtypen 
verder te bestuderen aangaande hun rol in de regulatie van hormoon 
(hyper-) secretie door sst-expresserende hypofyse adenoom cellen.
Hoofdstuk V beschrijft niet alleen het sst expressie patroon in hypofyse 
adenomen van patiënten met de ziekte van Cushing (CD), maar ook de 
functionele karakterisering van sst
2
 en sst
5
 receptoren in de regulatie van 
ACTH secretie. In patiënten die onbehandeld zijn voor CD, is gebleken 
dat OCT de ACTH en cortisol niet effectief kan onderdrukken, wat 
waarschijnlijk verklaard wordt door een down-regulatie van sst
2
 expressie 
door glucocorticoïden. Deze hypothese wordt ondersteund door onze 
observaties in muizen corticotrophe AtT-20 cellen, waarin een down-
regulatie van sst
2
 mRNA en eiwit door glucocorticoïden is aangetoond. De 
supprimerende effecten op ACTH afgifte door AtT-20 cellen en primaire 
kweken van humane corticotrophe adenoom cellen gecombineerd met 
de observaties dat de sst
5 
relatief resistent is voor down-regulatie door 
glucocorticoïden, suggereren dat de sst
5 
een belangrijke rol speelt in de 
regulatie van ACTH secretie. Verder is gebleken dat voornamelijk de sst
5 
tot expressie komt in humane corticotrophe adenoom cellen en sst
2
 mRNA 
laag was in deze groep hypofyse adenomen. Dit ondersteunt nogmaals de 
klinische observatie dat OCT niet effectief is voor de behandeling van CD. 
Derhalve hypothetiseren wij dat SRIF-analogen met bindingsaffi niteit 
voor sst
5
 en sst
2
, of zelfs universele SRIF-analogen, mogelijkerwijs een 
nieuwe medicamenteuze behandelingsoptie kunnen worden om ACTH 
en cortisol hypersecretie in onbehandelde CD patiënten te controleren.
In hoofdstuk VI-1 is een overzicht gegeven omtrent de rol van nieuwe 
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SRIF-analogen in de behandeling van neuro-endocriene tumoren. Een 
potentieel medisch probleem tijdens langdurige behandeling met de sst
2
-
prefererende SRIF-analogen OCT en Lanreotide is het ongevoelig worden 
van de tumor cellen voor de remmende werking van SRIF-analogen op 
hormoon secretie. Dit fenomeen wordt tachyphylaxie genoemd. Daarom 
hebben wij in hoofdstuk VI-2 het optreden van tachyphylaxis voor de 
remmende werking van SRIF-analogen op adenylyl cyclase activiteit in 
sst
2
 + sst
5
 tot expressie brengende HEK 293 cellen verder onderzocht. 
Langdurige OCT-behandeling, in overeenstemming met klinische ervaring 
met OCT in carcinoid tumoren, resulteerde in een compleet ongevoelig 
worden van de sst
2 
receptor. In tegenstelling tot OCT, induceerden 
SOM230 en BIM-23023, een sst
2
-specifi ek SRIF-analoog, een afname 
in gevoeligheid van de sst
2
 welke geclassifi ceerd moet worden als zijnde 
een partiële tachyphylaxis. De sst
5
, vergeleken met de sst
2
, bleek in zijn 
geheel minder gevoelig te zijn voor het optreden van tachyphylaxis. 
Deze observaties met de sst
5
 subtype wijzen wellicht op een mogelijke 
behandelingsoptie in patiënten met een neuro-endocriene tumor die 
ongevoelig zijn geworden voor de huidige generatie sst
2
-prefererende 
SRIF-analogen. Tevens suggereren deze agonist-selectieve inducties van 
tachyphylaxis van een enkele sst subtype, dat aparte agonist-geïnduceerde 
receptor conformaties verantwoordelijk voor deze effecten kunnen zijn.
Een potentieel nieuw medicamenteus gereedschap in de behandeling van 
neuro-endocriene tumoren inclusief hypofyse adenomen, BIM-23A760, 
bindend aan sst
2
+sst
5
 en de dopamine D2 receptor (D2R), is kritisch 
onderzocht in sst
2
+sst
5
+D2R tot expressie brengende HEK 293 cellen. 
Dit is beschreven in hoofdstuk VI-3. De functionele effectiviteit van 
BIM-23A760 in ons cellijn model ondersteunt niet het concept van oligo-
heterodimerisatie tussen sst
2,  
sst
5
 en de D2R. De effectiviteit van BIM-
23A760, vergeleken met de mono-receptor SRIF-analogen en de D2R-
agonist Cabergoline, in mono-receptor getransfecteerde HEK 293 cellen 
om adenylyl cyclase activiteit te remmen, bleek niet verschillend te zijn ten 
opzichte van hun effectiviteit in HEK 293 cellen die getransfecteerd waren 
met alle drie de receptoren. BIM-23A760, met eenzelfde bindingsaffi niteit 
voor D2R als zijn interne controle BIM-53097, bleek zelfs meer potent 
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dan BIM-53097 om adenylyl cyclase activiteit te remmen. Derhalve, 
hypothetiseren wij dat het dopastatine chimeer BIM-23A760 een 
specifi eke ligand-monoreceptor interactie veroorzaakt ten opzichte van 
de individuele monoreceptor liganden, welke op zichzelf reeds een goede 
verklaring kan vormen waarom BIM-23A760 een betere potentie heeft.
In hoofdstuk VII worden zowel de resultaten van onze studies 
bediscussieerd, alsmede de mogelijke klinische signifi cantie 
en potentiële toekomstige ontwikkelingen met het gebruik van 
nieuwe sst subtype selectieve en universele SRIF-analogen.
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Het volbrengen van een proefschrift geeft net zoveel voldoening als het 
winnen van een grote sportprijs. Het vormt mijns inziens het hoogtepunt 
in een veelal prille wetenschappelijke carrière. Net als in de sport echter, 
moeten er bergen bloed, zweet en tranen verzet worden eer de erkenning 
in de wacht gesleept kan worden. Wederom gaat ook in de wetenschap 
dit niet zonder dat er een team achter de onervaren promovendus staat. 
Derhalve wil ik een aantal mensen in dit kader dan ook gaarne bedanken.
Mijn technisch directeur, prof. dr. Steven Lamberts. Beste professor 
Lamberts, net als in een grote topsport organisatie dient er altijd een leider 
aanwezig te zijn die de grote lijnen uitzet en vooruit kijkt. In retrospect 
had ik niet een betere keuze kunnen maken door in te stemmen met uw 
voorstel om de SOM230 studie in acromegalie te gaan begeleiden. Niet 
alleen is mijn project een ideale combinatie van klinisch en fundamenteel 
onderzoek gebleken, maar het heeft mij tevens in staat gesteld om binnen 
de endocrinologie met de top te werken. Het respect en ontzag wat ik op 
internationale bijeenkomsten voor ‘Rotterdam’ in het algemeen en voor u 
in het bijzonder ben tegengekomen, was indrukwekkend en veelzeggend. 
Ik wil u dan ook enorm bedanken voor uw vertrouwen in een jonge 
dokter, uw enthousiasme voor het onderzoek, uw immer aanwezige 
sociale noot, de snelle respons aangaande manuscripten en voor alle 
internationale meetings waar ik heb mogen vertellen over ons werk. 
Il allenatore, mijn wetenschappelijke trainer-coach en co-promotor, dr. 
Leo Hofl and. Beste Leo, in jouw arena heb ik mijzelf mogen ontplooien 
als wetenschapper. Het stimuleren van een eigen visie omtrent aanvullende 
proeven, alsmede het geven van zelfverantwoordelijkheid heb ik enorm 
gewaardeerd. Vaak liet je mijzelf een weg uitstippelen, echter met enige 
regelmaat moest jij mijn enthousiasme temperen, maar desalniettemin 
heeft jouw denkwijze absoluut bijgedragen aan een fantastische periode. 
Zeker gezien het feit dat ik hierdoor in staat ben gebleken om het 
onderzoek te combineren met topvolleybal. Je kritische blik met oog 
voor detail, alsmede jouw ervaring in het geven van wetenschappelijke 
prestaties, zijn voor mij van grote waarde gebleken. Daarnaast hebben 
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we samen prachtige internationale congressen zoals Lyon, New York 
en San Diego, mogen bezoeken. Veelal hebben we hier, onder het genot 
van een vino rosso, nieuwe ideeën en hypothesen opgedaan welke dan in 
het lab verder uitgewerkt werden. Leo, enorm bedankt voor je steun en 
vertrouwen, alsmede voor je ‘vaderlijke schouder’ aangaande mijn soms 
desperate en onmogelijke combinatie van wetenschap, sport en familie. 
Als scheidsrechters van mijn proefschrift wil ik graag prof. dr A.H.J. 
Danser, prof. dr. ir. T.J. Visser en prof. dr. A.J. van der Lelij bedanken voor 
het feit dat zij zitting hebben willen nemen in de kleine promotiecommissie 
en voor de inhoudelijke beoordeling van het proefschrift. Een extra woord 
van dank gaat uit naar prof. dr. A.J. van der Lelij. Beste Aart-Jan, enorm 
bedankt voor je inzet en steun bij het volbrengen van de twee klinische 
studie met SOM230 in de acromegalie. Tevens ben ik je zeer erkentelijk 
voor je ondersteuning aangaande mijn internationale congresbezoeken.
Mijn paranimfen Marlijn en Christiaan. Lieve Marlijn, zonder jou was er 
helemaal geen boekje geweest. Althans niet binnen de tijdspan die er nu 
mee gemoeid is geweest. Onze ‘fl ow’ is goud geworden. De samenwerking 
is fantastisch geweest. Dankzij jou inzet, expertise en enthousiasme is 
mijn verblijf op het lab niet allen een succes geworden maar is ‘het kleine 
baasje’ tevens in staat geweest om een promotieonderzoek te combineren 
met topvolleybal. Marlijn, het is dan ook niet meer dan logisch dat jij een 
van mijn paranimfen bent. Ontzettend bedankt voor een geweldige tijd! 
Ik hoop oprecht dat ik op tijd terug ben op het lab om samen met jou het 
onderzoek weer op te pakken, want anders zit je reeds met Piet in Frankrijk, 
maar dan moet daar een kweeklab met incubator in de schuur komen……...
Christiaan, wie had gedacht dat na het bestuderen van de ‘internal 
pearls’ jij verder zou gaan met de open einden van dit proefschrift? ’s 
Nachts op het gras van de Westersingel, het Tramhuys, Leidens ontzet 
en de koffi ebar, het zijn zomaar een aantal illustere plekken waar 
we samen door de jaren heen goede fi losoferende plekken hebben 
gevoerd over geneeskunde en het leven. Super dat jij mijn paranimf 
bent en heel veel succes met de open vraagstukken op kamer Ee585. 
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Mijn trouwe teamgenoten van het laboratorium Neuro-Endocrinologie, 
Diana en Peter. Lieve Diana, jouw aanwezigheid op het lab zorgde 
altijd voor een warme sfeer op het lab, zowel letterlijk als fi guurlijk. De 
thermostaat was immers jouw domein, maar daarnaast immer liefdevol, 
zorgzaam en betrokken bij het wel en wee van mijn wetenschappelijke en 
vaderlijke vliegkunsten. Niet alleen was je altijd bereid om mee te denken 
met al die PCR proeven, maar ook je opvoedkundige adviezen heb ik 
enorm gewaardeerd. En we gaan zeker een keer met de families zeilen! 
Beste Peter, onze ‘brainstorm’ sessies ’s morgens vroeg op het lab waren 
fantastisch. Onder het genot van een bakkie koffi e hebben we samen heel 
veel resultaten besproken en aanvullende proeven opgezet. Tevens ben 
ik jou enorm veel dank verschuldigd voor de ontelbare trainingen met de 
bindingsstudies en al die andere experimenten, zoals bijvoorbeeld met de 
vetcellen. Ook jij stond altijd letterlijk ieder moment van de dag voor mij 
klaar. Een super collega ben je, en hopelijk zal je in staat zijn om jouw 
fantastische data met de bijnieren ooit zelf in een boekje te comprimeren.
Alle medewerkers van het laboratorium Endocrinologie wil ik bedanken 
voor een altijd gezellige sfeer. Een aantal collega’s wil ik graag nog 
even expliciet noemen. Piet Uitterlinden, enorm bedankt voor al die 
IGFBP-1, totaal en vrij IGF-I bepalingen die je verricht hebt voor de 
klinische studie met SOM230. Ronald van der Wal, bedankt voor je 
muzikale computer ondersteuning. Zonder de ‘know-how’ van Anke en 
Miriam was de CRE-LUC essay nooit een succes voor somatostatine 
receptor onderzoek geworden. Dames, er was wel eens een probleempje, 
een besmetting of een mislukte maxi, maar altijd konden mijn HEK 
cellen op jullie rekenen. Bedankt hiervoor! Anche, caro Giovanni, 
grazie per essere a destra di mia tavola per studiare la lingua italiana!
Richard Feelders en Wouter de Herder, mijn klinische endo-trainers, 
bedankt voor jullie expertise en hulp ten tijde van de SOM230 studie op 
de CRU en 4 Noord.
Edith, bedankt voor je hulp bij al die administratieve handelingen.
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De collega’s van de CRU en afdeling 4 Noord, in het bijzonder Titia, 
Lenie, Joke, Wendy en Sjaan, wil ik ontzettend bedanken voor de tomeloze 
inzet bij alle bloeddrukmetingen en (nachtelijke) bloedafnames tijdens de 
klinische studies met SOM230 bij onze acromegalie patiënten.
Frans Bukkens en Remko de Bruijn ben ik zeer erkentelijk voor hun 
tijd en energie die zij beiden hebben gespendeerd aan respectievelijk de 
voorkant en de lay-out van mijn proefschrift.
Beste Arend, je moet de hazen laten lopen om het edelhert te kunnen 
pakken, toch? Zonder jouw vertrouwen had mijn volleybalcarrière niet 
geweest wat hij nu geworden is. Hiervoor kan ik je niet genoeg bedanken. 
Gracias!
Het sportmoment van de 20e eeuw is terecht de Olympische volleybal 
fi nale van Atlanta 1996 geworden. De regisseur van die onvergetelijke 
wedstrijd, Peter Blangé, heeft mij niet alleen als volleyballer maar ook 
als mens op een hoger mentaal niveau gebracht. Trainer, iedere dag in 
de zaal met jou is een feest geweest. Net zoals dat ontbijtje in Dupnitza! 
Genieten was het, iedere seconde. Bedankt voor een onvergetelijke tijd, 
maar vooral ook dank voor je vertrouwen in mij dat geleid heeft tot een 
combi van Europees topvolleybal en geneeskunde. 
Mijn teamgenoten bij VC Nesselande, in het bijzonder Ace, Allanus, 
Appie, Capitan, Cootje, Dirkus, Gijssie, Gras, Kris, Merx, Smits en Sol, 
lekker knallen was het met jullie! Winst en verlies ligt soms heel dicht bij 
elkaar, dat hoef ik jullie niet te vertellen. Maar een fantastische tijd is het 
wel geweest, waarvoor veel dank. 
Schoonfamilie heb je niet voor het kiezen, maar Plony, Paul & Hannie, 
Robin & Wendy en Ellen, vanaf de eerste dag heb ik me thuis gevoeld bij 
jullie allemaal. Bedankt voor jullie support en steun de afgelopen jaren! 
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Zonder goede vrienden vaart niemand wel. Dek & Jel en Tinus & Dijkie, 
dag en nacht was er wel een bakkie troost of een luisterend oor in tijden 
van mentale of geestelijke onrust. Huize Van der Hoek zal ook altijd voor 
jullie openstaan!
Pa & Ma, betere ouders kan een kind zich niet wensen. Boshoek 8 is het 
fundament van mijn leven geweest. Mille grazie.
Mijn Danielle, zoals een oude fi sh al terecht heeft gememoreerd: it’s hard 
to express the way I feel about you without getting involved with the old 
cliché…..I love you.
Tim en Naud, “you are the sunshine’s of my life, that’s why I will always 
be around. You guys are the apples of my eye, forever you will be in my 
heart”.
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De auteur van dit proefschrift werd geboren op 12 september 1974 
te Dordrecht. Na het Atheneum gevolgd te hebben op de openbare 
scholengemeenschap (O.S.G.) Walburg te Zwijndrecht, studeerde hij 
Biologie aan de Universiteit te Leiden. Het doctoraal examen werd 
behaald in 1997. Hierna werd aangevangen met de studie geneeskunde 
aan de Erasmus Universiteit te Rotterdam. Het artsexamen werd met lof 
afgelegd in 2002. Vervolgens werd in juni 2002 als arts-onderzoeker onder 
leiding van prof. dr. S.W.J. Lamberts en dr. L.J. Hofl and aangevangen 
met het promotieonderzoek, zoals in dit proefschrift beschreven. Vanaf 
1 september 2005 startte hij met de opleiding tot internist in het Albert 
Schweitzer Ziekenhuis te Dordrecht (opleider dr. A.C.M. van Vliet).
Gedurende zijn opleiding tot bioloog en arts, alsmede tijdens 
zijn promotieonderzoek, heeft de auteur tevens een sportieve 
volleybalcarrière genoten bij VC Nesselande te Rotterdam. In zijn 
acht jaar als semi-professionele volleyballer heeft hij onder andere 
drie Nationale indoor volleybal kampioenschappen, een Nationaal 
beachvolleybal kampioenschap, een zilveren medaille tijdens de 
Top Teams Cup Europa cup fi nale en een Nationale bekertitel 
gewonnen. Daarnaast heeft hij gedurende zijn eerste jaar als arts-
onderzoeker deel uitgemaakt van het Nationaal volleybal team.
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